{"10ce102dd3c76f690ebe84048a5d734598b3d2f1": [["BackgroundAn increasing percentage of the population uses various social media platforms such as Facebook, Twitter, and Tumblr for reasons varying from casual conversations to debating social issues.", [["increasing", "OBSERVATION_MODIFIER", 13, 23], ["percentage", "OBSERVATION_MODIFIER", 24, 34], ["population", "OBSERVATION_MODIFIER", 42, 52]]], ["Around 68% of U.S. adults use Facebook [1] which has over 180 million daily active users in the U.S. and Canada [2] who spend around 40 min per day on this medium [3] .", [["adults", "ORGANISM", 19, 25]]], ["A recent study by PricewaterhouseCoopers showed that in the United States, 24% of adults post about their health experiences on social media with 16% of them posting reviews of medications, treatments, doctors or health [4] .", [["adults", "ORGANISM", 82, 88], ["A recent study", "TEST", 0, 14], ["social media", "TREATMENT", 128, 140], ["medications", "TREATMENT", 177, 188], ["treatments", "TREATMENT", 190, 200]]], ["Facebook use for disease surveillance [6] or public health issues [7] [8] [9] shows its broad scope for improving public health.", [["Facebook", "CHEMICAL", 0, 8], ["disease surveillance", "TEST", 17, 37]]], ["For example, studies have been conducted to assess Facebook's potential in engaging smokers in smoking cessation treatment [10] and to evaluate it's scope in recruitment and retention of young adult American veterans into an online alcohol intervention study [11] .", [["smoking", "CHEMICAL", 95, 102], ["alcohol", "CHEMICAL", 232, 239], ["alcohol", "CHEMICAL", 232, 239], ["studies", "TEST", 13, 20]]], ["In the context of this study the interactions between the U.S. Federal health agencies and Facebook users are meant to promote better healthcare knowledge through successful information dissemination and consumption.BackgroundThe importance of social media for communicating to a broad audience is well acknowledged in journalism [16] , politics [17] , marketing [18] , entertainment [19] , etc. Healthcare organizations such as the Centers for Disease Control and Prevention (CDC) or Food and Drug Administration (FDA) have a crucial responsibility to inform the public of critical pandemic events like the spread of H1N1 [6, 20] or Coronavirus [21] and about drug recalls [22] and sexual health information [23] .", [["H1N1", "DISEASE", 618, 622], ["this study", "TEST", 18, 28], ["Disease Control", "TREATMENT", 445, 460], ["critical pandemic events", "PROBLEM", 574, 598], ["H1N1", "PROBLEM", 618, 622], ["Coronavirus", "PROBLEM", 634, 645]]], ["Like the CDC, the National Cancer Institute of National Institutes of Health (NIH) also has several thousand posts, but their response is quite low compared to the other two organizations.", [["Cancer", "DISEASE", 27, 33]]], ["The nature of public engagement with an organization's messages is an active focus of research in health sciences and in marketing [24] .", [["active", "OBSERVATION_MODIFIER", 70, 76]]], ["In contrast to surveys, our study of engagement on social medial is 'observational' where we assess public activities in response to posts by U.S. Federal health agencies.BackgroundWe address two specific questions with respect to Facebook posts from U.S. Federal health agencies and the responses they generate.", [["our study", "TEST", 24, 33]]], ["Second, which Facebook account and post features are associated with the interval length between an agency's Facebook post and the last activity it generates?BackgroundWe analyze an almost comprehensive set of Facebook posts from 72 Facebook accounts of 24 U.S. Federal health agencies.", [["length", "OBSERVATION_MODIFIER", 82, 88]]], ["We explore the features related to our second question using survival models.", [["survival models", "TREATMENT", 61, 76]]], ["Features we examine include standard ones such as the number of page likes as well as less studied features relating to the semantic content of a post.Data collection Agencies & accountsWe selected health agencies through the Health and Human Services (HHS) Social Hub website [29] which lists all Facebook accounts affiliated to various U.S. Federal health agencies.Posts & activityThe Facebook Graph API [30] was used to collect all posts from an account's timeline as of late January 2013.", [["Human", "ORGANISM", 237, 242], ["Human", "SPECIES", 237, 242], ["semantic content", "OBSERVATION", 124, 140]]], ["For each post, we recorded its unique identifier, number of likes, shares, comments and other metadata as described below.Account and post featuresWe included features that are generally used in Facebook-based studies [12, 31, 32] as well as those that are seldom considered (see Table 1 ).Page likesThe number of page likes shows the number of users endorsing an account.", [["post features", "OBSERVATION_MODIFIER", 134, 147]]], ["Perhaps more positive sentiment is linked with greater activity, or maybe the reverse holds.", [["positive", "OBSERVATION_MODIFIER", 13, 21], ["sentiment", "OBSERVATION", 22, 31]]], ["SentiStrength has been widely applied to social media postings [35] and has been shown to outperform other lexical classifiers [36] .", [["SentiStrength", "TREATMENT", 0, 13]]], ["SentiStrength classifies each Facebook post into positive and negative on a scale of +/\u22121 (neutral) to +/\u22125 (extreme).ContentOne aspect of Facebook analysis that is often overlooked is post content.", [["a scale", "TEST", 74, 81], ["Facebook analysis", "TEST", 139, 156], ["post content", "OBSERVATION", 185, 197]]], ["For example, a post about information dissemination of the outbreak of West Nile virus (\"West Nile virus is a potentially serious illness.", [["West Nile virus", "DISEASE", 71, 86], ["West Nile virus", "DISEASE", 89, 104], ["West Nile virus", "ORGANISM", 71, 86], ["West Nile virus", "ORGANISM", 89, 104], ["West Nile virus", "SPECIES", 71, 86], ["West Nile virus", "SPECIES", 89, 104], ["West Nile virus", "SPECIES", 71, 86], ["West Nile virus", "SPECIES", 89, 104], ["West Nile virus", "PROBLEM", 71, 86]]], ["The semantic types of the MeSH terms are mapped to the fifteen higher level semantic groups by the National Library of Medicine [41] .", [["the MeSH terms", "TREATMENT", 22, 36], ["semantic", "OBSERVATION_MODIFIER", 4, 12], ["types", "OBSERVATION_MODIFIER", 13, 18], ["MeSH", "OBSERVATION", 26, 30]]], ["For example, the high level semantic group \"Disorders\" comprises of 12 semantic types, namely, Acquired Abnormality, Anatomical Abnormality, Cell or Molecular Dysfunction, Congenital Abnormality, Disease or Syndrome, Experimental Model of Disease, Finding, Injury or Poisoning, Mental or Behavioral Dysfunction, Neoplastic Process, Pathologic Function, and Sign or Symptom.Choice of modelAs shown later, around 20% of Facebook posts have zero activity (i.e. they receive no likes, shares or comments).", [["Cell", "ANATOMY", 141, 145], ["Acquired Abnormality", "DISEASE", 95, 115], ["Anatomical Abnormality", "DISEASE", 117, 139], ["Cell or Molecular Dysfunction", "DISEASE", 141, 170], ["Congenital Abnormality", "DISEASE", 172, 194], ["Disease or Syndrome", "DISEASE", 196, 215], ["Disease", "DISEASE", 239, 246], ["Injury", "DISEASE", 257, 263], ["Poisoning", "DISEASE", 267, 276], ["Mental or Behavioral Dysfunction", "DISEASE", 278, 310], ["Cell", "CELL", 141, 145], ["the high level semantic group \"Disorders", "PROBLEM", 13, 53], ["Acquired Abnormality", "PROBLEM", 95, 115], ["Anatomical Abnormality", "PROBLEM", 117, 139], ["Molecular Dysfunction", "PROBLEM", 149, 170], ["Congenital Abnormality", "PROBLEM", 172, 194], ["Disease", "PROBLEM", 196, 203], ["Syndrome", "PROBLEM", 207, 215], ["Experimental Model of Disease", "PROBLEM", 217, 246], ["Injury", "PROBLEM", 257, 263], ["Poisoning", "PROBLEM", 267, 276], ["Mental or Behavioral Dysfunction", "PROBLEM", 278, 310], ["Neoplastic Process", "PROBLEM", 312, 330], ["Pathologic Function", "PROBLEM", 332, 351], ["Sign or Symptom", "PROBLEM", 357, 372], ["high", "OBSERVATION_MODIFIER", 17, 21], ["Anatomical Abnormality", "OBSERVATION", 117, 139], ["Molecular Dysfunction", "OBSERVATION", 149, 170], ["Neoplastic", "OBSERVATION_MODIFIER", 312, 322]]], ["This type of distribution of data where the variance (of activity count) is much greater than the mean implies overdispersed data [42] with zero-inflation [43] .", [["the variance", "TEST", 40, 52], ["activity count", "TEST", 57, 71], ["zero-inflation", "TEST", 140, 154]]], ["Typically linear models such as Poisson or negative binomial regression are used to model count data.", [["Poisson or negative binomial regression", "PROBLEM", 32, 71], ["model count data", "TEST", 84, 100], ["linear", "OBSERVATION_MODIFIER", 10, 16], ["negative", "OBSERVATION_MODIFIER", 43, 51], ["binomial regression", "OBSERVATION", 52, 71]]], ["However the zero-inflation and overdispersion (p < 0.001) requires using two-part count data models such as the hurdle regression model [44] .", [["the zero-inflation", "PROBLEM", 8, 26], ["overdispersion", "OBSERVATION_MODIFIER", 31, 45]]], ["Hurdle models have two separate components: a zero-portion used to fit the sizeable portion of zero counts in the data and a count-portion to fit the non-zero counts of the data.", [["a zero-portion", "TREATMENT", 44, 58], ["zero counts", "OBSERVATION", 95, 106]]], ["The zero-portion models whether a count is zero (no activity) or not using a binomial probability model.", [["a count", "TEST", 32, 39]]], ["The count portion determines the conditional distribution of the non-zero counts using a zero-truncated negative binomial or Poisson model.", [["The count portion", "TEST", 0, 17]]], ["Previous studies on social media engagement [10, [45] [46] [47] have shown the power of hurdle models for modeling data with similar characteristics.Choice of modelWe compared different count data regression models (namely, the Poisson, negative binomial, hurdle Poisson and hurdle negative binomial (HNB)) using standard goodness-of-fit measures.", [["Previous studies", "TEST", 0, 16], ["regression models", "TEST", 197, 214]]], ["The HNB model had the lowest AIC value (297667.3) compared to the Poisson (1,443,334), negative binomial (304590.7) and hurdle Poisson (1,292,709) models, signifying a better fit.", [["The HNB model", "TEST", 0, 13], ["the Poisson", "TEST", 62, 73]]], ["The Vuong statistics signifies that hurdle negative binomial model has a better fit compared to the other models.", [["binomial model", "OBSERVATION", 52, 66]]], ["Our comparison of full and nested models such as hurdle negative binomial and negative binomial using the likelihood ratio test also indicates that the former model fits our data best.", [["the likelihood ratio test", "TEST", 102, 127]]], ["Variance inflation factor (VIF) yielded VIF scores for all independent variables in our regression analysis that were within the range of zero to five indicating no multicollinearity issues.Choice of modelThe temporal characteristics of a post are also of interest.", [["Variance inflation factor", "PROTEIN", 0, 25], ["VIF", "PROTEIN", 27, 30], ["VIF", "PROTEIN", 40, 43], ["Variance inflation factor", "PROBLEM", 0, 25], ["VIF scores", "TEST", 40, 50], ["all independent variables", "PROBLEM", 55, 80], ["our regression analysis", "TEST", 84, 107], ["multicollinearity issues", "PROBLEM", 165, 189], ["no", "UNCERTAINTY", 162, 164], ["multicollinearity issues", "OBSERVATION", 165, 189], ["temporal", "OBSERVATION_MODIFIER", 209, 217]]], ["We use methods from survival analysis [48] , the branch of statistics dedicated to modeling such temporal behavior.", [["survival analysis", "TEST", 20, 37]]], ["Seventeen are NIH division such as NIH/NIDA, NIH/NIMH and NIH/ NICHD.", [["NIH/NIDA, NIH/NIMH and NIH/ NICHD", "DISEASE", 35, 68]]], ["Some agencies have quite a few accounts such as NIH/NLM (6 accounts: Women's_Health_Resources, NLM_4_Caregivers, etc.), CDC (10 accounts: CDC_Tobacco_Free, Health_Hazard_Evaluation_Program, etc.), OS (16 accounts: HealthCare.gov, Medi-cal_Reserve_Corps, etc.) while several others have just one account such as ACF, FDA, NIH/NCCAM, etc. Table 2 lists the various agencies, the number of accounts for each and of accounts.Agencies & accountsAs shown in Table 3 Table 4 shows the top 10 accounts ranked by activity per post.", [["Women", "SPECIES", 69, 74]]], ["CDC's official account, with the most number of posts (2867), also leads in total number of activities (285,347).", [["total", "OBSERVATION_MODIFIER", 76, 81]]], ["(115,940) .Agencies & accountsPost types Table 6 shows the various types of post as well as their counts.", [["their counts", "TEST", 92, 104]]], ["Links are the most common (28,830) while questions are the least common (74).SentimentIn Table 7 , we see that Facebook posts are generally positive (percentage of moderate to extreme positive is 61.89% while for negative this percentage is 47.04%).", [["moderate", "OBSERVATION_MODIFIER", 164, 172]]], ["Regression coefficients in the zero-portion are exponentiated as odds ratios (OR) while the exponentiated regression coefficients in the count portion are treated as incident rate ratios (IRR) [52] .", [["Regression coefficients in the zero-portion", "PROBLEM", 0, 43], ["the exponentiated regression coefficients", "PROBLEM", 88, 129], ["incident rate ratios", "TEST", 166, 186]]], ["When we interpret the results of a particular variable we consider all other variables to remain constant.Analysis for activity presenceThe coefficients of the logit regression in the zero portion of the model indicate how the features relate to crossing the 'hurdle' of obtaining at least one activity (i.e. either a like, share or comment).Analysis for activity abundanceWe now analyze the coefficients of the negative binomial regression in the count portion of the hurdle model (Table 9 ).", [["Analysis", "TEST", 106, 114], ["the logit regression", "TREATMENT", 156, 176], ["Analysis", "TEST", 342, 350], ["activity abundanceWe", "TEST", 355, 375]]], ["This allows us to focus on posts that cross the 'hurdle' of getting at least one activity.Analysis for activity abundanceGiven a unit increase in the log-transformed count of page likes, the rate of activity is expected to increase by a factor of 6.033, while holding all other variable in the model constant.", [["Analysis", "TEST", 90, 98], ["activity abundance", "TEST", 103, 121]]], ["For sentiment, a unit increase in positive sentiment increases the rate of activity by a factor of 1.126 while a unit increase in negative sentiment decreases the rate of activity by a factor of 0.934, with allModeling activity life spanThe median number of days between a date of posting and date of last activity is zero.", [["positive sentiment", "PROBLEM", 34, 52], ["positive sentiment", "OBSERVATION", 34, 52]]], ["Regression coefficients from the Cox proportional hazards model are exponentiated as hazard ratios (HR) and used in the interpretation of the survival models.", [["Regression coefficients", "PROBLEM", 0, 23], ["the Cox proportional hazards model", "PROBLEM", 29, 63]]], ["For binary variables (each post type or each semantic group) the time to last activity may increase or decrease based on the presence of a feature compared to its absence in a post.", [["binary variables", "PROBLEM", 4, 20], ["increase", "OBSERVATION_MODIFIER", 91, 99], ["decrease", "OBSERVATION_MODIFIER", 103, 111]]], ["A unit increase in positive sentiment increases the time to last activity by 2.1% while a unit increase in negative sentiment has no significant association with the time to last activity.", [["A unit increase", "TREATMENT", 0, 15], ["positive sentiment", "PROBLEM", 19, 37], ["unit", "OBSERVATION_MODIFIER", 2, 6], ["increase", "OBSERVATION_MODIFIER", 7, 15], ["positive sentiment", "OBSERVATION", 19, 37]]], ["Of the various post types, the presence of photos or videos are both linked to an increase in the time to last activity.", [["various", "OBSERVATION_MODIFIER", 7, 14], ["post types", "OBSERVATION_MODIFIER", 15, 25], ["increase", "OBSERVATION_MODIFIER", 82, 90]]], ["The other post types are not significantly associated with the time to last activity.", [["post types", "OBSERVATION_MODIFIER", 10, 20]]], ["'Devices' , 'Organizations' and 'Occupations' are the only ones that decrease the time to last activity by 14.7, 4.3 and 5.6% respectively.DiscussionOur results show that there is considerable difference between levels of Facebook use and public engagement among organizations.", [["considerable", "OBSERVATION_MODIFIER", 180, 192], ["difference", "OBSERVATION_MODIFIER", 193, 203]]], ["OS and CDC have the most Facebook posts while NIH/NINDS and NIH/NIGMS have less than 200 posts.", [["NIH/NIGMS", "TEST", 60, 69]]], ["Overall, less than 5% of Facebook posts get more than 100 total shares, likes or comments.", [["less", "OBSERVATION_MODIFIER", 9, 13]]], ["The presence of positive sentiment in posts from these government agencies is associated with higher activity.", [["positive", "OBSERVATION_MODIFIER", 16, 24], ["sentiment", "OBSERVATION", 25, 34], ["higher activity", "OBSERVATION", 94, 109]]], ["We found that posts about activities and behaviors, and phenomenon are positively associated with level of engagement.", [["phenomenon", "PROBLEM", 56, 66]]], ["Here we compare and contrast the findings from our previous Twitter-based study to our findings from this study.", [["this study", "TEST", 101, 111]]], ["This is likely due of the relative simplicity of Twitter postings.", [["likely due of", "UNCERTAINTY", 8, 21], ["simplicity", "OBSERVATION", 35, 45]]], ["Comparison of the results of the statistical models from the two platforms reveals many interesting findings.", [["the statistical models", "TEST", 29, 51], ["the two platforms", "TEST", 57, 74]]], ["In terms of semantic categorization, we find that across both social media platforms posts about activities and behaviors, and phenomenon are positively associated with level of engagement.", [["semantic categorization", "TEST", 12, 35], ["semantic categorization", "OBSERVATION", 12, 35]]], ["Overall, we find our results to be consistent and our methods to be robust for engagement analysis on Facebook and Twitter.LimitationsOur research has a few limitations.", [["engagement analysis", "TEST", 79, 98], ["few", "OBSERVATION_MODIFIER", 153, 156]]], ["While our longitudinal data analysis shows that for four out of five posts all activities are generated on the date of the posting itself, we cannot guarantee that a post won't gather any activity after months or years.", [["our longitudinal data analysis", "TEST", 6, 36]]], ["This limitation, however, is bound to affect almost any social media based research conducted at a specific point in time and that uses these counts or similar ones as metrics.", [["these counts", "TEST", 136, 148]]], ["Second, our study focused only on U.S. Federal health agencies and thus our findings may not be generalizable to other organizations.", [["our study", "TEST", 8, 17]]], ["While we find ample evidence where our findings mirror those of Facebook studies in other domains (as shown in the Discussion section), we would like to investigate the generalizability of our approach in future studies.", [["Facebook studies", "TEST", 64, 80], ["future studies", "TEST", 205, 219]]], ["While we included many commonly used features as well as some novel ones in this study, there could be other features such as post frequency [58] or posting time [59] that also have correlation to engagement.ConclusionWhile some previous studies (referenced earlier) have focused on engagement of health departments at a local level, to the best of our knowledge, we present the first comprehensive analyses of engagement with U.S. Federal health agencies on Facebook.", [["this study", "TEST", 76, 86], ["some previous studies", "TEST", 224, 245]]], ["Examination of over 45,000 Facebook posts from 72 Facebook accounts belonging to 24 U.S. Federal health agencies reveals a wide range of activity across these accounts.", [["Examination", "TEST", 0, 11]]], ["We find that a very small fraction of the 45,000 posts get more than 100 likes, shares or comments, while one-fifth of posts see no activity at all.", [["a very small fraction", "PROBLEM", 13, 34], ["very", "OBSERVATION_MODIFIER", 15, 19], ["small", "OBSERVATION_MODIFIER", 20, 25], ["fraction", "OBSERVATION_MODIFIER", 26, 34]]], ["Content analyses of the posts show, for example, that the majority of posts contain links and are generally positive in sentiment.", [["Content analyses", "TEST", 0, 16], ["generally", "OBSERVATION_MODIFIER", 98, 107], ["positive", "OBSERVATION", 108, 116]]], ["Statistical analyses show that the number of page likes of an account is associated with higher engagement.", [["Statistical analyses", "TEST", 0, 20]]]], "65f744f76ed6aff2387ea9922e808fa228c03756": [["donor characteristics that may allow for targeting of more potent donors would greatly facilitate 23 effective collection. scores of 3 to 6, who had a mean NT50 antibody titer of 1:696.", [["donors", "ORGANISM", 66, 72], ["more potent donors", "TREATMENT", 54, 72], ["scores", "TEST", 123, 129], ["a mean NT50 antibody titer", "TEST", 149, 175]]], ["While these results may seem to 78 support the notion of higher titers with increased disease severity, the numbers of CP donors in 79 higher WHO scores in this study are too low to determine significance.", [["CP donors", "ORGANISM", 119, 128], ["increased disease severity", "PROBLEM", 76, 102], ["CP donors", "PROBLEM", 119, 128], ["this study", "TEST", 156, 166], ["increased", "OBSERVATION_MODIFIER", 76, 85], ["disease", "OBSERVATION", 86, 93]]], ["For CP donor age ( Figure 80 2A), the NT50s were significantly correlated (p = 0.0019), yet with little predictive value (R 2 = 81 0.09466) and targeting advance age donors for CP collection may therefore not be very effective.82On average, the CP collected from male donors (N = 61) had a significantly higher mean NT50 83 than from female donors (N=38), yet whether the mean titer difference of 1:220 has any 84 functional relevance is questionable ( Figure 2B ).", [["donors", "ORGANISM", 166, 172], ["donors", "ORGANISM", 268, 274], ["donors", "ORGANISM", 341, 347], ["CP", "PROBLEM", 4, 6], ["the NT50s", "TEST", 34, 43], ["CP collection", "PROBLEM", 177, 190], ["the CP", "PROBLEM", 241, 247], ["a significantly higher mean NT50", "PROBLEM", 288, 320], ["the mean titer difference", "TEST", 368, 393]]]], "PMC7250605": [["The required amount of training data thus grows quickly with the number of data sources to be integrated.", [["training data", "TEST", 23, 36], ["amount", "OBSERVATION_MODIFIER", 13, 19]]], ["Labeling large amounts of data is a tedious task.", [["large", "OBSERVATION_MODIFIER", 9, 14], ["amounts", "OBSERVATION_MODIFIER", 15, 22]]], ["Active learning for entity resolution aims at minimizing the human labeling effort by iteratively selecting only an informative subset of record pairs for labeling.", [["human", "ORGANISM", 61, 66], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 61, 66]]], ["In each active learning iteration, one or more informative record pairs are selected and provided to a human annotator for labeling.", [["human", "ORGANISM", 103, 108], ["human", "SPECIES", 103, 108], ["human", "SPECIES", 103, 108], ["active", "OBSERVATION_MODIFIER", 8, 14]]], ["The most informative record pairs are the ones that cause the highest disagreement among the members of the committee.IntroductionA problem which frequently arises in active learning, is the lack of labeled data in the early iterations, known as the cold start problem [9].", [["IntroductionA problem", "PROBLEM", 118, 139]]], ["To circumvent the cold start problem, existing active learning methods for entity resolution require the human annotator to label a small set of record pairs.", [["human", "ORGANISM", 105, 110], ["human", "SPECIES", 105, 110], ["human", "SPECIES", 105, 110], ["the cold start problem", "PROBLEM", 14, 36], ["existing active learning methods", "TREATMENT", 38, 70]]], ["This set is either selected randomly [9, 18] or based on the distribution of pre-calculated similarity scores [2, 19] before the active learning starts.", [["pre-calculated similarity scores", "PROBLEM", 77, 109], ["active", "OBSERVATION_MODIFIER", 129, 135]]], ["However, solving the cold start problem by manually annotating a subset of the data is contradicting the main principle of active learning, that of minimizing the human labeling effort.IntroductionWe propose an alternative method for dealing with the cold start problem.", [["human", "ORGANISM", 163, 168], ["human", "SPECIES", 163, 168], ["human", "SPECIES", 163, 168], ["the cold start problem", "PROBLEM", 17, 39], ["an alternative method", "TREATMENT", 208, 229], ["the cold start problem", "PROBLEM", 247, 269], ["active", "OBSERVATION_MODIFIER", 123, 129]]], ["In addition, it is part of the complete active learning cycle as it is used for model training and record pair selection.", [["model training", "TREATMENT", 80, 94]]], ["Bootstrapping active learning with unsupervised labeled pairs guarantees high anytime performance and stability.", [["stability", "OBSERVATION_MODIFIER", 102, 111]]]], "dbb01e8e29c35e6067014defe96bd11fe5af6f44": [["Comprehensive sexuality education to prevent gender-based violence.", [["violence", "DISEASE", 58, 66]]], ["2018. https://en.unesco.org/news/comprehensive-sexualityeducation-prevent-gender-based-violence (accessed June 19, 2020COVID-19: Africa needs unprecedented attention to strengthen community health systemsAs the first cases of COVID-19 were confirmed in Liberia, in March, 2020, former President Ellen Johnson Sirleaf, 1 among others, 2 highlighted the need to adopt lessons learned from the response to the 2014-16 outbreak of Ebola virus disease in west Africa.", [["Ebola virus disease", "DISEASE", 427, 446], ["Ebola virus", "ORGANISM", 427, 438], ["Ebola virus", "SPECIES", 427, 438], ["Ebola virus", "SPECIES", 427, 438], ["COVID", "TEST", 226, 231], ["Ebola virus disease", "PROBLEM", 427, 446], ["Ebola virus disease", "OBSERVATION", 427, 446]]], ["Ebola claimed about 11 300 lives in 21 months across Liberia, Sierra Leone, and Guinea.", [["Ebola", "DISEASE", 0, 5], ["Ebola", "ORGANISM", 0, 5]]], ["3 Comparisons to Ebola benefit from remembering the key differences between the two viruses.", [["Ebola", "DISEASE", 17, 22], ["Ebola", "ORGANISM", 17, 22]]], ["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a respiratory virus and is infectious among asymptomatic carriers.", [["acute respiratory syndrome coronavirus", "DISEASE", 7, 45], ["respiratory virus", "DISEASE", 66, 83], ["Severe acute respiratory syndrome coronavirus 2", "ORGANISM", 0, 47], ["SARS-CoV-2", "ORGANISM", 49, 59], ["Severe acute respiratory syndrome coronavirus", "SPECIES", 0, 45], ["SARS-CoV-2", "SPECIES", 49, 59], ["Severe acute respiratory syndrome coronavirus", "PROBLEM", 0, 45], ["SARS-CoV", "TEST", 49, 57], ["a respiratory virus", "PROBLEM", 64, 83], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["respiratory syndrome", "OBSERVATION", 13, 33], ["respiratory virus", "OBSERVATION", 66, 83], ["infectious", "OBSERVATION_MODIFIER", 91, 101]]], ["4 SARS-CoV-2 differs from Ebola virus in terms of the reproduction number (SARS-CoV-2 5\u00b77 vs Ebola 1\u00b75-1\u00b79), 5,6 incubation period (2-14 days vs 8-10 days on average), 7,8 and case fatality rate (this varies for SARS-CoV-2 but average is estimated at 4\u00b77% as of July 7, 2020, vs up to 90% for Ebola).", [["SARS", "DISEASE", 2, 6], ["Ebola virus", "DISEASE", 26, 37], ["SARS", "DISEASE", 75, 79], ["SARS", "DISEASE", 212, 216], ["Ebola", "DISEASE", 293, 298], ["SARS-CoV-2", "ORGANISM", 2, 12], ["Ebola virus", "ORGANISM", 26, 37], ["Ebola", "ORGANISM", 93, 98], ["Ebola", "ORGANISM", 293, 298], ["Ebola virus", "SPECIES", 26, 37], ["Ebola virus", "SPECIES", 26, 37], ["SARS-CoV", "SPECIES", 212, 220], ["Ebola virus", "PROBLEM", 26, 37], ["SARS", "TEST", 75, 79], ["CoV", "TEST", 80, 83], ["Ebola", "TEST", 93, 98], ["fatality rate", "TEST", 181, 194], ["SARS", "PROBLEM", 212, 216], ["CoV", "TEST", 217, 220], ["vs", "TEST", 276, 278], ["Ebola", "PROBLEM", 293, 298]]], ["9,10 COVID-19 is easier to transmit, harder to diagnose, and can quickly spread in communities.COVID-19: Africa needs unprecedented attention to strengthen community health systemsThe Ebola response showed the importance of investments that build health system resilience, notably investments in the health workforce.", [["Ebola", "DISEASE", 184, 189], ["Ebola", "ORGANISM", 184, 189]]], ["11 Unfortunately, community engagement largely occurred too late in the Ebola response.", [["Ebola", "DISEASE", 72, 77], ["Ebola", "ORGANISM", 72, 77]]], ["12, 13 To date, there are no studies of how well countries adopted the lessons learnt from Ebola for COVID-19 and this will be a critical future exercise.COVID-19: Africa needs unprecedented attention to strengthen community health systemsAt the onset of the COVID-19 pandemic in sub-Saharan Africa, governments took swift action to institute lockdown measures, activate incident management response systems, and mobilise front-line health workers to be trained.", [["Ebola", "DISEASE", 91, 96], ["Ebola", "ORGANISM", 91, 96], ["COVID", "TEST", 101, 106], ["the COVID", "TEST", 255, 264], ["institute lockdown measures", "TREATMENT", 333, 360]]], ["However, some months into the pandemic preliminary evidence suggests that human resources for health in sub-Saharan Africa have been inadequately prepared.", [["human", "ORGANISM", 74, 79], ["human", "SPECIES", 74, 79], ["human", "SPECIES", 74, 79]]], ["CHWs are a key component of pandemic response strategies, 16 they were used in the COVID-19 response in China, 17 recommendations on how CHWs can be supported to interrupt virus transmission while maintaining essential services and shielding vulnerable populations.", [["pandemic response strategies", "TREATMENT", 28, 56], ["shielding vulnerable populations", "TREATMENT", 232, 264]]], ["In Rivercess County, Liberia, where there has only been one suspected COVID-19 case that was confirmed negative as of June 30, 2020, some caregivers refuse to attend mobile clinics or facilities for vaccinations and there has been a reduction in care seeking among some adults (Saykpah R, unpublished).", [["vaccinations", "TREATMENT", 199, 211], ["a reduction in care", "TREATMENT", 231, 250]]], ["People fear health workers are spreading COVID-19 and CHWs, while trusted neighbours, have insufficient PPE to convince people otherwise.", [["People", "ORGANISM", 0, 6], ["people", "ORGANISM", 120, 126], ["People", "SPECIES", 0, 6], ["people", "SPECIES", 120, 126]]], ["The stakes are high for people's health if there is any reduction in care-seeking behaviour for preventable diseases.", [["people", "ORGANISM", 24, 30], ["people", "SPECIES", 24, 30], ["preventable diseases", "PROBLEM", 96, 116]]], ["19 To its credit, Liberia, scarred from the Ebola outbreak, has been training its National Community Health Assistants to prevent, detect, and respond to COVID-19 while maintaining essential services and is in the process of procuring PPE for CHWs.", [["Ebola", "DISEASE", 44, 49], ["COVID", "TEST", 154, 159], ["scarred", "OBSERVATION", 27, 34], ["Ebola outbreak", "OBSERVATION", 44, 58]]], ["20 COVID-19 is the new public health backdrop and we cannot wait to strengthen community health systems.", [["new", "OBSERVATION_MODIFIER", 19, 22]]], ["21 Indeed, the Africa Centres for Disease Control and Prevention is planning to recruit 1 million community health volunteers to support contact tracing across sub-Saharan Africa, 22 relying on existing CHW cadres.", [["volunteers", "ORGANISM", 115, 125], ["Disease Control", "TREATMENT", 34, 49]]], ["Ongoing efforts to leverage CHWs for the COVID-19 response must not be one-offs in the face of an emergency.", [["the COVID", "TEST", 37, 46]]], ["CHWs must be equipped, trained, and supported in the long term as a crucial human resource for health.COVID-19: Africa needs unprecedented attention to strengthen community health systemsTrillions of dollars have been committed 23 in just over 6 months for the COVID-19 response globally.", [["human", "ORGANISM", 76, 81], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 76, 81], ["the COVID", "TEST", 257, 266]]], ["A COVID-19 vaccine or therapy will take months to become commercially available and likely longer to access in lowincome countries.", [["A COVID-19 vaccine", "TREATMENT", 0, 18], ["therapy", "TREATMENT", 22, 29]]], ["24 If a vaccine, treatment, or reliable diagnostic is available, adoption in places with shortages of human resources for health will be a struggle.", [["human", "ORGANISM", 102, 107], ["human", "SPECIES", 102, 107], ["human", "SPECIES", 102, 107], ["a vaccine", "TREATMENT", 6, 15], ["treatment", "TREATMENT", 17, 26]]], ["Now is the time to invest in community health systems in sub-Saharan Africa and avert a greater crisis.COVID-19: Africa needs unprecedented attention to strengthen community health systemsWe declare no competing interests.", [["a greater crisis", "PROBLEM", 86, 102], ["greater", "OBSERVATION_MODIFIER", 88, 95], ["crisis", "OBSERVATION", 96, 102]]], ["The health of populations across the planet is in a perilous state during the COVID-19 pandemic, with more than 550 000 deaths worldwide as of July 10, 2020.", [["deaths", "DISEASE", 120, 126], ["COVID-19", "SPECIES", 78, 86], ["the COVID", "TEST", 74, 83], ["planet", "OBSERVATION", 37, 43]]], ["1 The disease burden is falling mainly on the most disadvantaged groups worldwide and there are major impacts on health systems across high, middle, and low-income countries.", [["The disease burden", "PROBLEM", 2, 20], ["disease", "OBSERVATION", 6, 13], ["falling", "OBSERVATION_MODIFIER", 24, 31], ["mainly", "OBSERVATION_MODIFIER", 32, 38], ["major", "OBSERVATION_MODIFIER", 96, 101], ["impacts", "OBSERVATION_MODIFIER", 102, 109], ["middle", "ANATOMY_MODIFIER", 141, 147]]], ["In parallel with these direct health impacts, the economic effects of lockdowns are leading to an unprecedented global recession which will have ramifications well into the future.", [["an unprecedented global recession", "PROBLEM", 95, 128], ["global", "OBSERVATION_MODIFIER", 112, 118], ["recession", "OBSERVATION", 119, 128]]], ["But while the focus is, rightly, on responding to the immediate threat of the pandemic, it is important to remember that over 40 million people die each year from non-communicable diseases (NCDs), more than 70% of all global deaths.", [["non-communicable diseases", "DISEASE", 163, 188], ["NCDs", "DISEASE", 190, 194], ["deaths", "DISEASE", 225, 231], ["people", "ORGANISM", 137, 143], ["people", "SPECIES", 137, 143], ["non-communicable diseases", "PROBLEM", 163, 188]]], ["2 Meanwhile, the climate and extinction crises pose unprecedented challenges to our planet, with government responses-as yet-inadequate.", [["extinction crises", "PROBLEM", 29, 46]]], ["3 Global temperatures are set to increase substantially over the coming decades, leading to untold health, environmental, and economic consequences, 4,5 while the unfolding sixth mass extinction threatens to unravel many of the essential ecosystems on which we all depend.", [["Global temperatures", "PROBLEM", 2, 21], ["the unfolding sixth mass extinction", "PROBLEM", 159, 194], ["ecosystems", "OBSERVATION", 238, 248]]], ["Responses to the COVID-19 pandemic show that nations can act rapidly and radically in response to major immediate threats to health, even at huge economic cost.", [["the COVID", "TEST", 13, 22]]], ["These actions have generated important co-benefits in terms of reductions in urban air pollution 4 and carbon dioxide emissions, at least over the short term.", [["carbon dioxide", "CHEMICAL", 103, 117], ["carbon dioxide", "CHEMICAL", 103, 117], ["carbon dioxide", "SIMPLE_CHEMICAL", 103, 117], ["urban air pollution", "TREATMENT", 77, 96], ["carbon dioxide emissions", "TREATMENT", 103, 127]]], ["6 Maintaining resilience during this pandemic-and those yet to come-will require these and many more long-term changes in patterns of travel, development, and human interactions.", [["human", "ORGANISM", 159, 164], ["human", "SPECIES", 159, 164], ["human", "SPECIES", 159, 164]]], ["[7] [8] [9] [10] [11] [12] These three major threats to population and planetary health-communicable diseases, NCDs, and the climate and environmental emergencies-are too often treated as distinct problems, but they are intimately entwined in a global syndemic as reflected in the top global risks identified by the World Economic Forum in 2020.", [["health-communicable diseases", "DISEASE", 81, 109], ["NCDs", "DISEASE", 111, 115], ["[7] [8] [9] [10] [11] [12]", "SIMPLE_CHEMICAL", 0, 26]]], ["13 They possess common underlying causes including unsustainable systems of agriculture, subsidies for harmful products, and overcrowded cities.", [["harmful products", "TREATMENT", 103, 119]]], ["The transmission of a novel coronavirus from bats to humans might be the dominant model of the genesis of the COVID-19 pandemic, but without urbanisation and global hypermobility it would have spread much more slowly and might have been contained; without high prevalence of NCDs 14 and air pollution 15 it would have exerted a much lower toll.COVID-19: Africa needs unprecedented attention to strengthen community health systemsBreaking the clinical, academic, and policy boundaries that promote separation of these threats demands new ways of understanding and tackling them in order to respond effectively to the combination of the worst pandemic for over a century with the largest economic downturn in modern history.", [["coronavirus", "DISEASE", 28, 39], ["hypermobility", "DISEASE", 165, 178], ["NCDs", "DISEASE", 275, 279], ["coronavirus", "ORGANISM", 28, 39], ["bats", "ORGANISM", 45, 49], ["humans", "ORGANISM", 53, 59], ["coronavirus", "SPECIES", 28, 39], ["humans", "SPECIES", 53, 59], ["humans", "SPECIES", 53, 59], ["a novel coronavirus", "PROBLEM", 20, 39], ["the COVID", "TEST", 106, 115], ["pandemic", "PROBLEM", 119, 127], ["global hypermobility", "PROBLEM", 158, 178], ["air pollution", "TREATMENT", 287, 300], ["global", "OBSERVATION_MODIFIER", 158, 164], ["hypermobility", "OBSERVATION", 165, 178]]], ["Foregrounding this economic context will be essential for any credible attempt to address these threats.COVID-19: Africa needs unprecedented attention to strengthen community health systemsThe dominant policy focus for tackling the key behaviours that contribute to NCDs worldwideunhealthy diets, smoking, alcohol consumption, and physical inactivity-largely ignores the roles of commercial and other non-state actors, publics, policy makers, and others in driving these behaviours.", [["NCDs", "DISEASE", 266, 270], ["smoking", "CHEMICAL", 297, 304], ["alcohol", "CHEMICAL", 306, 313], ["alcohol", "CHEMICAL", 306, 313], ["alcohol", "SIMPLE_CHEMICAL", 306, 313], ["dominant", "OBSERVATION_MODIFIER", 193, 201], ["policy", "OBSERVATION", 202, 208]]], ["16 As with COVID-19, The Lancet-Chatham House Commission on improving population health post COVID- 19", [["COVID", "TEST", 11, 16], ["COVID", "TEST", 93, 98]]]], "4b938c2f60ce863541ac9ca19fe0a98cd9a8730e": [["IntroductionDisulfide bonds have long been recognized as structural elements stabilizing proteins in harsh extracellular environments.", [["extracellular", "ANATOMY", 107, 120], ["Disulfide", "CHEMICAL", 12, 21], ["Disulfide bonds", "SIMPLE_CHEMICAL", 12, 27], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 107, 120], ["IntroductionDisulfide bonds", "TREATMENT", 0, 27], ["harsh", "OBSERVATION_MODIFIER", 101, 106], ["extracellular environments", "OBSERVATION", 107, 133]]], ["More recently, an additional concept has emerged: some disulfide bonds operate as dynamic scaffolds capable of regulated rearrangement into a variety of functional forms (Jordan and Gibbins, 2006) .", [["disulfide", "CHEMICAL", 55, 64], ["some disulfide bonds", "TREATMENT", 50, 70], ["dynamic scaffolds", "TREATMENT", 82, 99]]], ["Consistent with this notion, various cell surface processes have long been known to depend on catalyzed thiol-disulfide exchange including cell adhesion (Essex, 2004) , uptake of bacterial toxins (de Paiva et al, 1993) and viral fusion with the host membrane (Sanders, 2000) .", [["cell surface", "ANATOMY", 37, 49], ["cell", "ANATOMY", 139, 143], ["membrane", "ANATOMY", 250, 258], ["thiol", "CHEMICAL", 104, 109], ["disulfide", "CHEMICAL", 110, 119], ["cell", "CELL", 37, 41], ["thiol", "SIMPLE_CHEMICAL", 104, 109], ["cell", "CELL", 139, 143], ["membrane", "CELLULAR_COMPONENT", 250, 258], ["various cell surface processes", "PROBLEM", 29, 59], ["cell adhesion", "PROBLEM", 139, 152], ["bacterial toxins", "PROBLEM", 179, 195], ["viral fusion", "TREATMENT", 223, 235], ["various cell", "OBSERVATION", 29, 41], ["surface", "OBSERVATION_MODIFIER", 42, 49], ["cell adhesion", "OBSERVATION", 139, 152], ["viral fusion", "OBSERVATION", 223, 235]]], ["Moreover, a variety of cell surface signaling receptors appear to exist in more than one thiol-disulfide configuration, for example CD28 (Greene et al, 1996) .", [["cell surface", "ANATOMY", 23, 35], ["thiol", "CHEMICAL", 89, 94], ["disulfide", "CHEMICAL", 95, 104], ["cell", "CELL", 23, 27], ["CD28", "GENE_OR_GENE_PRODUCT", 132, 136], ["cell surface signaling receptors", "PROTEIN", 23, 55], ["CD28", "PROTEIN", 132, 136], ["cell surface signaling receptors", "TREATMENT", 23, 55]]], ["However, in most cases, neither the catalyst driving thioldisulfide exchange nor the functional differences between the redox forms have been elucidated.IntroductionA number of thiol-disulfide oxidoreductases are known to be secreted and to act on the cell surface.", [["cell surface", "ANATOMY", 252, 264], ["thioldisulfide", "CHEMICAL", 53, 67], ["thiol", "CHEMICAL", 177, 182], ["thioldisulfide", "CHEMICAL", 53, 67], ["thiol", "CHEMICAL", 177, 182], ["disulfide", "CHEMICAL", 183, 192], ["thioldisulfide", "SIMPLE_CHEMICAL", 53, 67], ["cell surface", "CELLULAR_COMPONENT", 252, 264], ["thiol-disulfide oxidoreductases", "PROTEIN", 177, 208], ["thiol-disulfide oxidoreductases", "TREATMENT", 177, 208]]], ["One of these redox catalysts is protein disulfide isomerase (PDI), a member of the thioredoxin (Trx) superfamily.", [["disulfide", "CHEMICAL", 40, 49], ["protein disulfide isomerase", "GENE_OR_GENE_PRODUCT", 32, 59], ["PDI", "GENE_OR_GENE_PRODUCT", 61, 64], ["thioredoxin", "GENE_OR_GENE_PRODUCT", 83, 94], ["Trx", "GENE_OR_GENE_PRODUCT", 96, 99], ["protein disulfide isomerase", "PROTEIN", 32, 59], ["PDI", "PROTEIN", 61, 64], ["thioredoxin (Trx) superfamily", "PROTEIN", 83, 112], ["these redox catalysts", "TREATMENT", 7, 28], ["the thioredoxin (Trx) superfamily", "TREATMENT", 79, 112], ["redox catalysts", "OBSERVATION", 13, 28]]], ["Cell surface-PDI has been found to act on transmembrane and surface-associated proteins, including the envelope protein of HIV-1, to cause its fusogenic conformation (Markovic et al, 2004) and integrins, to mediate platelet adhesion (Lahav et al, 2003) .", [["Cell surface", "ANATOMY", 0, 12], ["transmembrane", "ANATOMY", 42, 55], ["surface", "ANATOMY", 60, 67], ["platelet", "ANATOMY", 215, 223], ["Cell", "CELL", 0, 4], ["PDI", "GENE_OR_GENE_PRODUCT", 13, 16], ["transmembrane", "CELLULAR_COMPONENT", 42, 55], ["surface", "CELLULAR_COMPONENT", 60, 67], ["HIV-1", "ORGANISM", 123, 128], ["integrins", "GENE_OR_GENE_PRODUCT", 193, 202], ["platelet", "CELL", 215, 223], ["PDI", "PROTEIN", 13, 16], ["transmembrane and surface-associated proteins", "PROTEIN", 42, 87], ["envelope protein", "PROTEIN", 103, 119], ["integrins", "PROTEIN", 193, 202], ["HIV-1", "SPECIES", 123, 128], ["HIV-1", "SPECIES", 123, 128], ["Cell surface", "TEST", 0, 12], ["PDI", "PROBLEM", 13, 16], ["associated proteins", "PROBLEM", 68, 87], ["HIV", "PROBLEM", 123, 126], ["its fusogenic conformation", "PROBLEM", 139, 165], ["platelet adhesion", "PROBLEM", 215, 232], ["platelet adhesion", "OBSERVATION", 215, 232]]], ["Another thiol-disulfide oxidoreductase associated with extracellular functions is Trx1.", [["extracellular", "ANATOMY", 55, 68], ["thiol", "CHEMICAL", 8, 13], ["thiol", "CHEMICAL", 8, 13], ["disulfide", "CHEMICAL", 14, 23], ["thiol-disulfide oxidoreductase", "GENE_OR_GENE_PRODUCT", 8, 38], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 55, 68], ["Trx1", "GENE_OR_GENE_PRODUCT", 82, 86], ["thiol-disulfide oxidoreductase", "PROTEIN", 8, 38], ["Trx1", "PROTEIN", 82, 86], ["Another thiol-disulfide oxidoreductase", "TREATMENT", 0, 38], ["extracellular functions", "OBSERVATION", 55, 78]]], ["Best known for its intracellular roles, Trx1 reduces transiently formed disulfide bonds of cytosolic and nuclear target proteins and thereby participates in a multitude of fundamental processes, ranging from oxidant scavenging and DNA synthesis to regulation of apoptosis and cell proliferation (Powis and Montfort, 2001) .", [["intracellular", "ANATOMY", 19, 32], ["cytosolic", "ANATOMY", 91, 100], ["nuclear", "ANATOMY", 105, 112], ["cell", "ANATOMY", 276, 280], ["disulfide", "CHEMICAL", 72, 81], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 19, 32], ["Trx1", "GENE_OR_GENE_PRODUCT", 40, 44], ["cytosolic", "CELLULAR_COMPONENT", 91, 100], ["nuclear", "CELLULAR_COMPONENT", 105, 112], ["oxidant", "SIMPLE_CHEMICAL", 208, 215], ["DNA", "CELLULAR_COMPONENT", 231, 234], ["cell", "CELL", 276, 280], ["Trx1", "PROTEIN", 40, 44], ["cytosolic and nuclear target proteins", "PROTEIN", 91, 128], ["cytosolic and nuclear target proteins", "PROBLEM", 91, 128], ["fundamental processes", "PROBLEM", 172, 193], ["oxidant scavenging", "TREATMENT", 208, 226], ["DNA synthesis", "PROBLEM", 231, 244], ["apoptosis", "PROBLEM", 262, 271], ["cell proliferation", "PROBLEM", 276, 294], ["disulfide bonds", "OBSERVATION", 72, 87], ["apoptosis", "OBSERVATION_MODIFIER", 262, 271], ["cell proliferation", "OBSERVATION", 276, 294]]], ["In addition, Trx1 is released to the extracellular environment by a variety of normal and neoplastic cells (Rubartelli et al, 1992) .", [["extracellular", "ANATOMY", 37, 50], ["neoplastic cells", "ANATOMY", 90, 106], ["Trx1", "GENE_OR_GENE_PRODUCT", 13, 17], ["extracellular environment", "CELLULAR_COMPONENT", 37, 62], ["neoplastic cells", "CELL", 90, 106], ["Trx1", "PROTEIN", 13, 17], ["normal and neoplastic cells", "CELL_TYPE", 79, 106], ["Trx1", "OBSERVATION", 13, 17], ["neoplastic cells", "OBSERVATION", 90, 106]]], ["Human Trx1 was first purified as a cytokine-like factor from supernatants of virally transformed lymphocytes and initially named adult T-cell leukemia-derived factor (Tagaya et al, 1988) , Tac-inducing factor (Tagaya et al, 1989) , B-cell stimulatory factor or 'B cell IL-1' (Wakasugi et al, 1990) .", [["supernatants", "ANATOMY", 61, 73], ["lymphocytes", "ANATOMY", 97, 108], ["B cell", "ANATOMY", 262, 268], ["Human", "ORGANISM", 0, 5], ["Trx1", "GENE_OR_GENE_PRODUCT", 6, 10], ["lymphocytes", "CELL", 97, 108], ["T-cell leukemia", "CANCER", 135, 150], ["Tac-inducing factor", "GENE_OR_GENE_PRODUCT", 189, 208], ["B-cell stimulatory factor", "GENE_OR_GENE_PRODUCT", 232, 257], ["B cell IL-1", "GENE_OR_GENE_PRODUCT", 262, 273], ["Human Trx1", "PROTEIN", 0, 10], ["cytokine-like factor", "PROTEIN", 35, 55], ["virally transformed lymphocytes", "CELL_LINE", 77, 108], ["Tac-inducing factor", "PROTEIN", 189, 208], ["B-cell stimulatory factor", "PROTEIN", 232, 257], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human Trx1", "TREATMENT", 0, 10], ["a cytokine-like factor", "PROBLEM", 33, 55], ["virally transformed lymphocytes", "PROBLEM", 77, 108], ["B-cell stimulatory factor", "TREATMENT", 232, 257], ["'B cell IL", "TREATMENT", 261, 271], ["transformed lymphocytes", "OBSERVATION", 85, 108], ["cell leukemia", "OBSERVATION", 137, 150]]], ["Extracellular Trx1 is present in the circulation of healthy subjects and its levels increase under inflammatory conditions, including viral infection (Nakamura et al, 2001a) .", [["Extracellular", "ANATOMY", 0, 13], ["viral infection", "DISEASE", 134, 149], ["Trx1", "GENE_OR_GENE_PRODUCT", 14, 18], ["Trx1", "PROTEIN", 14, 18], ["Extracellular Trx1", "TEST", 0, 18], ["inflammatory conditions", "PROBLEM", 99, 122], ["viral infection", "PROBLEM", 134, 149], ["Trx1", "OBSERVATION", 14, 18], ["circulation", "ANATOMY_MODIFIER", 37, 48], ["increase", "OBSERVATION_MODIFIER", 84, 92], ["inflammatory", "OBSERVATION_MODIFIER", 99, 111], ["viral", "OBSERVATION_MODIFIER", 134, 139], ["infection", "OBSERVATION", 140, 149]]], ["Circulatory Trx1 acts as a chemoattractant for monocytes, neutrophils and lymphocytes (Bertini et al, 1999) , and inhibits neutrophil migration into inflammatory sites both in vitro and in vivo (Nakamura et al, 2001b) .", [["monocytes", "ANATOMY", 47, 56], ["neutrophils", "ANATOMY", 58, 69], ["lymphocytes", "ANATOMY", 74, 85], ["neutrophil", "ANATOMY", 123, 133], ["inflammatory sites", "ANATOMY", 149, 167], ["Trx1", "GENE_OR_GENE_PRODUCT", 12, 16], ["monocytes", "CELL", 47, 56], ["neutrophils", "CELL", 58, 69], ["lymphocytes", "CELL", 74, 85], ["neutrophil", "CELL", 123, 133], ["Trx1", "PROTEIN", 12, 16], ["monocytes", "CELL_TYPE", 47, 56], ["neutrophils", "CELL_TYPE", 58, 69], ["lymphocytes", "CELL_TYPE", 74, 85], ["neutrophil", "CELL_TYPE", 123, 133], ["monocytes", "TEST", 47, 56], ["neutrophils", "TEST", 58, 69], ["lymphocytes", "TEST", 74, 85], ["Bertini et al", "TEST", 87, 100], ["neutrophil migration into inflammatory sites", "PROBLEM", 123, 167], ["lymphocytes", "ANATOMY", 74, 85], ["neutrophil migration", "OBSERVATION", 123, 143], ["inflammatory sites", "OBSERVATION", 149, 167]]], ["More recently, Trx1 was found to be secreted by dendritic cells upon cognate T-cell recognition and to contribute to subsequent T-cell activation (Angelini et al, 2002) .IntroductionAt present, the mechanism(s) and pathway(s) by which extracellular Trx1 influences cellular behavior remain unknown.", [["dendritic cells", "ANATOMY", 48, 63], ["T-cell", "ANATOMY", 77, 83], ["T-cell", "ANATOMY", 128, 134], ["extracellular", "ANATOMY", 235, 248], ["cellular", "ANATOMY", 265, 273], ["Trx1", "GENE_OR_GENE_PRODUCT", 15, 19], ["dendritic cells", "CELL", 48, 63], ["T-cell", "CELL", 77, 83], ["T-cell", "CELL", 128, 134], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 235, 248], ["Trx1", "GENE_OR_GENE_PRODUCT", 249, 253], ["cellular", "CELL", 265, 273], ["Trx1", "PROTEIN", 15, 19], ["dendritic cells", "CELL_TYPE", 48, 63], ["extracellular Trx1", "PROTEIN", 235, 253], ["subsequent T-cell activation", "PROBLEM", 117, 145], ["IntroductionAt", "TREATMENT", 170, 184], ["dendritic cells", "OBSERVATION", 48, 63]]], ["As many of its reported extracellular activities depend on a functional active site, it appears likely that Trx1 catalyzes thiol-disulfide exchange in one or more cell surface target proteins through its enzymatic activity.", [["extracellular", "ANATOMY", 24, 37], ["cell surface", "ANATOMY", 163, 175], ["thiol-disulfide", "CHEMICAL", 123, 138], ["thiol", "CHEMICAL", 123, 128], ["disulfide", "CHEMICAL", 129, 138], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 24, 37], ["Trx1", "GENE_OR_GENE_PRODUCT", 108, 112], ["thiol-disulfide", "SIMPLE_CHEMICAL", 123, 138], ["cell surface", "CELLULAR_COMPONENT", 163, 175], ["Trx1", "PROTEIN", 108, 112], ["cell surface target proteins", "PROTEIN", 163, 191], ["Trx1 catalyzes thiol-disulfide exchange", "TREATMENT", 108, 147], ["appears likely", "UNCERTAINTY", 88, 102], ["enzymatic activity", "OBSERVATION", 204, 222]]], ["However, thiol-disulfide exchange reactions, even if highly specific, are too transient to be detected by conventional techniques.", [["thiol-disulfide", "CHEMICAL", 9, 24], ["thiol", "CHEMICAL", 9, 14], ["disulfide", "CHEMICAL", 15, 24], ["thiol-disulfide", "SIMPLE_CHEMICAL", 9, 24], ["thiol-disulfide exchange reactions", "PROBLEM", 9, 43], ["disulfide exchange", "OBSERVATION", 15, 33]]], ["To date, only a single cell surface receptor, CD4, a member of the immunoglobulin superfamily, has been shown to be susceptible to Trx1 redox activity (Matthias et al, 2002) .", [["cell surface", "ANATOMY", 23, 35], ["cell", "CELL", 23, 27], ["CD4", "GENE_OR_GENE_PRODUCT", 46, 49], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 67, 81], ["Trx1", "GENE_OR_GENE_PRODUCT", 131, 135], ["cell surface receptor", "PROTEIN", 23, 44], ["CD4", "PROTEIN", 46, 49], ["immunoglobulin superfamily", "PROTEIN", 67, 93], ["Trx1", "PROTEIN", 131, 135], ["the immunoglobulin superfamily", "TEST", 63, 93]]], ["Other cell surface proteins targeted by the enzymatic activity of Trx1 await identification.IntroductionIn this study, we address the question as to which cell surface receptors expressed on lymphocytes specifically interact with extracellular Trx1 by way of disulfide bond exchange.", [["cell surface", "ANATOMY", 6, 18], ["cell surface", "ANATOMY", 155, 167], ["lymphocytes", "ANATOMY", 191, 202], ["extracellular", "ANATOMY", 230, 243], ["disulfide", "CHEMICAL", 259, 268], ["cell", "CELL", 6, 10], ["Trx1", "GENE_OR_GENE_PRODUCT", 66, 70], ["cell", "CELL", 155, 159], ["lymphocytes", "CELL", 191, 202], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 230, 243], ["Trx1", "GENE_OR_GENE_PRODUCT", 244, 248], ["cell surface proteins", "PROTEIN", 6, 27], ["Trx1", "PROTEIN", 66, 70], ["cell surface receptors", "PROTEIN", 155, 177], ["lymphocytes", "CELL_TYPE", 191, 202], ["extracellular Trx1", "PROTEIN", 230, 248], ["Other cell surface proteins", "TEST", 0, 27], ["this study", "TEST", 107, 117], ["cell surface receptors", "TREATMENT", 155, 177], ["extracellular Trx1", "TREATMENT", 230, 248], ["disulfide bond exchange", "TREATMENT", 259, 282], ["surface", "OBSERVATION_MODIFIER", 11, 18]]], ["Using a kinetic trapping technique that enables the detection and isolation of otherwise short-lived reaction intermediates on the surface of intact cells, we identify and validate the tumor necrosis factor receptor superfamily member CD30 (TNFRSF8) as the principal target molecule for Trx1 on infected and transformed lymphocytes.", [["surface", "ANATOMY", 131, 138], ["cells", "ANATOMY", 149, 154], ["lymphocytes", "ANATOMY", 320, 331], ["tumor", "DISEASE", 185, 190], ["necrosis", "DISEASE", 191, 199], ["surface", "CELLULAR_COMPONENT", 131, 138], ["cells", "CELL", 149, 154], ["tumor necrosis factor receptor", "GENE_OR_GENE_PRODUCT", 185, 215], ["CD30", "GENE_OR_GENE_PRODUCT", 235, 239], ["TNFRSF8", "GENE_OR_GENE_PRODUCT", 241, 248], ["Trx1", "GENE_OR_GENE_PRODUCT", 287, 291], ["lymphocytes", "CELL", 320, 331], ["intact cells", "CELL_TYPE", 142, 154], ["tumor necrosis factor receptor superfamily member", "PROTEIN", 185, 234], ["CD30", "PROTEIN", 235, 239], ["TNFRSF8", "PROTEIN", 241, 248], ["Trx1", "PROTEIN", 287, 291], ["infected and transformed lymphocytes", "CELL_TYPE", 295, 331], ["a kinetic trapping technique", "TREATMENT", 6, 34], ["the detection", "TEST", 48, 61], ["otherwise short-lived reaction", "PROBLEM", 79, 109], ["the tumor necrosis", "PROBLEM", 181, 199], ["Trx1 on infected and transformed lymphocytes", "PROBLEM", 287, 331], ["otherwise", "OBSERVATION_MODIFIER", 79, 88], ["short", "OBSERVATION_MODIFIER", 89, 94], ["intact cells", "OBSERVATION", 142, 154], ["tumor", "OBSERVATION", 185, 190], ["transformed lymphocytes", "OBSERVATION", 308, 331]]], ["The cell surface activity of Trx1 is highly selective, discriminating between different members of the TNFR superfamily.", [["cell surface", "ANATOMY", 4, 16], ["cell", "CELL", 4, 8], ["Trx1", "GENE_OR_GENE_PRODUCT", 29, 33], ["TNFR", "GENE_OR_GENE_PRODUCT", 103, 107], ["Trx1", "PROTEIN", 29, 33], ["TNFR superfamily", "PROTEIN", 103, 119], ["cell", "OBSERVATION", 4, 8], ["surface", "OBSERVATION_MODIFIER", 9, 16], ["activity", "OBSERVATION_MODIFIER", 17, 25], ["selective", "OBSERVATION_MODIFIER", 44, 53]]], ["Trx1-mediated thiol-disulfide exchange leads to a structural change in the CD30 ectodomain that can be detected with conformationsensitive antibodies.", [["thiol-disulfide", "CHEMICAL", 14, 29], ["thiol", "CHEMICAL", 14, 19], ["disulfide", "CHEMICAL", 20, 29], ["Trx1", "GENE_OR_GENE_PRODUCT", 0, 4], ["thiol-disulfide", "SIMPLE_CHEMICAL", 14, 29], ["CD30", "GENE_OR_GENE_PRODUCT", 75, 79], ["Trx1", "PROTEIN", 0, 4], ["CD30 ectodomain", "PROTEIN", 75, 90], ["conformationsensitive antibodies", "PROTEIN", 117, 149], ["Trx1", "TEST", 0, 4], ["thiol-disulfide exchange", "TREATMENT", 14, 38], ["a structural change in the CD30 ectodomain", "PROBLEM", 48, 90], ["conformationsensitive antibodies", "PROBLEM", 117, 149], ["CD30", "ANATOMY", 75, 79]]], ["We demonstrate that disulfide exchange between Trx1 and CD30 interferes with binding of the CD30 ligand (CD30L) to its cognate receptor and that Trx1 affects CD30-dependent changes in lymphocyte effector function.", [["lymphocyte", "ANATOMY", 184, 194], ["disulfide", "CHEMICAL", 20, 29], ["Trx1", "GENE_OR_GENE_PRODUCT", 47, 51], ["CD30", "GENE_OR_GENE_PRODUCT", 56, 60], ["CD30 ligand", "GENE_OR_GENE_PRODUCT", 92, 103], ["CD30L", "GENE_OR_GENE_PRODUCT", 105, 110], ["Trx1", "GENE_OR_GENE_PRODUCT", 145, 149], ["CD30", "GENE_OR_GENE_PRODUCT", 158, 162], ["lymphocyte", "CELL", 184, 194], ["Trx1", "PROTEIN", 47, 51], ["CD30", "PROTEIN", 56, 60], ["CD30 ligand", "PROTEIN", 92, 103], ["CD30L", "PROTEIN", 105, 110], ["Trx1", "PROTEIN", 145, 149], ["CD30", "PROTEIN", 158, 162], ["disulfide exchange between Trx1", "TREATMENT", 20, 51], ["dependent changes in lymphocyte effector function", "PROBLEM", 163, 212], ["dependent", "OBSERVATION_MODIFIER", 163, 172], ["lymphocyte effector function", "OBSERVATION", 184, 212]]], ["As CD30 is implicated in both stimulatory and apoptotic signaling, our findings suggest that Trx1 interacts with CD30 to modulate lymphocyte behavior and survival under conditions of infection and inflammation.ResultsTo identify candidate Trx1 target proteins on the cell surface of lymphoid cells, we applied a trapping technique based on the reaction mechanism.", [["lymphocyte", "ANATOMY", 130, 140], ["cell surface", "ANATOMY", 267, 279], ["lymphoid cells", "ANATOMY", 283, 297], ["infection", "DISEASE", 183, 192], ["inflammation", "DISEASE", 197, 209], ["CD30", "GENE_OR_GENE_PRODUCT", 3, 7], ["Trx1", "GENE_OR_GENE_PRODUCT", 93, 97], ["CD30", "GENE_OR_GENE_PRODUCT", 113, 117], ["lymphocyte", "CELL", 130, 140], ["Trx1", "GENE_OR_GENE_PRODUCT", 239, 243], ["cell surface", "CELLULAR_COMPONENT", 267, 279], ["lymphoid cells", "CELL", 283, 297], ["CD30", "PROTEIN", 3, 7], ["Trx1", "PROTEIN", 93, 97], ["CD30", "PROTEIN", 113, 117], ["Trx1 target proteins", "PROTEIN", 239, 259], ["lymphoid cells", "CELL_TYPE", 283, 297], ["Trx1 interacts", "PROBLEM", 93, 107], ["CD30 to modulate lymphocyte behavior", "PROBLEM", 113, 149], ["infection", "PROBLEM", 183, 192], ["inflammation", "PROBLEM", 197, 209], ["lymphoid cells", "TREATMENT", 283, 297], ["a trapping technique", "TREATMENT", 310, 330], ["the reaction mechanism", "TREATMENT", 340, 362], ["apoptotic signaling", "OBSERVATION", 46, 65], ["infection", "OBSERVATION", 183, 192], ["inflammation", "OBSERVATION", 197, 209], ["lymphoid cells", "OBSERVATION", 283, 297]]], ["This approach makes use of the finding that mutant thiol-dependent oxidoreductases lacking the C-terminal cysteine of the CXXC active site motif form long-lived mixed disulfide intermediates with target proteins.", [["thiol", "CHEMICAL", 51, 56], ["thiol", "CHEMICAL", 51, 56], ["C", "CHEMICAL", 95, 96], ["cysteine", "CHEMICAL", 106, 114], ["disulfide", "CHEMICAL", 167, 176], ["cysteine", "AMINO_ACID", 106, 114], ["mutant thiol-dependent oxidoreductases", "PROTEIN", 44, 82], ["C-terminal cysteine", "PROTEIN", 95, 114], ["CXXC active site motif", "PROTEIN", 122, 144], ["target proteins", "PROTEIN", 196, 211], ["mutant thiol-dependent oxidoreductases", "PROBLEM", 44, 82], ["target proteins", "PROBLEM", 196, 211]]], ["Thus, target proteins remain covalently linked to the mutant oxidoreductase and become amenable to isolation and analysis (principle shown in Figure 1A ).", [["target proteins", "PROTEIN", 6, 21], ["mutant oxidoreductase", "PROTEIN", 54, 75], ["target proteins", "PROBLEM", 6, 21], ["isolation and analysis", "TEST", 99, 121]]], ["Kinetic trapping has been applied previously to identify interaction partners of Trx family members in plants (Motohashi et al, 2001) and in the secretory pathway of human lymphocytes .", [["lymphocytes", "ANATOMY", 172, 183], ["Trx", "GENE_OR_GENE_PRODUCT", 81, 84], ["human", "ORGANISM", 166, 171], ["lymphocytes", "CELL", 172, 183], ["Trx family members", "PROTEIN", 81, 99], ["human lymphocytes", "CELL_TYPE", 166, 183], ["human", "SPECIES", 166, 171], ["human", "SPECIES", 166, 171], ["Kinetic trapping", "PROBLEM", 0, 16], ["human lymphocytes", "ANATOMY", 166, 183]]], ["In these studies, the CXXC-based trapping technique identified both established and novel target proteins, subsequently confirmed by independent techniques, demonstrating the competence of this technique to identify bona fide interaction partners.Mechanism-based kinetic trapping can be applied to human Trx1To determine whether kinetic trapping can be applied to human Trx1, we created recombinant wild-type and mutant Trx proteins, each equipped with a C-terminal dual affinity tag composed of a streptavidin-binding peptide (SBP) and a hexahistidine tag.", [["C", "CHEMICAL", 455, 456], ["human", "ORGANISM", 298, 303], ["Trx1To", "GENE_OR_GENE_PRODUCT", 304, 310], ["human", "ORGANISM", 364, 369], ["Trx1", "GENE_OR_GENE_PRODUCT", 370, 374], ["Trx", "GENE_OR_GENE_PRODUCT", 420, 423], ["streptavidin-binding peptide", "SIMPLE_CHEMICAL", 498, 526], ["CXXC", "PROTEIN", 22, 26], ["target proteins", "PROTEIN", 90, 105], ["human Trx1To", "PROTEIN", 298, 310], ["human Trx1", "PROTEIN", 364, 374], ["recombinant wild-type and mutant", "PROTEIN", 387, 419], ["Trx proteins", "PROTEIN", 420, 432], ["C-terminal dual affinity tag", "PROTEIN", 455, 483], ["streptavidin", "PROTEIN", 498, 510], ["SBP", "PROTEIN", 528, 531], ["hexahistidine tag", "PROTEIN", 539, 556], ["human", "SPECIES", 298, 303], ["human", "SPECIES", 364, 369], ["human", "SPECIES", 298, 303], ["human", "SPECIES", 364, 369], ["these studies", "TEST", 3, 16], ["the CXXC", "TEST", 18, 26], ["this technique", "TREATMENT", 189, 203], ["based kinetic trapping", "PROBLEM", 257, 279], ["human Trx1To", "TREATMENT", 298, 310], ["kinetic trapping", "PROBLEM", 329, 345], ["human Trx1", "TREATMENT", 364, 374], ["Trx proteins", "TEST", 420, 432], ["a C-terminal dual affinity tag", "PROBLEM", 453, 483], ["a streptavidin-binding peptide", "PROBLEM", 496, 526], ["SBP", "TEST", 528, 531], ["a hexahistidine tag", "TREATMENT", 537, 556], ["kinetic trapping", "OBSERVATION", 263, 279]]], ["To create a trapping mutant, the second cysteine of the 32 CXXC 35 motif was replaced by serine (C35S).", [["cysteine", "CHEMICAL", 40, 48], ["serine", "CHEMICAL", 89, 95], ["cysteine", "AMINO_ACID", 40, 48], ["serine", "AMINO_ACID", 89, 95], ["32 CXXC 35 motif", "PROTEIN", 56, 72], ["a trapping mutant", "PROBLEM", 10, 27]]], ["Trx1 harbors three additional cysteine residues distal to the active site (cysteines 62, 69 and 73).", [["cysteine", "CHEMICAL", 30, 38], ["cysteines", "CHEMICAL", 75, 84], ["Trx1", "GENE_OR_GENE_PRODUCT", 0, 4], ["cysteine", "AMINO_ACID", 30, 38], ["Trx1", "PROTEIN", 0, 4], ["active site", "PROTEIN", 62, 73], ["cysteines 62, 69 and 73", "PROTEIN", 75, 98], ["additional cysteine residues", "TREATMENT", 19, 47], ["cysteines", "TEST", 75, 84], ["cysteine residues", "OBSERVATION", 30, 47], ["distal", "OBSERVATION_MODIFIER", 48, 54], ["active", "OBSERVATION_MODIFIER", 62, 68]]], ["As these residues are dispensable for catalytic activity but may cause oxidative inactivation by either intra-or intermolecular disulfide bond formation (Casagrande et al, 2002; Watson et al, 2003) , we also created mutants containing amino-acid substitutions for those additional cysteines ( Figure 1B ; CCCCC, CCAAA, CSCCC, CSAAA and SSAAA annotate the identity of residues 32, 35, 62, 69 and 73).Mechanism-based kinetic trapping can be applied to human Trx1To test whether Trx1(C35S)-based trapping is capable of identifying known Trx1 target proteins, Trx1(CSAAA) was allowed to react with cytosolic proteins released from digitoninpermeabilized cells.", [["cytosolic", "ANATOMY", 594, 603], ["cells", "ANATOMY", 650, 655], ["amino-acid", "CHEMICAL", 235, 245], ["disulfide", "CHEMICAL", 128, 137], ["amino-acid", "CHEMICAL", 235, 245], ["cysteines", "CHEMICAL", 281, 290], ["amino-acid", "SIMPLE_CHEMICAL", 235, 245], ["human", "ORGANISM", 450, 455], ["Trx1To", "GENE_OR_GENE_PRODUCT", 456, 462], ["Trx1", "GENE_OR_GENE_PRODUCT", 476, 480], ["Trx1", "GENE_OR_GENE_PRODUCT", 534, 538], ["Trx1", "GENE_OR_GENE_PRODUCT", 556, 560], ["CSAAA", "GENE_OR_GENE_PRODUCT", 561, 566], ["cells", "CELL", 650, 655], ["Figure 1B", "PROTEIN", 293, 302], ["CCCCC", "PROTEIN", 305, 310], ["CCAAA", "PROTEIN", 312, 317], ["CSCCC", "PROTEIN", 319, 324], ["CSAAA", "PROTEIN", 326, 331], ["SSAAA", "PROTEIN", 336, 341], ["human Trx1To", "PROTEIN", 450, 462], ["Trx1(C35S)", "PROTEIN", 476, 486], ["Trx1 target proteins", "PROTEIN", 534, 554], ["Trx1", "PROTEIN", 556, 560], ["CSAAA", "PROTEIN", 561, 566], ["cytosolic proteins", "PROTEIN", 594, 612], ["digitoninpermeabilized cells", "CELL_LINE", 627, 655], ["human", "SPECIES", 450, 455], ["human", "SPECIES", 450, 455], ["oxidative inactivation", "PROBLEM", 71, 93], ["amino-acid substitutions", "TREATMENT", 235, 259], ["CCCCC", "TEST", 305, 310], ["CCAAA", "TEST", 312, 317], ["CSCCC", "TEST", 319, 324], ["based kinetic trapping", "PROBLEM", 409, 431], ["human Trx1To test", "TEST", 450, 467], ["Trx1", "TEST", 476, 480], ["cytosolic proteins", "TEST", 594, 612], ["kinetic trapping", "OBSERVATION", 415, 431]]], ["Incubation led to the formation of a reproducible pattern of distinct mixed disulfide conjugates as visualized by silver staining of a SDS-PAGE gel under nonreducing conditions ( Figure 1C , lane 7).", [["silver", "CHEMICAL", 114, 120], ["disulfide", "CHEMICAL", 76, 85], ["silver", "CHEMICAL", 114, 120], ["SDS", "CHEMICAL", 135, 138], ["disulfide conjugates", "SIMPLE_CHEMICAL", 76, 96], ["silver", "SIMPLE_CHEMICAL", 114, 120], ["Incubation", "TREATMENT", 0, 10], ["distinct mixed disulfide conjugates", "PROBLEM", 61, 96], ["a SDS", "TREATMENT", 133, 138], ["distinct", "OBSERVATION_MODIFIER", 61, 69], ["mixed", "OBSERVATION_MODIFIER", 70, 75], ["disulfide conjugates", "OBSERVATION", 76, 96]]], ["In accordance with the trapping mechanism, conjugation strictly depended on the availability of the N-terminal thiol (Cys-32) and the concurrent absence of the C-terminal thiol (Cys-35), as wild-type or cysteine-free Trx1 did not capture any proteins ( Figure 1C, lanes 3, 5 and 9 ).", [["thiol", "CHEMICAL", 111, 116], ["Cys-32", "CHEMICAL", 118, 124], ["thiol", "CHEMICAL", 171, 176], ["Cys-35", "CHEMICAL", 178, 184], ["cysteine", "CHEMICAL", 203, 211], ["N-", "CHEMICAL", 100, 102], ["thiol", "CHEMICAL", 111, 116], ["Cys", "CHEMICAL", 118, 121], ["C", "CHEMICAL", 160, 161], ["thiol", "CHEMICAL", 171, 176], ["Cys", "CHEMICAL", 178, 181], ["cysteine", "CHEMICAL", 203, 211], ["Cys-35", "SIMPLE_CHEMICAL", 178, 184], ["cysteine", "AMINO_ACID", 203, 211], ["Trx1", "GENE_OR_GENE_PRODUCT", 217, 221], ["Trx1", "PROTEIN", 217, 221], ["Figure 1C, lanes 3, 5 and 9", "PROTEIN", 253, 280], ["the N-terminal thiol", "TREATMENT", 96, 116], ["Cys", "TEST", 118, 121], ["Cys", "TEST", 178, 181], ["cysteine", "TEST", 203, 211]]], ["The pattern of trapped proteins was not significantly influenced by the presence or absence of the non-catalytic cysteines (data not shown).", [["cysteines", "CHEMICAL", 113, 122], ["trapped proteins", "PROTEIN", 15, 31], ["non-catalytic cysteines", "PROTEIN", 99, 122], ["trapped proteins", "PROBLEM", 15, 31], ["the non-catalytic cysteines", "PROBLEM", 95, 122], ["trapped proteins", "OBSERVATION", 15, 31]]], ["The main cytosolic interaction partner of Trx1(CSAAA) was identified as peroxiredoxin-1 (Prx1) by liquid chromatography tandem mass spectrometry (LC-MS/MS).", [["cytosolic", "ANATOMY", 9, 18], ["Trx1", "GENE_OR_GENE_PRODUCT", 42, 46], ["CSAAA", "GENE_OR_GENE_PRODUCT", 47, 52], ["peroxiredoxin-1", "GENE_OR_GENE_PRODUCT", 72, 87], ["Prx1", "GENE_OR_GENE_PRODUCT", 89, 93], ["cytosolic interaction partner", "PROTEIN", 9, 38], ["Trx1", "PROTEIN", 42, 46], ["CSAAA", "PROTEIN", 47, 52], ["peroxiredoxin-1", "PROTEIN", 72, 87], ["Prx1", "PROTEIN", 89, 93], ["peroxiredoxin", "TEST", 72, 85], ["liquid chromatography tandem mass spectrometry", "TEST", 98, 144], ["main", "OBSERVATION_MODIFIER", 4, 8], ["cytosolic interaction", "OBSERVATION", 9, 30]]], ["The Trx1-Prx1 association was further confirmed by immunoblotting (data not shown).", [["Trx1", "GENE_OR_GENE_PRODUCT", 4, 8], ["Prx1", "GENE_OR_GENE_PRODUCT", 9, 13], ["Trx1", "PROTEIN", 4, 8], ["Prx1", "PROTEIN", 9, 13], ["immunoblotting (data", "TEST", 51, 71]]], ["The Trx1-Prx1 disulfide-linked conjugate is maintained under non-reducing conditions ( Figure 1C , lane 7) and cleaved into its monomer constituents under reducing conditions ( Figure 1C , lane 8).Mechanism-based kinetic trapping can be applied to human Trx1To test whether Trx1(CSAAA) would also undergo authentic interactions under conditions more typical of an extracellular environment, we allowed Trx1(CSAAA) to react with human plasma proteins.", [["extracellular", "ANATOMY", 364, 377], ["plasma", "ANATOMY", 434, 440], ["disulfide", "CHEMICAL", 14, 23], ["Trx1", "GENE_OR_GENE_PRODUCT", 4, 8], ["Prx1", "GENE_OR_GENE_PRODUCT", 9, 13], ["human", "ORGANISM", 248, 253], ["Trx1To", "GENE_OR_GENE_PRODUCT", 254, 260], ["Trx1", "GENE_OR_GENE_PRODUCT", 274, 278], ["CSAAA", "GENE_OR_GENE_PRODUCT", 279, 284], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 364, 377], ["Trx1", "GENE_OR_GENE_PRODUCT", 402, 406], ["CSAAA", "GENE_OR_GENE_PRODUCT", 407, 412], ["human", "ORGANISM", 428, 433], ["plasma", "ORGANISM_SUBSTANCE", 434, 440], ["Trx1", "PROTEIN", 4, 8], ["Prx1 disulfide-linked conjugate", "PROTEIN", 9, 40], ["human Trx1To", "PROTEIN", 248, 260], ["Trx1", "PROTEIN", 274, 278], ["CSAAA", "PROTEIN", 279, 284], ["Trx1", "PROTEIN", 402, 406], ["CSAAA", "PROTEIN", 407, 412], ["human plasma proteins", "PROTEIN", 428, 449], ["human", "SPECIES", 248, 253], ["human", "SPECIES", 428, 433], ["human", "SPECIES", 248, 253], ["human", "SPECIES", 428, 433], ["The Trx1-Prx1 disulfide", "TREATMENT", 0, 23], ["based kinetic trapping", "PROBLEM", 207, 229], ["human Trx1To test", "TEST", 248, 265], ["human plasma proteins", "TREATMENT", 428, 449], ["kinetic trapping", "OBSERVATION", 213, 229]]], ["To avoid nonspecific absorbance to high-abundance serum proteins, we applied Trx1(CSAAA) to a o30 kDa plasma ultrafiltrate, leading to the capture of a small number of proteins, as visualized by colloidal Coomassie staining ( Figure 1D ).", [["serum", "ANATOMY", 50, 55], ["plasma", "ANATOMY", 102, 108], ["Coomassie", "CHEMICAL", 205, 214], ["serum", "ORGANISM_SUBSTANCE", 50, 55], ["Trx1", "GENE_OR_GENE_PRODUCT", 77, 81], ["CSAAA", "GENE_OR_GENE_PRODUCT", 82, 87], ["plasma", "ORGANISM_SUBSTANCE", 102, 108], ["ultrafiltrate", "ORGANISM_SUBSTANCE", 109, 122], ["Coomassie", "SIMPLE_CHEMICAL", 205, 214], ["serum proteins", "PROTEIN", 50, 64], ["Trx1", "PROTEIN", 77, 81], ["CSAAA", "PROTEIN", 82, 87], ["nonspecific absorbance", "PROBLEM", 9, 31], ["high-abundance serum proteins", "PROBLEM", 35, 64], ["Trx1(CSAAA)", "TREATMENT", 77, 88], ["a o30 kDa plasma ultrafiltrate", "TREATMENT", 92, 122], ["a small number of proteins", "PROBLEM", 150, 176], ["nonspecific", "OBSERVATION_MODIFIER", 9, 20], ["small", "OBSERVATION_MODIFIER", 152, 157]]], ["Using LC-MS/MS, the principal interaction partner from the plasma ultrafiltrate was identified as peroxiredoxin-2 (Prx2), a well-established target protein of Trx1, recently found to be present in human plasma (Chen et al, 2004) .", [["plasma", "ANATOMY", 59, 65], ["plasma", "ANATOMY", 203, 209], ["plasma", "ORGANISM_SUBSTANCE", 59, 65], ["ultrafiltrate", "ORGANISM_SUBSTANCE", 66, 79], ["peroxiredoxin-2", "GENE_OR_GENE_PRODUCT", 98, 113], ["Prx2", "GENE_OR_GENE_PRODUCT", 115, 119], ["Trx1", "GENE_OR_GENE_PRODUCT", 159, 163], ["human", "ORGANISM", 197, 202], ["plasma", "ORGANISM_SUBSTANCE", 203, 209], ["peroxiredoxin-2", "PROTEIN", 98, 113], ["Prx2", "PROTEIN", 115, 119], ["Trx1", "PROTEIN", 159, 163], ["human", "SPECIES", 197, 202], ["human", "SPECIES", 197, 202], ["MS", "PROBLEM", 12, 14], ["the plasma ultrafiltrate", "TREATMENT", 55, 79], ["peroxiredoxin", "TREATMENT", 98, 111]]], ["These experiments provided proof-of-principle evidence that kinetic trapping is capable of capturing and identifying proven target proteins of human Trx1 from both intra-and extracellular environments.Trx1 kinetic trapping is mediated by specific protein-protein interactionsTo further investigate whether the capture of proteins by Trx1(CSAAA) is Trx-specific, we directly compared Trx1(CSAAA) with the corresponding trapping mutant of another member of the Trx superfamily, glutaredoxin-1 Grx1(CSAAA) (CSAAA annotates the identity of residues 22, 25, 7, 78 and 82).", [["extracellular", "ANATOMY", 174, 187], ["human", "ORGANISM", 143, 148], ["Trx1", "GENE_OR_GENE_PRODUCT", 149, 153], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 174, 187], ["Trx1", "GENE_OR_GENE_PRODUCT", 201, 205], ["Trx1", "GENE_OR_GENE_PRODUCT", 333, 337], ["CSAAA", "GENE_OR_GENE_PRODUCT", 338, 343], ["Trx", "GENE_OR_GENE_PRODUCT", 348, 351], ["Trx1", "GENE_OR_GENE_PRODUCT", 383, 387], ["CSAAA", "GENE_OR_GENE_PRODUCT", 388, 393], ["Trx", "GENE_OR_GENE_PRODUCT", 459, 462], ["glutaredoxin-1 Grx1", "GENE_OR_GENE_PRODUCT", 476, 495], ["CSAAA", "GENE_OR_GENE_PRODUCT", 496, 501], ["target proteins", "PROTEIN", 124, 139], ["human Trx1", "PROTEIN", 143, 153], ["Trx1", "PROTEIN", 201, 205], ["Trx1", "PROTEIN", 333, 337], ["CSAAA", "PROTEIN", 338, 343], ["Trx", "PROTEIN", 348, 351], ["Trx1", "PROTEIN", 383, 387], ["CSAAA", "PROTEIN", 388, 393], ["Trx superfamily", "PROTEIN", 459, 474], ["glutaredoxin-1 Grx1", "PROTEIN", 476, 495], ["CSAAA", "PROTEIN", 496, 501], ["CSAAA", "PROTEIN", 504, 509], ["residues 22, 25, 7, 78 and 82", "PROTEIN", 536, 565], ["human", "SPECIES", 143, 148], ["human", "SPECIES", 143, 148], ["kinetic trapping", "PROBLEM", 60, 76], ["human Trx1", "TREATMENT", 143, 153], ["Trx1 kinetic trapping", "PROBLEM", 201, 222], ["glutaredoxin", "TREATMENT", 476, 488], ["kinetic trapping", "OBSERVATION", 60, 76], ["kinetic trapping", "OBSERVATION", 206, 222]]], ["Grx1, like Trx1, uses its active site thiol to act as a disulfide reductase in the cytosolic environment.", [["cytosolic", "ANATOMY", 83, 92], ["thiol", "CHEMICAL", 38, 43], ["disulfide", "CHEMICAL", 56, 65], ["Grx1", "GENE_OR_GENE_PRODUCT", 0, 4], ["Trx1", "GENE_OR_GENE_PRODUCT", 11, 15], ["Grx1", "PROTEIN", 0, 4], ["Trx1", "PROTEIN", 11, 15], ["disulfide reductase", "PROTEIN", 56, 75], ["a disulfide reductase", "TREATMENT", 54, 75], ["Trx1", "OBSERVATION", 11, 15], ["cytosolic environment", "OBSERVATION", 83, 104]]], ["However, in contrast to Trx1, Grx1 is specialized in the recognition and reduction of protein-glutathione mixed disulfide bonds and forms mixed disulfide intermediates with glutathione rather than with proteins (Yang et al, 1998; Peltoniemi et al, 2006) .", [["glutathione", "CHEMICAL", 94, 105], ["glutathione", "CHEMICAL", 173, 184], ["glutathione", "CHEMICAL", 94, 105], ["disulfide", "CHEMICAL", 112, 121], ["disulfide", "CHEMICAL", 144, 153], ["glutathione", "CHEMICAL", 173, 184], ["Trx1", "GENE_OR_GENE_PRODUCT", 24, 28], ["Grx1", "GENE_OR_GENE_PRODUCT", 30, 34], ["glutathione", "SIMPLE_CHEMICAL", 94, 105], ["glutathione", "SIMPLE_CHEMICAL", 173, 184], ["Trx1", "PROTEIN", 24, 28], ["Grx1", "PROTEIN", 30, 34], ["protein-glutathione mixed disulfide bonds", "TREATMENT", 86, 127], ["mixed disulfide intermediates", "PROBLEM", 138, 167], ["disulfide bonds", "OBSERVATION", 112, 127]]], ["As expected, we did not detect trapping of peroxiredoxins (or other Trx1-interacting proteins) by Grx1(CSAAA), neither on silver gels ( Figure 1E , lanes 3 and 4) nor by immunoblotting (data not shown).", [["silver", "CHEMICAL", 122, 128], ["peroxiredoxins", "GENE_OR_GENE_PRODUCT", 43, 57], ["Trx1-interacting proteins", "GENE_OR_GENE_PRODUCT", 68, 93], ["Grx1", "GENE_OR_GENE_PRODUCT", 98, 102], ["CSAAA", "GENE_OR_GENE_PRODUCT", 103, 108], ["peroxiredoxins", "PROTEIN", 43, 57], ["Trx1", "PROTEIN", 68, 72], ["interacting proteins", "PROTEIN", 73, 93], ["Grx1", "PROTEIN", 98, 102], ["CSAAA", "PROTEIN", 103, 108], ["peroxiredoxins", "PROBLEM", 43, 57], ["immunoblotting (data", "TEST", 170, 190]]], ["The activity and thiol reactivity of the Grx1 trapping mutant was confirmed in independent experiments (data not shown), thus demonstrating that the mere availability of an active site thiol does not explain the profile of proteins captured by the Trx1 trapping mutant.", [["thiol", "CHEMICAL", 17, 22], ["thiol", "CHEMICAL", 185, 190], ["thiol", "CHEMICAL", 17, 22], ["thiol", "CHEMICAL", 185, 190], ["thiol", "SIMPLE_CHEMICAL", 17, 22], ["Grx1", "GENE_OR_GENE_PRODUCT", 41, 45], ["Trx1", "GENE_OR_GENE_PRODUCT", 248, 252], ["Grx1", "PROTEIN", 41, 45], ["Trx1 trapping mutant", "PROTEIN", 248, 268], ["an active site thiol", "PROBLEM", 170, 190], ["Trx1 trapping", "OBSERVATION", 248, 261]]], ["Instead, our results support the notion that Trx-mediated reducing activity is steered toward distinct target disulfide bonds by specific protein-protein interactions.Kinetic trapping can be applied to detect Trx1 interactions on the cell surfaceHaving established the Trx1 kinetic trapping approach for soluble target proteins, we asked whether the kinetic trapping technique can also be applied to the surface of intact cells in culture.", [["cell surface", "ANATOMY", 234, 246], ["surface", "ANATOMY", 404, 411], ["cells", "ANATOMY", 422, 427], ["disulfide", "CHEMICAL", 110, 119], ["Trx", "GENE_OR_GENE_PRODUCT", 45, 48], ["Trx1", "GENE_OR_GENE_PRODUCT", 209, 213], ["cell surface", "CELLULAR_COMPONENT", 234, 246], ["Trx1", "GENE_OR_GENE_PRODUCT", 269, 273], ["surface", "CELLULAR_COMPONENT", 404, 411], ["cells", "CELL", 422, 427], ["Trx", "PROTEIN", 45, 48], ["Trx1", "PROTEIN", 209, 213], ["Trx1", "PROTEIN", 269, 273], ["soluble target proteins", "PROTEIN", 304, 327], ["intact cells", "CELL_TYPE", 415, 427], ["Kinetic trapping", "TREATMENT", 167, 183], ["Trx1 interactions", "PROBLEM", 209, 226], ["the Trx1 kinetic trapping approach", "TREATMENT", 265, 299], ["soluble target proteins", "TREATMENT", 304, 327], ["the kinetic trapping technique", "TREATMENT", 346, 376], ["culture", "TEST", 431, 438], ["intact cells", "OBSERVATION", 415, 427]]], ["Given previous indications of disulfide bond exchange between CD4 and wild-type Trx1 (Matthias et al, 2002) , we asked whether kinetic trapping would enable us to detect this interaction on the surface of the CD4 positive promyelocytic cell line U937.", [["surface", "ANATOMY", 194, 201], ["CD4 positive promyelocytic cell line U937", "ANATOMY", 209, 250], ["disulfide", "CHEMICAL", 30, 39], ["CD4", "GENE_OR_GENE_PRODUCT", 62, 65], ["Trx1", "GENE_OR_GENE_PRODUCT", 80, 84], ["surface", "CELLULAR_COMPONENT", 194, 201], ["CD4", "GENE_OR_GENE_PRODUCT", 209, 212], ["promyelocytic cell line U937", "CELL", 222, 250], ["CD4", "PROTEIN", 62, 65], ["wild-type Trx1", "PROTEIN", 70, 84], ["CD4 positive promyelocytic cell line U937", "CELL_LINE", 209, 250], ["disulfide bond exchange", "TREATMENT", 30, 53], ["CD4", "TEST", 62, 65], ["kinetic trapping", "PROBLEM", 127, 143], ["promyelocytic cell line", "OBSERVATION", 222, 245]]], ["In brief, we allowed mutant Trx1 to interact with the surface of live cells, removed unreacted oxidoreductase by washing and collected disulfide-linked Trx1 complexes from cellular lysates by and non-trapping (SSAAA) mutants of Trx1 were incubated with a o30 kDa fraction prepared from fresh human serum.", [["surface", "ANATOMY", 54, 61], ["cells", "ANATOMY", 70, 75], ["cellular lysates", "ANATOMY", 172, 188], ["serum", "ANATOMY", 298, 303], ["disulfide", "CHEMICAL", 135, 144], ["Trx1", "GENE_OR_GENE_PRODUCT", 28, 32], ["surface", "CELLULAR_COMPONENT", 54, 61], ["cells", "CELL", 70, 75], ["Trx1", "GENE_OR_GENE_PRODUCT", 152, 156], ["cellular lysates", "ORGANISM_SUBSTANCE", 172, 188], ["SSAAA", "GENE_OR_GENE_PRODUCT", 210, 215], ["Trx1", "GENE_OR_GENE_PRODUCT", 228, 232], ["human", "ORGANISM", 292, 297], ["serum", "ORGANISM_SUBSTANCE", 298, 303], ["mutant Trx1", "PROTEIN", 21, 32], ["live cells", "CELL_TYPE", 65, 75], ["unreacted oxidoreductase", "PROTEIN", 85, 109], ["disulfide-linked Trx1 complexes", "PROTEIN", 135, 166], ["non-trapping (SSAAA) mutants", "PROTEIN", 196, 224], ["Trx1", "PROTEIN", 228, 232], ["human", "SPECIES", 292, 297], ["human", "SPECIES", 292, 297], ["mutant Trx1", "TREATMENT", 21, 32], ["Trx1 complexes", "PROBLEM", 152, 166], ["cellular lysates", "TEST", 172, 188], ["a o30 kDa fraction", "TREATMENT", 253, 271], ["fresh human serum", "TEST", 286, 303]]], ["Disulfide-linked complexes were analyzed by colloidal Coomassie staining under non-reducing and reducing conditions.", [["Disulfide", "CHEMICAL", 0, 9], ["Coomassie", "CHEMICAL", 54, 63], ["Coomassie", "SIMPLE_CHEMICAL", 54, 63], ["Disulfide-linked complexes", "PROTEIN", 0, 26], ["Disulfide-linked complexes", "TREATMENT", 0, 26], ["colloidal Coomassie staining", "TREATMENT", 44, 72], ["colloidal Coomassie", "OBSERVATION", 44, 63]]], ["The Trx1-Prx2 conjugate and the Trx1 dimer as well as monomeric Prx2 and Trx1 are indicated.", [["Trx1", "GENE_OR_GENE_PRODUCT", 4, 8], ["Prx2", "GENE_OR_GENE_PRODUCT", 9, 13], ["Trx1", "GENE_OR_GENE_PRODUCT", 32, 36], ["Prx2", "GENE_OR_GENE_PRODUCT", 64, 68], ["Trx1", "GENE_OR_GENE_PRODUCT", 73, 77], ["Trx1", "PROTEIN", 4, 8], ["Prx2 conjugate", "PROTEIN", 9, 23], ["Trx1 dimer", "PROTEIN", 32, 42], ["Prx2", "PROTEIN", 64, 68], ["Trx1", "PROTEIN", 73, 77], ["The Trx1", "TEST", 0, 8], ["the Trx1 dimer", "TREATMENT", 28, 42], ["monomeric Prx2", "TREATMENT", 54, 68], ["Trx1", "TREATMENT", 73, 77], ["Trx1 dimer", "OBSERVATION", 32, 42]]], ["(E) Kinetic trapping is mediated by specific protein-protein interactions.", [["Kinetic trapping", "PROBLEM", 4, 20], ["Kinetic trapping", "OBSERVATION", 4, 20]]], ["Cytosolic proteins from digitonin-permeabilized Jurkat cells were incubated with SAv sepharose, Grx1(CSAAA) or Trx1(CSAAA).", [["Cytosolic", "ANATOMY", 0, 9], ["Jurkat cells", "ANATOMY", 48, 60], ["digitonin", "CHEMICAL", 24, 33], ["digitonin", "CHEMICAL", 24, 33], ["digitonin", "SIMPLE_CHEMICAL", 24, 33], ["Jurkat cells", "CELL", 48, 60], ["SAv sepharose", "GENE_OR_GENE_PRODUCT", 81, 94], ["Grx1", "GENE_OR_GENE_PRODUCT", 96, 100], ["CSAAA", "GENE_OR_GENE_PRODUCT", 101, 106], ["Trx1", "GENE_OR_GENE_PRODUCT", 111, 115], ["CSAAA", "GENE_OR_GENE_PRODUCT", 116, 121], ["Cytosolic proteins", "PROTEIN", 0, 18], ["digitonin-permeabilized Jurkat cells", "CELL_LINE", 24, 60], ["SAv sepharose", "PROTEIN", 81, 94], ["Grx1", "PROTEIN", 96, 100], ["CSAAA", "PROTEIN", 101, 106], ["Trx1", "PROTEIN", 111, 115], ["CSAAA", "PROTEIN", 116, 121], ["Cytosolic proteins", "TEST", 0, 18], ["digitonin", "TEST", 24, 33], ["permeabilized Jurkat cells", "PROBLEM", 34, 60], ["SAv sepharose", "PROBLEM", 81, 94], ["Trx1(CSAAA)", "PROBLEM", 111, 122], ["Jurkat cells", "OBSERVATION", 48, 60], ["SAv sepharose", "OBSERVATION", 81, 94]]], ["Disulfide-linked complexes were analyzed by silver staining under nonreducing and reducing conditions.", [["silver", "CHEMICAL", 44, 50], ["Disulfide", "CHEMICAL", 0, 9], ["silver", "CHEMICAL", 44, 50], ["silver", "SIMPLE_CHEMICAL", 44, 50], ["Disulfide-linked complexes", "PROTEIN", 0, 26], ["Disulfide-linked complexes", "TREATMENT", 0, 26], ["silver staining under nonreducing and reducing conditions", "PROBLEM", 44, 101]]], ["Trx1 conjugates formed with Prx1 and Prx2 are indicated.", [["Trx1", "GENE_OR_GENE_PRODUCT", 0, 4], ["Prx1", "GENE_OR_GENE_PRODUCT", 28, 32], ["Prx2", "GENE_OR_GENE_PRODUCT", 37, 41], ["Trx1", "PROTEIN", 0, 4], ["Prx1", "PROTEIN", 28, 32], ["Prx2", "PROTEIN", 37, 41], ["Trx1 conjugates", "TREATMENT", 0, 15], ["Prx1 and Prx2", "TREATMENT", 28, 41]]], ["Other bands correspond to additional cytosolic proteins interacting with Trx1. streptavidin (SAv) affinity purification.", [["cytosolic", "ANATOMY", 37, 46], ["SAv", "CHEMICAL", 93, 96], ["Trx1", "GENE_OR_GENE_PRODUCT", 73, 77], ["streptavidin", "SIMPLE_CHEMICAL", 79, 91], ["SAv", "SIMPLE_CHEMICAL", 93, 96], ["cytosolic proteins", "PROTEIN", 37, 55], ["Trx1", "PROTEIN", 73, 77], ["SAv", "PROTEIN", 93, 96], ["Other bands", "PROBLEM", 0, 11], ["additional cytosolic proteins", "PROBLEM", 26, 55], ["streptavidin (SAv) affinity purification", "TREATMENT", 79, 119], ["cytosolic proteins", "OBSERVATION", 37, 55]]], ["We found that cell surface CD4 forms a mixed disulfide with exogenously added Trx1(CSAAA) (Supplementary Figure S1 , left panel), which could be dissociated by DTT treatment (Supplementary Figure S1 , right panel).", [["cell surface", "ANATOMY", 14, 26], ["DTT", "CHEMICAL", 160, 163], ["disulfide", "CHEMICAL", 45, 54], ["DTT", "CHEMICAL", 160, 163], ["cell", "CELL", 14, 18], ["CD4", "GENE_OR_GENE_PRODUCT", 27, 30], ["Trx1", "GENE_OR_GENE_PRODUCT", 78, 82], ["DTT", "SIMPLE_CHEMICAL", 160, 163], ["cell surface CD4", "PROTEIN", 14, 30], ["Trx1", "PROTEIN", 78, 82], ["CSAAA", "PROTEIN", 83, 88], ["S1", "PROTEIN", 112, 114], ["cell surface CD4", "TEST", 14, 30], ["Supplementary Figure S1 , left panel", "TEST", 91, 127], ["DTT treatment", "TREATMENT", 160, 173], ["cell surface CD4", "OBSERVATION", 14, 30], ["left panel", "ANATOMY", 117, 127], ["right", "ANATOMY_MODIFIER", 201, 206]]], ["This result confirmed that kinetic trapping can indeed be used to identify specific Trx1-reactive cell surface proteins and should therefore allow de novo identification of previously unknown cell surface target proteins.Kinetic trapping on the surface of lymphoid cell lines identifies a prominent Trx1 interaction partnerHuman Trx1 was first identified as an autocrine factor secreted by and acting on virally transformed lymphoid cell lines.", [["cell surface", "ANATOMY", 98, 110], ["cell surface", "ANATOMY", 192, 204], ["surface", "ANATOMY", 245, 252], ["lymphoid cell lines", "ANATOMY", 256, 275], ["lymphoid cell lines", "ANATOMY", 424, 443], ["Trx1", "GENE_OR_GENE_PRODUCT", 84, 88], ["cell", "CELL", 98, 102], ["cell", "CELL", 192, 196], ["surface", "CELLULAR_COMPONENT", 245, 252], ["lymphoid cell lines", "CELL", 256, 275], ["Trx1", "GENE_OR_GENE_PRODUCT", 299, 303], ["Human", "ORGANISM", 323, 328], ["Trx1", "GENE_OR_GENE_PRODUCT", 329, 333], ["lymphoid cell lines", "CELL", 424, 443], ["Trx1", "PROTEIN", 84, 88], ["reactive cell surface proteins", "PROTEIN", 89, 119], ["cell surface target proteins", "PROTEIN", 192, 220], ["lymphoid cell lines", "CELL_LINE", 256, 275], ["Trx1 interaction partner", "PROTEIN", 299, 323], ["Human Trx1", "PROTEIN", 323, 333], ["autocrine factor", "PROTEIN", 361, 377], ["virally transformed lymphoid cell lines", "CELL_LINE", 404, 443], ["Human", "SPECIES", 323, 328], ["Human", "SPECIES", 323, 328], ["kinetic trapping", "PROBLEM", 27, 43], ["reactive cell surface proteins", "PROBLEM", 89, 119], ["Kinetic trapping", "PROBLEM", 221, 237], ["lymphoid cell lines", "TREATMENT", 256, 275], ["Human Trx1", "TREATMENT", 323, 333], ["kinetic trapping", "OBSERVATION", 27, 43], ["reactive cell", "OBSERVATION", 89, 102], ["trapping", "OBSERVATION", 229, 237], ["lymphoid cell lines", "OBSERVATION", 256, 275], ["prominent", "OBSERVATION_MODIFIER", 289, 298], ["Trx1 interaction", "OBSERVATION", 299, 315], ["lymphoid cell lines", "OBSERVATION", 424, 443]]], ["We therefore applied cell surface trapping to a human EBV-transformed lymphoblastoid B-cell line (LCL-721.220) derived from the same parental cell line (LCL-721) as the 3B6 cell line, originally used in the description of the costimulatory factor '3B6-IL1', later identified as Trx1 (Wakasugi et al, 1990) .", [["cell surface", "ANATOMY", 21, 33], ["lymphoblastoid B-cell line", "ANATOMY", 70, 96], ["LCL-721.220", "ANATOMY", 98, 109], ["cell line", "ANATOMY", 142, 151], ["LCL-721", "ANATOMY", 153, 160], ["3B6 cell line", "ANATOMY", 169, 182], ["LCL-721", "CHEMICAL", 153, 160], ["cell", "CELL", 21, 25], ["human", "ORGANISM", 48, 53], ["EBV", "ORGANISM", 54, 57], ["lymphoblastoid B-cell line", "CELL", 70, 96], ["LCL-721.220", "CELL", 98, 109], ["cell line", "CELL", 142, 151], ["LCL-721", "CELL", 153, 160], ["3B6 cell line", "CELL", 169, 182], ["3B6-IL1", "GENE_OR_GENE_PRODUCT", 248, 255], ["Trx1", "GENE_OR_GENE_PRODUCT", 278, 282], ["human EBV-transformed lymphoblastoid B-cell line", "CELL_LINE", 48, 96], ["LCL-721.220", "CELL_LINE", 98, 109], ["parental cell line", "CELL_LINE", 133, 151], ["LCL-721", "CELL_LINE", 153, 160], ["3B6 cell line", "CELL_LINE", 169, 182], ["costimulatory factor", "PROTEIN", 226, 246], ["3B6", "PROTEIN", 248, 251], ["IL1", "PROTEIN", 252, 255], ["Trx1", "PROTEIN", 278, 282], ["human", "SPECIES", 48, 53], ["human", "SPECIES", 48, 53], ["cell surface trapping", "TREATMENT", 21, 42], ["a human EBV", "TEST", 46, 57], ["lymphoblastoid B-cell line", "TREATMENT", 70, 96], ["LCL", "TEST", 98, 101], ["LCL", "TEST", 153, 156], ["the 3B6 cell line", "TREATMENT", 165, 182], ["cell line", "OBSERVATION", 87, 96], ["cell line", "OBSERVATION", 142, 151], ["cell line", "OBSERVATION", 173, 182]]], ["Mixed disulfide complexes, which formed on the surface of LCL-721.220 cells were isolated and analyzed by Trx1-specific immunoblotting to visualize overall mixed disulfide conjugates.", [["surface", "ANATOMY", 47, 54], ["LCL-721.220 cells", "ANATOMY", 58, 75], ["disulfide", "CHEMICAL", 6, 15], ["disulfide", "CHEMICAL", 162, 171], ["surface", "CELLULAR_COMPONENT", 47, 54], ["LCL-721.220 cells", "CELL", 58, 75], ["Trx1", "GENE_OR_GENE_PRODUCT", 106, 110], ["disulfide conjugates", "SIMPLE_CHEMICAL", 162, 182], ["disulfide complexes", "PROTEIN", 6, 25], ["LCL-721.220 cells", "CELL_LINE", 58, 75], ["Trx1", "PROTEIN", 106, 110], ["Mixed disulfide complexes", "PROBLEM", 0, 25], ["LCL", "TEST", 58, 61], ["Trx1", "TEST", 106, 110], ["disulfide complexes", "OBSERVATION", 6, 25], ["LCL", "ANATOMY", 58, 61], ["disulfide conjugates", "OBSERVATION", 162, 182]]], ["Interestingly, we found that Trx1 predominantly engages a single protein on the lymphoblastoid surface, suggesting a highly selective interaction ( Figure 2A , lane 3).", [["lymphoblastoid surface", "ANATOMY", 80, 102], ["Trx1", "GENE_OR_GENE_PRODUCT", 29, 33], ["lymphoblastoid surface", "CELLULAR_COMPONENT", 80, 102], ["Trx1", "PROTEIN", 29, 33], ["Trx1", "PROBLEM", 29, 33], ["Trx1", "OBSERVATION", 29, 33], ["lymphoblastoid", "ANATOMY", 80, 94], ["highly", "OBSERVATION_MODIFIER", 117, 123], ["selective", "OBSERVATION_MODIFIER", 124, 133]]], ["As expected, the trapping product, a mixed disulfide conjugate of about 160 kDa, was susceptible to reduction ( Figure 2A , lane 4).", [["disulfide", "CHEMICAL", 43, 52], ["160 kDa", "OBSERVATION_MODIFIER", 72, 79]]], ["The 160 kDa conjugate did not form on the surface of the EBV-negative Burkitts lymphoma cell line BL-41 ( Figure 2B ).", [["surface", "ANATOMY", 42, 49], ["Burkitts lymphoma cell line BL-41", "ANATOMY", 70, 103], ["lymphoma", "DISEASE", 79, 87], ["surface", "CELLULAR_COMPONENT", 42, 49], ["EBV", "ORGANISM", 57, 60], ["Burkitts lymphoma cell line BL-41", "CELL", 70, 103], ["Figure 2B", "CELL", 106, 115], ["160 kDa conjugate", "PROTEIN", 4, 21], ["EBV-negative Burkitts lymphoma cell line BL-41", "CELL_LINE", 57, 103], ["The 160 kDa conjugate", "TEST", 0, 21], ["the EBV", "TEST", 53, 60], ["Burkitts lymphoma", "PROBLEM", 70, 87], ["BL", "TEST", 98, 100], ["EBV", "ANATOMY", 57, 60], ["Burkitts lymphoma cell line", "OBSERVATION", 70, 97]]], ["In contrast, a conjugate of the same size was found to be formed on the surface of CCRF-CEM T cells ( Figure 2C ) and YT large granular lymphoma cells (data not shown).", [["surface", "ANATOMY", 72, 79], ["CCRF-CEM T cells", "ANATOMY", 83, 99], ["YT large granular lymphoma cells", "ANATOMY", 118, 150], ["granular lymphoma", "DISEASE", 127, 144], ["surface", "CELLULAR_COMPONENT", 72, 79], ["CCRF-CEM T cells", "CELL", 83, 99], ["Figure 2C", "CELL", 102, 111], ["YT large granular lymphoma cells", "CELL", 118, 150], ["CCRF-CEM T cells", "CELL_LINE", 83, 99], ["YT large granular lymphoma cells", "CELL_LINE", 118, 150], ["CCRF", "TEST", 83, 87], ["CEM T cells", "TEST", 88, 99], ["Figure 2C", "TEST", 102, 111], ["YT large granular lymphoma cells", "PROBLEM", 118, 150], ["size", "OBSERVATION_MODIFIER", 37, 41], ["large", "OBSERVATION_MODIFIER", 121, 126], ["granular lymphoma cells", "OBSERVATION", 127, 150]]], ["Pretreatment of the cell surface with the alkylating agent iodoacetamide (IAA) did not interfere with the formation of the 160 kDa mixed disulfide conjugate, thus confirming that the conjugate was formed by the expected disulfide exchange mechanism (rather than by de novo disulfide bond formation between two thiol groups).CD30/TNFRSF8 is the principal Trx1 sensitive receptor on various lymphoid cell linesTo identify the unknown Trx1 target protein, we performed cell surface trapping on a larger scale (5 \u00c210 9 LCL-721.220 cells), purified the Trx1-interacting surface protein by SAv affinity purification and visualized the protein by colloidal Coomassie staining ( Figure 3A , left panel).", [["cell surface", "ANATOMY", 20, 32], ["lymphoid cell lines", "ANATOMY", 389, 408], ["cell surface", "ANATOMY", 466, 478], ["LCL-721.220 cells", "ANATOMY", 515, 532], ["surface", "ANATOMY", 565, 572], ["alkylating agent iodoacetamide", "CHEMICAL", 42, 72], ["IAA", "CHEMICAL", 74, 77], ["thiol", "CHEMICAL", 310, 315], ["iodoacetamide", "CHEMICAL", 59, 72], ["IAA", "CHEMICAL", 74, 77], ["disulfide", "CHEMICAL", 137, 146], ["disulfide", "CHEMICAL", 220, 229], ["disulfide", "CHEMICAL", 273, 282], ["thiol", "CHEMICAL", 310, 315], ["Coomassie", "CHEMICAL", 650, 659], ["cell surface", "CELLULAR_COMPONENT", 20, 32], ["iodoacetamide", "SIMPLE_CHEMICAL", 59, 72], ["IAA", "SIMPLE_CHEMICAL", 74, 77], ["CD30", "GENE_OR_GENE_PRODUCT", 324, 328], ["TNFRSF8", "GENE_OR_GENE_PRODUCT", 329, 336], ["Trx1", "GENE_OR_GENE_PRODUCT", 354, 358], ["lymphoid cell lines", "CELL", 389, 408], ["Trx1", "GENE_OR_GENE_PRODUCT", 432, 436], ["cell", "CELL", 466, 470], ["LCL-721.220 cells", "CELL", 515, 532], ["Trx1", "GENE_OR_GENE_PRODUCT", 548, 552], ["SAv", "SIMPLE_CHEMICAL", 584, 587], ["Coomassie", "SIMPLE_CHEMICAL", 650, 659], ["CD30", "PROTEIN", 324, 328], ["TNFRSF8", "PROTEIN", 329, 336], ["Trx1 sensitive receptor", "PROTEIN", 354, 377], ["lymphoid cell lines", "CELL_LINE", 389, 408], ["Trx1 target protein", "PROTEIN", 432, 451], ["LCL-721.220 cells", "CELL_LINE", 515, 532], ["Trx1", "PROTEIN", 548, 552], ["interacting surface protein", "PROTEIN", 553, 580], ["SAv", "PROTEIN", 584, 587], ["the cell surface", "TREATMENT", 16, 32], ["the alkylating agent iodoacetamide", "TREATMENT", 38, 72], ["novo disulfide bond formation", "TREATMENT", 268, 297], ["CD30", "TEST", 324, 328], ["various lymphoid cell lines", "TREATMENT", 381, 408], ["a larger scale", "TEST", 491, 505], ["LCL", "TEST", 515, 518], ["the Trx1", "TEST", 544, 552], ["SAv affinity purification", "TEST", 584, 609], ["the protein", "TEST", 625, 636], ["colloidal Coomassie staining", "TEST", 640, 668], ["left panel", "TEST", 683, 693], ["cell", "OBSERVATION", 20, 24], ["surface", "OBSERVATION_MODIFIER", 25, 32], ["various lymphoid cell lines", "OBSERVATION", 381, 408], ["left", "ANATOMY_MODIFIER", 683, 687]]], ["The 160 kDa band was absent in the control precipitation with Trx1(CCAAA).", [["Trx1", "GENE_OR_GENE_PRODUCT", 62, 66], ["CCAAA", "GENE_OR_GENE_PRODUCT", 67, 72], ["160 kDa band", "PROTEIN", 4, 16], ["Trx1", "PROTEIN", 62, 66], ["CCAAA", "PROTEIN", 67, 72], ["The 160 kDa band", "TEST", 0, 16]]], ["Corresponding bands from non-reducing and reducing lanes were subjected to tryptic digestion and LC-MS/MS analysis.", [["Corresponding bands", "PROBLEM", 0, 19], ["reducing lanes", "TREATMENT", 42, 56], ["tryptic digestion", "PROBLEM", 75, 92], ["LC", "TEST", 97, 99], ["MS/MS analysis", "TEST", 100, 114], ["bands", "OBSERVATION_MODIFIER", 14, 19]]], ["From both samples the unknown protein was identified as TNFRSF8 (CD30), a member of the TNFR superfamily.", [["samples", "ANATOMY", 10, 17], ["TNFRSF8", "GENE_OR_GENE_PRODUCT", 56, 63], ["CD30", "GENE_OR_GENE_PRODUCT", 65, 69], ["TNFR", "GENE_OR_GENE_PRODUCT", 88, 92], ["TNFRSF8", "PROTEIN", 56, 63], ["CD30", "PROTEIN", 65, 69], ["TNFR superfamily", "PROTEIN", 88, 104], ["unknown protein", "OBSERVATION", 22, 37]]], ["To validate the direct covalent interaction between Trx1(CSAAA) and CD30, an aliquot of trapped complexes from the same experiment was separated under non-reducing and reducing conditions and subjected to immunoblotting analysis with anti-Trx1 ( Figure 3A , middle panel) and anti-CD30 antibodies ( Figure 3A , right panel), respectively.", [["Trx1", "GENE_OR_GENE_PRODUCT", 52, 56], ["CSAAA", "GENE_OR_GENE_PRODUCT", 57, 62], ["CD30", "GENE_OR_GENE_PRODUCT", 68, 72], ["anti-Trx1", "GENE_OR_GENE_PRODUCT", 234, 243], ["anti-CD30 antibodies", "GENE_OR_GENE_PRODUCT", 276, 296], ["Trx1", "PROTEIN", 52, 56], ["CSAAA", "PROTEIN", 57, 62], ["CD30", "PROTEIN", 68, 72], ["anti-Trx1", "PROTEIN", 234, 243], ["Figure 3A", "PROTEIN", 246, 255], ["middle panel", "PROTEIN", 258, 270], ["anti-CD30 antibodies", "PROTEIN", 276, 296], ["Figure 3A", "PROTEIN", 299, 308], ["an aliquot of trapped complexes", "TREATMENT", 74, 105], ["immunoblotting analysis", "TEST", 205, 228], ["anti-Trx1", "TREATMENT", 234, 243], ["middle panel", "TEST", 258, 270], ["anti-CD30 antibodies", "TEST", 276, 296]]], ["The observed mobility difference between non-reducing (NR) and reducing (R) lanes demonstrated the formation of a mixed disulfide conjugate ( Figure 3A , right panel).", [["disulfide", "CHEMICAL", 120, 129], ["The observed mobility difference", "PROBLEM", 0, 32], ["reducing (R) lanes", "TREATMENT", 63, 81], ["mobility", "OBSERVATION_MODIFIER", 13, 21], ["right", "ANATOMY_MODIFIER", 154, 159]]], ["Additional immunoblotting experiments demonstrated that low nanomolar concentrations of Trx1(CSAAA) are sufficient to detect the interaction with CD30 ( Figure 3B ) and also confirmed that trapping of CD30 depends on the N-terminal cysteine of the CXXC motif ( Figure 3C, lanes 1-8) .", [["N", "CHEMICAL", 221, 222], ["cysteine", "CHEMICAL", 232, 240], ["Trx1", "GENE_OR_GENE_PRODUCT", 88, 92], ["CSAAA", "GENE_OR_GENE_PRODUCT", 93, 98], ["CD30", "GENE_OR_GENE_PRODUCT", 146, 150], ["Figure 3B", "GENE_OR_GENE_PRODUCT", 153, 162], ["CD30", "GENE_OR_GENE_PRODUCT", 201, 205], ["Trx1", "PROTEIN", 88, 92], ["CSAAA", "PROTEIN", 93, 98], ["CD30", "PROTEIN", 146, 150], ["Figure 3B", "PROTEIN", 153, 162], ["CD30", "PROTEIN", 201, 205], ["N-terminal cysteine", "PROTEIN", 221, 240], ["CXXC motif", "PROTEIN", 248, 258], ["Figure 3C, lanes 1-8", "PROTEIN", 261, 281], ["Additional immunoblotting experiments", "TEST", 0, 37], ["low nanomolar concentrations", "PROBLEM", 56, 84], ["CD30 depends", "PROBLEM", 201, 213], ["the N-terminal cysteine of the CXXC motif", "TREATMENT", 217, 258]]], ["Application of the Grx1 trapping mutant under the same conditions did not lead to its conjugation to CD30 ( FigureTrx1 discriminates between CD30 and other members of the TNFR superfamilyEctodomains of TNFR superfamily proteins typically are composed of one to four cysteine-rich domains (CRDs), each normally harboring three disulfide bonds (Bodmer et al, 2002) .", [["cysteine", "CHEMICAL", 266, 274], ["disulfide", "CHEMICAL", 326, 335], ["Grx1", "GENE_OR_GENE_PRODUCT", 19, 23], ["CD30", "GENE_OR_GENE_PRODUCT", 101, 105], ["FigureTrx1", "GENE_OR_GENE_PRODUCT", 108, 118], ["CD30", "GENE_OR_GENE_PRODUCT", 141, 145], ["TNFR", "GENE_OR_GENE_PRODUCT", 171, 175], ["TNFR", "GENE_OR_GENE_PRODUCT", 202, 206], ["Grx1", "PROTEIN", 19, 23], ["CD30", "PROTEIN", 101, 105], ["FigureTrx1", "PROTEIN", 108, 118], ["CD30", "PROTEIN", 141, 145], ["TNFR superfamily", "PROTEIN", 171, 187], ["TNFR superfamily proteins", "PROTEIN", 202, 227], ["cysteine-rich domains", "PROTEIN", 266, 287], ["CRDs", "PROTEIN", 289, 293], ["the Grx1 trapping", "TREATMENT", 15, 32], ["TNFR superfamily proteins", "TREATMENT", 202, 227]]], ["To exclude the possibility that Trx1 interacts with CRDs uniformly, we tested whether Trx1 discriminates between distinct members of the TNFR superfamily.", [["Trx1", "GENE_OR_GENE_PRODUCT", 32, 36], ["CRDs", "GENE_OR_GENE_PRODUCT", 52, 56], ["Trx1", "GENE_OR_GENE_PRODUCT", 86, 90], ["TNFR", "GENE_OR_GENE_PRODUCT", 137, 141], ["Trx1", "PROTEIN", 32, 36], ["CRDs", "PROTEIN", 52, 56], ["Trx1", "PROTEIN", 86, 90], ["TNFR superfamily", "PROTEIN", 137, 153], ["exclude the possibility", "UNCERTAINTY", 3, 26]]], ["As shown in Figure 4A , CD95 (TNFRSF6) did not form a mixed disulfide conjugate with Trx1(CSAAA) on the same cells under identical conditions.", [["cells", "ANATOMY", 109, 114], ["disulfide", "CHEMICAL", 60, 69], ["CD95", "GENE_OR_GENE_PRODUCT", 24, 28], ["TNFRSF6", "GENE_OR_GENE_PRODUCT", 30, 37], ["Trx1", "GENE_OR_GENE_PRODUCT", 85, 89], ["CSAAA", "SIMPLE_CHEMICAL", 90, 95], ["cells", "CELL", 109, 114], ["CD95", "PROTEIN", 24, 28], ["TNFRSF6", "PROTEIN", 30, 37], ["disulfide conjugate", "PROTEIN", 60, 79], ["Trx1", "PROTEIN", 85, 89], ["CSAAA", "PROTEIN", 90, 95], ["a mixed disulfide conjugate", "PROBLEM", 52, 79], ["Trx1(CSAAA)", "PROBLEM", 85, 96]]], ["The same result was obtained for the epidermal growth factor receptor (EGFR), which contains a total of 25 ectodomain disulfide bonds, and is expressed at substantial levels on A431 cells (Gill and Lazar, 1981 ) ( Figure 4B ).", [["A431 cells", "ANATOMY", 177, 187], ["disulfide", "CHEMICAL", 118, 127], ["epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 37, 69], ["EGFR", "GENE_OR_GENE_PRODUCT", 71, 75], ["A431 cells", "CELL", 177, 187], ["Gill", "CELL", 189, 193], ["epidermal growth factor receptor", "PROTEIN", 37, 69], ["EGFR", "PROTEIN", 71, 75], ["A431 cells", "CELL_LINE", 177, 187], ["a total of 25 ectodomain disulfide bonds", "TREATMENT", 93, 133]]], ["These findings indicate that Trx1 reactivity of cell surface receptors is selective and is not determined by the presence of CRDs or the number of ectodomain disulfide bonds.", [["cell surface", "ANATOMY", 48, 60], ["disulfide", "CHEMICAL", 158, 167], ["Trx1", "GENE_OR_GENE_PRODUCT", 29, 33], ["cell", "CELL", 48, 52], ["CRDs", "GENE_OR_GENE_PRODUCT", 125, 129], ["Trx1", "PROTEIN", 29, 33], ["cell surface receptors", "PROTEIN", 48, 70], ["CRDs", "PROTEIN", 125, 129], ["Trx1 reactivity of cell surface receptors", "PROBLEM", 29, 70], ["Trx1 reactivity", "OBSERVATION", 29, 44], ["cell", "OBSERVATION", 48, 52], ["surface", "OBSERVATION_MODIFIER", 53, 60], ["disulfide bonds", "OBSERVATION", 158, 173]]], ["To further exclude that Trx1 reactivity of receptors is determined or limited by surface expression levels, we ectopically overexpressed CD30 or other TNFR superfamily members under control of the same promoter in HeLa cells and analyzed Trx1 cell surface trapping by indirect immunofluorescence.", [["surface", "ANATOMY", 81, 88], ["HeLa cells", "ANATOMY", 214, 224], ["cell surface", "ANATOMY", 243, 255], ["Trx1", "GENE_OR_GENE_PRODUCT", 24, 28], ["CD30", "GENE_OR_GENE_PRODUCT", 137, 141], ["TNFR", "GENE_OR_GENE_PRODUCT", 151, 155], ["HeLa cells", "CELL", 214, 224], ["Trx1", "GENE_OR_GENE_PRODUCT", 238, 242], ["Trx1", "PROTEIN", 24, 28], ["CD30", "PROTEIN", 137, 141], ["TNFR superfamily members", "PROTEIN", 151, 175], ["HeLa cells", "CELL_LINE", 214, 224], ["Trx1", "PROTEIN", 238, 242], ["Trx1 reactivity of receptors", "PROBLEM", 24, 52], ["surface expression levels", "TEST", 81, 106], ["the same promoter in HeLa cells", "TREATMENT", 193, 224], ["Trx1 cell surface trapping", "TREATMENT", 238, 264], ["indirect immunofluorescence", "TEST", 268, 295], ["HeLa cells", "OBSERVATION", 214, 224], ["Trx1 cell", "OBSERVATION", 238, 247]]], ["While mock-transfected HeLa cells did not capture Trx1(CSAAA) on their surface ( Figure 4C , lower row), expression of CD30 led to a strong Trx1 surface association and colocalization of both proteins ( Figure 4C , upper row).", [["HeLa cells", "ANATOMY", 23, 33], ["surface", "ANATOMY", 71, 78], ["surface", "ANATOMY", 145, 152], ["HeLa cells", "CELL", 23, 33], ["Trx1", "GENE_OR_GENE_PRODUCT", 50, 54], ["CSAAA", "GENE_OR_GENE_PRODUCT", 55, 60], ["surface", "CELLULAR_COMPONENT", 71, 78], ["CD30", "GENE_OR_GENE_PRODUCT", 119, 123], ["Trx1", "GENE_OR_GENE_PRODUCT", 140, 144], ["mock-transfected HeLa cells", "CELL_LINE", 6, 33], ["Trx1", "PROTEIN", 50, 54], ["CSAAA", "PROTEIN", 55, 60], ["CD30", "PROTEIN", 119, 123], ["Trx1", "PROTEIN", 140, 144], ["Figure 4C", "PROTEIN", 203, 212], ["upper row", "PROTEIN", 215, 224], ["transfected HeLa cells", "PROBLEM", 11, 33]]], ["In contrast, expression of CD95 ( Figure 4D ), TNFR1 or NGFR (data not shown) did not promote Trx1 interactions with the cell surface, further strengthening the notion that Trx1 reactivity is a specific property of CD30.", [["cell surface", "ANATOMY", 121, 133], ["CD95", "GENE_OR_GENE_PRODUCT", 27, 31], ["Figure 4D", "GENE_OR_GENE_PRODUCT", 34, 43], ["TNFR1", "GENE_OR_GENE_PRODUCT", 47, 52], ["NGFR", "GENE_OR_GENE_PRODUCT", 56, 60], ["Trx1", "GENE_OR_GENE_PRODUCT", 94, 98], ["cell surface", "CELLULAR_COMPONENT", 121, 133], ["Trx1", "GENE_OR_GENE_PRODUCT", 173, 177], ["CD30", "GENE_OR_GENE_PRODUCT", 215, 219], ["CD95", "PROTEIN", 27, 31], ["Figure 4D", "PROTEIN", 34, 43], ["TNFR1", "PROTEIN", 47, 52], ["NGFR", "PROTEIN", 56, 60], ["Trx1", "PROTEIN", 94, 98], ["Trx1", "PROTEIN", 173, 177], ["CD30", "PROTEIN", 215, 219], ["TNFR1", "TEST", 47, 52], ["NGFR (data", "TEST", 56, 66], ["Trx1 reactivity", "TEST", 173, 188]]], ["The domain structure of human CD30 differs from other members of the TNFR superfamily and from its murine homologue by the presence of two additional CRDs, arising from the internal duplication of two exons (Burgess et al, 2004) .", [["human", "ORGANISM", 24, 29], ["CD30", "GENE_OR_GENE_PRODUCT", 30, 34], ["TNFR", "GENE_OR_GENE_PRODUCT", 69, 73], ["murine", "ORGANISM", 99, 105], ["CRDs", "GENE_OR_GENE_PRODUCT", 150, 154], ["human CD30", "PROTEIN", 24, 34], ["TNFR superfamily", "PROTEIN", 69, 85], ["CRDs", "PROTEIN", 150, 154], ["exons", "DNA", 201, 206], ["human", "SPECIES", 24, 29], ["murine", "SPECIES", 99, 105], ["human", "SPECIES", 24, 29], ["two additional CRDs", "PROBLEM", 135, 154], ["human CD30", "OBSERVATION", 24, 34], ["CRDs", "OBSERVATION", 150, 154], ["internal", "ANATOMY_MODIFIER", 173, 181]]], ["We asked whether this unusual feature might confer Trx1 reactivity to human CD30 and tested whether the shorter murine CD30 could also interact with Trx1.", [["Trx1", "GENE_OR_GENE_PRODUCT", 51, 55], ["human", "ORGANISM", 70, 75], ["CD30", "GENE_OR_GENE_PRODUCT", 76, 80], ["murine", "ORGANISM", 112, 118], ["CD30", "GENE_OR_GENE_PRODUCT", 119, 123], ["Trx1", "GENE_OR_GENE_PRODUCT", 149, 153], ["Trx1", "PROTEIN", 51, 55], ["human CD30", "PROTEIN", 70, 80], ["murine CD30", "PROTEIN", 112, 123], ["Trx1", "PROTEIN", 149, 153], ["human", "SPECIES", 70, 75], ["murine", "SPECIES", 112, 118], ["human", "SPECIES", 70, 75]]], ["As shown in Figure 4E , murine CD30 expressed on the Rauscher murine leukemia virus-induced T-cell lymphoma line RMA is efficiently targeted by Trx1(CSAAA), thus demonstrating that the additional CRDs in human CD30 are not required for Trx1 reactivity.", [["T-cell lymphoma line", "ANATOMY", 92, 112], ["T-cell lymphoma", "DISEASE", 92, 107], ["murine", "ORGANISM", 24, 30], ["CD30", "GENE_OR_GENE_PRODUCT", 31, 35], ["Rauscher murine leukemia virus", "ORGANISM", 53, 83], ["T-cell lymphoma line", "CELL", 92, 112], ["Trx1", "GENE_OR_GENE_PRODUCT", 144, 148], ["CSAAA", "GENE_OR_GENE_PRODUCT", 149, 154], ["CRDs", "GENE_OR_GENE_PRODUCT", 196, 200], ["human", "ORGANISM", 204, 209], ["CD30", "GENE_OR_GENE_PRODUCT", 210, 214], ["Trx1", "GENE_OR_GENE_PRODUCT", 236, 240], ["murine CD30", "PROTEIN", 24, 35], ["Rauscher murine leukemia virus-induced T-cell lymphoma line", "CELL_LINE", 53, 112], ["Trx1", "PROTEIN", 144, 148], ["CSAAA", "PROTEIN", 149, 154], ["CRDs", "PROTEIN", 196, 200], ["human CD30", "PROTEIN", 204, 214], ["Trx1", "PROTEIN", 236, 240], ["murine", "SPECIES", 24, 30], ["murine", "SPECIES", 62, 68], ["human", "SPECIES", 204, 209], ["Rauscher murine leukemia virus", "SPECIES", 53, 83], ["human", "SPECIES", 204, 209], ["murine CD30", "TEST", 24, 35], ["the Rauscher murine leukemia virus", "PROBLEM", 49, 83], ["T-cell lymphoma line RMA", "TREATMENT", 92, 116], ["the additional CRDs in human CD30", "TEST", 181, 214], ["Trx1 reactivity", "PROBLEM", 236, 251], ["leukemia virus", "OBSERVATION", 69, 83], ["cell lymphoma", "OBSERVATION", 94, 107]]], ["The result also suggests that the enzymatic affinity of Trx1 for CD30 has been conserved during mammalian evolution.Trx1 catalyzes disulfide bond reduction in CD30 and induces a conformational change disrupting the Ki-1 epitopeTo demonstrate by an independent method that Trx1 attacks and breaks a disulfide bond in CD30, we used thiol-specific cell surface biotinylation to verify that Trx1 activity generates free thiols within the CD30 ectodomain (Supplementary Figure S3 ).", [["cell surface", "ANATOMY", 345, 357], ["thiol", "CHEMICAL", 330, 335], ["thiols", "CHEMICAL", 416, 422], ["disulfide", "CHEMICAL", 131, 140], ["disulfide", "CHEMICAL", 298, 307], ["thiol", "CHEMICAL", 330, 335], ["thiols", "CHEMICAL", 416, 422], ["Trx1", "GENE_OR_GENE_PRODUCT", 56, 60], ["CD30", "GENE_OR_GENE_PRODUCT", 65, 69], ["Trx1", "GENE_OR_GENE_PRODUCT", 116, 120], ["CD30", "GENE_OR_GENE_PRODUCT", 159, 163], ["Ki-1", "GENE_OR_GENE_PRODUCT", 215, 219], ["Trx1", "GENE_OR_GENE_PRODUCT", 272, 276], ["CD30", "GENE_OR_GENE_PRODUCT", 316, 320], ["cell", "CELL", 345, 349], ["Trx1", "GENE_OR_GENE_PRODUCT", 387, 391], ["free thiols", "SIMPLE_CHEMICAL", 411, 422], ["CD30", "GENE_OR_GENE_PRODUCT", 434, 438], ["Trx1", "PROTEIN", 56, 60], ["CD30", "PROTEIN", 65, 69], ["Trx1", "PROTEIN", 116, 120], ["CD30", "PROTEIN", 159, 163], ["Ki-1 epitopeTo", "PROTEIN", 215, 229], ["Trx1", "PROTEIN", 272, 276], ["CD30", "PROTEIN", 316, 320], ["Trx1", "PROTEIN", 387, 391], ["CD30 ectodomain", "PROTEIN", 434, 449], ["CD30", "PROBLEM", 65, 69], ["Trx1 catalyzes disulfide bond reduction", "TREATMENT", 116, 155], ["a conformational change", "PROBLEM", 176, 199], ["Trx1 attacks", "PROBLEM", 272, 284], ["breaks a disulfide bond in CD30", "PROBLEM", 289, 320], ["thiol", "TREATMENT", 330, 335], ["specific cell surface biotinylation", "TREATMENT", 336, 371], ["Trx1 activity", "PROBLEM", 387, 400], ["disulfide bond", "OBSERVATION", 131, 145]]], ["Subsequent analysis of CD30 cell surface expression by flow cytometry and fluorescence microscopy revealed that a brief treatment of CD30 \u00fe cells with wild-type Trx1 led to the complete loss of CD30 recognition by the Ki-1 antibody ( Figure 5A , upper panel and Figure 5B , second column).", [["CD30 cell surface", "ANATOMY", 23, 40], ["CD30 \u00fe cells", "ANATOMY", 133, 145], ["CD30", "GENE_OR_GENE_PRODUCT", 23, 27], ["CD30", "GENE_OR_GENE_PRODUCT", 133, 137], ["Trx1", "GENE_OR_GENE_PRODUCT", 161, 165], ["CD30", "GENE_OR_GENE_PRODUCT", 194, 198], ["Ki-1", "GENE_OR_GENE_PRODUCT", 218, 222], ["CD30", "PROTEIN", 23, 27], ["CD30", "PROTEIN", 133, 137], ["wild-type Trx1", "PROTEIN", 151, 165], ["CD30", "PROTEIN", 194, 198], ["Ki-1 antibody", "PROTEIN", 218, 231], ["Subsequent analysis", "TEST", 0, 19], ["CD30 cell surface expression", "TEST", 23, 51], ["flow cytometry", "TEST", 55, 69], ["fluorescence microscopy", "TEST", 74, 97], ["CD30 \u00fe cells", "PROBLEM", 133, 145], ["type Trx1", "PROBLEM", 156, 165], ["CD30 recognition", "TEST", 194, 210], ["the Ki", "TEST", 214, 220], ["Figure", "TEST", 234, 240], ["upper panel", "TEST", 246, 257], ["Figure 5B", "TEST", 262, 271], ["CD30 cell", "OBSERVATION", 23, 32]]], ["Similar results were obtained when another monoclonal antibody against CD30, MAB229 (R&D Systems; Clone 81337), was used to examine CD30 expression ( Figure 5A , middle panel).", [["CD30", "GENE_OR_GENE_PRODUCT", 71, 75], ["MAB229", "GENE_OR_GENE_PRODUCT", 77, 83], ["CD30", "GENE_OR_GENE_PRODUCT", 132, 136], ["monoclonal antibody", "PROTEIN", 43, 62], ["CD30", "PROTEIN", 71, 75], ["MAB229", "PROTEIN", 77, 83], ["R&D", "PROTEIN", 85, 88], ["Clone 81337", "PROTEIN", 98, 109], ["CD30", "PROTEIN", 132, 136], ["another monoclonal antibody", "TEST", 35, 62], ["CD30", "TEST", 71, 75], ["middle panel", "TEST", 162, 174]]], ["Under the same conditions, recognition by the Ber-H2 antibody was only slightly affected ( Figure 5A , lower panel and Figure 5B , third column), indicating that Trx1-mediated disulfide bond reduction (and possibly rearrangement) induces a structural alteration in the CD30 ectodomain, which disrupts or conceals the Ki-1 epitope.Trx1 catalyzes disulfide bond reduction in CD30 and induces a conformational change disrupting the Ki-1 epitopePursuant to the observation that recognition of CD30 by antibodies Ki-1 and MAB229 is affected by CD30 redox state, we used flow cytometry to analyze the response of CD30 to with Trx1(CSAAA) and complexes were analyzed by anti-EGFR immunoblotting.", [["disulfide", "CHEMICAL", 176, 185], ["disulfide", "CHEMICAL", 345, 354], ["Ber-H2", "GENE_OR_GENE_PRODUCT", 46, 52], ["Trx1", "GENE_OR_GENE_PRODUCT", 162, 166], ["CD30", "GENE_OR_GENE_PRODUCT", 269, 273], ["Ki-1", "GENE_OR_GENE_PRODUCT", 317, 321], ["Trx1", "GENE_OR_GENE_PRODUCT", 330, 334], ["CD30", "GENE_OR_GENE_PRODUCT", 373, 377], ["Ki-1", "GENE_OR_GENE_PRODUCT", 429, 433], ["CD30", "GENE_OR_GENE_PRODUCT", 489, 493], ["Ki-1", "GENE_OR_GENE_PRODUCT", 508, 512], ["MAB229", "GENE_OR_GENE_PRODUCT", 517, 523], ["CD30", "GENE_OR_GENE_PRODUCT", 539, 543], ["CD30", "GENE_OR_GENE_PRODUCT", 607, 611], ["Trx1", "GENE_OR_GENE_PRODUCT", 620, 624], ["CSAAA", "GENE_OR_GENE_PRODUCT", 625, 630], ["anti-EGFR", "GENE_OR_GENE_PRODUCT", 663, 672], ["Ber-H2 antibody", "PROTEIN", 46, 61], ["Trx1", "PROTEIN", 162, 166], ["CD30 ectodomain", "PROTEIN", 269, 284], ["Ki-1 epitope", "PROTEIN", 317, 329], ["Trx1", "PROTEIN", 330, 334], ["CD30", "PROTEIN", 373, 377], ["Ki-1 epitopePursuant", "PROTEIN", 429, 449], ["CD30", "PROTEIN", 489, 493], ["antibodies Ki-1", "PROTEIN", 497, 512], ["MAB229", "PROTEIN", 517, 523], ["CD30", "PROTEIN", 539, 543], ["CD30", "PROTEIN", 607, 611], ["Trx1", "PROTEIN", 620, 624], ["CSAAA", "PROTEIN", 625, 630], ["anti-EGFR", "PROTEIN", 663, 672], ["the Ber-H2 antibody", "TEST", 42, 61], ["slightly affected", "PROBLEM", 71, 88], ["lower panel", "TEST", 103, 114], ["Figure 5B", "TEST", 119, 128], ["Trx1-mediated disulfide bond reduction", "TREATMENT", 162, 200], ["a structural alteration in the CD30 ectodomain", "PROBLEM", 238, 284], ["Trx1 catalyzes disulfide bond reduction", "TREATMENT", 330, 369], ["a conformational change", "PROBLEM", 390, 413], ["CD30", "TEST", 489, 493], ["antibodies Ki", "TEST", 497, 510], ["flow cytometry", "TEST", 565, 579], ["Trx1(CSAAA)", "TREATMENT", 620, 631], ["anti-EGFR immunoblotting", "TREATMENT", 663, 687], ["disulfide bond", "OBSERVATION", 176, 190], ["CD30 ectodomain", "OBSERVATION", 269, 284], ["disulfide bond", "OBSERVATION", 345, 359]]], ["Cellular lysate was included as control.", [["Cellular lysate", "ANATOMY", 0, 15], ["Cellular lysate", "TREATMENT", 0, 15], ["lysate", "OBSERVATION", 9, 15]]], ["(C) HeLa cells were transiently transfected with an expression construct for human CD30 or empty vector incubated with Trx1(CSAAA) and analyzed by immunofluorescence microscopy using CD30-and Trx1-specific antibodies (scale bar, 20 mm).", [["HeLa cells", "ANATOMY", 4, 14], ["HeLa cells", "CELL", 4, 14], ["human", "ORGANISM", 77, 82], ["CD30", "GENE_OR_GENE_PRODUCT", 83, 87], ["Trx1", "GENE_OR_GENE_PRODUCT", 119, 123], ["CSAAA", "GENE_OR_GENE_PRODUCT", 124, 129], ["CD30", "GENE_OR_GENE_PRODUCT", 183, 187], ["Trx1", "GENE_OR_GENE_PRODUCT", 192, 196], ["HeLa cells", "CELL_LINE", 4, 14], ["human CD30", "PROTEIN", 77, 87], ["Trx1", "PROTEIN", 119, 123], ["CSAAA", "PROTEIN", 124, 129], ["CD30", "PROTEIN", 183, 187], ["Trx1", "PROTEIN", 192, 196], ["specific antibodies", "PROTEIN", 197, 216], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 77, 82], ["HeLa cells", "PROBLEM", 4, 14], ["an expression construct", "TREATMENT", 49, 72], ["human CD30", "TREATMENT", 77, 87], ["empty vector", "TREATMENT", 91, 103], ["immunofluorescence microscopy", "TEST", 147, 176], ["CD30", "TEST", 183, 187], ["Trx1", "TEST", 192, 196]]], ["(D) HeLa cells were transiently transfected with expression constructs for human CD30 or CD95, treated as described in (C) and analyzed by immunofluorescence microscopy using CD30-, Trx1-and CD95-specific antibodies (scale bar, 20 mm).", [["HeLa cells", "ANATOMY", 4, 14], ["D) HeLa cells", "CELL", 1, 14], ["human", "ORGANISM", 75, 80], ["CD30", "GENE_OR_GENE_PRODUCT", 81, 85], ["CD95", "GENE_OR_GENE_PRODUCT", 89, 93], ["CD30", "GENE_OR_GENE_PRODUCT", 175, 179], ["Trx1", "GENE_OR_GENE_PRODUCT", 182, 186], ["CD95", "GENE_OR_GENE_PRODUCT", 191, 195], ["HeLa cells", "CELL_LINE", 4, 14], ["expression constructs", "DNA", 49, 70], ["human CD30", "PROTEIN", 75, 85], ["CD95", "PROTEIN", 89, 93], ["CD30", "PROTEIN", 175, 179], ["Trx1", "PROTEIN", 182, 186], ["CD95", "PROTEIN", 191, 195], ["specific antibodies", "PROTEIN", 196, 215], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 75, 80], ["HeLa cells", "PROBLEM", 4, 14], ["expression constructs", "TREATMENT", 49, 70], ["human CD30", "TEST", 75, 85], ["CD95", "TREATMENT", 89, 93], ["immunofluorescence microscopy", "TEST", 139, 168], ["CD30", "TEST", 175, 179], ["Trx1", "TEST", 182, 186], ["CD95", "TEST", 191, 195]]], ["(E) RMA mouse lymphoma cells were incubated with Trx1(CSAAA) or Trx1(CCAAA).", [["lymphoma cells", "ANATOMY", 14, 28], ["lymphoma", "DISEASE", 14, 22], ["mouse", "ORGANISM", 8, 13], ["lymphoma cells", "CELL", 14, 28], ["Trx1", "GENE_OR_GENE_PRODUCT", 49, 53], ["CSAAA", "GENE_OR_GENE_PRODUCT", 54, 59], ["Trx1", "GENE_OR_GENE_PRODUCT", 64, 68], ["CCAAA", "GENE_OR_GENE_PRODUCT", 69, 74], ["(E) RMA mouse lymphoma cells", "CELL_LINE", 0, 28], ["Trx1", "PROTEIN", 49, 53], ["CSAAA", "PROTEIN", 54, 59], ["Trx1", "PROTEIN", 64, 68], ["CCAAA", "PROTEIN", 69, 74], ["mouse", "SPECIES", 8, 13], ["mouse", "SPECIES", 8, 13], ["RMA mouse lymphoma cells", "PROBLEM", 4, 28], ["lymphoma cells", "OBSERVATION", 14, 28]]], ["Disulfide-linked Trx1 complexes were analyzed by anti-mouse CD30 (mCD30) immunoblotting under non-reducing and reducing conditions.", [["Disulfide", "CHEMICAL", 0, 9], ["Trx1", "GENE_OR_GENE_PRODUCT", 17, 21], ["CD30", "GENE_OR_GENE_PRODUCT", 60, 64], ["mCD30", "GENE_OR_GENE_PRODUCT", 66, 71], ["Disulfide-linked Trx1 complexes", "PROTEIN", 0, 31], ["anti-mouse CD30", "PROTEIN", 49, 64], ["mCD30", "PROTEIN", 66, 71], ["Disulfide-linked Trx1 complexes", "TREATMENT", 0, 31], ["anti-mouse CD30 (mCD30", "TREATMENT", 49, 71], ["Trx1 complexes", "OBSERVATION", 17, 31]]], ["The disulfide-linked Trx1-mCD30 complex and monomeric mCD30 are indicated.", [["disulfide", "CHEMICAL", 4, 13], ["Trx1", "GENE_OR_GENE_PRODUCT", 21, 25], ["mCD30", "GENE_OR_GENE_PRODUCT", 26, 31], ["mCD30", "GENE_OR_GENE_PRODUCT", 54, 59], ["Trx1", "PROTEIN", 21, 25], ["mCD30 complex", "PROTEIN", 26, 39], ["monomeric mCD30", "PROTEIN", 44, 59], ["The disulfide", "TREATMENT", 0, 13], ["monomeric mCD30", "TREATMENT", 44, 59]]], ["The additional band of higher molecular weight has not been further characterized but might represent a conjugate between Trx1 and a dimer of mCD30. reduction in greater detail.", [["Trx1", "GENE_OR_GENE_PRODUCT", 122, 126], ["mCD30", "GENE_OR_GENE_PRODUCT", 142, 147], ["Trx1", "PROTEIN", 122, 126], ["dimer", "PROTEIN", 133, 138], ["mCD30", "PROTEIN", 142, 147], ["The additional band of higher molecular weight", "PROBLEM", 0, 46], ["a dimer of mCD30", "TREATMENT", 131, 147], ["band", "OBSERVATION_MODIFIER", 15, 19], ["higher", "OBSERVATION_MODIFIER", 23, 29], ["might represent", "UNCERTAINTY", 86, 101], ["conjugate", "OBSERVATION", 104, 113], ["greater", "OBSERVATION_MODIFIER", 162, 169]]], ["Addition of oxidized Trx1 did not influence antibody reactivity of CD30 (data not shown).", [["Trx1", "GENE_OR_GENE_PRODUCT", 21, 25], ["CD30", "GENE_OR_GENE_PRODUCT", 67, 71], ["Trx1", "PROTEIN", 21, 25], ["CD30", "PROTEIN", 67, 71], ["oxidized Trx1", "TREATMENT", 12, 25], ["antibody reactivity", "TEST", 44, 63], ["CD30 (data", "TEST", 67, 77]]], ["When reduced Trx1 was applied in the absence of a regenerating system, a conformational change in CD30 could be observed, but remained incomplete (data not shown).", [["Trx1", "GENE_OR_GENE_PRODUCT", 13, 17], ["CD30", "GENE_OR_GENE_PRODUCT", 98, 102], ["Trx1", "PROTEIN", 13, 17], ["CD30", "PROTEIN", 98, 102], ["reduced Trx1", "TREATMENT", 5, 17], ["a regenerating system", "PROBLEM", 48, 69], ["a conformational change in CD30", "PROBLEM", 71, 102]]], ["Complete and sustained loss of antibody reactivity required a source of reducing equivalents for the oxidoreductase.", [["oxidoreductase", "GENE_OR_GENE_PRODUCT", 101, 115], ["oxidoreductase", "PROTEIN", 101, 115], ["sustained loss of antibody reactivity", "PROBLEM", 13, 50], ["the oxidoreductase", "TREATMENT", 97, 115], ["sustained", "OBSERVATION_MODIFIER", 13, 22], ["loss", "OBSERVATION_MODIFIER", 23, 27], ["antibody reactivity", "OBSERVATION", 31, 50]]], ["Both DTT and Trx reductase (TrxR)/NADPH were found to be effective as regenerating systems.", [["DTT", "CHEMICAL", 5, 8], ["NADPH", "CHEMICAL", 34, 39], ["DTT", "CHEMICAL", 5, 8], ["NADPH", "CHEMICAL", 34, 39], ["DTT", "SIMPLE_CHEMICAL", 5, 8], ["Trx reductase", "GENE_OR_GENE_PRODUCT", 13, 26], ["TrxR", "GENE_OR_GENE_PRODUCT", 28, 32], ["NADPH", "SIMPLE_CHEMICAL", 34, 39], ["Trx reductase", "PROTEIN", 13, 26], ["TrxR", "PROTEIN", 28, 32], ["NADPH", "PROTEIN", 34, 39], ["Both DTT", "TEST", 0, 8], ["Trx reductase", "TEST", 13, 26], ["TrxR)/NADPH", "TEST", 28, 39], ["Trx reductase", "OBSERVATION", 13, 26]]], ["Importantly, neither DTT nor TrxR/NADPH had an effect when applied in the absence of Trx1 ( Figure 5A , middle panel and data not shown).", [["DTT", "CHEMICAL", 21, 24], ["NADPH", "CHEMICAL", 34, 39], ["DTT", "CHEMICAL", 21, 24], ["NADPH", "CHEMICAL", 34, 39], ["DTT", "SIMPLE_CHEMICAL", 21, 24], ["TrxR", "GENE_OR_GENE_PRODUCT", 29, 33], ["NADPH", "SIMPLE_CHEMICAL", 34, 39], ["Trx1", "GENE_OR_GENE_PRODUCT", 85, 89], ["TrxR", "PROTEIN", 29, 33], ["Trx1", "PROTEIN", 85, 89], ["Figure 5A", "PROTEIN", 92, 101], ["TrxR/NADPH", "TEST", 29, 39], ["middle panel", "TEST", 104, 116]]], ["Wild-type Grx1 ( Figure 5C , left panel) and the redox-inactive mutant of Trx1 ( Figure 5C , middle panel) did not alter the redox-sensitive CD30 epitopes.", [["Grx1", "GENE_OR_GENE_PRODUCT", 10, 14], ["Figure 5C", "GENE_OR_GENE_PRODUCT", 17, 26], ["Trx1", "GENE_OR_GENE_PRODUCT", 74, 78], ["CD30", "GENE_OR_GENE_PRODUCT", 141, 145], ["Wild-type Grx1", "PROTEIN", 0, 14], ["Figure 5C , left panel", "PROTEIN", 17, 39], ["redox-inactive mutant", "PROTEIN", 49, 70], ["Trx1", "PROTEIN", 74, 78], ["Figure 5C", "PROTEIN", 81, 90], ["middle panel", "PROTEIN", 93, 105], ["CD30 epitopes", "PROTEIN", 141, 154], ["left panel", "TEST", 29, 39], ["the redox", "TEST", 45, 54], ["middle panel", "TEST", 93, 105], ["the redox", "TEST", 121, 130]]], ["Other cell surface receptors, for example CD28, analyzed in parallel on the same cells were unaffected by Trx1 treatment ( Figure 5C, right panel) .", [["cell surface", "ANATOMY", 6, 18], ["cells", "ANATOMY", 81, 86], ["cell", "CELL", 6, 10], ["CD28", "GENE_OR_GENE_PRODUCT", 42, 46], ["cells", "CELL", 81, 86], ["Trx1", "GENE_OR_GENE_PRODUCT", 106, 110], ["cell surface receptors", "PROTEIN", 6, 28], ["CD28", "PROTEIN", 42, 46], ["Trx1", "PROTEIN", 106, 110], ["Other cell surface receptors", "TEST", 0, 28], ["example CD28", "TEST", 34, 46], ["Trx1 treatment", "TREATMENT", 106, 120], ["right panel", "TEST", 134, 145], ["surface receptors", "OBSERVATION", 11, 28]]], ["Loss of CD30 antibody recognition typically occurred within minutes ( Figure 5D , upper panel).", [["CD30", "GENE_OR_GENE_PRODUCT", 8, 12], ["CD30 antibody", "PROTEIN", 8, 21], ["Loss of CD30 antibody recognition", "PROBLEM", 0, 33], ["CD30 antibody", "OBSERVATION", 8, 21]]], ["Testing the influence of Trx1 concentration under the same conditions, consistent effects on CD30 conformation became evident at concentrations around 100 nM ( Figure 5D , lower panel).Trx1-mediated disulfide exchange interferes with CD30 receptor-ligand interactionsThe observation that antibody binding to CD30 is influenced by Trx1 suggested a redox-dependent conformational change within the CD30 ectodomain.", [["disulfide", "CHEMICAL", 199, 208], ["Trx1", "GENE_OR_GENE_PRODUCT", 25, 29], ["CD30", "GENE_OR_GENE_PRODUCT", 93, 97], ["Trx1", "GENE_OR_GENE_PRODUCT", 185, 189], ["disulfide", "AMINO_ACID", 199, 208], ["CD30", "GENE_OR_GENE_PRODUCT", 234, 238], ["CD30", "GENE_OR_GENE_PRODUCT", 308, 312], ["Trx1", "GENE_OR_GENE_PRODUCT", 330, 334], ["CD30", "GENE_OR_GENE_PRODUCT", 396, 400], ["Trx1", "PROTEIN", 25, 29], ["CD30", "PROTEIN", 93, 97], ["Trx1", "PROTEIN", 185, 189], ["CD30", "PROTEIN", 234, 238], ["CD30", "PROTEIN", 308, 312], ["Trx1", "PROTEIN", 330, 334], ["CD30 ectodomain", "PROTEIN", 396, 411], ["Trx1 concentration", "TREATMENT", 25, 43], ["CD30 conformation", "TREATMENT", 93, 110], ["Trx1-mediated disulfide exchange", "TREATMENT", 185, 217], ["CD30 receptor", "TREATMENT", 234, 247], ["antibody binding", "PROBLEM", 288, 304], ["CD30", "TEST", 308, 312], ["Trx1", "TEST", 330, 334], ["a redox-dependent conformational change within the CD30 ectodomain", "PROBLEM", 345, 411], ["dependent", "OBSERVATION_MODIFIER", 353, 362], ["conformational change", "OBSERVATION", 363, 384], ["CD30 ectodomain", "OBSERVATION", 396, 411]]], ["To test whether Trx1-mediated reduction of CD30 influences binding of CD30 to its ligand (CD30L), we analyzed the interaction between CD30 and recombinant soluble CD30L (sCD30L) on the cell surface by flow cytometry.", [["cell surface", "ANATOMY", 185, 197], ["Trx1", "GENE_OR_GENE_PRODUCT", 16, 20], ["CD30", "GENE_OR_GENE_PRODUCT", 43, 47], ["CD30", "GENE_OR_GENE_PRODUCT", 70, 74], ["CD30L", "GENE_OR_GENE_PRODUCT", 90, 95], ["CD30", "GENE_OR_GENE_PRODUCT", 134, 138], ["CD30L", "GENE_OR_GENE_PRODUCT", 163, 168], ["sCD30L", "GENE_OR_GENE_PRODUCT", 170, 176], ["cell surface", "CELLULAR_COMPONENT", 185, 197], ["Trx1", "PROTEIN", 16, 20], ["CD30", "PROTEIN", 43, 47], ["CD30", "PROTEIN", 70, 74], ["CD30L", "PROTEIN", 90, 95], ["CD30", "PROTEIN", 134, 138], ["recombinant soluble CD30L", "PROTEIN", 143, 168], ["sCD30L", "PROTEIN", 170, 176], ["Trx1", "TEST", 16, 20], ["CD30 and recombinant soluble CD30L (sCD30L", "TREATMENT", 134, 176], ["flow cytometry", "TEST", 201, 215], ["CD30", "OBSERVATION", 43, 47], ["flow cytometry", "OBSERVATION", 201, 215]]], ["A brief incubation of CD30 \u00fe Hodgkin's lymphoma HDLM-2 cells with wild-type Trx1 led to a substantial loss in CD30L binding to the cell surface ( Figure 6A) .", [["CD30 \u00fe Hodgkin's lymphoma HDLM-2 cells", "ANATOMY", 22, 60], ["cell surface", "ANATOMY", 131, 143], ["lymphoma", "DISEASE", 39, 47], ["CD30", "GENE_OR_GENE_PRODUCT", 22, 26], ["-2 cells", "CELL", 52, 60], ["Trx1", "GENE_OR_GENE_PRODUCT", 76, 80], ["CD30L", "GENE_OR_GENE_PRODUCT", 110, 115], ["cell surface", "CELLULAR_COMPONENT", 131, 143], ["CD30", "PROTEIN", 22, 26], ["Hodgkin's lymphoma HDLM-2 cells", "CELL_LINE", 29, 60], ["wild-type Trx1", "PROTEIN", 66, 80], ["CD30L", "PROTEIN", 110, 115], ["Hodgkin's lymphoma HDLM", "PROBLEM", 29, 52], ["type Trx1", "PROBLEM", 71, 80], ["a substantial loss in CD30L binding", "PROBLEM", 88, 123], ["Hodgkin's lymphoma", "OBSERVATION", 29, 47], ["substantial", "OBSERVATION_MODIFIER", 90, 101], ["loss", "OBSERVATION", 102, 106]]], ["A similar result was obtained for the large granular lymphoma Figure S4) .", [["granular lymphoma", "ANATOMY", 44, 61], ["lymphoma", "DISEASE", 53, 61], ["the large granular lymphoma", "PROBLEM", 34, 61], ["large", "OBSERVATION_MODIFIER", 38, 43], ["granular lymphoma", "OBSERVATION", 44, 61]]], ["The same effect was evident in the absence of an exogenously added reducing system (Supplementary Figure S5) , thus demonstrating that under the given conditions Trx1-substrate interactions are not limited by oxidative inactivation.", [["Trx1", "GENE_OR_GENE_PRODUCT", 162, 166], ["Trx1", "PROTEIN", 162, 166], ["oxidative inactivation", "PROBLEM", 209, 231], ["oxidative inactivation", "OBSERVATION", 209, 231]]], ["As shown by fluorescence microscopy, sCD30L binds to the surface of CD30-transfected HeLa cells and colocalizes with its receptor ( Figure 6B , upper row).", [["surface", "ANATOMY", 57, 64], ["HeLa cells", "ANATOMY", 85, 95], ["sCD30L", "GENE_OR_GENE_PRODUCT", 37, 43], ["surface", "CELLULAR_COMPONENT", 57, 64], ["CD30", "GENE_OR_GENE_PRODUCT", 68, 72], ["HeLa cells", "CELL", 85, 95], ["Figure 6B", "GENE_OR_GENE_PRODUCT", 132, 141], ["sCD30L", "PROTEIN", 37, 43], ["CD30", "PROTEIN", 68, 72], ["HeLa cells", "CELL_LINE", 85, 95], ["Figure 6B", "PROTEIN", 132, 141], ["fluorescence microscopy", "TEST", 12, 35], ["CD30", "TEST", 68, 72], ["transfected HeLa cells", "PROBLEM", 73, 95], ["CD30", "ANATOMY", 68, 72], ["HeLa cells", "OBSERVATION", 85, 95]]], ["Treatment of HeLa cells with Trx1(CCAAA) ( Figure 6B , middle row) but not a redox-inactive mutant ( Figure 6B , lower row) strongly interferes with CD30L binding and colocalization.Trx1-mediated reducing activity interrupts agonist-induced CD30 signaling in YT cellsGiven its influence on ligand binding, we reasoned that Trx1 might interfere with CD30-mediated signaling.", [["HeLa cells", "ANATOMY", 13, 23], ["YT cells", "ANATOMY", 259, 267], ["HeLa cells", "CELL", 13, 23], ["Trx1(CCAAA) ( Figure 6B", "GENE_OR_GENE_PRODUCT", 29, 52], ["CD30L", "GENE_OR_GENE_PRODUCT", 149, 154], ["Trx1", "GENE_OR_GENE_PRODUCT", 182, 186], ["CD30", "GENE_OR_GENE_PRODUCT", 241, 245], ["YT cells", "CELL", 259, 267], ["Trx1", "GENE_OR_GENE_PRODUCT", 323, 327], ["CD30", "GENE_OR_GENE_PRODUCT", 349, 353], ["HeLa cells", "CELL_LINE", 13, 23], ["Trx1", "PROTEIN", 29, 33], ["CCAAA", "PROTEIN", 34, 39], ["Figure 6B", "PROTEIN", 43, 52], ["middle row", "PROTEIN", 55, 65], ["redox-inactive mutant", "PROTEIN", 77, 98], ["Figure 6B", "PROTEIN", 101, 110], ["CD30L", "PROTEIN", 149, 154], ["Trx1", "PROTEIN", 182, 186], ["CD30", "PROTEIN", 241, 245], ["YT cells", "CELL_LINE", 259, 267], ["Trx1", "PROTEIN", 323, 327], ["CD30", "PROTEIN", 349, 353], ["HeLa cells", "PROBLEM", 13, 23], ["Trx1", "TEST", 29, 33], ["CCAAA", "TEST", 34, 39], ["a redox", "TEST", 75, 82], ["inactive mutant", "PROBLEM", 83, 98], ["Trx1", "TEST", 182, 186], ["CD30 signaling in YT cells", "PROBLEM", 241, 267], ["Trx1", "PROBLEM", 323, 327], ["HeLa cells", "OBSERVATION", 13, 23], ["cells", "OBSERVATION", 262, 267]]], ["To test whether Trx1-mediated conformational alteration of CD30 affects CD30-dependent cellular responses, we made use of the YT large granular lymphoma line that has previously been used to study signals emanating from CD30 and to define the genes regulated by such signals (Muta et al, 2000) .", [["cellular", "ANATOMY", 87, 95], ["granular lymphoma line", "ANATOMY", 135, 157], ["granular lymphoma", "DISEASE", 135, 152], ["Trx1", "GENE_OR_GENE_PRODUCT", 16, 20], ["CD30", "GENE_OR_GENE_PRODUCT", 59, 63], ["CD30", "GENE_OR_GENE_PRODUCT", 72, 76], ["cellular", "CELL", 87, 95], ["YT large granular lymphoma line", "CELL", 126, 157], ["CD30", "GENE_OR_GENE_PRODUCT", 220, 224], ["Trx1", "PROTEIN", 16, 20], ["CD30", "PROTEIN", 59, 63], ["CD30", "PROTEIN", 72, 76], ["YT large granular lymphoma line", "CELL_LINE", 126, 157], ["CD30", "PROTEIN", 220, 224], ["Trx1", "TEST", 16, 20], ["the YT large granular lymphoma line", "TREATMENT", 122, 157], ["study signals", "TEST", 191, 204], ["large", "OBSERVATION_MODIFIER", 129, 134], ["granular lymphoma line", "OBSERVATION", 135, 157]]], ["Consistent with previous results (Bowen et al, 1993) , we observed that stimulation of CD30 with either agonistic antibodies or sCD30L led to upregulation of the IL-2Ra chain (CD25) within 24 h ( Figure 7A , lower panel, compare columns 3, 4 and 7).", [["CD30", "GENE_OR_GENE_PRODUCT", 87, 91], ["sCD30L", "GENE_OR_GENE_PRODUCT", 128, 134], ["IL-2Ra chain", "GENE_OR_GENE_PRODUCT", 162, 174], ["CD25", "GENE_OR_GENE_PRODUCT", 176, 180], ["CD30", "PROTEIN", 87, 91], ["agonistic antibodies", "PROTEIN", 104, 124], ["sCD30L", "PROTEIN", 128, 134], ["IL-2Ra chain", "PROTEIN", 162, 174], ["CD25", "PROTEIN", 176, 180], ["CD30", "TEST", 87, 91], ["agonistic antibodies", "PROBLEM", 104, 124], ["sCD30L", "PROBLEM", 128, 134], ["the IL", "TEST", 158, 164], ["Figure 7A", "TEST", 196, 205], ["lower panel", "TEST", 208, 219], ["columns", "TEST", 229, 236]]], ["Treatment of YT cells with Trx1(CCAAA) (but not with redox-inactive Trx1) prevented CD25 upregulation ( Figure 7A , lower panel, columns 5 and 8), concomitant with the redox change in CD30 ( Figure 7A , upper panel, column 4), thus demonstrating that the redox interaction between Trx1 and CD30 has a pronounced influence on CD30-mediated gene expression.Trx1-mediated reducing activity interrupts agonist-induced CD30 signaling in YT cellsYT cells respond to CD30 signals by downregulating the expression of cytotoxic effector molecules, including FasL, thus decreasing their cytotoxicity against Fas-expressing target cells (Bowen et al, 1993; Muta et al, 2000) .", [["YT cells", "ANATOMY", 13, 21], ["YT cells", "ANATOMY", 432, 440], ["YT cells", "ANATOMY", 440, 448], ["cells", "ANATOMY", 620, 625], ["YT cells", "CELL", 13, 21], ["Trx1", "GENE_OR_GENE_PRODUCT", 27, 31], ["CCAAA", "GENE_OR_GENE_PRODUCT", 32, 37], ["Trx1", "GENE_OR_GENE_PRODUCT", 68, 72], ["CD25", "GENE_OR_GENE_PRODUCT", 84, 88], ["CD30", "GENE_OR_GENE_PRODUCT", 184, 188], ["Trx1", "GENE_OR_GENE_PRODUCT", 281, 285], ["CD30", "GENE_OR_GENE_PRODUCT", 290, 294], ["CD30", "GENE_OR_GENE_PRODUCT", 325, 329], ["Trx1", "GENE_OR_GENE_PRODUCT", 355, 359], ["CD30", "GENE_OR_GENE_PRODUCT", 414, 418], ["YT cells", "CELL", 432, 440], ["YT cells", "CELL", 440, 448], ["CD30", "GENE_OR_GENE_PRODUCT", 460, 464], ["FasL", "GENE_OR_GENE_PRODUCT", 549, 553], ["cells", "CELL", 620, 625], ["YT cells", "CELL_LINE", 13, 21], ["Trx1", "PROTEIN", 27, 31], ["CCAAA", "PROTEIN", 32, 37], ["Trx1", "PROTEIN", 68, 72], ["CD25", "PROTEIN", 84, 88], ["CD30", "PROTEIN", 184, 188], ["Figure 7A", "PROTEIN", 191, 200], ["Trx1", "PROTEIN", 281, 285], ["CD30", "PROTEIN", 290, 294], ["CD30", "PROTEIN", 325, 329], ["Trx1", "PROTEIN", 355, 359], ["CD30", "PROTEIN", 414, 418], ["YT cells", "CELL_LINE", 432, 440], ["YT cells", "CELL_LINE", 440, 448], ["CD30", "PROTEIN", 460, 464], ["cytotoxic effector molecules", "PROTEIN", 509, 537], ["FasL", "PROTEIN", 549, 553], ["Fas-expressing target cells", "CELL_LINE", 598, 625], ["YT cells", "PROBLEM", 13, 21], ["Trx1(CCAAA", "TEST", 27, 37], ["redox", "TEST", 53, 58], ["CD25 upregulation", "TEST", 84, 101], ["Figure 7A", "TEST", 104, 113], ["lower panel", "TEST", 116, 127], ["columns", "TEST", 129, 136], ["the redox change", "PROBLEM", 164, 180], ["CD30", "TEST", 184, 188], ["upper panel", "TEST", 203, 214], ["Trx1", "TEST", 355, 359], ["CD30 signaling in YT cells", "PROBLEM", 414, 440], ["YT cells", "PROBLEM", 440, 448], ["CD30 signals", "TEST", 460, 472], ["cytotoxic effector molecules", "PROBLEM", 509, 537], ["FasL", "PROBLEM", 549, 553], ["cells", "OBSERVATION", 435, 440], ["cytotoxic effector molecules", "OBSERVATION", 509, 537]]], ["To test if Trx1 influences CD30-mediated suppression of cytotoxicity, we treated YT cells with Trx1(CCAAA) or Trx1(SSAAA) before stimulation with agonistic anti-CD30 antibody and quantified cytotoxicity against Cr-labeled Raji cells.", [["YT cells", "ANATOMY", 81, 89], ["Raji cells", "ANATOMY", 222, 232], ["Trx1", "GENE_OR_GENE_PRODUCT", 11, 15], ["CD30", "GENE_OR_GENE_PRODUCT", 27, 31], ["YT cells", "CELL", 81, 89], ["Trx1", "GENE_OR_GENE_PRODUCT", 95, 99], ["CCAAA", "GENE_OR_GENE_PRODUCT", 100, 105], ["Trx1", "GENE_OR_GENE_PRODUCT", 110, 114], ["SSAAA", "GENE_OR_GENE_PRODUCT", 115, 120], ["anti-CD30", "GENE_OR_GENE_PRODUCT", 156, 165], ["Cr-labeled Raji cells", "CELL", 211, 232], ["Trx1", "PROTEIN", 11, 15], ["CD30", "PROTEIN", 27, 31], ["YT cells", "CELL_LINE", 81, 89], ["Trx1", "PROTEIN", 95, 99], ["CCAAA", "PROTEIN", 100, 105], ["Trx1", "PROTEIN", 110, 114], ["SSAAA", "PROTEIN", 115, 120], ["anti-CD30 antibody", "PROTEIN", 156, 174], ["Cr-labeled Raji cells", "CELL_LINE", 211, 232], ["CD30", "TEST", 27, 31], ["cytotoxicity", "PROBLEM", 56, 68], ["YT cells", "TREATMENT", 81, 89], ["Trx1(CCAAA)", "TREATMENT", 95, 106], ["Trx1(SSAAA)", "TREATMENT", 110, 121], ["stimulation", "TREATMENT", 129, 140], ["agonistic anti-CD30 antibody", "TEST", 146, 174], ["quantified cytotoxicity", "PROBLEM", 179, 202], ["Cr-labeled Raji cells", "PROBLEM", 211, 232], ["Raji cells", "OBSERVATION", 222, 232]]], ["Upon CD30 stimulation, cytotoxicity was markedly reduced ( Figure 7B , compare columns 1 and 4).", [["CD30", "GENE_OR_GENE_PRODUCT", 5, 9], ["CD30", "PROTEIN", 5, 9], ["CD30 stimulation", "TEST", 5, 21], ["cytotoxicity", "TEST", 23, 35], ["markedly reduced", "PROBLEM", 40, 56], ["Figure 7B", "TEST", 59, 68], ["columns", "TEST", 79, 86], ["markedly", "OBSERVATION_MODIFIER", 40, 48], ["reduced", "OBSERVATION_MODIFIER", 49, 56]]], ["The decrease in cytotoxicity was completely reversed by Trx1(CCAAA) but not the catalytically inactive mutant (SSAAA) ( Figure 7B , columns 5 and 6).", [["Trx1", "GENE_OR_GENE_PRODUCT", 56, 60], ["CCAAA", "GENE_OR_GENE_PRODUCT", 61, 66], ["Trx1", "PROTEIN", 56, 60], ["CCAAA", "PROTEIN", 61, 66], ["catalytically inactive mutant", "PROTEIN", 80, 109], ["SSAAA", "PROTEIN", 111, 116], ["The decrease in cytotoxicity", "PROBLEM", 0, 28], ["Figure 7B", "TEST", 120, 129], ["columns", "TEST", 132, 139], ["decrease", "OBSERVATION_MODIFIER", 4, 12], ["cytotoxicity", "OBSERVATION", 16, 28]]], ["As judged by RT-PCR, changes in cytotoxicity correlated with changes in FasL mRNA expression ( Figure 7B, lower panel) .", [["FasL", "GENE_OR_GENE_PRODUCT", 72, 76], ["FasL mRNA", "RNA", 72, 81], ["RT-PCR", "TEST", 13, 19], ["changes in cytotoxicity", "PROBLEM", 21, 44], ["changes in FasL mRNA expression", "PROBLEM", 61, 92], ["Figure 7B", "TEST", 95, 104]]], ["These results confirm that the catalytic activity of Trx1 modulates CD30-dependent changes in cellular behavior and function.DiscussionAccumulating evidence indicates that the reduction and rearrangement of disulfide bonds constitutes a mechanism controlling protein function on the cell surface (Hogg, 2003) .", [["cellular", "ANATOMY", 94, 102], ["cell surface", "ANATOMY", 283, 295], ["disulfide", "CHEMICAL", 207, 216], ["Trx1", "GENE_OR_GENE_PRODUCT", 53, 57], ["CD30", "GENE_OR_GENE_PRODUCT", 68, 72], ["cellular", "CELL", 94, 102], ["cell surface", "CELLULAR_COMPONENT", 283, 295], ["Trx1", "PROTEIN", 53, 57], ["CD30", "PROTEIN", 68, 72], ["dependent changes in cellular behavior", "PROBLEM", 73, 111], ["the reduction", "TREATMENT", 172, 185], ["rearrangement of disulfide bonds", "TREATMENT", 190, 222], ["dependent", "OBSERVATION_MODIFIER", 73, 82], ["cellular behavior", "OBSERVATION", 94, 111]]], ["The idea that disulfide bonds can act as dynamical redox switches, specifically operated by secreted redox catalysts, represents a novel concept in signal transduction (Jordan and Gibbins, 2006) .", [["disulfide", "CHEMICAL", 14, 23], ["disulfide bonds", "SIMPLE_CHEMICAL", 14, 29], ["disulfide bonds", "PROBLEM", 14, 29], ["dynamical redox switches", "TREATMENT", 41, 65], ["secreted redox catalysts", "TREATMENT", 92, 116], ["disulfide bonds", "OBSERVATION", 14, 29]]], ["However, technical difficulties in detecting and analyzing individual disulfide rearrangements on the cell surface have made progress slow.DiscussionTrx1 is recognized as one of the most important regulators of cellular and organismal redox homeostasis (Gromer et al, 2004) .", [["cell surface", "ANATOMY", 102, 114], ["cellular", "ANATOMY", 211, 219], ["disulfide", "CHEMICAL", 70, 79], ["cell surface", "CELLULAR_COMPONENT", 102, 114], ["DiscussionTrx1", "GENE_OR_GENE_PRODUCT", 139, 153], ["cellular", "CELL", 211, 219], ["DiscussionTrx1", "PROTEIN", 139, 153], ["technical difficulties", "PROBLEM", 9, 31], ["analyzing individual disulfide rearrangements", "PROBLEM", 49, 94], ["redox homeostasis", "OBSERVATION", 235, 252]]], ["In particular, intracellular Trx1 counteracts oxidative stress, promotes cell growth and inhibits apoptosis.", [["intracellular", "ANATOMY", 15, 28], ["cell", "ANATOMY", 73, 77], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 15, 28], ["Trx1", "GENE_OR_GENE_PRODUCT", 29, 33], ["cell", "CELL", 73, 77], ["intracellular Trx1", "PROTEIN", 15, 33], ["apoptosis", "PROBLEM", 98, 107], ["intracellular", "OBSERVATION", 15, 28], ["Trx1 counteracts", "OBSERVATION", 29, 45], ["oxidative stress", "OBSERVATION", 46, 62], ["cell growth", "OBSERVATION", 73, 84]]], ["Under conditions of oxidative stress, Trx1 is released by cells and accumulates at sites of inflammation (Nordberg and Arner, 2001) .", [["cells", "ANATOMY", 58, 63], ["sites", "ANATOMY", 83, 88], ["inflammation", "DISEASE", 92, 104], ["Trx1", "GENE_OR_GENE_PRODUCT", 38, 42], ["cells", "CELL", 58, 63], ["Trx1", "PROTEIN", 38, 42], ["oxidative stress", "PROBLEM", 20, 36], ["inflammation", "PROBLEM", 92, 104], ["oxidative stress", "OBSERVATION", 20, 36], ["inflammation", "OBSERVATION", 92, 104]]], ["Numerous studies have reported that secretory Trx1 influences effector functions and proliferation of lymphocytes (Nakamura et al, 1997) .", [["lymphocytes", "ANATOMY", 102, 113], ["Trx1", "GENE_OR_GENE_PRODUCT", 46, 50], ["lymphocytes", "CELL", 102, 113], ["secretory Trx1", "PROTEIN", 36, 50], ["lymphocytes", "CELL_TYPE", 102, 113], ["Numerous studies", "TEST", 0, 16], ["secretory Trx1 influences effector functions", "PROBLEM", 36, 80], ["proliferation", "OBSERVATION_MODIFIER", 85, 98]]], ["However, proteins and pathways coupling extracellular Trx1 redox activity to defined cellular responses have remained unknown.", [["extracellular", "ANATOMY", 40, 53], ["cellular", "ANATOMY", 85, 93], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 40, 53], ["Trx1", "GENE_OR_GENE_PRODUCT", 54, 58], ["cellular", "CELL", 85, 93], ["Trx1", "PROTEIN", 54, 58]]], ["In this study, we addressed the question regarding which lymphocyte surface receptors are targeted and regulated by the redox activity of extracellular Trx1.", [["lymphocyte surface", "ANATOMY", 57, 75], ["extracellular", "ANATOMY", 138, 151], ["lymphocyte", "CELL", 57, 67], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 138, 151], ["Trx1", "GENE_OR_GENE_PRODUCT", 152, 156], ["lymphocyte surface receptors", "PROTEIN", 57, 85], ["extracellular Trx1", "PROTEIN", 138, 156], ["this study", "TEST", 3, 13], ["lymphocyte surface receptors", "TREATMENT", 57, 85], ["extracellular Trx1", "TREATMENT", 138, 156], ["extracellular Trx1", "OBSERVATION", 138, 156]]], ["For this purpose, we made use of a mechanism-based kinetic trapping approach to capture mixed disulfide intermediates formed between exogenous Trx1 and its target proteins on the cell surface of living cells.", [["cell surface", "ANATOMY", 179, 191], ["cells", "ANATOMY", 202, 207], ["disulfide", "CHEMICAL", 94, 103], ["Trx1", "GENE_OR_GENE_PRODUCT", 143, 147], ["cell surface", "CELLULAR_COMPONENT", 179, 191], ["cells", "CELL", 202, 207], ["Trx1", "PROTEIN", 143, 147], ["target proteins", "PROTEIN", 156, 171], ["living cells", "CELL_TYPE", 195, 207], ["a mechanism-based kinetic trapping approach", "TREATMENT", 33, 76], ["mixed disulfide intermediates", "PROBLEM", 88, 117], ["exogenous Trx1", "TREATMENT", 133, 147], ["kinetic trapping", "OBSERVATION", 51, 67], ["exogenous Trx1", "OBSERVATION", 133, 147], ["living cells", "OBSERVATION", 195, 207]]], ["To our knowledge, this is the first reported application of kinetic trapping to identify novel target proteins of mammalian Trx1 and the first application of this technique to the surface of intact cells.", [["surface", "ANATOMY", 180, 187], ["cells", "ANATOMY", 198, 203], ["Trx1", "GENE_OR_GENE_PRODUCT", 124, 128], ["surface", "CELLULAR_COMPONENT", 180, 187], ["cells", "CELL", 198, 203], ["target proteins", "PROTEIN", 95, 110], ["mammalian Trx1", "PROTEIN", 114, 128], ["intact cells", "CELL_TYPE", 191, 203], ["kinetic trapping", "TREATMENT", 60, 76], ["mammalian Trx1", "TREATMENT", 114, 128], ["this technique", "TREATMENT", 158, 172], ["mammalian Trx1", "OBSERVATION", 114, 128], ["intact cells", "OBSERVATION", 191, 203]]], ["We demonstrate that Trx1 interacts with intraand extracellular target proteins in a highly selective manner, guided by specific protein-protein recognition rather than random encounters with disulfide bonds.DiscussionApplying the approach to the surface of cell lines representative of the lymphoid lineage, we observed that Trx1 basically targets a single cell surface protein, subsequently identified as TNF receptor superfamily member 8, also known as CD30.", [["extracellular", "ANATOMY", 49, 62], ["surface", "ANATOMY", 246, 253], ["cell lines", "ANATOMY", 257, 267], ["lymphoid lineage", "ANATOMY", 290, 306], ["cell surface", "ANATOMY", 357, 369], ["disulfide", "CHEMICAL", 191, 200], ["Trx1", "GENE_OR_GENE_PRODUCT", 20, 24], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 49, 62], ["disulfide bonds", "SIMPLE_CHEMICAL", 191, 206], ["surface", "CELLULAR_COMPONENT", 246, 253], ["cell lines", "CELL", 257, 267], ["lymphoid lineage", "CELL", 290, 306], ["Trx1", "GENE_OR_GENE_PRODUCT", 325, 329], ["cell surface", "CELLULAR_COMPONENT", 357, 369], ["TNF receptor superfamily member 8", "GENE_OR_GENE_PRODUCT", 406, 439], ["CD30", "GENE_OR_GENE_PRODUCT", 455, 459], ["Trx1", "PROTEIN", 20, 24], ["intraand extracellular target proteins", "PROTEIN", 40, 78], ["cell lines", "CELL_LINE", 257, 267], ["lymphoid lineage", "CELL_TYPE", 290, 306], ["Trx1", "PROTEIN", 325, 329], ["single cell surface protein", "PROTEIN", 350, 377], ["TNF receptor superfamily member 8", "PROTEIN", 406, 439], ["CD30", "PROTEIN", 455, 459], ["intraand extracellular target proteins", "TREATMENT", 40, 78], ["cell lines", "TREATMENT", 257, 267], ["a single cell surface protein", "TEST", 348, 377], ["Trx1", "OBSERVATION", 20, 24], ["cell lines", "OBSERVATION", 257, 267], ["lymphoid lineage", "OBSERVATION", 290, 306]]], ["The pronounced preference of Trx1 for one particular target protein might seem surprising, but could be due to the fact that we assessed Trx1 reactivity of proteins as they are embedded in their natural microenvironment, namely the intact surface of the active plasma membrane of living cells.", [["surface", "ANATOMY", 239, 246], ["plasma membrane", "ANATOMY", 261, 276], ["cells", "ANATOMY", 287, 292], ["Trx1", "GENE_OR_GENE_PRODUCT", 29, 33], ["Trx1", "GENE_OR_GENE_PRODUCT", 137, 141], ["surface", "CELLULAR_COMPONENT", 239, 246], ["plasma membrane", "CELLULAR_COMPONENT", 261, 276], ["cells", "CELL", 287, 292], ["Trx1", "PROTEIN", 29, 33], ["Trx1", "PROTEIN", 137, 141], ["living cells", "CELL_TYPE", 280, 292], ["Trx1", "TREATMENT", 29, 33], ["Trx1 reactivity of proteins", "PROBLEM", 137, 164], ["Trx1", "OBSERVATION", 29, 33], ["intact", "OBSERVATION_MODIFIER", 232, 238], ["surface", "OBSERVATION_MODIFIER", 239, 246], ["active plasma membrane", "OBSERVATION", 254, 276], ["living cells", "OBSERVATION", 280, 292]]], ["It is conceivable that protein disulfide exchange interactions are limited and controlled by their native context and location.DiscussionTo scrutinize the specificity of the observed interaction, we asked if the preference of Trx1 for CD30 might be caused by an unusual density of disulfide bonds within CD30 and/or exceptional cell surface expression levels.", [["cell surface", "ANATOMY", 328, 340], ["disulfide", "CHEMICAL", 31, 40], ["disulfide", "CHEMICAL", 281, 290], ["Trx1", "GENE_OR_GENE_PRODUCT", 226, 230], ["CD30", "GENE_OR_GENE_PRODUCT", 235, 239], ["CD30", "GENE_OR_GENE_PRODUCT", 304, 308], ["cell surface", "CELLULAR_COMPONENT", 328, 340], ["Trx1", "PROTEIN", 226, 230], ["CD30", "PROTEIN", 235, 239], ["CD30", "PROTEIN", 304, 308], ["protein disulfide exchange interactions", "PROBLEM", 23, 62], ["CD30", "PROBLEM", 235, 239], ["an unusual density of disulfide bonds", "PROBLEM", 259, 296], ["protein", "OBSERVATION", 23, 30], ["disulfide exchange", "OBSERVATION", 31, 49], ["unusual", "OBSERVATION_MODIFIER", 262, 269], ["density", "OBSERVATION", 270, 277], ["disulfide bonds", "OBSERVATION", 281, 296], ["exceptional cell", "OBSERVATION", 316, 332], ["surface expression", "OBSERVATION", 333, 351]]], ["Although the CD30 ectodomain harbors a significant number of predicted disulfide bridges within CRDs, it does not appear to be unusual in terms of disulfide bond composition/density when compared to other members of the superfamily.", [["disulfide", "CHEMICAL", 71, 80], ["disulfide", "CHEMICAL", 147, 156], ["CD30", "GENE_OR_GENE_PRODUCT", 13, 17], ["CRDs", "PATHOLOGICAL_FORMATION", 96, 100], ["CD30 ectodomain", "PROTEIN", 13, 28], ["disulfide bridges", "PROTEIN", 71, 88], ["CRDs", "PROTEIN", 96, 100], ["disulfide bond composition/density", "PROBLEM", 147, 181], ["significant", "OBSERVATION_MODIFIER", 39, 50], ["number", "OBSERVATION_MODIFIER", 51, 57], ["disulfide bridges", "OBSERVATION", 71, 88], ["does not appear to be", "UNCERTAINTY", 105, 126], ["unusual", "OBSERVATION", 127, 134], ["disulfide bond", "OBSERVATION", 147, 161], ["density", "OBSERVATION", 174, 181]]], ["When tested experimentally, Trx1 failed to interact with other CRD-containing proteins, including the EGFR featuring a total of 25 ectodomain disulfide bonds.", [["disulfide", "CHEMICAL", 142, 151], ["Trx1", "GENE_OR_GENE_PRODUCT", 28, 32], ["CRD", "GENE_OR_GENE_PRODUCT", 63, 66], ["EGFR", "GENE_OR_GENE_PRODUCT", 102, 106], ["Trx1", "PROTEIN", 28, 32], ["CRD-containing proteins", "PROTEIN", 63, 86], ["EGFR", "PROTEIN", 102, 106], ["the EGFR", "TEST", 98, 106], ["a total of 25 ectodomain disulfide bonds", "TREATMENT", 117, 157]]], ["The preference for CD30 could not be explained by exceptional surface expression levels either.", [["surface", "ANATOMY", 62, 69], ["CD30", "GENE_OR_GENE_PRODUCT", 19, 23], ["CD30", "PROTEIN", 19, 23], ["CD30", "PROBLEM", 19, 23]]], ["While Hodgkin's disease cell lines typically express high levels of CD30, other cell lines including LCL-721.220 or CCRF-CEM show at least 20-to 100-fold lower expression as determined by flow cytometry, yet the same selective targeting was observed.", [["Hodgkin's disease cell lines", "ANATOMY", 6, 34], ["cell lines", "ANATOMY", 80, 90], ["LCL-721.220", "ANATOMY", 101, 112], ["CCRF-CEM", "ANATOMY", 116, 124], ["Hodgkin's disease", "DISEASE", 6, 23], ["Hodgkin's disease cell lines", "CELL", 6, 34], ["CD30", "GENE_OR_GENE_PRODUCT", 68, 72], ["cell lines", "CELL", 80, 90], ["LCL-721.220", "CELL", 101, 112], ["CCRF-CEM", "CELL", 116, 124], ["Hodgkin's disease cell lines", "CELL_LINE", 6, 34], ["CD30", "PROTEIN", 68, 72], ["cell lines", "CELL_LINE", 80, 90], ["LCL-721.220", "CELL_LINE", 101, 112], ["CCRF-CEM", "CELL_LINE", 116, 124], ["Hodgkin's disease cell lines", "PROBLEM", 6, 34], ["high levels of CD30", "PROBLEM", 53, 72], ["other cell lines", "TEST", 74, 90], ["LCL", "TEST", 101, 104], ["CCRF", "TEST", 116, 120], ["CEM", "TEST", 121, 124], ["flow cytometry", "TEST", 188, 202], ["cell lines", "OBSERVATION", 24, 34], ["high levels", "OBSERVATION_MODIFIER", 53, 64], ["cell lines", "OBSERVATION", 80, 90], ["LCL", "ANATOMY", 101, 104], ["flow cytometry", "OBSERVATION", 188, 202]]], ["Conversely, ectopic overexpression of several related TNFR superfamily members in HeLa cells did not lead to their interaction with Trx1, yet CD30 strongly interacted on the same cells under the same conditions.", [["HeLa cells", "ANATOMY", 82, 92], ["cells", "ANATOMY", 179, 184], ["TNFR", "GENE_OR_GENE_PRODUCT", 54, 58], ["HeLa cells", "CELL", 82, 92], ["Trx1", "GENE_OR_GENE_PRODUCT", 132, 136], ["CD30", "GENE_OR_GENE_PRODUCT", 142, 146], ["cells", "CELL", 179, 184], ["TNFR superfamily members", "PROTEIN", 54, 78], ["HeLa cells", "CELL_LINE", 82, 92], ["Trx1", "PROTEIN", 132, 136], ["CD30", "PROTEIN", 142, 146], ["ectopic overexpression", "PROBLEM", 12, 34], ["HeLa cells", "PROBLEM", 82, 92]]], ["Consistent with these findings, recent experiments demonstrate that Trx1 targets a particular site within the CD30 ectodomain (Y Balmer and TP Dick, unpublished data) .DiscussionTo facilitate identification of low-abundance cell surface proteins, in vitro trapping experiments were typically performed using Trx1 concentrations of 1-3 mM.", [["cell surface", "ANATOMY", 224, 236], ["Trx1", "GENE_OR_GENE_PRODUCT", 68, 72], ["CD30", "GENE_OR_GENE_PRODUCT", 110, 114], ["TP Dick", "GENE_OR_GENE_PRODUCT", 140, 147], ["cell", "CELL", 224, 228], ["Trx1", "GENE_OR_GENE_PRODUCT", 308, 312], ["Trx1", "PROTEIN", 68, 72], ["CD30 ectodomain", "PROTEIN", 110, 125], ["Y Balmer", "PROTEIN", 127, 135], ["low-abundance cell surface proteins", "PROTEIN", 210, 245], ["Trx1", "PROTEIN", 308, 312], ["Trx1 targets a particular site", "PROBLEM", 68, 98], ["TP Dick", "TEST", 140, 147], ["low-abundance cell surface proteins", "PROBLEM", 210, 245], ["vitro trapping experiments", "TEST", 250, 276], ["Trx1 concentrations", "TEST", 308, 327], ["CD30 ectodomain", "OBSERVATION", 110, 125], ["low", "OBSERVATION_MODIFIER", 210, 213]]], ["However, when disulfide exchange was subsequently tested at lower concentrations, Trx1(CSAAA) concentrations in the low nanomolar range (4-40 nM) were found to give rise to the formation of proportional amounts of Trx1-CD30 mixed disulfide intermediates ( Figure 3B ), thus demonstrating that the observed interaction is compatible with the expected physiological concentration range of secretory Trx1 (see below).DiscussionWild-type Trx1 is known to act as a multiple-turnover catalyst if a suitable reducing system and electron source is provided for its regeneration.", [["disulfide", "CHEMICAL", 14, 23], ["disulfide", "CHEMICAL", 230, 239], ["Trx1", "GENE_OR_GENE_PRODUCT", 82, 86], ["CSAAA", "SIMPLE_CHEMICAL", 87, 92], ["Trx1", "GENE_OR_GENE_PRODUCT", 214, 218], ["CD30", "GENE_OR_GENE_PRODUCT", 219, 223], ["Trx1", "GENE_OR_GENE_PRODUCT", 397, 401], ["Trx1", "GENE_OR_GENE_PRODUCT", 434, 438], ["electron", "SIMPLE_CHEMICAL", 521, 529], ["Trx1", "PROTEIN", 82, 86], ["CSAAA", "PROTEIN", 87, 92], ["Trx1", "PROTEIN", 214, 218], ["CD30", "PROTEIN", 219, 223], ["secretory Trx1", "PROTEIN", 387, 401], ["DiscussionWild-type Trx1", "PROTEIN", 414, 438], ["disulfide exchange", "TREATMENT", 14, 32], ["Trx1(CSAAA) concentrations", "TEST", 82, 108], ["Trx1", "TEST", 214, 218], ["secretory Trx1", "PROBLEM", 387, 401], ["a multiple-turnover catalyst", "TREATMENT", 458, 486], ["its regeneration", "PROBLEM", 553, 569], ["low nanomolar", "OBSERVATION_MODIFIER", 116, 129], ["compatible with", "UNCERTAINTY", 321, 336], ["secretory Trx1", "OBSERVATION", 387, 401]]], ["In agreement with these considerations, we observed that sustained reduction of CD30 in cell culture requires a Trx1 regenerating system.", [["cell culture", "ANATOMY", 88, 100], ["CD30", "GENE_OR_GENE_PRODUCT", 80, 84], ["cell", "CELL", 88, 92], ["Trx1", "GENE_OR_GENE_PRODUCT", 112, 116], ["CD30", "PROTEIN", 80, 84], ["Trx1", "PROTEIN", 112, 116], ["CD30 in cell culture", "PROBLEM", 80, 100], ["a Trx1 regenerating system", "TREATMENT", 110, 136]]], ["Using flow cytometry to monitor conformational changes in the CD30 ectodomain, CD30 was found to respond to Trx1 concentrations in the nanomolar range, starting at around 100 nM ( Figure 5E , lower panel).", [["CD30", "GENE_OR_GENE_PRODUCT", 62, 66], ["CD30", "GENE_OR_GENE_PRODUCT", 79, 83], ["Trx1", "GENE_OR_GENE_PRODUCT", 108, 112], ["CD30 ectodomain", "PROTEIN", 62, 77], ["CD30", "PROTEIN", 79, 83], ["Trx1", "PROTEIN", 108, 112], ["flow cytometry", "TEST", 6, 20], ["conformational changes", "PROBLEM", 32, 54], ["the CD30 ectodomain", "TEST", 58, 77], ["Trx1 concentrations", "TEST", 108, 127]]], ["However, the minimal Trx1 concentration required for sustained CD30 reduction might be substantially lower in specific environments, which are efficient in delivering reducing equivalents and preventing oxidative inactivation of Trx1.DiscussionAt present, it is not clear how extracellular Trx1 is regenerated in vivo.", [["extracellular", "ANATOMY", 276, 289], ["Trx1", "GENE_OR_GENE_PRODUCT", 21, 25], ["CD30", "GENE_OR_GENE_PRODUCT", 63, 67], ["Trx1", "GENE_OR_GENE_PRODUCT", 229, 233], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 276, 289], ["Trx1", "GENE_OR_GENE_PRODUCT", 290, 294], ["Trx1", "PROTEIN", 21, 25], ["CD30", "PROTEIN", 63, 67], ["Trx1", "PROTEIN", 229, 233], ["extracellular Trx1", "PROTEIN", 276, 294], ["the minimal Trx1 concentration", "PROBLEM", 9, 39], ["sustained CD30 reduction", "TREATMENT", 53, 77], ["oxidative inactivation of Trx1", "TREATMENT", 203, 233], ["minimal", "OBSERVATION_MODIFIER", 13, 20], ["Trx1 concentration", "OBSERVATION", 21, 39]]], ["Despite the overall oxidizing character of the extracellular compartment, reductive processes are known to take place on the cell surface.", [["extracellular compartment", "ANATOMY", 47, 72], ["cell surface", "ANATOMY", 125, 137], ["extracellular compartment", "CELLULAR_COMPONENT", 47, 72], ["cell surface", "CELLULAR_COMPONENT", 125, 137], ["reductive processes", "PROBLEM", 74, 93], ["oxidizing character", "OBSERVATION", 20, 39], ["extracellular", "ANATOMY_MODIFIER", 47, 60], ["compartment", "ANATOMY", 61, 72], ["reductive processes", "OBSERVATION", 74, 93]]], ["On the one hand, there is longstanding evidence for the existence of transplasma membrane redox systems delivering electrons to the cell surface (Crane et al, 1985) .", [["membrane", "ANATOMY", 81, 89], ["cell surface", "ANATOMY", 132, 144], ["cell surface", "CELLULAR_COMPONENT", 132, 144], ["transplasma membrane redox systems", "TREATMENT", 69, 103], ["longstanding evidence for", "UNCERTAINTY", 26, 51]]], ["On the other hand, Trx1 may be regenerated by co-secreted reductants, as Trx1 secretion in DC-T co-culture is accompanied by the release of reduced cysteine and the creation of a reducing microenvironment between interacting cells (Angelini et al, 2002) .", [["DC", "ANATOMY", 91, 93], ["cells", "ANATOMY", 225, 230], ["cysteine", "CHEMICAL", 148, 156], ["cysteine", "CHEMICAL", 148, 156], ["Trx1", "GENE_OR_GENE_PRODUCT", 19, 23], ["Trx1", "GENE_OR_GENE_PRODUCT", 73, 77], ["DC-T", "CELL", 91, 95], ["cysteine", "AMINO_ACID", 148, 156], ["cells", "CELL", 225, 230], ["Trx1", "PROTEIN", 19, 23], ["Trx1", "PROTEIN", 73, 77], ["DC", "CELL_TYPE", 91, 93], ["interacting cells", "CELL_TYPE", 213, 230], ["co-secreted reductants", "TREATMENT", 46, 68], ["Trx1 secretion", "TEST", 73, 87], ["reduced cysteine", "PROBLEM", 140, 156], ["a reducing microenvironment between interacting cells", "TREATMENT", 177, 230]]], ["In addition, TrxR was found to be secreted by activated monocytes and might be part of an extracellular Trx1 reducing system (Soderberg et al, 2000) .DiscussionThe concentration of Trx1 in human plasma is in the low nanomolar range (1-5 nM), and is found to be elevated several-fold under inflammatory conditions (Yoshida et al, 1999) .", [["monocytes", "ANATOMY", 56, 65], ["extracellular", "ANATOMY", 90, 103], ["plasma", "ANATOMY", 195, 201], ["TrxR", "GENE_OR_GENE_PRODUCT", 13, 17], ["monocytes", "CELL", 56, 65], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 90, 103], ["Trx1", "GENE_OR_GENE_PRODUCT", 104, 108], ["Trx1", "GENE_OR_GENE_PRODUCT", 181, 185], ["human", "ORGANISM", 189, 194], ["plasma", "ORGANISM_SUBSTANCE", 195, 201], ["TrxR", "PROTEIN", 13, 17], ["activated monocytes", "CELL_TYPE", 46, 65], ["Trx1", "PROTEIN", 104, 108], ["Trx1", "PROTEIN", 181, 185], ["human", "SPECIES", 189, 194], ["human", "SPECIES", 189, 194], ["TrxR", "TEST", 13, 17], ["activated monocytes", "PROBLEM", 46, 65], ["Trx1 in human plasma", "TEST", 181, 201], ["elevated several-fold under inflammatory conditions", "PROBLEM", 261, 312], ["activated monocytes", "OBSERVATION", 46, 65], ["extracellular", "OBSERVATION_MODIFIER", 90, 103], ["Trx1", "OBSERVATION", 104, 108], ["elevated", "OBSERVATION", 261, 269], ["several", "OBSERVATION_MODIFIER", 270, 277], ["-fold", "OBSERVATION_MODIFIER", 277, 282], ["inflammatory", "OBSERVATION_MODIFIER", 289, 301]]], ["However, plasma Trx1 is oxidized and appears to represent systemic dilution of Trx1 previously released within tissues.", [["plasma", "ANATOMY", 9, 15], ["tissues", "ANATOMY", 111, 118], ["plasma", "ORGANISM_SUBSTANCE", 9, 15], ["Trx1", "GENE_OR_GENE_PRODUCT", 16, 20], ["Trx1", "GENE_OR_GENE_PRODUCT", 79, 83], ["tissues", "TISSUE", 111, 118], ["plasma Trx1", "PROTEIN", 9, 20], ["Trx1", "PROTEIN", 79, 83], ["plasma Trx1", "TEST", 9, 20], ["systemic dilution of Trx1", "PROBLEM", 58, 83], ["appears to represent", "UNCERTAINTY", 37, 57], ["systemic", "OBSERVATION_MODIFIER", 58, 66], ["dilution", "OBSERVATION", 67, 75], ["Trx1", "OBSERVATION", 79, 83]]], ["Accordingly, local tissue concentrations of secretory Trx1, for example, within activated lymph nodes, are expected to be markedly higher than in plasma.", [["tissue", "ANATOMY", 19, 25], ["lymph nodes", "ANATOMY", 90, 101], ["plasma", "ANATOMY", 146, 152], ["tissue", "TISSUE", 19, 25], ["Trx1", "GENE_OR_GENE_PRODUCT", 54, 58], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 90, 101], ["plasma", "ORGANISM_SUBSTANCE", 146, 152], ["secretory Trx1", "PROTEIN", 44, 58], ["secretory Trx1", "TEST", 44, 58], ["activated lymph nodes", "PROBLEM", 80, 101], ["local tissue", "OBSERVATION_MODIFIER", 13, 25], ["concentrations", "OBSERVATION_MODIFIER", 26, 40], ["secretory Trx1", "OBSERVATION", 44, 58], ["lymph nodes", "OBSERVATION", 90, 101], ["markedly", "OBSERVATION_MODIFIER", 122, 130], ["higher", "OBSERVATION_MODIFIER", 131, 137]]], ["Overall Trx1 concentrations in mammalian tissues can be as high as 20 mM (Gromer et al, 2004) .", [["tissues", "ANATOMY", 41, 48], ["Trx1", "GENE_OR_GENE_PRODUCT", 8, 12], ["mammalian tissues", "TISSUE", 31, 48], ["Trx1", "PROTEIN", 8, 12], ["Trx1 concentrations", "OBSERVATION", 8, 27], ["mammalian tissues", "OBSERVATION", 31, 48]]], ["Certain Trx1-secreting cell types, including macrophages and dendritic cells, distinctly upregulate expression of Trx1 upon activation (Angelini et al, 2002) .", [["cell", "ANATOMY", 23, 27], ["macrophages", "ANATOMY", 45, 56], ["dendritic cells", "ANATOMY", 61, 76], ["Trx1", "GENE_OR_GENE_PRODUCT", 8, 12], ["cell", "CELL", 23, 27], ["macrophages", "CELL", 45, 56], ["dendritic cells", "CELL", 61, 76], ["Trx1", "GENE_OR_GENE_PRODUCT", 114, 118], ["Trx1", "PROTEIN", 8, 12], ["macrophages", "CELL_TYPE", 45, 56], ["dendritic cells", "CELL_TYPE", 61, 76], ["Trx1", "PROTEIN", 114, 118], ["macrophages", "PROBLEM", 45, 56], ["dendritic cells", "PROBLEM", 61, 76], ["secreting cell types", "OBSERVATION", 13, 33], ["macrophages", "ANATOMY", 45, 56], ["dendritic cells", "OBSERVATION", 61, 76]]], ["In vitro studies of Trx1 secretion suggest that a substantial fraction of intracellular Trx1 can be released within a few hours (Rubartelli et al, 1992) .", [["intracellular", "ANATOMY", 74, 87], ["Trx1", "GENE_OR_GENE_PRODUCT", 20, 24], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 74, 87], ["Trx1", "GENE_OR_GENE_PRODUCT", 88, 92], ["Trx1", "PROTEIN", 20, 24], ["intracellular Trx1", "PROTEIN", 74, 92], ["Trx1 secretion", "PROBLEM", 20, 34], ["intracellular Trx1", "TREATMENT", 74, 92], ["substantial", "OBSERVATION_MODIFIER", 50, 61], ["fraction", "OBSERVATION_MODIFIER", 62, 70], ["intracellular Trx1", "OBSERVATION", 74, 92]]], ["Although direct measurements of extracellular Trx1 within tissues are not available, physiologically relevant extracellular Trx1 concentrations may well reach into the upper nanomolar, if not lower micromolar range.DiscussionWe found that Trx1-mediated disulfide reduction changes the conformation and functional properties of the CD30 ectodomain.", [["extracellular", "ANATOMY", 32, 45], ["tissues", "ANATOMY", 58, 65], ["extracellular", "ANATOMY", 110, 123], ["disulfide", "CHEMICAL", 253, 262], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 32, 45], ["Trx1", "GENE_OR_GENE_PRODUCT", 46, 50], ["tissues", "TISSUE", 58, 65], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 110, 123], ["Trx1", "GENE_OR_GENE_PRODUCT", 124, 128], ["Trx1", "GENE_OR_GENE_PRODUCT", 239, 243], ["CD30", "GENE_OR_GENE_PRODUCT", 331, 335], ["extracellular Trx1", "PROTEIN", 32, 50], ["Trx1", "PROTEIN", 124, 128], ["Trx1", "PROTEIN", 239, 243], ["CD30 ectodomain", "PROTEIN", 331, 346], ["direct measurements of extracellular Trx1", "TEST", 9, 50], ["extracellular Trx1 concentrations", "TREATMENT", 110, 143], ["Trx1-mediated disulfide reduction", "TREATMENT", 239, 272], ["the CD30 ectodomain", "PROBLEM", 327, 346], ["extracellular Trx1", "OBSERVATION", 32, 50], ["Trx1 concentrations", "OBSERVATION", 124, 143], ["upper nanomolar", "ANATOMY", 168, 183], ["CD30 ectodomain", "OBSERVATION", 331, 346]]], ["In the reduced state, CD30 lost its ability to interact with its cognate ligand CD30L or agonistic antibodies.", [["CD30", "GENE_OR_GENE_PRODUCT", 22, 26], ["CD30L", "GENE_OR_GENE_PRODUCT", 80, 85], ["CD30", "PROTEIN", 22, 26], ["CD30L", "PROTEIN", 80, 85], ["agonistic antibodies", "PROTEIN", 89, 109], ["agonistic antibodies", "PROBLEM", 89, 109], ["reduced", "OBSERVATION_MODIFIER", 7, 14]]], ["The presence of catalytically active Trx1 impeded CD30-dependent signaling in the YT lymphoma cell line, as demonstrated by its effect on CD25 and FasL expression, as well as its influence on cytotoxicity against Fas-expressing target cells.DiscussionThe physiological role of the CD30-CD30L system has remained unclear.", [["YT lymphoma cell line", "ANATOMY", 82, 103], ["cells", "ANATOMY", 235, 240], ["CD30-CD30L system", "ANATOMY", 281, 298], ["lymphoma", "DISEASE", 85, 93], ["Trx1", "GENE_OR_GENE_PRODUCT", 37, 41], ["CD30", "GENE_OR_GENE_PRODUCT", 50, 54], ["YT lymphoma cell line", "CELL", 82, 103], ["CD25", "GENE_OR_GENE_PRODUCT", 138, 142], ["FasL", "GENE_OR_GENE_PRODUCT", 147, 151], ["cells", "CELL", 235, 240], ["CD30", "GENE_OR_GENE_PRODUCT", 281, 285], ["CD30L", "GENE_OR_GENE_PRODUCT", 286, 291], ["Trx1", "PROTEIN", 37, 41], ["CD30", "PROTEIN", 50, 54], ["YT lymphoma cell line", "CELL_LINE", 82, 103], ["CD25", "PROTEIN", 138, 142], ["FasL", "PROTEIN", 147, 151], ["Fas-expressing target cells", "CELL_LINE", 213, 240], ["CD30", "PROTEIN", 281, 285], ["CD30L", "PROTEIN", 286, 291], ["catalytically active Trx1", "PROBLEM", 16, 41], ["CD30", "TEST", 50, 54], ["dependent signaling in the YT lymphoma cell line", "PROBLEM", 55, 103], ["CD25", "TEST", 138, 142], ["FasL expression", "TEST", 147, 162], ["cytotoxicity", "TEST", 192, 204], ["Fas-expressing target cells", "PROBLEM", 213, 240], ["the CD30-CD30L system", "TREATMENT", 277, 298], ["catalytically", "OBSERVATION_MODIFIER", 16, 29], ["active", "OBSERVATION_MODIFIER", 30, 36], ["Trx1", "OBSERVATION", 37, 41], ["CD30", "OBSERVATION", 50, 54], ["dependent", "OBSERVATION_MODIFIER", 55, 64], ["signaling", "OBSERVATION_MODIFIER", 65, 74], ["YT", "ANATOMY", 82, 84], ["lymphoma cell line", "OBSERVATION", 85, 103], ["effect", "OBSERVATION_MODIFIER", 128, 134], ["target cells", "OBSERVATION", 228, 240]]], ["In vitro studies focusing on CD30 \u00fe lymphoid malignancies showed that triggering of CD30 signaling can induce either proliferation, activation, growth arrest or apoptosis, depending on cell type and stimulatory conditions (Schneider and Hubinger, 2002) .", [["CD30 \u00fe lymphoid malignancies", "ANATOMY", 29, 57], ["cell", "ANATOMY", 185, 189], ["lymphoid malignancies", "DISEASE", 36, 57], ["CD30", "GENE_OR_GENE_PRODUCT", 29, 33], ["lymphoid malignancies", "CANCER", 36, 57], ["CD30", "GENE_OR_GENE_PRODUCT", 84, 88], ["cell", "CELL", 185, 189], ["CD30", "PROTEIN", 29, 33], ["CD30", "PROTEIN", 84, 88], ["vitro studies", "TEST", 3, 16], ["lymphoid malignancies", "PROBLEM", 36, 57], ["CD30 signaling", "PROBLEM", 84, 98], ["proliferation", "PROBLEM", 117, 130], ["growth arrest", "PROBLEM", 144, 157], ["apoptosis", "PROBLEM", 161, 170], ["lymphoid malignancies", "OBSERVATION", 36, 57], ["proliferation", "OBSERVATION", 117, 130]]], ["In vivo, cell surface expression of CD30 appears to be tightly regulated and restricted to B and T lymphocytes undergoing activation in lymphoid tissues.", [["cell surface", "ANATOMY", 9, 21], ["B", "ANATOMY", 91, 92], ["T lymphocytes", "ANATOMY", 97, 110], ["lymphoid tissues", "ANATOMY", 136, 152], ["cell", "CELL", 9, 13], ["CD30", "GENE_OR_GENE_PRODUCT", 36, 40], ["B", "CELL", 91, 92], ["T lymphocytes", "CELL", 97, 110], ["lymphoid tissues", "TISSUE", 136, 152], ["CD30", "PROTEIN", 36, 40], ["B and T lymphocytes", "CELL_TYPE", 91, 110], ["CD30", "PROBLEM", 36, 40], ["activation in lymphoid tissues", "PROBLEM", 122, 152], ["CD30", "OBSERVATION", 36, 40], ["lymphocytes", "OBSERVATION", 99, 110], ["lymphoid tissues", "OBSERVATION", 136, 152]]], ["It has been proposed that CD30 provides proliferation and/or survival signals during lymphocyte responses (Croft, 2003) .DiscussionUnder inflammatory conditions, CD30 expression is markedly induced.", [["lymphocyte", "ANATOMY", 85, 95], ["CD30", "GENE_OR_GENE_PRODUCT", 26, 30], ["lymphocyte", "CELL", 85, 95], ["CD30", "GENE_OR_GENE_PRODUCT", 162, 166], ["CD30", "PROTEIN", 26, 30], ["CD30", "PROTEIN", 162, 166], ["survival signals", "PROBLEM", 61, 77], ["lymphocyte responses", "TEST", 85, 105], ["inflammatory conditions", "PROBLEM", 137, 160], ["markedly", "OBSERVATION_MODIFIER", 181, 189]]], ["In vivo activation of CD30 can be monitored by the release of sCD30, shed from the plasma membrane upon CD30L binding (Hansen et al, 2000) .", [["plasma membrane", "ANATOMY", 83, 98], ["CD30", "GENE_OR_GENE_PRODUCT", 22, 26], ["sCD30", "GENE_OR_GENE_PRODUCT", 62, 67], ["plasma membrane", "CELLULAR_COMPONENT", 83, 98], ["CD30L", "GENE_OR_GENE_PRODUCT", 104, 109], ["CD30", "PROTEIN", 22, 26], ["sCD30", "PROTEIN", 62, 67], ["CD30L", "PROTEIN", 104, 109]]], ["Similar to serum Trx1, serum sCD30 is increased in infection, autoimmunity and allergy, for example systemic lupus erythematosus, rheumatoid arthritis and atopic dermatitis (Horie and Watanabe, 1998) .", [["serum", "ANATOMY", 11, 16], ["serum", "ANATOMY", 23, 28], ["infection", "DISEASE", 51, 60], ["autoimmunity", "DISEASE", 62, 74], ["allergy", "DISEASE", 79, 86], ["systemic lupus erythematosus", "DISEASE", 100, 128], ["rheumatoid arthritis", "DISEASE", 130, 150], ["atopic dermatitis", "DISEASE", 155, 172], ["serum", "ORGANISM_SUBSTANCE", 11, 16], ["Trx1", "GENE_OR_GENE_PRODUCT", 17, 21], ["serum", "ORGANISM_SUBSTANCE", 23, 28], ["sCD30", "GENE_OR_GENE_PRODUCT", 29, 34], ["serum Trx1", "PROTEIN", 11, 21], ["serum sCD30", "PROTEIN", 23, 34], ["serum Trx1", "TEST", 11, 21], ["serum sCD30", "TEST", 23, 34], ["infection", "PROBLEM", 51, 60], ["autoimmunity", "PROBLEM", 62, 74], ["allergy", "PROBLEM", 79, 86], ["systemic lupus erythematosus", "PROBLEM", 100, 128], ["rheumatoid arthritis", "PROBLEM", 130, 150], ["atopic dermatitis", "PROBLEM", 155, 172], ["increased", "OBSERVATION_MODIFIER", 38, 47], ["infection", "OBSERVATION", 51, 60], ["systemic", "OBSERVATION_MODIFIER", 100, 108], ["lupus erythematosus", "OBSERVATION", 109, 128], ["rheumatoid arthritis", "OBSERVATION", 130, 150], ["atopic dermatitis", "OBSERVATION", 155, 172]]], ["Both Trx1 and CD30 appear to play a role in the regulation of the antiviral inflammatory response.", [["Trx1", "GENE_OR_GENE_PRODUCT", 5, 9], ["CD30", "GENE_OR_GENE_PRODUCT", 14, 18], ["Trx1", "PROTEIN", 5, 9], ["CD30", "PROTEIN", 14, 18], ["the antiviral inflammatory response", "TREATMENT", 62, 97], ["Trx1", "OBSERVATION", 5, 9], ["CD30", "OBSERVATION", 14, 18], ["antiviral inflammatory", "OBSERVATION", 66, 88]]], ["Both Trx1 secretion and CD30 expression have been associated with virally transformed lymphocytes.", [["lymphocytes", "ANATOMY", 86, 97], ["Trx1", "GENE_OR_GENE_PRODUCT", 5, 9], ["CD30", "GENE_OR_GENE_PRODUCT", 24, 28], ["lymphocytes", "CELL", 86, 97], ["Trx1", "PROTEIN", 5, 9], ["CD30", "PROTEIN", 24, 28], ["virally transformed lymphocytes", "CELL_LINE", 66, 97], ["virally transformed lymphocytes", "PROBLEM", 66, 97], ["Trx1 secretion", "OBSERVATION", 5, 19], ["associated with", "UNCERTAINTY", 50, 65], ["virally", "OBSERVATION_MODIFIER", 66, 73], ["transformed lymphocytes", "OBSERVATION", 74, 97]]], ["Elevated levels of sCD30 occur during viral infection.", [["viral infection", "DISEASE", 38, 53], ["sCD30", "GENE_OR_GENE_PRODUCT", 19, 24], ["sCD30", "PROTEIN", 19, 24], ["Elevated levels of sCD30", "PROBLEM", 0, 24], ["viral infection", "PROBLEM", 38, 53], ["sCD30", "OBSERVATION", 19, 24], ["viral", "OBSERVATION_MODIFIER", 38, 43], ["infection", "OBSERVATION", 44, 53]]], ["Likewise, viral infection leads to elevated Trx1 plasma levels and several studies indicate that secreted Trx1 modulates the antiviral inflammatory process (Nakamura et al, 2001b (Nakamura et al, , 2002 .DiscussionIn this study, we have identified an enzyme-substrate relationship between Trx1 and CD30, a receptor of activated lymphocytes involved in the regulation of inflammation.", [["plasma", "ANATOMY", 49, 55], ["lymphocytes", "ANATOMY", 328, 339], ["viral infection", "DISEASE", 10, 25], ["inflammation", "DISEASE", 370, 382], ["Trx1", "GENE_OR_GENE_PRODUCT", 44, 48], ["plasma", "ORGANISM_SUBSTANCE", 49, 55], ["Trx1", "GENE_OR_GENE_PRODUCT", 106, 110], ["Trx1", "GENE_OR_GENE_PRODUCT", 289, 293], ["CD30", "GENE_OR_GENE_PRODUCT", 298, 302], ["lymphocytes", "CELL", 328, 339], ["Trx1", "PROTEIN", 44, 48], ["Trx1", "PROTEIN", 106, 110], ["Trx1", "PROTEIN", 289, 293], ["CD30", "PROTEIN", 298, 302], ["activated lymphocytes", "CELL_TYPE", 318, 339], ["viral infection", "PROBLEM", 10, 25], ["elevated Trx1 plasma levels", "PROBLEM", 35, 62], ["several studies", "TEST", 67, 82], ["secreted Trx1 modulates the antiviral inflammatory process", "PROBLEM", 97, 155], ["this study", "TEST", 217, 227], ["an enzyme", "TEST", 248, 257], ["Trx1", "TEST", 289, 293], ["activated lymphocytes", "PROBLEM", 318, 339], ["inflammation", "PROBLEM", 370, 382], ["viral", "OBSERVATION_MODIFIER", 10, 15], ["infection", "OBSERVATION", 16, 25], ["secreted Trx1", "OBSERVATION", 97, 110], ["antiviral inflammatory", "OBSERVATION", 125, 147], ["CD30", "ANATOMY", 298, 302], ["activated lymphocytes", "OBSERVATION", 318, 339], ["inflammation", "OBSERVATION", 370, 382]]], ["As lymphocytes migrate between different microenvironments, it is conceivable that Trx1 catalyzes disulfide exchange dynamically, activating or inactivating the CD30 pathway in response to the redox environment.", [["lymphocytes", "ANATOMY", 3, 14], ["disulfide", "CHEMICAL", 98, 107], ["lymphocytes", "CELL", 3, 14], ["Trx1", "GENE_OR_GENE_PRODUCT", 83, 87], ["disulfide", "SIMPLE_CHEMICAL", 98, 107], ["CD30", "GENE_OR_GENE_PRODUCT", 161, 165], ["lymphocytes", "CELL_TYPE", 3, 14], ["Trx1", "PROTEIN", 83, 87], ["CD30", "PROTEIN", 161, 165], ["Trx1 catalyzes disulfide exchange", "TREATMENT", 83, 116]]], ["The interaction between Trx1 and CD30 might represent a regulatory link between oxidative stress and lymphocyte function.", [["lymphocyte", "ANATOMY", 101, 111], ["Trx1", "GENE_OR_GENE_PRODUCT", 24, 28], ["CD30", "GENE_OR_GENE_PRODUCT", 33, 37], ["lymphocyte", "CELL", 101, 111], ["Trx1", "PROTEIN", 24, 28], ["CD30", "PROTEIN", 33, 37], ["lymphocyte function", "OBSERVATION", 101, 120]]], ["Understanding of this relationship in vivo awaits the generation of suitable experimental tools.Materials and methodsCell culture BL-41, CCRF-CEM, HDLM-2, Jurkat, RMA and U937 cells were cultured in RPMI 1640 (Gibco) supplemented with 10% heatinactivated fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco).", [["Cell", "ANATOMY", 117, 121], ["BL-41", "ANATOMY", 130, 135], ["CCRF-CEM", "ANATOMY", 137, 145], ["HDLM-2", "ANATOMY", 147, 153], ["Jurkat", "ANATOMY", 155, 161], ["RMA", "ANATOMY", 163, 166], ["U937 cells", "ANATOMY", 171, 181], ["serum", "ANATOMY", 268, 273], ["L-glutamine", "CHEMICAL", 280, 291], ["penicillin", "CHEMICAL", 302, 312], ["streptomycin", "CHEMICAL", 327, 339], ["L-glutamine", "CHEMICAL", 280, 291], ["penicillin", "CHEMICAL", 302, 312], ["streptomycin", "CHEMICAL", 327, 339], ["Cell", "CELL", 117, 121], ["BL-41", "CELL", 130, 135], ["CCRF-CEM", "CELL", 137, 145], ["HDLM-2", "CELL", 147, 153], ["Jurkat", "CELL", 155, 161], ["RMA", "CELL", 163, 166], ["U937 cells", "CELL", 171, 181], ["Gibco", "ORGANISM_SUBSTANCE", 210, 215], ["bovine", "ORGANISM", 261, 267], ["serum", "ORGANISM_SUBSTANCE", 268, 273], ["L-glutamine", "SIMPLE_CHEMICAL", 280, 291], ["penicillin", "SIMPLE_CHEMICAL", 302, 312], ["streptomycin", "SIMPLE_CHEMICAL", 327, 339], ["CCRF-CEM", "CELL_LINE", 137, 145], ["HDLM", "CELL_LINE", 147, 151], ["Jurkat", "CELL_LINE", 155, 161], ["RMA", "CELL_LINE", 163, 166], ["U937 cells", "CELL_LINE", 171, 181], ["bovine", "SPECIES", 261, 267], ["bovine", "SPECIES", 261, 267], ["Cell culture", "TEST", 117, 129], ["BL", "TEST", 130, 132], ["CCRF", "TEST", 137, 141], ["CEM", "TEST", 142, 145], ["HDLM", "TEST", 147, 151], ["Jurkat", "TEST", 155, 161], ["U937 cells", "TEST", 171, 181], ["RPMI", "TEST", 199, 203], ["10% heatinactivated fetal bovine serum", "TREATMENT", 235, 273], ["2 mM L-glutamine", "TREATMENT", 275, 291], ["penicillin", "TREATMENT", 302, 312], ["streptomycin", "TREATMENT", 327, 339], ["Jurkat", "ANATOMY", 155, 161]]], ["LCL-721.220 and YT cells were cultured in IMDM (Gibco), HeLa and A431 cells in DMEM (Gibco) with the same supplements.Substrate trappingDepending on the type of experiment, recombinant trapping mutant was applied to cytosolic preparations, human serum ultrafiltrate or intact cells.", [["LCL-721.220", "ANATOMY", 0, 11], ["YT cells", "ANATOMY", 16, 24], ["HeLa", "ANATOMY", 56, 60], ["A431 cells", "ANATOMY", 65, 75], ["cytosolic", "ANATOMY", 216, 225], ["serum ultrafiltrate", "ANATOMY", 246, 265], ["cells", "ANATOMY", 276, 281], ["LCL-721.220", "CELL", 0, 11], ["YT cells", "CELL", 16, 24], ["IMDM", "CELL", 42, 46], ["Gibco", "ORGANISM_SUBSTANCE", 48, 53], ["HeLa", "CELL", 56, 60], ["A431 cells", "CELL", 65, 75], ["human", "ORGANISM", 240, 245], ["serum", "ORGANISM_SUBSTANCE", 246, 251], ["ultrafiltrate", "ORGANISM_SUBSTANCE", 252, 265], ["cells", "CELL", 276, 281], ["LCL-721.220", "CELL_LINE", 0, 11], ["YT cells", "CELL_LINE", 16, 24], ["HeLa", "CELL_LINE", 56, 60], ["A431 cells", "CELL_LINE", 65, 75], ["recombinant trapping mutant", "PROTEIN", 173, 200], ["human serum ultrafiltrate or intact cells", "CELL_TYPE", 240, 281], ["human", "SPECIES", 240, 245], ["human", "SPECIES", 240, 245], ["LCL", "TEST", 0, 3], ["YT cells", "TEST", 16, 24], ["IMDM", "TEST", 42, 46], ["Gibco", "TEST", 48, 53], ["HeLa", "TEST", 56, 60], ["the same supplements", "TREATMENT", 97, 117], ["recombinant trapping mutant", "PROBLEM", 173, 200], ["cytosolic preparations", "TREATMENT", 216, 238], ["human serum ultrafiltrate", "TREATMENT", 240, 265], ["intact cells", "OBSERVATION", 269, 281]]], ["A detailed description of the different substrate trapping protocols is provided as Supplementary information.Analysis of CD30 redox state by flow cytometryFor reduction of cell surface CD30, 2.5 \u00c210 5 cells were incubated with 5 mM Trx1 together with 200 mM DTT or 100 nM human Trx reductase (TrxR)/500 mM NADPH for 30 min at 41C.", [["cell surface", "ANATOMY", 173, 185], ["\u00c210 5 cells", "ANATOMY", 196, 207], ["NADPH", "CHEMICAL", 307, 312], ["DTT", "CHEMICAL", 259, 262], ["NADPH", "CHEMICAL", 307, 312], ["CD30", "GENE_OR_GENE_PRODUCT", 122, 126], ["cell", "CELL", 173, 177], ["CD30", "GENE_OR_GENE_PRODUCT", 186, 190], ["cells", "CELL", 202, 207], ["Trx1", "GENE_OR_GENE_PRODUCT", 233, 237], ["DTT", "SIMPLE_CHEMICAL", 259, 262], ["human", "ORGANISM", 273, 278], ["Trx reductase", "GENE_OR_GENE_PRODUCT", 279, 292], ["TrxR", "GENE_OR_GENE_PRODUCT", 294, 298], ["NADPH", "SIMPLE_CHEMICAL", 307, 312], ["CD30", "PROTEIN", 122, 126], ["CD30", "PROTEIN", 186, 190], ["2.5 \u00c210 5 cells", "CELL_LINE", 192, 207], ["Trx1", "PROTEIN", 233, 237], ["human Trx reductase", "PROTEIN", 273, 292], ["TrxR", "PROTEIN", 294, 298], ["human", "SPECIES", 273, 278], ["human", "SPECIES", 273, 278], ["the different substrate trapping protocols", "TREATMENT", 26, 68], ["CD30 redox", "TEST", 122, 132], ["flow cytometry", "TEST", 142, 156], ["cell surface CD30", "TEST", 173, 190], ["mM DTT", "TEST", 256, 262], ["nM human Trx reductase", "TREATMENT", 270, 292], ["TrxR", "TEST", 294, 298], ["CD30 redox", "OBSERVATION", 122, 132], ["flow cytometry", "OBSERVATION", 142, 156], ["cell", "OBSERVATION", 173, 177], ["surface CD30", "OBSERVATION", 178, 190]]], ["To monitor reduction of cell surface CD30, cells were stained with anti-human CD30 monoclonal antibody MAB229 (R&D Systems), anti-human CD30 monoclonal antibody Ki-1 (Santa Cruz) or anti-human CD30 monoclonal antibody Ber-H2 (DakoCytomation) followed by incubation with R-PE-conjugated goat F(ab') 2 anti-mouse Ig's (Biosource).", [["cell surface", "ANATOMY", 24, 36], ["cells", "ANATOMY", 43, 48], ["R-PE", "CHEMICAL", 270, 274], ["cell", "CELL", 24, 28], ["CD30", "GENE_OR_GENE_PRODUCT", 37, 41], ["cells", "CELL", 43, 48], ["CD30", "GENE_OR_GENE_PRODUCT", 78, 82], ["CD30", "GENE_OR_GENE_PRODUCT", 136, 140], ["Ki-1", "GENE_OR_GENE_PRODUCT", 161, 165], ["anti-human", "ORGANISM", 182, 192], ["CD30", "GENE_OR_GENE_PRODUCT", 193, 197], ["DakoCytomation", "SIMPLE_CHEMICAL", 226, 240], ["R-PE", "SIMPLE_CHEMICAL", 270, 274], ["Ig", "GENE_OR_GENE_PRODUCT", 311, 313], ["CD30", "PROTEIN", 37, 41], ["anti-human CD30 monoclonal antibody MAB229", "PROTEIN", 67, 109], ["R&D Systems", "PROTEIN", 111, 122], ["anti-human CD30 monoclonal antibody Ki-1", "PROTEIN", 125, 165], ["Santa Cruz", "PROTEIN", 167, 177], ["anti-human CD30 monoclonal antibody", "PROTEIN", 182, 217], ["Ber-H2", "PROTEIN", 218, 224], ["DakoCytomation", "PROTEIN", 226, 240], ["anti-mouse Ig", "PROTEIN", 300, 313], ["Biosource", "PROTEIN", 317, 326], ["goat", "SPECIES", 286, 290], ["anti-mouse", "SPECIES", 300, 310], ["cell surface CD30", "TEST", 24, 41], ["anti-human CD30 monoclonal antibody", "TEST", 67, 102], ["anti-human CD30 monoclonal antibody", "TEST", 125, 160], ["Ki", "TEST", 161, 163], ["Santa Cruz", "TEST", 167, 177], ["anti-human CD30 monoclonal antibody Ber-H2", "TREATMENT", 182, 224], ["PE", "PROBLEM", 272, 274], ["conjugated goat F(ab')", "TREATMENT", 275, 297], ["cell", "OBSERVATION", 24, 28], ["surface CD30", "OBSERVATION", 29, 41], ["PE", "OBSERVATION", 272, 274]]], ["For control, cells were stained with R-PE-conjugated anti-human CD28 monoclonal antibody (BD Pharmingen).", [["cells", "ANATOMY", 13, 18], ["R-PE", "CHEMICAL", 37, 41], ["cells", "CELL", 13, 18], ["R-PE", "SIMPLE_CHEMICAL", 37, 41], ["CD28", "GENE_OR_GENE_PRODUCT", 64, 68], ["R-PE-conjugated anti-human CD28 monoclonal antibody", "PROTEIN", 37, 88], ["BD Pharmingen", "PROTEIN", 90, 103], ["R-PE", "TEST", 37, 41], ["conjugated anti-human CD28 monoclonal antibody", "TREATMENT", 42, 88], ["PE", "OBSERVATION", 39, 41]]], ["Cells were analyzed using a FACSCalibur (Becton Dickinson) and CellQuest software.CD30L binding assayA total of 2.5 \u00c210 5 cells were incubated with 5 mM Trx1 (SBP-CCCCC) and 200 mM DTT for 30 min at 371C, washed three times and incubated with 250 ng/ml recombinant CD30L-His 10 (R&D Systems) for 10 min at RT.", [["Cells", "ANATOMY", 0, 5], ["\u00c210 5 cells", "ANATOMY", 116, 127], ["DTT", "CHEMICAL", 181, 184], ["Cells", "CELL", 0, 5], ["CD30L", "GENE_OR_GENE_PRODUCT", 82, 87], ["cells", "CELL", 122, 127], ["Trx1", "GENE_OR_GENE_PRODUCT", 153, 157], ["SBP-CCCCC", "GENE_OR_GENE_PRODUCT", 159, 168], ["DTT", "SIMPLE_CHEMICAL", 181, 184], ["CD30L", "PROTEIN", 82, 87], ["2.5 \u00c210 5 cells", "CELL_LINE", 112, 127], ["Trx1", "PROTEIN", 153, 157], ["SBP", "PROTEIN", 159, 162], ["CD30L", "PROTEIN", 265, 270], ["SBP", "TEST", 159, 162]]], ["After washing, cells were stained with anti-polyHis monoclonal antibody (Sigma) followed by incubation with R-PE-conjugated goat F(ab') 2 anti-mouse Ig's (Biosource).Immunofluorescence microscopyHeLa cells were seeded on coverslips and transfected with expression constructs using CaCl 2 precipitation.", [["cells", "ANATOMY", 15, 20], ["microscopyHeLa cells", "ANATOMY", 185, 205], ["anti-poly", "CHEMICAL", 39, 48], ["R-PE", "CHEMICAL", 108, 112], ["anti-poly", "CHEMICAL", 39, 48], ["His", "CHEMICAL", 48, 51], ["CaCl 2", "CHEMICAL", 281, 287], ["cells", "CELL", 15, 20], ["R-PE", "SIMPLE_CHEMICAL", 108, 112], ["microscopyHeLa cells", "CELL", 185, 205], ["CaCl 2", "SIMPLE_CHEMICAL", 281, 287], ["monoclonal antibody", "PROTEIN", 52, 71], ["Sigma", "PROTEIN", 73, 78], ["anti-mouse Ig", "PROTEIN", 138, 151], ["Biosource", "PROTEIN", 155, 164], ["microscopyHeLa cells", "CELL_LINE", 185, 205], ["expression constructs", "DNA", 253, 274], ["goat", "SPECIES", 124, 128], ["anti-mouse", "SPECIES", 138, 148], ["anti-poly", "TREATMENT", 39, 48], ["His monoclonal antibody", "TEST", 48, 71], ["PE", "PROBLEM", 110, 112], ["Immunofluorescence microscopyHeLa cells", "PROBLEM", 166, 205], ["CaCl 2 precipitation", "TREATMENT", 281, 301], ["PE", "OBSERVATION", 110, 112]]], ["After 2 days, transfected cells were fixed with 3% formaldehyde and 2% sucrose in PBS for 7 min at RT.", [["cells", "ANATOMY", 26, 31], ["formaldehyde", "CHEMICAL", 51, 63], ["sucrose", "CHEMICAL", 71, 78], ["formaldehyde", "CHEMICAL", 51, 63], ["sucrose", "CHEMICAL", 71, 78], ["cells", "CELL", 26, 31], ["formaldehyde", "SIMPLE_CHEMICAL", 51, 63], ["sucrose", "SIMPLE_CHEMICAL", 71, 78], ["transfected cells", "CELL_LINE", 14, 31], ["transfected cells", "TREATMENT", 14, 31], ["3% formaldehyde", "TREATMENT", 48, 63], ["2% sucrose in PBS", "TREATMENT", 68, 85]]], ["Fixed cells were washed three times with PBS and incubated with different Trx1 constructs or recombinant CD30L (R&D Systems).", [["cells", "ANATOMY", 6, 11], ["cells", "CELL", 6, 11], ["Trx1", "GENE_OR_GENE_PRODUCT", 74, 78], ["CD30L", "GENE_OR_GENE_PRODUCT", 105, 110], ["Trx1 constructs", "DNA", 74, 89], ["recombinant CD30L", "PROTEIN", 93, 110], ["R&D Systems", "PROTEIN", 112, 123], ["Fixed cells", "PROBLEM", 0, 11], ["PBS", "TREATMENT", 41, 44], ["different Trx1 constructs", "TREATMENT", 64, 89]]], ["Proteins were visualized using appropriate primary antibodies (Anti-CD30L polyclonal antibody (R&D Systems), anti-CD30 monoclonal antibodies Ki-1 (Santa Cruz) or Ber-H2 (DakoCytomation), anti-CD95 monoclonal antibody (a kind gift from Dr P Krammer), anti-Trx1 polyclonal antibody (M Preuss and TP Dick, unpublished) followed by FITC-conjugated anti-goat IgG, FITC-conjugated anti-rabbit IgG or TRITC-conjugated anti-mouse IgG and analyzed with a Nikon C1Si confocal microscope.Supplementary dataSupplementary data are available at The EMBO Journal Online (http://www.embojournal.org).", [["FITC", "CHEMICAL", 328, 332], ["FITC", "CHEMICAL", 359, 363], ["Ki-1", "GENE_OR_GENE_PRODUCT", 141, 145], ["Ber-H2", "SIMPLE_CHEMICAL", 162, 168], ["DakoCytomation", "GENE_OR_GENE_PRODUCT", 170, 184], ["anti-CD95", "GENE_OR_GENE_PRODUCT", 187, 196], ["Trx1", "GENE_OR_GENE_PRODUCT", 255, 259], ["FITC", "SIMPLE_CHEMICAL", 328, 332], ["anti-goat IgG", "SIMPLE_CHEMICAL", 344, 357], ["FITC", "SIMPLE_CHEMICAL", 359, 363], ["anti-rabbit IgG", "SIMPLE_CHEMICAL", 375, 390], ["TRITC", "SIMPLE_CHEMICAL", 394, 399], ["primary antibodies", "PROTEIN", 43, 61], ["Anti-CD30L polyclonal antibody", "PROTEIN", 63, 93], ["R&D Systems", "PROTEIN", 95, 106], ["anti-CD30 monoclonal antibodies Ki-1", "PROTEIN", 109, 145], ["Santa Cruz", "PROTEIN", 147, 157], ["Ber-H2", "PROTEIN", 162, 168], ["DakoCytomation", "PROTEIN", 170, 184], ["anti-CD95 monoclonal antibody", "PROTEIN", 187, 216], ["Dr P Krammer", "PROTEIN", 235, 247], ["Trx1 polyclonal antibody", "PROTEIN", 255, 279], ["FITC-conjugated anti-goat IgG", "PROTEIN", 328, 357], ["FITC-conjugated anti-rabbit IgG", "PROTEIN", 359, 390], ["TRITC-conjugated anti-mouse IgG", "PROTEIN", 394, 425], ["anti-rabbit", "SPECIES", 375, 386], ["anti-mouse", "SPECIES", 411, 421], ["anti-rabbit", "SPECIES", 375, 386], ["Proteins", "TEST", 0, 8], ["appropriate primary antibodies", "TEST", 31, 61], ["Anti-CD30L polyclonal antibody", "TEST", 63, 93], ["anti-CD30 monoclonal antibodies", "TEST", 109, 140], ["Ki", "TEST", 141, 143], ["Santa Cruz", "TEST", 147, 157], ["Ber-H2", "TEST", 162, 168], ["DakoCytomation", "TEST", 170, 184], ["anti-CD95 monoclonal antibody", "TEST", 187, 216], ["Krammer", "TEST", 240, 247], ["anti-Trx1 polyclonal antibody", "TEST", 250, 279], ["Preuss", "TEST", 283, 289], ["TP Dick", "TEST", 294, 301], ["FITC", "TEST", 328, 332], ["conjugated anti-goat IgG", "TEST", 333, 357], ["FITC", "TEST", 359, 363], ["conjugated anti-rabbit IgG", "TREATMENT", 364, 390], ["TRITC-conjugated anti-mouse IgG", "TREATMENT", 394, 425]]]], "PMC7088629": [["IntroductionVaccines have been used to prevent a wide range of infectious and non-infectious diseases (Poland et al. 2002).", [["infectious and non-infectious diseases", "DISEASE", 63, 101], ["IntroductionVaccines", "TREATMENT", 0, 20], ["infectious and non-infectious diseases", "PROBLEM", 63, 101], ["wide range", "OBSERVATION_MODIFIER", 49, 59], ["infectious", "OBSERVATION", 63, 73], ["non-infectious", "OBSERVATION_MODIFIER", 78, 92]]], ["Vaccine antigens are composed of antigenic proteins and are devoid of pathogenic genes, so cannot establish infection (Strugnell et al. 2011).", [["infection", "DISEASE", 108, 117], ["Vaccine antigens", "PROTEIN", 0, 16], ["antigenic proteins", "PROTEIN", 33, 51], ["pathogenic genes", "DNA", 70, 86], ["Vaccine antigens", "TREATMENT", 0, 16], ["antigenic proteins", "TREATMENT", 33, 51], ["pathogenic genes", "PROBLEM", 70, 86], ["infection", "PROBLEM", 108, 117]]], ["Vaccine antigens can be produced using a variety of host expression systems, including genetically engineered bacterial, yeast, mammalian and plant cells.", [["cells", "ANATOMY", 148, 153], ["yeast", "CELL", 121, 126], ["mammalian", "CELL", 128, 137], ["plant cells", "CELL", 142, 153], ["Vaccine antigens", "PROTEIN", 0, 16], ["genetically engineered bacterial, yeast, mammalian and plant cells", "CELL_TYPE", 87, 153], ["yeast", "SPECIES", 121, 126], ["yeast", "SPECIES", 121, 126], ["Vaccine antigens", "TREATMENT", 0, 16], ["host expression systems", "TREATMENT", 52, 75], ["genetically engineered bacterial, yeast, mammalian and plant cells", "PROBLEM", 87, 153], ["plant cells", "OBSERVATION", 142, 153]]], ["Plants are attractive expression vehicles for commercial production of vaccine antigens.", [["vaccine antigens", "PROTEIN", 71, 87], ["attractive expression vehicles", "TREATMENT", 11, 41], ["commercial production of vaccine antigens", "TREATMENT", 46, 87]]], ["Plant-based vaccines hold great promise as they are cost-effective, easy-to-administer, easy-to-store, fail-safe and acceptable, particularly in developing countries (Lal et al. 2007; Sala et al. 2003).", [["Plant-based vaccines", "TREATMENT", 0, 20]]], ["Novel approaches to improve the yield and biosafety of plant-based vaccines have been proposed (Hern\u00e1ndez et al. 2014).", [["plant-based vaccines", "TREATMENT", 55, 75]]], ["Agroinfiltration is a simple, efficient and robust method for transient protein expression (Leuzinger et al. 2013).IntroductionPorcine epidemic diarrhea virus (PEDV), classified as a member of group I of the genus Alphacoronavirus, the family Coronaviridae, and the order Nidovirales, causes porcine epidemic diarrhea (PED) in pigs of all ages, especially in newborn pigs (Pensaert and de Bouck 1978).", [["IntroductionPorcine epidemic diarrhea", "DISEASE", 115, 152], ["porcine epidemic diarrhea", "DISEASE", 292, 317], ["PED", "DISEASE", 319, 322], ["IntroductionPorcine epidemic diarrhea virus", "ORGANISM", 115, 158], ["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 214, 230], ["pigs", "ORGANISM", 327, 331], ["pigs", "ORGANISM", 367, 371], ["epidemic diarrhea virus", "SPECIES", 135, 158], ["porcine", "SPECIES", 292, 299], ["pigs", "SPECIES", 327, 331], ["pigs", "SPECIES", 367, 371], ["IntroductionPorcine epidemic diarrhea virus", "SPECIES", 115, 158], ["PEDV", "SPECIES", 160, 164], ["pigs", "SPECIES", 327, 331], ["pigs", "SPECIES", 367, 371], ["Agroinfiltration", "PROBLEM", 0, 16], ["transient protein expression", "PROBLEM", 62, 90], ["IntroductionPorcine epidemic diarrhea virus (PEDV", "PROBLEM", 115, 164], ["Nidovirales", "TREATMENT", 272, 283], ["porcine epidemic diarrhea", "PROBLEM", 292, 317], ["simple", "OBSERVATION_MODIFIER", 22, 28], ["protein expression", "OBSERVATION", 72, 90]]], ["PEDV disrupts villus enterocytes and causes villi atrophy within the jejunum and ileum, leading to a mortality rate of up to 95 % in infected suckling pigs (Ducatelle et al. 1981).", [["villus enterocytes", "ANATOMY", 14, 32], ["villi", "ANATOMY", 44, 49], ["jejunum", "ANATOMY", 69, 76], ["ileum", "ANATOMY", 81, 86], ["PEDV", "CHEMICAL", 0, 4], ["villi atrophy", "DISEASE", 44, 57], ["PEDV", "SIMPLE_CHEMICAL", 0, 4], ["villus enterocytes", "TISSUE", 14, 32], ["villi", "MULTI-TISSUE_STRUCTURE", 44, 49], ["jejunum", "MULTI-TISSUE_STRUCTURE", 69, 76], ["ileum", "ORGAN", 81, 86], ["pigs", "ORGANISM", 151, 155], ["PEDV", "PROTEIN", 0, 4], ["pigs", "SPECIES", 151, 155], ["PEDV", "SPECIES", 0, 4], ["pigs", "SPECIES", 151, 155], ["PEDV", "PROBLEM", 0, 4], ["villi atrophy within the jejunum and ileum", "PROBLEM", 44, 86], ["a mortality rate", "TEST", 99, 115], ["villus enterocytes", "OBSERVATION", 14, 32], ["villi atrophy", "OBSERVATION", 44, 57], ["jejunum", "ANATOMY", 69, 76], ["ileum", "ANATOMY", 81, 86], ["infected", "OBSERVATION_MODIFIER", 133, 141], ["suckling pigs", "OBSERVATION", 142, 155]]], ["Outbreaks of this disease, which have been reported in many pig farming countries, have led to severe economic losses in Canada (Turgeon et al. 1980), Japan (Takahashi et al. 1983), China (Li et al. 2012), Thailand (Puranaveja et al. 2009), Korea (Lee and Lee 2014), the United States (Stevenson et al. 2013) and, more recently, in Austria (Steinrigl et al. 2015).IntroductionThe genome of PEDV consists of a single molecule of linear positive-sense single-stranded RNA.", [["pig", "ORGANISM", 60, 63], ["PEDV", "CANCER", 390, 394], ["PEDV", "DNA", 390, 394], ["linear positive-sense single-stranded RNA", "RNA", 428, 469], ["pig", "SPECIES", 60, 63], ["pig", "SPECIES", 60, 63], ["this disease", "PROBLEM", 13, 25], ["PEDV", "PROBLEM", 390, 394], ["linear positive-sense single-stranded RNA", "PROBLEM", 428, 469], ["disease", "OBSERVATION", 18, 25], ["severe", "OBSERVATION_MODIFIER", 95, 101], ["linear", "OBSERVATION_MODIFIER", 428, 434], ["positive", "OBSERVATION", 435, 443], ["stranded RNA", "OBSERVATION_MODIFIER", 457, 469]]], ["The complete sequence of the genome of strain CV777 was found to be 28,033 nucleotides in length, excluding the poly A-tail (Kocherhans et al. 2001).", [["nucleotides", "CHEMICAL", 75, 86], ["strain CV777", "ORGANISM", 39, 51], ["nucleotides in length", "PROBLEM", 75, 96]]], ["The large spike glycoprotein peplomer (S), one of four structural proteins, stimulates production of neutralizing antibodies in the host.", [["S", "PROTEIN", 39, 40], ["structural proteins", "PROTEIN", 55, 74], ["neutralizing antibodies", "PROTEIN", 101, 124], ["The large spike glycoprotein peplomer", "PROBLEM", 0, 37], ["four structural proteins", "PROBLEM", 50, 74], ["neutralizing antibodies in the host", "PROBLEM", 101, 136], ["large", "OBSERVATION_MODIFIER", 4, 9], ["spike", "OBSERVATION_MODIFIER", 10, 15], ["glycoprotein peplomer", "OBSERVATION", 16, 37]]], ["The predicted S polypeptide is 1383 amino acids long, contains 29 potential N-linked glycosylation sites and shows structural features similar to those of the coronavirus spike protein (Duarte and Laude 1994).", [["amino acids", "CHEMICAL", 36, 47], ["amino acids", "CHEMICAL", 36, 47], ["N", "CHEMICAL", 76, 77], ["amino acids", "AMINO_ACID", 36, 47], ["N-linked glycosylation sites", "PROTEIN", 76, 104], ["coronavirus spike protein", "PROTEIN", 159, 184], ["The predicted S polypeptide", "TEST", 0, 27], ["amino acids", "TEST", 36, 47], ["29 potential N-linked glycosylation sites", "PROBLEM", 63, 104], ["structural features", "PROBLEM", 115, 134], ["the coronavirus spike protein", "PROBLEM", 155, 184], ["29 potential", "OBSERVATION_MODIFIER", 63, 75]]], ["The PEDV S protein can be divided into the S1 domain (aa 1\u2013789) and S2 domain (aa 790\u20131383) based on the presence of the conserved nonamer and GxCx motifs at the proteolytic cleavage site of the S protein of other members of coronavirus group II (Follis et al. 2006).", [["PEDV S", "GENE_OR_GENE_PRODUCT", 4, 10], ["coronavirus group II", "ORGANISM", 225, 245], ["PEDV S protein", "PROTEIN", 4, 18], ["S1 domain", "PROTEIN", 43, 52], ["aa 1\u2013789", "PROTEIN", 54, 62], ["S2 domain", "PROTEIN", 68, 77], ["aa 790\u20131383", "PROTEIN", 79, 90], ["conserved nonamer and GxCx motifs", "DNA", 121, 154], ["proteolytic cleavage site", "PROTEIN", 162, 187], ["S protein", "PROTEIN", 195, 204], ["coronavirus group II", "PROTEIN", 225, 245], ["coronavirus group", "SPECIES", 225, 242], ["The PEDV S protein", "TEST", 0, 18], ["the conserved nonamer and GxCx motifs", "TREATMENT", 117, 154], ["the proteolytic cleavage site", "PROBLEM", 158, 187], ["S1", "ANATOMY", 43, 45]]], ["Within the S1 domain, two important epitope domains were determined.", [["S1 domain", "PROTEIN", 11, 20], ["epitope domains", "PROTEIN", 36, 51], ["two important epitope domains", "PROBLEM", 22, 51], ["S1", "ANATOMY", 11, 13], ["important", "OBSERVATION_MODIFIER", 26, 35], ["epitope", "OBSERVATION", 36, 43]]], ["The first domain is the PEDV-neutralizing epitope (CO-26 K equivalent, COE gene), which is 139 aa long and spans the region aa 499\u2013638 (Chang et al. 2002).", [["PEDV", "PROTEIN", 24, 28], ["CO", "PROTEIN", 51, 53], ["COE gene", "DNA", 71, 79], ["the PEDV", "TEST", 20, 28], ["neutralizing epitope", "TEST", 29, 49], ["CO", "TEST", 51, 53]]], ["Sun et al. identified the second epitope domain, designated S1D (aa 636\u2013789), and reported that it induces neutralizing antibodies (Sun et al. 2008).", [["S1D", "GENE_OR_GENE_PRODUCT", 60, 63], ["epitope domain", "PROTEIN", 33, 47], ["S1D", "PROTEIN", 60, 63], ["aa 636\u2013789", "PROTEIN", 65, 75], ["neutralizing antibodies", "PROTEIN", 107, 130], ["the second epitope domain", "PROBLEM", 22, 47], ["neutralizing antibodies", "PROBLEM", 107, 130], ["neutralizing antibodies", "OBSERVATION", 107, 130]]], ["In this study, the S1D gene alone, and that fused with the cholera toxin B subunit (CTB) gene of Vibrio cholerae, were cloned into plant expression vectors.", [["S1D", "GENE_OR_GENE_PRODUCT", 19, 22], ["cholera toxin B subunit", "GENE_OR_GENE_PRODUCT", 59, 82], ["CTB", "GENE_OR_GENE_PRODUCT", 84, 87], ["Vibrio cholerae", "ORGANISM", 97, 112], ["S1D gene", "DNA", 19, 27], ["cholera toxin B subunit (CTB) gene", "DNA", 59, 93], ["plant expression vectors", "DNA", 131, 155], ["Vibrio cholerae", "SPECIES", 97, 112], ["Vibrio cholerae", "SPECIES", 97, 112], ["this study", "TEST", 3, 13], ["the cholera toxin B subunit (CTB) gene of Vibrio cholerae", "TREATMENT", 55, 112]]], ["These vectors were transiently expressed in Nicotiana benthamiana (N. benthamiana) using agroinfiltration.", [["Nicotiana benthamiana", "ORGANISM", 44, 65], ["N. benthamiana", "ORGANISM", 67, 81], ["Nicotiana benthamiana", "SPECIES", 44, 65], ["N. benthamiana", "SPECIES", 67, 81], ["Nicotiana benthamiana", "SPECIES", 44, 65], ["N. benthamiana", "SPECIES", 67, 81], ["agroinfiltration", "PROBLEM", 89, 105], ["Nicotiana benthamiana", "OBSERVATION", 44, 65]]], ["The proteins were orally administered to mice to induce specific immune responses.Construction of S1D and a CTB\u2013S1D fusion gene for transient expression in N. benthamiana ::: Materials and methodsTo construct an S1D gene for transient expression in N. benthamiana, plasmid pMYV98 containing the spike protein gene of PEDV was used as a template for PCR.", [["plasmid", "ANATOMY", 265, 272], ["mice", "ORGANISM", 41, 45], ["S1D", "GENE_OR_GENE_PRODUCT", 98, 101], ["CTB\u2013S1D", "GENE_OR_GENE_PRODUCT", 108, 115], ["N. benthamiana", "ORGANISM", 156, 170], ["S1D", "GENE_OR_GENE_PRODUCT", 212, 215], ["N. benthamiana", "ORGANISM", 249, 263], ["pMYV98", "GENE_OR_GENE_PRODUCT", 273, 279], ["PEDV", "GENE_OR_GENE_PRODUCT", 317, 321], ["S1D", "PROTEIN", 98, 101], ["CTB\u2013S1D fusion gene", "DNA", 108, 127], ["S1D gene", "DNA", 212, 220], ["plasmid pMYV98", "DNA", 265, 279], ["spike protein gene", "DNA", 295, 313], ["PEDV", "DNA", 317, 321], ["mice", "SPECIES", 41, 45], ["N. benthamiana", "SPECIES", 156, 170], ["N. benthamiana", "SPECIES", 249, 263], ["mice", "SPECIES", 41, 45], ["N. benthamiana", "SPECIES", 156, 170], ["N. benthamiana", "SPECIES", 249, 263], ["PEDV", "SPECIES", 317, 321], ["The proteins", "TREATMENT", 0, 12], ["a CTB\u2013S1D fusion gene", "TREATMENT", 106, 127], ["plasmid pMYV98", "TREATMENT", 265, 279], ["PEDV", "PROBLEM", 317, 321], ["PCR", "TEST", 349, 352]]], ["A pair of primers (forward primer 5\u2032-GGATCC GAC GTT TCT TTT ATG AC-3\u2032 and reverse primer 5\u2032-GGTACC AAT ACT CAT ACT AAA G-3\u2032) was designed to amplify the S1D gene.", [["S1D", "GENE_OR_GENE_PRODUCT", 153, 156], ["forward primer 5", "DNA", 19, 35], ["reverse primer 5", "DNA", 74, 90], ["AAA G", "DNA", 115, 120], ["S1D gene", "DNA", 153, 161], ["A pair of primers (forward primer", "TREATMENT", 0, 33], ["GGATCC", "TEST", 37, 43], ["GAC GTT", "TREATMENT", 44, 51], ["TCT", "TEST", 52, 55], ["TTT ATG AC", "TREATMENT", 56, 66], ["reverse primer", "TREATMENT", 74, 88]]], ["A BamHI restriction site at the 5\u2032-end and KpnI at the 3\u2032-end of the sequence was included to facilitate cloning.", [["BamHI", "GENE_OR_GENE_PRODUCT", 2, 7], ["KpnI", "GENE_OR_GENE_PRODUCT", 43, 47], ["BamHI restriction site", "DNA", 2, 24], ["5\u2032-end", "DNA", 32, 38], ["KpnI", "DNA", 43, 47], ["3\u2032-end", "DNA", 55, 61], ["A BamHI restriction site", "TREATMENT", 0, 24]]], ["The S1D gene was amplified using Ex Taq (Takara Bio, Shiga, Japan) with the following PCR conditions: one cycle at 94 \u00b0C for 5 min; 30 cycles at 94 \u00b0C for 30 s, 58 \u00b0C for 30 s and 72 \u00b0C for 30 s, followed by one cycle at 72 \u00b0C for 5 min.", [["S1D", "GENE_OR_GENE_PRODUCT", 4, 7], ["S1D gene", "DNA", 4, 12], ["Ex Taq", "DNA", 33, 39], ["Ex Taq (Takara Bio", "TREATMENT", 33, 51]]], ["The products were cloned into the pGEM\u00aeT-Easy vector (Promega, Madison, WI, USA), creating plasmid pMYV712.", [["pMYV712", "GENE_OR_GENE_PRODUCT", 99, 106], ["pGEM\u00aeT-Easy vector", "DNA", 34, 52], ["plasmid pMYV712", "DNA", 91, 106], ["creating plasmid pMYV712", "TREATMENT", 82, 106]]], ["Gene identity was confirmed via sequencing using the universal primers T7 and SP6.", [["SP6", "GENE_OR_GENE_PRODUCT", 78, 81], ["universal primers T7", "DNA", 53, 73], ["SP6", "DNA", 78, 81], ["the universal primers T7", "TREATMENT", 49, 73]]], ["The BamHI and KpnI digested fragment containing the S1D gene from pMYV712 was introduced into the same sites of digested plant-expression vector pMYV497 under the regulation of the duplicated Cauliflower mosaic viral 35S promoter (dp35S), CTB signal peptide, ER retention signal (SEKDEL) (Munro and Pelham 1987) and Nos-T, yielding pMYV717. pMYV508 harboring the p19 protein of tomato bushy stunt virus (TBSV), which prevents post-transcriptional gene silencing (PTGS) in infiltrated tissues, was used for co-expression (Voinnet et al. 2003).Construction of S1D and a CTB\u2013S1D fusion gene for transient expression in N. benthamiana ::: Materials and methodsTo construct the CTB\u2013S1D fusion gene, the BamHI and KpnI-digested fragment containing the S1D gene from plasmid pMYV712 was inserted into the same sites of plasmid pMYV498 to generate plasmid pMYV719.", [["tissues", "ANATOMY", 484, 491], ["plasmid", "ANATOMY", 812, 819], ["plasmid", "ANATOMY", 840, 847], ["pMYV712", "CHEMICAL", 66, 73], ["pMYV508", "CHEMICAL", 341, 348], ["BamHI", "GENE_OR_GENE_PRODUCT", 4, 9], ["KpnI", "GENE_OR_GENE_PRODUCT", 14, 18], ["fragment", "CELLULAR_COMPONENT", 28, 36], ["S1D", "GENE_OR_GENE_PRODUCT", 52, 55], ["pMYV712", "GENE_OR_GENE_PRODUCT", 66, 73], ["pMYV497", "GENE_OR_GENE_PRODUCT", 145, 152], ["CTB signal peptide", "GENE_OR_GENE_PRODUCT", 239, 257], ["ER", "GENE_OR_GENE_PRODUCT", 259, 261], ["Nos-T", "GENE_OR_GENE_PRODUCT", 316, 321], ["pMYV717", "GENE_OR_GENE_PRODUCT", 332, 339], ["pMYV508", "GENE_OR_GENE_PRODUCT", 341, 348], ["p19", "GENE_OR_GENE_PRODUCT", 363, 366], ["tomato bushy stunt virus", "ORGANISM", 378, 402], ["TBSV", "ORGANISM", 404, 408], ["tissues", "TISSUE", 484, 491], ["S1D", "GENE_OR_GENE_PRODUCT", 558, 561], ["CTB\u2013S1D", "GENE_OR_GENE_PRODUCT", 568, 575], ["N. benthamiana", "ORGANISM", 616, 630], ["CTB\u2013S1D", "GENE_OR_GENE_PRODUCT", 673, 680], ["BamHI", "GENE_OR_GENE_PRODUCT", 698, 703], ["KpnI", "GENE_OR_GENE_PRODUCT", 708, 712], ["fragment", "CELLULAR_COMPONENT", 722, 730], ["S1D", "GENE_OR_GENE_PRODUCT", 746, 749], ["pMYV712", "GENE_OR_GENE_PRODUCT", 768, 775], ["pMYV498", "GENE_OR_GENE_PRODUCT", 820, 827], ["pMYV719", "GENE_OR_GENE_PRODUCT", 848, 855], ["BamHI and KpnI digested fragment", "DNA", 4, 36], ["S1D gene", "DNA", 52, 60], ["pMYV712", "DNA", 66, 73], ["digested plant-expression vector pMYV497", "DNA", 112, 152], ["Cauliflower mosaic viral 35S promoter", "DNA", 192, 229], ["dp35S", "DNA", 231, 236], ["ER", "PROTEIN", 259, 261], ["Nos-T", "DNA", 316, 321], ["pMYV717", "DNA", 332, 339], ["pMYV508", "PROTEIN", 341, 348], ["p19 protein", "PROTEIN", 363, 374], ["PTGS", "DNA", 463, 467], ["S1D", "PROTEIN", 558, 561], ["CTB\u2013S1D fusion gene", "DNA", 568, 587], ["CTB\u2013S1D fusion gene", "DNA", 673, 692], ["BamHI and KpnI-digested fragment", "DNA", 698, 730], ["S1D gene", "DNA", 746, 754], ["plasmid pMYV712", "DNA", 760, 775], ["plasmid pMYV498", "DNA", 812, 827], ["pMYV719", "DNA", 848, 855], ["tomato bushy stunt virus", "SPECIES", 378, 402], ["N. benthamiana", "SPECIES", 616, 630], ["tomato bushy stunt virus", "SPECIES", 378, 402], ["TBSV", "SPECIES", 404, 408], ["N. benthamiana", "SPECIES", 616, 630], ["The BamHI and KpnI digested fragment", "TREATMENT", 0, 36], ["the S1D gene from pMYV712", "TREATMENT", 48, 73], ["the duplicated Cauliflower mosaic viral 35S promoter", "TREATMENT", 177, 229], ["CTB signal peptide", "TEST", 239, 257], ["ER retention signal", "TEST", 259, 278], ["tomato bushy stunt virus", "PROBLEM", 378, 402], ["post-transcriptional gene silencing (PTGS) in infiltrated tissues", "PROBLEM", 426, 491], ["a CTB\u2013S1D fusion gene", "TREATMENT", 566, 587], ["the CTB\u2013S1D fusion gene", "TREATMENT", 669, 692], ["the BamHI and KpnI-digested fragment", "TREATMENT", 694, 730], ["the S1D gene", "TREATMENT", 742, 754], ["plasmid pMYV712", "TREATMENT", 760, 775], ["plasmid pMYV498", "TREATMENT", 812, 827], ["plasmid pMYV719", "TREATMENT", 840, 855], ["fragment", "OBSERVATION_MODIFIER", 28, 36], ["mosaic viral", "OBSERVATION", 204, 216], ["35S promoter", "OBSERVATION", 217, 229], ["gene silencing", "OBSERVATION", 447, 461], ["infiltrated tissues", "ANATOMY", 472, 491]]], ["This plasmid contains dp35S, CTB adjuvant fused with S1D at the N-terminus, an ER retention signal (SEKDEL) and Nos-T.", [["plasmid", "ANATOMY", 5, 12], ["ER", "ANATOMY", 79, 81], ["N", "CHEMICAL", 64, 65], ["dp35S", "GENE_OR_GENE_PRODUCT", 22, 27], ["CTB", "GENE_OR_GENE_PRODUCT", 29, 32], ["S1D", "GENE_OR_GENE_PRODUCT", 53, 56], ["ER", "GENE_OR_GENE_PRODUCT", 79, 81], ["plasmid", "DNA", 5, 12], ["dp35S", "PROTEIN", 22, 27], ["S1D", "PROTEIN", 53, 56], ["N-terminus", "PROTEIN", 64, 74], ["ER", "PROTEIN", 79, 81], ["SEKDEL", "PROTEIN", 100, 106], ["T.", "SPECIES", 116, 118], ["This plasmid", "TREATMENT", 0, 12], ["dp35S", "TREATMENT", 22, 27], ["CTB adjuvant", "TREATMENT", 29, 41], ["an ER retention signal", "TEST", 76, 98], ["retention signal", "OBSERVATION", 82, 98]]], ["Plasmids pMYV717 and pMYV719 were transformed into Agrobacterium tumefaciens strain LBA4404 together with the helper plasmid pRK2013 using the tri-parental mating method (Horsch et al. 1985).Construction of the S1D gene for expression in E. coli and production of mouse anti-S1D antibody ::: Materials and methodsThe plasmid pMYV98 containing the spike protein gene from PEDV was used as a template for PCR.", [["plasmid", "ANATOMY", 317, 324], ["pMYV719", "CHEMICAL", 21, 28], ["pMYV717", "GENE_OR_GENE_PRODUCT", 9, 16], ["pMYV719", "GENE_OR_GENE_PRODUCT", 21, 28], ["Agrobacterium tumefaciens strain", "ORGANISM", 51, 83], ["LBA4404", "ORGANISM", 84, 91], ["pRK2013", "GENE_OR_GENE_PRODUCT", 125, 132], ["S1D", "GENE_OR_GENE_PRODUCT", 211, 214], ["E. coli", "ORGANISM", 238, 245], ["mouse", "ORGANISM", 264, 269], ["anti-S1D", "GENE_OR_GENE_PRODUCT", 270, 278], ["pMYV98", "GENE_OR_GENE_PRODUCT", 325, 331], ["PEDV", "GENE_OR_GENE_PRODUCT", 371, 375], ["pMYV719", "DNA", 21, 28], ["helper plasmid pRK2013", "DNA", 110, 132], ["S1D gene", "DNA", 211, 219], ["mouse anti-S1D antibody", "PROTEIN", 264, 287], ["pMYV98", "DNA", 325, 331], ["spike protein gene", "DNA", 347, 365], ["PEDV", "DNA", 371, 375], ["Agrobacterium tumefaciens", "SPECIES", 51, 76], ["E. coli", "SPECIES", 238, 245], ["mouse", "SPECIES", 264, 269], ["Agrobacterium tumefaciens", "SPECIES", 51, 76], ["E. coli", "SPECIES", 238, 245], ["mouse", "SPECIES", 264, 269], ["PEDV", "SPECIES", 371, 375], ["the helper plasmid", "TREATMENT", 106, 124], ["the tri-parental mating method", "TREATMENT", 139, 169], ["the S1D gene", "TREATMENT", 207, 219], ["E. coli", "PROBLEM", 238, 245], ["The plasmid pMYV98", "TREATMENT", 313, 331], ["the spike protein gene", "PROBLEM", 343, 365], ["PEDV", "PROBLEM", 371, 375], ["PCR", "TEST", 403, 406]]], ["A pair of primers (forward primer 5\u2032-GGATCC GAC GTT TCT TTT ATG AC-3\u2032 and reverse primer 5\u2032-GGTACCTTAAAT ACT CAT ACT AAA G-3\u2032) was designed to amplify a PCR fragment containing the S1D gene and a stop codon (TAA) upstream of the KpnI enzyme site.", [["S1D", "GENE_OR_GENE_PRODUCT", 181, 184], ["KpnI", "GENE_OR_GENE_PRODUCT", 229, 233], ["forward primer 5", "DNA", 19, 35], ["reverse primer 5", "DNA", 74, 90], ["AAA G", "DNA", 117, 122], ["PCR fragment", "DNA", 153, 165], ["S1D gene", "DNA", 181, 189], ["stop codon", "DNA", 196, 206], ["TAA", "DNA", 208, 211], ["KpnI enzyme site", "DNA", 229, 245], ["A pair of primers (forward primer", "TREATMENT", 0, 33], ["GGATCC GAC GTT", "TREATMENT", 37, 51], ["TCT", "TEST", 52, 55], ["TTT ATG AC", "TREATMENT", 56, 66], ["reverse primer", "TREATMENT", 74, 88], ["GGTACCTTAAAT ACT CAT ACT AAA G", "TREATMENT", 92, 122], ["a PCR fragment", "PROBLEM", 151, 165], ["the S1D gene", "TREATMENT", 177, 189], ["a stop codon (TAA)", "TREATMENT", 194, 212], ["the KpnI enzyme site", "PROBLEM", 225, 245]]], ["A BamHI restriction site at the 5\u2032-end and KpnI at the 3\u2032-end of the sequence was included to facilitate cloning.", [["BamHI", "GENE_OR_GENE_PRODUCT", 2, 7], ["KpnI", "GENE_OR_GENE_PRODUCT", 43, 47], ["BamHI restriction site", "DNA", 2, 24], ["5\u2032-end", "DNA", 32, 38], ["KpnI", "DNA", 43, 47], ["3\u2032-end", "DNA", 55, 61], ["A BamHI restriction site", "TREATMENT", 0, 24]]], ["The S1D gene for expression in E. coli was amplified using Ex Taq (Takara Bio) with the PCR conditions described above and cloned into the pGEM\u00aeT-Easy vector (Promega), creating plasmid pMYV711.", [["S1D", "GENE_OR_GENE_PRODUCT", 4, 7], ["E. coli", "ORGANISM", 31, 38], ["pMYV711", "GENE_OR_GENE_PRODUCT", 186, 193], ["S1D gene", "DNA", 4, 12], ["Ex Taq", "DNA", 59, 65], ["Takara Bio", "DNA", 67, 77], ["pGEM", "DNA", 139, 143], ["T-Easy vector", "DNA", 144, 157], ["plasmid pMYV711", "DNA", 178, 193], ["E. coli", "SPECIES", 31, 38], ["E. coli", "SPECIES", 31, 38], ["expression in E. coli", "PROBLEM", 17, 38], ["Ex Taq (Takara Bio", "TREATMENT", 59, 77], ["the PCR conditions", "TREATMENT", 84, 102], ["Easy vector (Promega)", "TREATMENT", 146, 167], ["creating plasmid pMYV711", "TREATMENT", 169, 193]]], ["Gene identity was confirmed via sequencing using the universal primers T7 and SP6.", [["SP6", "GENE_OR_GENE_PRODUCT", 78, 81], ["universal primers T7", "DNA", 53, 73], ["SP6", "DNA", 78, 81], ["the universal primers T7", "TREATMENT", 49, 73]]], ["The BamHI and KpnI-digested fragment containing the S1D gene from pMYV711 was introduced into the same sites of the E. coli expression vector pQE-30 (Qiagen, Hilden, Germany), yielding pMYV714.", [["pMYV711", "CHEMICAL", 66, 73], ["BamHI", "GENE_OR_GENE_PRODUCT", 4, 9], ["KpnI", "GENE_OR_GENE_PRODUCT", 14, 18], ["fragment", "CELLULAR_COMPONENT", 28, 36], ["S1D", "GENE_OR_GENE_PRODUCT", 52, 55], ["pMYV711", "GENE_OR_GENE_PRODUCT", 66, 73], ["E. coli", "ORGANISM", 116, 123], ["pMYV714", "GENE_OR_GENE_PRODUCT", 185, 192], ["BamHI and KpnI-digested fragment", "DNA", 4, 36], ["S1D gene", "DNA", 52, 60], ["pMYV711", "DNA", 66, 73], ["pQE", "DNA", 142, 145], ["E. coli", "SPECIES", 116, 123], ["E. coli", "SPECIES", 116, 123], ["The BamHI and KpnI-digested fragment", "TREATMENT", 0, 36], ["the S1D gene from pMYV711", "TREATMENT", 48, 73], ["the E. coli expression vector", "TREATMENT", 112, 141], ["digested fragment", "OBSERVATION", 19, 36], ["E. coli", "OBSERVATION", 116, 123]]], ["The plasmid was confirmed by restriction enzyme mapping.", [["plasmid", "ANATOMY", 4, 11], ["The plasmid", "TREATMENT", 0, 11], ["enzyme mapping", "TEST", 41, 55]]], ["Plasmid pMYV714 was transformed into E. coli expression host strain SG13009 (Qiagen) for production of recombination protein.Construction of the S1D gene for expression in E. coli and production of mouse anti-S1D antibody ::: Materials and methodsPurification of the recombinant S1D protein synthesized in E. coli was performed under denaturating conditions in 8 M urea (Kim et al. 2009).", [["pMYV714", "CHEMICAL", 8, 15], ["urea", "CHEMICAL", 365, 369], ["urea", "CHEMICAL", 365, 369], ["pMYV714", "GENE_OR_GENE_PRODUCT", 8, 15], ["E. coli", "ORGANISM", 37, 44], ["Qiagen", "ORGANISM_SUBSTANCE", 77, 83], ["S1D", "GENE_OR_GENE_PRODUCT", 145, 148], ["E. coli", "ORGANISM", 172, 179], ["mouse", "ORGANISM", 198, 203], ["anti-S1D", "GENE_OR_GENE_PRODUCT", 204, 212], ["S1D", "GENE_OR_GENE_PRODUCT", 279, 282], ["E. coli", "ORGANISM", 306, 313], ["pMYV714", "DNA", 8, 15], ["recombination protein", "PROTEIN", 103, 124], ["S1D gene", "DNA", 145, 153], ["mouse anti-S1D antibody", "PROTEIN", 198, 221], ["recombinant S1D protein", "PROTEIN", 267, 290], ["E. coli", "SPECIES", 37, 44], ["E. coli", "SPECIES", 172, 179], ["mouse", "SPECIES", 198, 203], ["E. coli", "SPECIES", 306, 313], ["E. coli", "SPECIES", 37, 44], ["E. coli", "SPECIES", 172, 179], ["mouse", "SPECIES", 198, 203], ["E. coli", "SPECIES", 306, 313], ["Plasmid pMYV714", "TREATMENT", 0, 15], ["recombination protein", "PROBLEM", 103, 124], ["the S1D gene", "TREATMENT", 141, 153], ["E. coli", "PROBLEM", 172, 179], ["the recombinant S1D protein synthesized", "PROBLEM", 263, 302], ["E. coli", "PROBLEM", 306, 313], ["E. coli", "OBSERVATION_MODIFIER", 37, 44]]], ["Briefly, a bacterial colony harboring the S1D gene was inoculated into 5 mL of Luria Bertani (LB) medium containing ampicillin (100 mg/l) and kanamycin (5 mg/L), and incubated overnight at 37 \u00b0C. The culture was transferred to 200 mL of LB medium and incubation continued at 37 \u00b0C for 2 h to an OD600 of 0.6\u20130.8.", [["colony", "ANATOMY", 21, 27], ["ampicillin", "CHEMICAL", 116, 126], ["kanamycin", "CHEMICAL", 142, 151], ["ampicillin", "CHEMICAL", 116, 126], ["kanamycin", "CHEMICAL", 142, 151], ["S1D", "GENE_OR_GENE_PRODUCT", 42, 45], ["ampicillin", "SIMPLE_CHEMICAL", 116, 126], ["kanamycin", "SIMPLE_CHEMICAL", 142, 151], ["S1D gene", "DNA", 42, 50], ["Luria Bertani", "SPECIES", 79, 92], ["a bacterial colony harboring the S1D gene", "TREATMENT", 9, 50], ["Luria Bertani (LB) medium", "TREATMENT", 79, 104], ["ampicillin", "TREATMENT", 116, 126], ["kanamycin", "TREATMENT", 142, 151], ["The culture", "TEST", 196, 207], ["bacterial colony harboring", "OBSERVATION", 11, 37]]], ["Expression of the recombinant proteins was induced by adding iso-propyl-\u03b2-D-thiogalactopyranoside (IPTG) to a final concentration of 10 mM, followed by incubation for a further 6 h at 37 \u00b0C. The cells were harvested by centrifugation and lysed in 10 mL of \u2018buffer Z\u2019 (8 M urea, 100 mM NaCl, 20 mM HEPES, pH 8.0) by sonication on ice (20 min; 20 s runs with 15 s breaks between each run).", [["cells", "ANATOMY", 195, 200], ["iso-propyl-\u03b2-D-thiogalactopyranoside", "CHEMICAL", 61, 97], ["IPTG", "CHEMICAL", 99, 103], ["urea", "CHEMICAL", 272, 276], ["NaCl", "CHEMICAL", 285, 289], ["iso-propyl-\u03b2-D-thiogalactopyranoside", "CHEMICAL", 61, 97], ["IPTG", "CHEMICAL", 99, 103], ["urea", "CHEMICAL", 272, 276], ["NaCl", "CHEMICAL", 285, 289], ["HEPES", "CHEMICAL", 297, 302], ["iso-propyl-\u03b2-D-thiogalactopyranoside", "SIMPLE_CHEMICAL", 61, 97], ["IPTG", "SIMPLE_CHEMICAL", 99, 103], ["cells", "CELL", 195, 200], ["urea", "SIMPLE_CHEMICAL", 272, 276], ["recombinant proteins", "PROTEIN", 18, 38], ["the recombinant proteins", "PROBLEM", 14, 38], ["iso-propyl-\u03b2-D-thiogalactopyranoside (IPTG", "TREATMENT", 61, 103], ["20 mM HEPES", "TREATMENT", 291, 302], ["pH", "TEST", 304, 306]]], ["After centrifugation at 10,000 rpm for 10 min at 4 \u00b0C using a JA-14 rotor (Beckman Coulter, Pasadena, CA, USA) to remove cell debris, imidazole was added to the bacterial lysate supernatant to a final concentration of 10 mM and the sample was loaded onto a 2 mL nickel column (Ni\u2013NTA; Invitrogen, Carlsbad, CA, USA).", [["cell", "ANATOMY", 121, 125], ["supernatant", "ANATOMY", 178, 189], ["sample", "ANATOMY", 232, 238], ["JA", "CHEMICAL", 62, 64], ["imidazole", "CHEMICAL", 134, 143], ["nickel", "CHEMICAL", 262, 268], ["Ni\u2013NTA", "CHEMICAL", 277, 283], ["JA-14", "CHEMICAL", 62, 67], ["imidazole", "CHEMICAL", 134, 143], ["nickel", "CHEMICAL", 262, 268], ["Ni\u2013NTA", "CHEMICAL", 277, 283], ["cell", "CELL", 121, 125], ["imidazole", "SIMPLE_CHEMICAL", 134, 143], ["centrifugation", "TREATMENT", 6, 20], ["a JA-14 rotor (Beckman Coulter", "TREATMENT", 60, 90], ["cell debris", "TREATMENT", 121, 132], ["imidazole", "TREATMENT", 134, 143], ["the bacterial lysate", "TREATMENT", 157, 177], ["a 2 mL nickel column", "TREATMENT", 255, 275], ["Ni\u2013NTA", "TREATMENT", 277, 283], ["cell debris", "OBSERVATION", 121, 132]]], ["The histidine-affinity column was washed with 15 mL of buffer Z plus imidazole (10 mM) to remove weakly bound proteins of E. coli origin.", [["histidine", "CHEMICAL", 4, 13], ["imidazole", "CHEMICAL", 69, 78], ["histidine", "CHEMICAL", 4, 13], ["imidazole", "CHEMICAL", 69, 78], ["histidine", "AMINO_ACID", 4, 13], ["imidazole", "SIMPLE_CHEMICAL", 69, 78], ["E. coli", "ORGANISM", 122, 129], ["E. coli", "SPECIES", 122, 129], ["E. coli", "SPECIES", 122, 129], ["The histidine-affinity column", "TREATMENT", 0, 29], ["buffer Z plus imidazole", "TREATMENT", 55, 78], ["E. coli origin", "PROBLEM", 122, 136], ["E. coli origin", "OBSERVATION", 122, 136]]], ["The His-tagged recombinant proteins were eluted with buffer Z plus 250 mM imidazole.", [["imidazole", "CHEMICAL", 74, 83], ["imidazole", "CHEMICAL", 74, 83], ["imidazole", "SIMPLE_CHEMICAL", 74, 83], ["His-tagged recombinant proteins", "PROTEIN", 4, 35], ["The His-tagged recombinant proteins", "TREATMENT", 0, 35], ["buffer Z", "TREATMENT", 53, 61]]], ["The purified recombinant proteins were quantified by Bradford protein assays (Bio-Rad, Hercules, CA, USA) and dialyzed in phosphate-buffered saline (PBS) containing 8.0 g/L NaCl, 0.2 g/L KCl, 1.44 g/L Na2HPO4.2 H2O and 0.24 g/L KH2PO4 with pH 7.4 to remove urea and imidazole.", [["phosphate", "CHEMICAL", 122, 131], ["NaCl", "CHEMICAL", 173, 177], ["KCl", "CHEMICAL", 187, 190], ["H2O", "CHEMICAL", 211, 214], ["urea", "CHEMICAL", 257, 261], ["imidazole", "CHEMICAL", 266, 275], ["phosphate", "CHEMICAL", 122, 131], ["NaCl", "CHEMICAL", 173, 177], ["KCl", "CHEMICAL", 187, 190], ["H2O", "CHEMICAL", 211, 214], ["KH2PO4", "CHEMICAL", 228, 234], ["urea", "CHEMICAL", 257, 261], ["imidazole", "CHEMICAL", 266, 275], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 122, 147], ["Na2HPO4.2 H2O", "SIMPLE_CHEMICAL", 201, 214], ["urea", "SIMPLE_CHEMICAL", 257, 261], ["imidazole", "SIMPLE_CHEMICAL", 266, 275], ["purified recombinant proteins", "PROTEIN", 4, 33], ["The purified recombinant proteins", "PROBLEM", 0, 33], ["Bradford protein assays", "TEST", 53, 76], ["Bio", "TEST", 78, 81], ["Hercules", "TEST", 87, 95], ["CA", "TEST", 97, 99], ["dialyzed in phosphate", "TREATMENT", 110, 131], ["buffered saline (PBS)", "TREATMENT", 132, 153], ["NaCl", "TREATMENT", 173, 177], ["KCl", "TREATMENT", 187, 190], ["H2O", "TREATMENT", 211, 214], ["pH", "TEST", 240, 242], ["urea", "TEST", 257, 261], ["imidazole", "TREATMENT", 266, 275]]], ["After dialysis, the recombinant proteins were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting using a mouse anti-His tag antibody and injected into mice for antibody production.Construction of the S1D gene for expression in E. coli and production of mouse anti-S1D antibody ::: Materials and methodsFor production of mouse anti-S1D antibody, 50 \u00b5g of purified S1D protein mixed with Freund\u2019s complete adjuvant (Sigma\u2013Aldrich, St. Louis, MO, USA) were intravenously injected into the tail of mice.", [["tail", "ANATOMY", 537, 541], ["sodium dodecyl sulfate", "CHEMICAL", 58, 80], ["sodium dodecyl sulfate", "CHEMICAL", 58, 80], ["polyacrylamide", "CHEMICAL", 81, 95], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 58, 80], ["mouse", "ORGANISM", 156, 161], ["mice", "ORGANISM", 202, 206], ["S1D", "GENE_OR_GENE_PRODUCT", 251, 254], ["E. coli", "ORGANISM", 278, 285], ["mouse", "ORGANISM", 304, 309], ["S1D", "GENE_OR_GENE_PRODUCT", 315, 318], ["mouse", "ORGANISM", 371, 376], ["anti-S1D antibody", "GENE_OR_GENE_PRODUCT", 377, 394], ["S1D", "GENE_OR_GENE_PRODUCT", 414, 417], ["tail", "ORGANISM_SUBDIVISION", 537, 541], ["mice", "ORGANISM", 545, 549], ["recombinant proteins", "PROTEIN", 20, 40], ["mouse anti-His tag antibody", "PROTEIN", 156, 183], ["S1D gene", "DNA", 251, 259], ["mouse anti-S1D antibody", "PROTEIN", 304, 327], ["mouse anti-S1D antibody", "PROTEIN", 371, 394], ["S1D protein", "PROTEIN", 414, 425], ["mouse", "SPECIES", 156, 161], ["mice", "SPECIES", 202, 206], ["E. coli", "SPECIES", 278, 285], ["mouse", "SPECIES", 304, 309], ["mouse", "SPECIES", 371, 376], ["mice", "SPECIES", 545, 549], ["mouse", "SPECIES", 156, 161], ["mice", "SPECIES", 202, 206], ["E. coli", "SPECIES", 278, 285], ["mouse", "SPECIES", 304, 309], ["mouse", "SPECIES", 371, 376], ["mice", "SPECIES", 545, 549], ["dialysis", "TREATMENT", 6, 14], ["the recombinant proteins", "TREATMENT", 16, 40], ["sodium dodecyl sulfate", "TREATMENT", 58, 80], ["polyacrylamide gel electrophoresis", "TREATMENT", 81, 115], ["a mouse anti", "TREATMENT", 154, 166], ["His tag antibody", "TREATMENT", 167, 183], ["antibody production", "PROBLEM", 211, 230], ["the S1D gene", "TREATMENT", 247, 259], ["E. coli", "PROBLEM", 278, 285], ["methods", "TREATMENT", 346, 353], ["mouse anti-S1D antibody", "TEST", 371, 394], ["purified S1D protein", "TREATMENT", 405, 425], ["Freund", "TREATMENT", 437, 443]]], ["As a booster, 50 \u00b5g of purified S1D with Freund\u2019s incomplete adjuvant (Sigma\u2013Aldrich) was subcutaneously injected into mice twice at a 10-day interval (Leenaars and Hendriksen 2005).", [["subcutaneously", "ANATOMY", 90, 104], ["S1D", "GENE_OR_GENE_PRODUCT", 32, 35], ["Sigma\u2013Aldrich", "SIMPLE_CHEMICAL", 71, 84], ["mice", "ORGANISM", 119, 123], ["mice", "SPECIES", 119, 123], ["mice", "SPECIES", 119, 123], ["purified S1D", "TREATMENT", 23, 35], ["Freund\u2019s incomplete adjuvant (Sigma\u2013Aldrich)", "TREATMENT", 41, 85]]], ["Blood serum was collected at 3 days after the final booster and tested for antibody-binding activity with purified S1D antigen by Western blot analysis and subsequently used to detect expression of S1D protein in plants.Agroinfiltration procedure ::: Materials and methods", [["Blood serum", "ANATOMY", 0, 11], ["Blood serum", "ORGANISM_SUBSTANCE", 0, 11], ["S1D antigen", "GENE_OR_GENE_PRODUCT", 115, 126], ["S1D", "GENE_OR_GENE_PRODUCT", 198, 201], ["purified S1D antigen", "PROTEIN", 106, 126], ["S1D protein", "PROTEIN", 198, 209], ["Blood serum", "TEST", 0, 11], ["the final booster", "TREATMENT", 42, 59], ["antibody", "TEST", 75, 83], ["blot analysis", "TEST", 138, 151], ["S1D protein in plants", "PROBLEM", 198, 219]]]], "PMC7223178": [["IntroductionAtherosclerotic vascular disease (ASVD) is a chronic process, with a progressive course over many years, but it can cause acute clinical events, including acute coronary syndromes (ACS), myocardial infarction (MI) and stroke [1].", [["Atherosclerotic vascular", "ANATOMY", 12, 36], ["coronary", "ANATOMY", 173, 181], ["myocardial", "ANATOMY", 199, 209], ["Atherosclerotic vascular disease", "DISEASE", 12, 44], ["ASVD", "DISEASE", 46, 50], ["acute coronary syndromes", "DISEASE", 167, 191], ["ACS", "DISEASE", 193, 196], ["myocardial infarction", "DISEASE", 199, 220], ["MI", "DISEASE", 222, 224], ["stroke", "DISEASE", 230, 236], ["vascular", "MULTI-TISSUE_STRUCTURE", 28, 36], ["myocardial", "MULTI-TISSUE_STRUCTURE", 199, 209], ["Atherosclerotic vascular disease (ASVD)", "PROBLEM", 12, 51], ["a chronic process", "PROBLEM", 55, 72], ["acute clinical events", "PROBLEM", 134, 155], ["acute coronary syndromes", "PROBLEM", 167, 191], ["ACS", "PROBLEM", 193, 196], ["myocardial infarction", "PROBLEM", 199, 220], ["MI", "PROBLEM", 222, 224], ["stroke", "PROBLEM", 230, 236], ["Atherosclerotic", "OBSERVATION_MODIFIER", 12, 27], ["vascular", "ANATOMY", 28, 36], ["disease", "OBSERVATION", 37, 44], ["chronic", "OBSERVATION_MODIFIER", 57, 64], ["process", "OBSERVATION", 65, 72], ["progressive", "OBSERVATION_MODIFIER", 81, 92], ["course", "OBSERVATION_MODIFIER", 93, 99], ["acute", "OBSERVATION_MODIFIER", 134, 139], ["acute", "OBSERVATION_MODIFIER", 167, 172], ["coronary", "ANATOMY", 173, 181], ["myocardial", "ANATOMY", 199, 209], ["infarction", "OBSERVATION", 210, 220]]], ["Hypertension, hypercholesterolemia and other continuous effects or vascular bifurcation disorder blood flow shear force lead to endothelial cells (ECs) dysfunction or anatomical damage.", [["vascular", "ANATOMY", 67, 75], ["blood", "ANATOMY", 97, 102], ["endothelial cells", "ANATOMY", 128, 145], ["ECs", "ANATOMY", 147, 150], ["Hypertension", "DISEASE", 0, 12], ["hypercholesterolemia", "DISEASE", 14, 34], ["disorder", "DISEASE", 88, 96], ["vascular", "MULTI-TISSUE_STRUCTURE", 67, 75], ["blood", "ORGANISM_SUBSTANCE", 97, 102], ["endothelial cells", "CELL", 128, 145], ["ECs", "CELL", 147, 150], ["endothelial cells", "CELL_TYPE", 128, 145], ["ECs", "CELL_TYPE", 147, 150], ["Hypertension", "PROBLEM", 0, 12], ["hypercholesterolemia", "PROBLEM", 14, 34], ["other continuous effects", "PROBLEM", 39, 63], ["vascular bifurcation disorder", "PROBLEM", 67, 96], ["blood flow shear force", "PROBLEM", 97, 119], ["endothelial cells", "PROBLEM", 128, 145], ["dysfunction", "PROBLEM", 152, 163], ["anatomical damage", "PROBLEM", 167, 184], ["hypercholesterolemia", "OBSERVATION", 14, 34], ["vascular", "ANATOMY", 67, 75], ["bifurcation", "OBSERVATION", 76, 87], ["endothelial cells", "OBSERVATION", 128, 145], ["anatomical damage", "OBSERVATION", 167, 184]]], ["Lipids (mainly cholesterol and cholesterol esters) in the blood enter the arterial wall in the form of lipoproteins from the damaged ECs, causing local inflammation of the vessels [2].", [["blood", "ANATOMY", 58, 63], ["arterial wall", "ANATOMY", 74, 87], ["ECs", "ANATOMY", 133, 136], ["vessels", "ANATOMY", 172, 179], ["cholesterol", "CHEMICAL", 15, 26], ["cholesterol esters", "CHEMICAL", 31, 49], ["inflammation", "DISEASE", 152, 164], ["cholesterol", "CHEMICAL", 15, 26], ["cholesterol esters", "CHEMICAL", 31, 49], ["Lipids", "SIMPLE_CHEMICAL", 0, 6], ["cholesterol", "SIMPLE_CHEMICAL", 15, 26], ["cholesterol esters", "SIMPLE_CHEMICAL", 31, 49], ["blood", "ORGANISM_SUBSTANCE", 58, 63], ["arterial wall", "MULTI-TISSUE_STRUCTURE", 74, 87], ["ECs", "CELL", 133, 136], ["vessels", "MULTI-TISSUE_STRUCTURE", 172, 179], ["lipoproteins", "PROTEIN", 103, 115], ["damaged ECs", "CELL_TYPE", 125, 136], ["Lipids (mainly cholesterol and cholesterol esters", "TREATMENT", 0, 49], ["the blood", "TEST", 54, 63], ["local inflammation of the vessels", "PROBLEM", 146, 179], ["arterial wall", "ANATOMY", 74, 87], ["lipoproteins", "OBSERVATION", 103, 115], ["damaged ECs", "OBSERVATION", 125, 136], ["local", "OBSERVATION_MODIFIER", 146, 151], ["inflammation", "OBSERVATION", 152, 164], ["vessels", "ANATOMY", 172, 179]]], ["Pathological high expression of P-selectin and vascular cell adhesion molecule-1 (VCAM-1) in injured ECs mediates the adhesion of leukocytes (mainly lymphocytes and monocytes) in the blood and infiltrates into the endothelium [3].", [["ECs", "ANATOMY", 101, 104], ["leukocytes", "ANATOMY", 130, 140], ["lymphocytes", "ANATOMY", 149, 160], ["monocytes", "ANATOMY", 165, 174], ["blood", "ANATOMY", 183, 188], ["endothelium", "ANATOMY", 214, 225], ["P-selectin", "GENE_OR_GENE_PRODUCT", 32, 42], ["vascular cell adhesion molecule-1", "GENE_OR_GENE_PRODUCT", 47, 80], ["VCAM-1", "GENE_OR_GENE_PRODUCT", 82, 88], ["ECs", "CELL", 101, 104], ["leukocytes", "CELL", 130, 140], ["lymphocytes", "CELL", 149, 160], ["monocytes", "CELL", 165, 174], ["blood", "ORGANISM_SUBSTANCE", 183, 188], ["endothelium", "TISSUE", 214, 225], ["P-selectin", "PROTEIN", 32, 42], ["vascular cell adhesion molecule-1", "PROTEIN", 47, 80], ["VCAM", "PROTEIN", 82, 86], ["ECs", "CELL_TYPE", 101, 104], ["leukocytes", "CELL_TYPE", 130, 140], ["lymphocytes", "CELL_TYPE", 149, 160], ["monocytes", "CELL_TYPE", 165, 174], ["vascular cell adhesion molecule", "TEST", 47, 78], ["VCAM", "TEST", 82, 86], ["leukocytes", "TEST", 130, 140], ["lymphocytes", "TEST", 149, 160], ["monocytes", "TEST", 165, 174], ["the blood", "TEST", 179, 188], ["infiltrates into the endothelium", "PROBLEM", 193, 225], ["high expression", "OBSERVATION_MODIFIER", 13, 28], ["vascular cell", "ANATOMY", 47, 60], ["adhesion", "OBSERVATION_MODIFIER", 118, 126], ["leukocytes", "ANATOMY", 130, 140], ["blood", "ANATOMY", 183, 188], ["infiltrates", "OBSERVATION", 193, 204], ["endothelium", "ANATOMY", 214, 225]]], ["Inflammatory factors can stimulate monocytes to chemotaxis to the vascular wall and differentiate into macrophages, and form foam cells through phagocytosis of modified lipoproteins [such as oxidized low-density lipoprotein (ox-LDL)] [4].", [["monocytes", "ANATOMY", 35, 44], ["vascular wall", "ANATOMY", 66, 79], ["macrophages", "ANATOMY", 103, 114], ["foam cells", "ANATOMY", 125, 135], ["monocytes", "CELL", 35, 44], ["vascular wall", "TISSUE", 66, 79], ["macrophages", "CELL", 103, 114], ["foam cells", "CELL", 125, 135], ["oxidized low-density lipoprotein", "SIMPLE_CHEMICAL", 191, 223], ["ox-LDL", "SIMPLE_CHEMICAL", 225, 231], ["Inflammatory factors", "PROTEIN", 0, 20], ["monocytes", "CELL_TYPE", 35, 44], ["macrophages", "CELL_TYPE", 103, 114], ["foam cells", "CELL_TYPE", 125, 135], ["modified lipoproteins", "PROTEIN", 160, 181], ["oxidized low-density lipoprotein (ox-LDL", "PROTEIN", 191, 231], ["Inflammatory factors", "PROBLEM", 0, 20], ["chemotaxis", "TEST", 48, 58], ["macrophages", "PROBLEM", 103, 114], ["modified lipoproteins", "TREATMENT", 160, 181], ["vascular wall", "ANATOMY", 66, 79], ["macrophages", "OBSERVATION", 103, 114]]], ["With the development of inflammation, activated leukocytes and vascular ECs can release fibroblast growth regulating factor (FGF), induce the phenotype change of vascular smooth muscle cells (SMCs), migrate from the middle membrane through the inner elastic layer to the subintimal of arteries, proliferate and express a large number of cytokines and adhesion factors [5].", [["leukocytes", "ANATOMY", 48, 58], ["vascular ECs", "ANATOMY", 63, 75], ["vascular smooth muscle cells", "ANATOMY", 162, 190], ["SMCs", "ANATOMY", 192, 196], ["middle membrane", "ANATOMY", 216, 231], ["inner elastic layer", "ANATOMY", 244, 263], ["arteries", "ANATOMY", 285, 293], ["inflammation", "DISEASE", 24, 36], ["leukocytes", "CELL", 48, 58], ["vascular ECs", "CELL", 63, 75], ["fibroblast growth regulating factor", "GENE_OR_GENE_PRODUCT", 88, 123], ["FGF", "GENE_OR_GENE_PRODUCT", 125, 128], ["vascular smooth muscle cells", "CELL", 162, 190], ["SMCs", "CELL", 192, 196], ["middle membrane", "CELLULAR_COMPONENT", 216, 231], ["inner elastic layer", "TISSUE", 244, 263], ["arteries", "MULTI-TISSUE_STRUCTURE", 285, 293], ["activated leukocytes", "CELL_TYPE", 38, 58], ["vascular ECs", "CELL_TYPE", 63, 75], ["fibroblast growth regulating factor", "PROTEIN", 88, 123], ["FGF", "PROTEIN", 125, 128], ["vascular smooth muscle cells", "CELL_TYPE", 162, 190], ["SMCs", "CELL_TYPE", 192, 196], ["cytokines", "PROTEIN", 337, 346], ["adhesion factors", "PROTEIN", 351, 367], ["inflammation", "PROBLEM", 24, 36], ["activated leukocytes", "PROBLEM", 38, 58], ["vascular ECs", "TEST", 63, 75], ["the phenotype change of vascular smooth muscle cells", "PROBLEM", 138, 190], ["adhesion factors", "PROBLEM", 351, 367], ["inflammation", "OBSERVATION", 24, 36], ["activated leukocytes", "OBSERVATION", 38, 58], ["vascular", "ANATOMY", 63, 71], ["vascular", "ANATOMY", 162, 170], ["smooth muscle cells", "OBSERVATION", 171, 190], ["middle membrane", "ANATOMY", 216, 231], ["inner", "ANATOMY_MODIFIER", 244, 249], ["elastic", "ANATOMY_MODIFIER", 250, 257], ["layer", "ANATOMY_MODIFIER", 258, 263], ["subintimal", "ANATOMY_MODIFIER", 271, 281], ["arteries", "ANATOMY", 285, 293], ["large", "OBSERVATION_MODIFIER", 321, 326], ["number", "OBSERVATION_MODIFIER", 327, 333]]], ["In the late stage of atherosclerosis, inflammatory cytokines and matrix metalloproteinases (MMP) can degrade extracellular matrix proteins, which make the plaque easy to rupture.", [["extracellular matrix", "ANATOMY", 109, 129], ["plaque", "ANATOMY", 155, 161], ["atherosclerosis", "DISEASE", 21, 36], ["rupture", "DISEASE", 170, 177], ["matrix metalloproteinases", "GENE_OR_GENE_PRODUCT", 65, 90], ["MMP", "GENE_OR_GENE_PRODUCT", 92, 95], ["extracellular matrix", "CELLULAR_COMPONENT", 109, 129], ["plaque", "PATHOLOGICAL_FORMATION", 155, 161], ["inflammatory cytokines", "PROTEIN", 38, 60], ["matrix metalloproteinases", "PROTEIN", 65, 90], ["MMP", "PROTEIN", 92, 95], ["extracellular matrix proteins", "PROTEIN", 109, 138], ["atherosclerosis", "PROBLEM", 21, 36], ["inflammatory cytokines and matrix metalloproteinases (MMP)", "PROBLEM", 38, 96], ["extracellular matrix proteins", "TEST", 109, 138], ["the plaque", "PROBLEM", 151, 161], ["rupture", "PROBLEM", 170, 177], ["late stage", "OBSERVATION_MODIFIER", 7, 17], ["atherosclerosis", "OBSERVATION", 21, 36], ["inflammatory", "OBSERVATION_MODIFIER", 38, 50], ["matrix", "OBSERVATION_MODIFIER", 65, 71], ["metalloproteinases", "OBSERVATION_MODIFIER", 72, 90], ["plaque", "OBSERVATION", 155, 161], ["rupture", "OBSERVATION", 170, 177]]], ["In addition, inflammatory cells secrete vascular growth factors (VGF), which can promote the formation of blood vessels in the plaque, and eventually lead to MI or stroke [6].IntroductionAlthough the traditional risk factors of atherosclerosis, such as hyperlipidemia, hypertension, smoking, have been efficaciously cut down, the occurrence of atherosclerotic disease is still high.", [["inflammatory cells", "ANATOMY", 13, 31], ["blood vessels", "ANATOMY", 106, 119], ["plaque", "ANATOMY", 127, 133], ["atherosclerotic", "ANATOMY", 344, 359], ["plaque", "DISEASE", 127, 133], ["MI", "DISEASE", 158, 160], ["stroke", "DISEASE", 164, 170], ["atherosclerosis", "DISEASE", 228, 243], ["hyperlipidemia", "DISEASE", 253, 267], ["hypertension", "DISEASE", 269, 281], ["smoking", "CHEMICAL", 283, 290], ["atherosclerotic disease", "DISEASE", 344, 367], ["inflammatory cells", "CELL", 13, 31], ["vascular growth factors", "GENE_OR_GENE_PRODUCT", 40, 63], ["VGF", "GENE_OR_GENE_PRODUCT", 65, 68], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 106, 119], ["plaque", "PATHOLOGICAL_FORMATION", 127, 133], ["inflammatory cells", "CELL_TYPE", 13, 31], ["vascular growth factors", "PROTEIN", 40, 63], ["VGF", "PROTEIN", 65, 68], ["inflammatory cells secrete vascular growth factors", "PROBLEM", 13, 63], ["blood vessels in the plaque", "PROBLEM", 106, 133], ["MI", "PROBLEM", 158, 160], ["stroke", "PROBLEM", 164, 170], ["atherosclerosis", "PROBLEM", 228, 243], ["hyperlipidemia", "PROBLEM", 253, 267], ["hypertension", "PROBLEM", 269, 281], ["atherosclerotic disease", "PROBLEM", 344, 367], ["inflammatory cells", "OBSERVATION", 13, 31], ["vascular", "ANATOMY", 40, 48], ["blood vessels", "ANATOMY", 106, 119], ["plaque", "OBSERVATION", 127, 133], ["stroke", "OBSERVATION", 164, 170], ["atherosclerosis", "OBSERVATION", 228, 243], ["hyperlipidemia", "OBSERVATION", 253, 267], ["hypertension", "OBSERVATION", 269, 281], ["atherosclerotic", "OBSERVATION_MODIFIER", 344, 359], ["disease", "OBSERVATION", 360, 367], ["high", "OBSERVATION_MODIFIER", 377, 381]]], ["In addition, 30\u201350% of patients lack these typical risk factors, suggesting that other unknown factors are related to the pathogenesis [7].", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["the pathogenesis", "PROBLEM", 118, 134]]], ["Atherosclerosis was once thought to be a simple lipid accumulation lesion, but over the past decades emerging evidence has reported that atherosclerosis is a chronic inflammatory disease, suggesting that chronic infection plays a critical role in the development of atherosclerosis [8].", [["lesion", "ANATOMY", 67, 73], ["Atherosclerosis", "DISEASE", 0, 15], ["atherosclerosis", "DISEASE", 137, 152], ["chronic infection", "DISEASE", 204, 221], ["atherosclerosis", "DISEASE", 266, 281], ["Atherosclerosis", "PROBLEM", 0, 15], ["a simple lipid accumulation lesion", "PROBLEM", 39, 73], ["atherosclerosis", "PROBLEM", 137, 152], ["a chronic inflammatory disease", "PROBLEM", 156, 186], ["chronic infection", "PROBLEM", 204, 221], ["atherosclerosis", "PROBLEM", 266, 281], ["simple", "OBSERVATION_MODIFIER", 41, 47], ["lipid", "OBSERVATION_MODIFIER", 48, 53], ["accumulation", "OBSERVATION_MODIFIER", 54, 66], ["lesion", "OBSERVATION", 67, 73], ["atherosclerosis", "OBSERVATION", 137, 152], ["chronic", "OBSERVATION_MODIFIER", 158, 165], ["inflammatory", "OBSERVATION", 166, 178], ["chronic", "OBSERVATION_MODIFIER", 204, 211], ["infection", "OBSERVATION", 212, 221], ["atherosclerosis", "OBSERVATION", 266, 281]]], ["Fabricant and colleagues induced chicken atherosclerosis by infection with Marek\u2019s disease virus, and vaccination can prevent atherosclerotic changes caused by Marek\u2019s disease virus, which has aroused great interest in the study of the infectivity of atherosclerosis [9].", [["atherosclerotic", "ANATOMY", 126, 141], ["atherosclerosis", "DISEASE", 41, 56], ["infection", "DISEASE", 60, 69], ["Marek\u2019s disease", "DISEASE", 75, 90], ["atherosclerotic", "DISEASE", 126, 141], ["Marek\u2019s disease", "DISEASE", 160, 175], ["atherosclerosis", "DISEASE", 251, 266], ["chicken", "ORGANISM", 33, 40], ["Marek\u2019s disease virus", "ORGANISM", 75, 96], ["Marek\u2019s disease virus", "ORGANISM", 160, 181], ["chicken", "SPECIES", 33, 40], ["chicken", "SPECIES", 33, 40], ["Marek\u2019s disease virus", "SPECIES", 75, 96], ["Marek\u2019s disease virus", "SPECIES", 160, 181], ["chicken atherosclerosis", "PROBLEM", 33, 56], ["infection", "PROBLEM", 60, 69], ["Marek\u2019s disease virus", "PROBLEM", 75, 96], ["vaccination", "TREATMENT", 102, 113], ["atherosclerotic changes", "PROBLEM", 126, 149], ["Marek\u2019s disease virus", "PROBLEM", 160, 181], ["the study", "TEST", 219, 228], ["atherosclerosis", "PROBLEM", 251, 266], ["atherosclerosis", "OBSERVATION", 41, 56], ["infection", "OBSERVATION", 60, 69], ["atherosclerotic", "OBSERVATION", 126, 141], ["atherosclerosis", "OBSERVATION", 251, 266]]], ["Subsequently a series of infectious agents were proved to be closely related to atherosclerosis, including Chlamydia pneumoniae (C. pneumoniae) [10], Porphyromonas gingivalis (P. gingivalis) [11], Helicobacter pylori (H. pylori) [12], cytomegalovirus (CMV) [13], Epstein-Barr virus (EBV) [14], human immunodeficiency virus (HIV) [15], herpes simplex virus-1 (HSV-1) [16], HSV-2 [17] and hepatitis C virus (HCV) [18].", [["atherosclerosis", "DISEASE", 80, 95], ["Chlamydia pneumoniae", "DISEASE", 107, 127], ["Helicobacter pylori (H. pylori)", "DISEASE", 197, 228], ["cytomegalovirus (CMV)", "DISEASE", 235, 256], ["Epstein-Barr virus (EBV)", "DISEASE", 263, 287], ["human immunodeficiency virus (HIV)", "DISEASE", 294, 328], ["herpes simplex virus", "DISEASE", 335, 355], ["hepatitis C", "DISEASE", 387, 398], ["Chlamydia pneumoniae", "ORGANISM", 107, 127], ["C. pneumoniae", "ORGANISM", 129, 142], ["Porphyromonas gingivalis", "ORGANISM", 150, 174], ["P. gingivalis", "ORGANISM", 176, 189], ["Helicobacter pylori", "ORGANISM", 197, 216], ["H. pylori", "ORGANISM", 218, 227], ["cytomegalovirus", "ORGANISM", 235, 250], ["CMV", "ORGANISM", 252, 255], ["Epstein-Barr virus", "ORGANISM", 263, 281], ["EBV", "ORGANISM", 283, 286], ["human immunodeficiency virus (HIV) [15", "ORGANISM", 294, 332], ["herpes simplex virus-1", "ORGANISM", 335, 357], ["HSV-1) [16", "ORGANISM", 359, 369], ["HSV-2 [17]", "ORGANISM", 372, 382], ["hepatitis C virus", "ORGANISM", 387, 404], ["HCV", "ORGANISM", 406, 409], ["Chlamydia pneumoniae", "SPECIES", 107, 127], ["C. pneumoniae", "SPECIES", 129, 142], ["Porphyromonas gingivalis", "SPECIES", 150, 174], ["P. gingivalis", "SPECIES", 176, 189], ["Helicobacter pylori", "SPECIES", 197, 216], ["H. pylori", "SPECIES", 218, 227], ["Barr virus", "SPECIES", 271, 281], ["human immunodeficiency virus (HIV", "SPECIES", 294, 327], ["herpes simplex virus-1", "SPECIES", 335, 357], ["HSV-1", "SPECIES", 359, 364], ["HSV-2", "SPECIES", 372, 377], ["hepatitis C virus", "SPECIES", 387, 404], ["Chlamydia pneumoniae", "SPECIES", 107, 127], ["C. pneumoniae", "SPECIES", 129, 142], ["Porphyromonas gingivalis", "SPECIES", 150, 174], ["P. gingivalis", "SPECIES", 176, 189], ["Helicobacter pylori", "SPECIES", 197, 216], ["H. pylori", "SPECIES", 218, 227], ["CMV", "SPECIES", 252, 255], ["Epstein-Barr virus", "SPECIES", 263, 281], ["EBV", "SPECIES", 283, 286], ["human immunodeficiency virus", "SPECIES", 294, 322], ["HIV", "SPECIES", 324, 327], ["herpes simplex virus-1", "SPECIES", 335, 357], ["HSV-1", "SPECIES", 359, 364], ["HSV-2", "SPECIES", 372, 377], ["hepatitis C virus", "SPECIES", 387, 404], ["HCV", "SPECIES", 406, 409], ["infectious agents", "TREATMENT", 25, 42], ["atherosclerosis", "PROBLEM", 80, 95], ["Chlamydia pneumoniae (C. pneumoniae)", "PROBLEM", 107, 143], ["Porphyromonas gingivalis (P. gingivalis)", "TEST", 150, 190], ["Helicobacter pylori (H. pylori)", "TEST", 197, 228], ["cytomegalovirus (CMV)", "TEST", 235, 256], ["Epstein-Barr virus (EBV)", "TEST", 263, 287], ["human immunodeficiency virus", "PROBLEM", 294, 322], ["HIV)", "TEST", 324, 328], ["herpes simplex virus", "TEST", 335, 355], ["HSV", "TEST", 359, 362], ["HSV", "TEST", 372, 375], ["hepatitis C virus (HCV)", "PROBLEM", 387, 410], ["atherosclerosis", "OBSERVATION", 80, 95]]], ["A large number of studies have detected the presence of bacterial or viral pathogens in atherosclerotic plaques, suggesting that these pathogens can invade, lurk or replicate in cells, so as to play a direct role in the local plaque [19, 20].", [["atherosclerotic plaques", "ANATOMY", 88, 111], ["cells", "ANATOMY", 178, 183], ["plaque", "ANATOMY", 226, 232], ["atherosclerotic plaques", "DISEASE", 88, 111], ["plaque", "DISEASE", 226, 232], ["atherosclerotic plaques", "PATHOLOGICAL_FORMATION", 88, 111], ["cells", "CELL", 178, 183], ["plaque", "PATHOLOGICAL_FORMATION", 226, 232], ["studies", "TEST", 18, 25], ["bacterial or viral pathogens in atherosclerotic plaques", "PROBLEM", 56, 111], ["these pathogens", "PROBLEM", 129, 144], ["large", "OBSERVATION_MODIFIER", 2, 7], ["bacterial", "OBSERVATION_MODIFIER", 56, 65], ["viral", "OBSERVATION_MODIFIER", 69, 74], ["pathogens", "OBSERVATION_MODIFIER", 75, 84], ["atherosclerotic", "OBSERVATION_MODIFIER", 88, 103], ["plaques", "OBSERVATION", 104, 111], ["local", "OBSERVATION_MODIFIER", 220, 225], ["plaque", "OBSERVATION", 226, 232]]], ["The mechanisms by which these pathogens promote atherosclerosis are by promoting ECs inflammatory responses and macrophage-derived foam cell formation, as well as increasing SMCs proliferation and inhibiting their apoptosis.", [["ECs", "ANATOMY", 81, 84], ["macrophage", "ANATOMY", 112, 122], ["foam cell", "ANATOMY", 131, 140], ["SMCs", "ANATOMY", 174, 178], ["atherosclerosis", "DISEASE", 48, 63], ["ECs", "CELL", 81, 84], ["macrophage", "CELL", 112, 122], ["foam cell", "CELL", 131, 140], ["SMCs", "CELL", 174, 178], ["ECs", "CELL_TYPE", 81, 84], ["SMCs", "CELL_TYPE", 174, 178], ["atherosclerosis", "PROBLEM", 48, 63], ["macrophage-derived foam cell formation", "PROBLEM", 112, 150], ["increasing SMCs proliferation", "PROBLEM", 163, 192], ["their apoptosis", "PROBLEM", 208, 223], ["atherosclerosis", "OBSERVATION", 48, 63], ["inflammatory", "OBSERVATION_MODIFIER", 85, 97], ["foam cell formation", "OBSERVATION", 131, 150], ["SMCs", "ANATOMY", 174, 178], ["proliferation", "OBSERVATION", 179, 192]]], ["However, in most animal experiments, microbial infection can accelerate the progression of atherosclerotic plaque on the basis of dietary risk factors or genetic susceptibility or vascular damage, but it cannot be used as a single pathogenic factor to cause plaque formation.", [["atherosclerotic plaque", "ANATOMY", 91, 113], ["vascular", "ANATOMY", 180, 188], ["plaque", "ANATOMY", 258, 264], ["infection", "DISEASE", 47, 56], ["atherosclerotic plaque", "DISEASE", 91, 113], ["vascular damage", "DISEASE", 180, 195], ["plaque", "DISEASE", 258, 264], ["atherosclerotic plaque", "PATHOLOGICAL_FORMATION", 91, 113], ["vascular", "MULTI-TISSUE_STRUCTURE", 180, 188], ["plaque", "PATHOLOGICAL_FORMATION", 258, 264], ["microbial infection", "PROBLEM", 37, 56], ["atherosclerotic plaque", "PROBLEM", 91, 113], ["dietary risk factors", "PROBLEM", 130, 150], ["genetic susceptibility", "PROBLEM", 154, 176], ["vascular damage", "PROBLEM", 180, 195], ["a single pathogenic factor", "PROBLEM", 222, 248], ["plaque formation", "PROBLEM", 258, 274], ["most animal", "OBSERVATION_MODIFIER", 12, 23], ["microbial", "OBSERVATION_MODIFIER", 37, 46], ["infection", "OBSERVATION", 47, 56], ["progression", "OBSERVATION_MODIFIER", 76, 87], ["atherosclerotic", "OBSERVATION_MODIFIER", 91, 106], ["plaque", "OBSERVATION", 107, 113], ["vascular", "ANATOMY", 180, 188], ["damage", "OBSERVATION", 189, 195], ["plaque", "OBSERVATION", 258, 264]]], ["In addition, in epidemiological studies, a variety of infectious microbes is associated with atherosclerotic vascular disease, but several clinical trials have shown that anti-infective therapy is ineffective in reducing atherosclerotic cardiovascular events.", [["vascular", "ANATOMY", 109, 117], ["cardiovascular", "ANATOMY", 237, 251], ["infectious microbes", "DISEASE", 54, 73], ["atherosclerotic vascular disease", "DISEASE", 93, 125], ["atherosclerotic cardiovascular events", "DISEASE", 221, 258], ["vascular", "MULTI-TISSUE_STRUCTURE", 109, 117], ["atherosclerotic", "PATHOLOGICAL_FORMATION", 221, 236], ["cardiovascular", "ANATOMICAL_SYSTEM", 237, 251], ["epidemiological studies", "TEST", 16, 39], ["infectious microbes", "PROBLEM", 54, 73], ["atherosclerotic vascular disease", "PROBLEM", 93, 125], ["anti-infective therapy", "TREATMENT", 171, 193], ["reducing atherosclerotic cardiovascular events", "PROBLEM", 212, 258], ["infectious", "OBSERVATION", 54, 64], ["associated with", "UNCERTAINTY", 77, 92], ["atherosclerotic", "OBSERVATION_MODIFIER", 93, 108], ["vascular", "ANATOMY", 109, 117], ["disease", "OBSERVATION", 118, 125], ["anti-infective therapy", "OBSERVATION", 171, 193], ["atherosclerotic", "OBSERVATION_MODIFIER", 221, 236], ["cardiovascular", "ANATOMY", 237, 251]]], ["Therefore, the mechanism involved in infection to accelerate atherosclerosis has not been definitively identified until the exciting discovery related to signaling via toll-like receptors (TLRs) once again triggers a strong interest in immune defense mechanisms.IntroductionTLRs are the most characteristic members of pattern recognition receptors (PRRs) and play vital roles in innate immunity mechanisms [21].", [["infection", "DISEASE", 37, 46], ["atherosclerosis", "DISEASE", 61, 76], ["toll-like receptors", "GENE_OR_GENE_PRODUCT", 168, 187], ["TLRs", "GENE_OR_GENE_PRODUCT", 189, 193], ["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 318, 347], ["PRRs", "GENE_OR_GENE_PRODUCT", 349, 353], ["toll-like receptors", "PROTEIN", 168, 187], ["TLRs", "PROTEIN", 189, 193], ["pattern recognition receptors", "PROTEIN", 318, 347], ["PRRs", "PROTEIN", 349, 353], ["infection", "PROBLEM", 37, 46], ["accelerate atherosclerosis", "PROBLEM", 50, 76], ["IntroductionTLRs", "TREATMENT", 262, 278], ["infection", "OBSERVATION", 37, 46], ["atherosclerosis", "OBSERVATION", 61, 76]]], ["Located on the cell membrane or in the cytoplasm, PRRs can recognize conserved microbial structures called pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharides (LPS) released from Gram-negative bacteria or viral RNA, as well as host biomolecules associated with cell injury or necrosis called danger-associated molecular patterns (DAMPs) such as high mobility group protein B1 (HMGB1) [22].", [["cell membrane", "ANATOMY", 15, 28], ["cytoplasm", "ANATOMY", 39, 48], ["cell", "ANATOMY", 284, 288], ["LPS", "CHEMICAL", 183, 186], ["necrosis", "DISEASE", 299, 307], ["cell membrane", "CELLULAR_COMPONENT", 15, 28], ["cytoplasm", "ORGANISM_SUBSTANCE", 39, 48], ["PRRs", "GENE_OR_GENE_PRODUCT", 50, 54], ["pathogen-associated molecular patterns", "GENE_OR_GENE_PRODUCT", 107, 145], ["lipopolysaccharides", "SIMPLE_CHEMICAL", 162, 181], ["LPS", "SIMPLE_CHEMICAL", 183, 186], ["Gram", "GENE_OR_GENE_PRODUCT", 202, 206], ["cell", "CELL", 284, 288], ["danger-associated molecular patterns", "GENE_OR_GENE_PRODUCT", 315, 351], ["high mobility group protein B1", "GENE_OR_GENE_PRODUCT", 368, 398], ["HMGB1", "GENE_OR_GENE_PRODUCT", 400, 405], ["PRRs", "PROTEIN", 50, 54], ["pathogen-associated molecular patterns", "PROTEIN", 107, 145], ["PAMPs", "PROTEIN", 147, 152], ["viral RNA", "RNA", 228, 237], ["high mobility group protein B1", "PROTEIN", 368, 398], ["HMGB1", "PROTEIN", 400, 405], ["pathogen", "PROBLEM", 107, 115], ["lipopolysaccharides (LPS", "TEST", 162, 186], ["Gram-negative bacteria", "PROBLEM", 202, 224], ["viral RNA", "PROBLEM", 228, 237], ["host biomolecules", "PROBLEM", 250, 267], ["cell injury", "PROBLEM", 284, 295], ["necrosis", "PROBLEM", 299, 307], ["cell membrane", "OBSERVATION", 15, 28], ["negative bacteria", "OBSERVATION_MODIFIER", 207, 224], ["viral RNA", "OBSERVATION", 228, 237], ["cell injury", "OBSERVATION", 284, 295], ["necrosis", "OBSERVATION", 299, 307]]], ["TLRs orchestrate both pathogen-specific and cell type-specific host immune responses to fight infections.", [["cell", "ANATOMY", 44, 48], ["infections", "DISEASE", 94, 104], ["TLRs", "GENE_OR_GENE_PRODUCT", 0, 4], ["cell", "CELL", 44, 48], ["TLRs", "PROTEIN", 0, 4], ["fight infections", "PROBLEM", 88, 104]]], ["They play such a central role in initiating immune responses to a variety of pathogens that it is not surprising that in some cases inflammatory diseases such as atherosclerosis are caused by inappropriate activation of them [23].", [["atherosclerosis", "DISEASE", 162, 177], ["immune responses", "TREATMENT", 44, 60], ["some cases inflammatory diseases", "PROBLEM", 121, 153], ["atherosclerosis", "PROBLEM", 162, 177], ["inflammatory", "OBSERVATION_MODIFIER", 132, 144], ["atherosclerosis", "OBSERVATION", 162, 177]]], ["TLRs are considered to be an important factor in the pathogenesis of atherosclerosis.", [["atherosclerosis", "DISEASE", 69, 84], ["TLRs", "GENE_OR_GENE_PRODUCT", 0, 4], ["TLRs", "PROTEIN", 0, 4], ["TLRs", "TREATMENT", 0, 4], ["atherosclerosis", "PROBLEM", 69, 84], ["atherosclerosis", "OBSERVATION", 69, 84]]], ["TLR2-TLR1 heterodimer and TLR2-TLR6 heterodimer contributed to atherosclerosis in ApoE gene-knockout (ApoE\u2212/\u2212) mice and LDL receptor deficient (LDLR\u2212/\u2212) mice [24, 25].", [["atherosclerosis", "DISEASE", 63, 78], ["TLR2", "GENE_OR_GENE_PRODUCT", 0, 4], ["TLR1", "GENE_OR_GENE_PRODUCT", 5, 9], ["TLR2", "GENE_OR_GENE_PRODUCT", 26, 30], ["TLR6", "GENE_OR_GENE_PRODUCT", 31, 35], ["ApoE", "GENE_OR_GENE_PRODUCT", 82, 86], ["LDL receptor", "GENE_OR_GENE_PRODUCT", 120, 132], ["LDLR", "GENE_OR_GENE_PRODUCT", 144, 148], ["TLR2", "PROTEIN", 0, 4], ["TLR1 heterodimer", "PROTEIN", 5, 21], ["TLR2", "PROTEIN", 26, 30], ["TLR6 heterodimer", "PROTEIN", 31, 47], ["ApoE gene", "DNA", 82, 91], ["LDL receptor", "PROTEIN", 120, 132], ["LDLR", "PROTEIN", 144, 148], ["mice", "SPECIES", 111, 115], ["mice", "SPECIES", 153, 157], ["TLR2-TLR1 heterodimer", "TREATMENT", 0, 21], ["TLR2-TLR6 heterodimer", "TREATMENT", 26, 47], ["atherosclerosis", "PROBLEM", 63, 78], ["ApoE gene", "TEST", 82, 91], ["ApoE\u2212", "TEST", 102, 107], ["LDL receptor deficient", "TEST", 120, 142], ["atherosclerosis", "OBSERVATION", 63, 78]]], ["TLR4 deficiency improved the atherosclerosis index in ApoE\u2212/\u2212 and LDLR\u2212/\u2212 mice [26, 27].", [["atherosclerosis", "DISEASE", 29, 44], ["TLR4", "GENE_OR_GENE_PRODUCT", 0, 4], ["ApoE\u2212/\u2212", "GENE_OR_GENE_PRODUCT", 54, 61], ["LDLR", "GENE_OR_GENE_PRODUCT", 66, 70], ["TLR4", "PROTEIN", 0, 4], ["LDLR", "PROTEIN", 66, 70], ["mice", "SPECIES", 74, 78], ["mice", "SPECIES", 74, 78], ["TLR4 deficiency", "PROBLEM", 0, 15], ["the atherosclerosis index", "PROBLEM", 25, 50], ["ApoE\u2212", "TEST", 54, 59], ["deficiency", "OBSERVATION", 5, 15], ["atherosclerosis", "OBSERVATION_MODIFIER", 29, 44], ["index", "OBSERVATION_MODIFIER", 45, 50], ["LDLR", "ANATOMY", 66, 70]]], ["In addition, in endoplasmic TLRs, TLR3 can regulate the activities of MMP-2 and MMP-9 in macrophages, thus affecting the instability of atherosclerotic plaque [28].", [["endoplasmic", "ANATOMY", 16, 27], ["macrophages", "ANATOMY", 89, 100], ["atherosclerotic plaque", "ANATOMY", 136, 158], ["atherosclerotic plaque", "DISEASE", 136, 158], ["endoplasmic", "CELLULAR_COMPONENT", 16, 27], ["TLRs", "GENE_OR_GENE_PRODUCT", 28, 32], ["TLR3", "GENE_OR_GENE_PRODUCT", 34, 38], ["MMP-2", "GENE_OR_GENE_PRODUCT", 70, 75], ["MMP-9", "GENE_OR_GENE_PRODUCT", 80, 85], ["macrophages", "CELL", 89, 100], ["atherosclerotic plaque", "PATHOLOGICAL_FORMATION", 136, 158], ["endoplasmic TLRs", "PROTEIN", 16, 32], ["TLR3", "PROTEIN", 34, 38], ["MMP-2", "PROTEIN", 70, 75], ["MMP-9", "PROTEIN", 80, 85], ["macrophages", "CELL_TYPE", 89, 100], ["MMP", "TEST", 70, 73], ["MMP", "TEST", 80, 83], ["atherosclerotic plaque", "PROBLEM", 136, 158], ["endoplasmic TLRs", "ANATOMY", 16, 32], ["macrophages", "ANATOMY", 89, 100], ["atherosclerotic", "OBSERVATION_MODIFIER", 136, 151], ["plaque", "OBSERVATION", 152, 158]]], ["In response to vascular injury, foam cell accumulation and lesion formation, and in LDLR\u2212/\u2212 mice, TLR9 has been observed to spread inflammation [29].", [["vascular", "ANATOMY", 15, 23], ["foam cell", "ANATOMY", 32, 41], ["lesion", "ANATOMY", 59, 65], ["vascular injury", "DISEASE", 15, 30], ["inflammation", "DISEASE", 131, 143], ["vascular", "MULTI-TISSUE_STRUCTURE", 15, 23], ["foam cell", "CELL", 32, 41], ["lesion", "PATHOLOGICAL_FORMATION", 59, 65], ["LDLR", "GENE_OR_GENE_PRODUCT", 84, 88], ["TLR9", "GENE_OR_GENE_PRODUCT", 98, 102], ["LDLR", "PROTEIN", 84, 88], ["TLR9", "PROTEIN", 98, 102], ["mice", "SPECIES", 92, 96], ["mice", "SPECIES", 92, 96], ["vascular injury", "PROBLEM", 15, 30], ["foam cell accumulation", "PROBLEM", 32, 54], ["lesion formation", "PROBLEM", 59, 75], ["vascular", "ANATOMY", 15, 23], ["injury", "OBSERVATION", 24, 30], ["foam cell accumulation", "OBSERVATION", 32, 54], ["lesion", "OBSERVATION", 59, 65], ["LDLR", "ANATOMY", 84, 88]]], ["Interestingly, there is evidence that some endoplasmic TLRs can improve the occurrence of atherosclerosis.", [["endoplasmic", "ANATOMY", 43, 54], ["atherosclerosis", "DISEASE", 90, 105], ["endoplasmic", "CELLULAR_COMPONENT", 43, 54], ["TLRs", "GENE_OR_GENE_PRODUCT", 55, 59], ["endoplasmic TLRs", "PROTEIN", 43, 59], ["some endoplasmic TLRs", "PROBLEM", 38, 59], ["atherosclerosis", "PROBLEM", 90, 105], ["some", "OBSERVATION_MODIFIER", 38, 42], ["endoplasmic TLRs", "OBSERVATION", 43, 59], ["atherosclerosis", "OBSERVATION", 90, 105]]], ["It has been observed that TLR3 has a protective effect on the vascular wall after mechanical and hypercholesterolemia-induced arterial injury [30].", [["vascular wall", "ANATOMY", 62, 75], ["arterial", "ANATOMY", 126, 134], ["hypercholesterolemia", "DISEASE", 97, 117], ["arterial injury", "DISEASE", 126, 141], ["TLR3", "GENE_OR_GENE_PRODUCT", 26, 30], ["vascular wall", "MULTI-TISSUE_STRUCTURE", 62, 75], ["arterial", "MULTI-TISSUE_STRUCTURE", 126, 134], ["TLR3", "PROTEIN", 26, 30], ["mechanical and hypercholesterolemia", "TREATMENT", 82, 117], ["induced arterial injury", "PROBLEM", 118, 141], ["protective effect", "OBSERVATION", 37, 54], ["vascular wall", "ANATOMY", 62, 75], ["hypercholesterolemia", "OBSERVATION", 97, 117], ["arterial", "ANATOMY", 126, 134], ["injury", "OBSERVATION", 135, 141]]], ["TLR7 activation inhibited the activation of inflammatory macrophages and the production of cytokines [31].", [["inflammatory macrophages", "ANATOMY", 44, 68], ["TLR7", "GENE_OR_GENE_PRODUCT", 0, 4], ["macrophages", "CELL", 57, 68], ["TLR7", "PROTEIN", 0, 4], ["inflammatory macrophages", "CELL_TYPE", 44, 68], ["cytokines", "PROTEIN", 91, 100], ["TLR7 activation", "PROBLEM", 0, 15], ["inflammatory macrophages", "PROBLEM", 44, 68], ["inflammatory macrophages", "OBSERVATION", 44, 68]]], ["In addition, TLR9 gene deletion aggravated the atherosclerosis of ApoE\u2212/\u2212 mice fed with high-fat-diet (HFD) and a TLR9 agonist reduced the severity of the disease [32].", [["atherosclerosis", "DISEASE", 47, 62], ["TLR9", "GENE_OR_GENE_PRODUCT", 13, 17], ["ApoE\u2212", "ORGANISM", 66, 71], ["HFD", "SIMPLE_CHEMICAL", 103, 106], ["TLR9", "GENE_OR_GENE_PRODUCT", 114, 118], ["TLR9 gene deletion", "DNA", 13, 31], ["TLR9", "PROTEIN", 114, 118], ["mice", "SPECIES", 74, 78], ["mice", "SPECIES", 74, 78], ["TLR9 gene deletion", "PROBLEM", 13, 31], ["the atherosclerosis", "PROBLEM", 43, 62], ["a TLR9 agonist", "TREATMENT", 112, 126], ["the disease", "PROBLEM", 151, 162], ["atherosclerosis", "OBSERVATION", 47, 62], ["disease", "OBSERVATION", 155, 162]]], ["The mechanisms of atherogenesis induced by TLRs include the dysfunction of vascular cells, the recruitment of macrophages and other immune cells to the site of vascular injury, the formation of foam cells, and the instability of plaques, while the anti-atherosclerotic effect of TLRs is more in line with its evolutionary conservative function.", [["vascular cells", "ANATOMY", 75, 89], ["macrophages", "ANATOMY", 110, 121], ["immune cells", "ANATOMY", 132, 144], ["site", "ANATOMY", 152, 156], ["vascular", "ANATOMY", 160, 168], ["foam cells", "ANATOMY", 194, 204], ["plaques", "ANATOMY", 229, 236], ["atherogenesis", "DISEASE", 18, 31], ["vascular injury", "DISEASE", 160, 175], ["plaques", "DISEASE", 229, 236], ["TLRs", "GENE_OR_GENE_PRODUCT", 43, 47], ["vascular cells", "CELL", 75, 89], ["macrophages", "CELL", 110, 121], ["immune cells", "CELL", 132, 144], ["vascular", "MULTI-TISSUE_STRUCTURE", 160, 168], ["foam cells", "CELL", 194, 204], ["plaques", "PATHOLOGICAL_FORMATION", 229, 236], ["TLRs", "GENE_OR_GENE_PRODUCT", 279, 283], ["TLRs", "PROTEIN", 43, 47], ["vascular cells", "CELL_TYPE", 75, 89], ["macrophages", "CELL_TYPE", 110, 121], ["immune cells", "CELL_TYPE", 132, 144], ["foam cells", "CELL_TYPE", 194, 204], ["TLRs", "PROTEIN", 279, 283], ["atherogenesis", "PROBLEM", 18, 31], ["the dysfunction of vascular cells", "PROBLEM", 56, 89], ["macrophages", "PROBLEM", 110, 121], ["other immune cells", "PROBLEM", 126, 144], ["vascular injury", "PROBLEM", 160, 175], ["foam cells", "PROBLEM", 194, 204], ["the instability of plaques", "PROBLEM", 210, 236], ["TLRs", "TREATMENT", 279, 283], ["atherogenesis", "OBSERVATION", 18, 31], ["vascular cells", "ANATOMY", 75, 89], ["immune cells", "OBSERVATION", 132, 144], ["vascular", "ANATOMY", 160, 168], ["injury", "OBSERVATION", 169, 175], ["foam cells", "OBSERVATION", 194, 204], ["instability", "OBSERVATION_MODIFIER", 214, 225], ["plaques", "OBSERVATION", 229, 236], ["anti-atherosclerotic", "OBSERVATION_MODIFIER", 248, 268]]], ["To expand the positive effects of TLRs in identifying pathogens and minimize the negative ones should be the goal of researchers in the field of TLRs and atherosclerosis.IntroductionThe present review aims to summarize the latest progression and focus on the role of TLRs between microbial infection and atherosclerosis, hoping to provide a reference and treatment for strategy of atherosclerosis.", [["atherosclerosis", "DISEASE", 154, 169], ["microbial infection", "DISEASE", 280, 299], ["atherosclerosis", "DISEASE", 304, 319], ["atherosclerosis", "DISEASE", 381, 396], ["TLRs", "GENE_OR_GENE_PRODUCT", 34, 38], ["TLRs", "GENE_OR_GENE_PRODUCT", 145, 149], ["TLRs", "GENE_OR_GENE_PRODUCT", 267, 271], ["TLRs", "PROTEIN", 34, 38], ["TLRs", "PROTEIN", 145, 149], ["TLRs", "PROTEIN", 267, 271], ["TLRs", "TREATMENT", 34, 38], ["pathogens", "PROBLEM", 54, 63], ["atherosclerosis", "PROBLEM", 154, 169], ["the latest progression", "PROBLEM", 219, 241], ["microbial infection", "PROBLEM", 280, 299], ["atherosclerosis", "PROBLEM", 304, 319], ["treatment", "TREATMENT", 355, 364], ["atherosclerosis", "PROBLEM", 381, 396], ["positive effects", "OBSERVATION_MODIFIER", 14, 30], ["atherosclerosis", "OBSERVATION", 154, 169], ["infection", "OBSERVATION", 290, 299], ["atherosclerosis", "OBSERVATION", 304, 319], ["atherosclerosis", "OBSERVATION", 381, 396]]], ["We pay special attention to three research areas: (1) the biological characteristics and functions of TLRs are systematically summarized; (2) advances in research on the relationship between different pathogens and atherosclerosis, and the role or potential role of TLRs in inducing or accelerating atherosclerosis; (3) current status and potential therapeutic targets of antibiotic and vaccine therapy for infection and targeting TLRs in atherosclerotic diseases.", [["atherosclerotic", "ANATOMY", 439, 454], ["atherosclerosis", "DISEASE", 215, 230], ["atherosclerosis", "DISEASE", 299, 314], ["infection", "DISEASE", 407, 416], ["atherosclerotic diseases", "DISEASE", 439, 463], ["TLRs", "GENE_OR_GENE_PRODUCT", 102, 106], ["TLRs", "GENE_OR_GENE_PRODUCT", 266, 270], ["TLRs", "GENE_OR_GENE_PRODUCT", 431, 435], ["TLRs", "PROTEIN", 102, 106], ["TLRs", "PROTEIN", 266, 270], ["TLRs", "PROTEIN", 431, 435], ["different pathogens", "PROBLEM", 191, 210], ["atherosclerosis", "PROBLEM", 215, 230], ["accelerating atherosclerosis", "PROBLEM", 286, 314], ["antibiotic", "TREATMENT", 372, 382], ["vaccine therapy", "TREATMENT", 387, 402], ["infection", "PROBLEM", 407, 416], ["atherosclerotic diseases", "PROBLEM", 439, 463], ["atherosclerosis", "OBSERVATION", 215, 230], ["atherosclerosis", "OBSERVATION", 299, 314], ["atherosclerotic", "OBSERVATION_MODIFIER", 439, 454], ["diseases", "OBSERVATION", 455, 463]]], ["Finally, we summarize the full text, trying to explore the future research direction and potential drug treatment targets of atherosclerosis.Classification and structure of TLRs ::: Biological characteristics of TLRsThe research history of TLRs dates back to the last century and as early as 1991 the homology between the Drosophila toll receptors and the interleukin-1 (IL-1) receptors was identified by Gay and Keith [33].", [["atherosclerosis", "DISEASE", 125, 140], ["TLRs", "GENE_OR_GENE_PRODUCT", 212, 216], ["interleukin-1", "GENE_OR_GENE_PRODUCT", 356, 369], ["IL-1) receptors", "GENE_OR_GENE_PRODUCT", 371, 386], ["TLRs", "PROTEIN", 173, 177], ["TLRs", "PROTEIN", 212, 216], ["TLRs", "PROTEIN", 240, 244], ["Drosophila toll receptors", "PROTEIN", 322, 347], ["interleukin-1 (IL-1) receptors", "PROTEIN", 356, 386], ["Drosophila", "SPECIES", 322, 332], ["Drosophila", "SPECIES", 322, 332], ["potential drug treatment", "TREATMENT", 89, 113], ["atherosclerosis", "PROBLEM", 125, 140], ["the Drosophila toll receptors", "TREATMENT", 318, 347], ["the interleukin-1 (IL", "TREATMENT", 352, 373], ["atherosclerosis", "OBSERVATION", 125, 140]]], ["In 1994, Nomura et al. discovered the first sequence of a mammalian TLR homologue [34].", [["TLR", "GENE_OR_GENE_PRODUCT", 68, 71], ["mammalian TLR homologue", "PROTEIN", 58, 81], ["a mammalian TLR homologue", "TREATMENT", 56, 81]]], ["In 1996, it was discovered to be involved in anti-fungal immunity by Lemaitre et al. [35].", [["anti-fungal immunity", "TREATMENT", 45, 65]]], ["In 1997, Medzhitov et al. identified TLRs as vertebrate homologs of the Drosophila spp. determining Drosophila dorsal ventral polarity during Drosophila embryo development [36].", [["dorsal ventral", "ANATOMY", 111, 125], ["embryo", "ANATOMY", 153, 159], ["TLRs", "GENE_OR_GENE_PRODUCT", 37, 41], ["Drosophila spp", "ORGANISM", 72, 86], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 153, 159], ["TLRs", "PROTEIN", 37, 41], ["Drosophila", "SPECIES", 72, 82], ["Drosophila", "SPECIES", 100, 110], ["Drosophila", "SPECIES", 142, 152], ["Drosophila", "SPECIES", 100, 110], ["Drosophila", "SPECIES", 142, 152], ["the Drosophila spp", "PROBLEM", 68, 86], ["Drosophila dorsal ventral polarity", "PROBLEM", 100, 134], ["Drosophila embryo development", "PROBLEM", 142, 171], ["Drosophila spp", "OBSERVATION", 72, 86], ["dorsal", "ANATOMY_MODIFIER", 111, 117], ["ventral", "ANATOMY_MODIFIER", 118, 125], ["Drosophila embryo", "OBSERVATION", 142, 159]]], ["They also demonstrated that chimera of the intracellular domain of TLRs and the extracellular domain of CD4 activate nuclear factor kappa-B (NF-\u03baB), which thereby raises the expression of inflammatory cytokines IL-1, IL-6, IL-8 and costimulatory molecules B7.1. and eventually activates T lymphocytes.", [["intracellular", "ANATOMY", 43, 56], ["extracellular", "ANATOMY", 80, 93], ["T lymphocytes", "ANATOMY", 287, 300], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 43, 56], ["TLRs", "GENE_OR_GENE_PRODUCT", 67, 71], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 80, 93], ["CD4", "GENE_OR_GENE_PRODUCT", 104, 107], ["nuclear factor kappa-B", "GENE_OR_GENE_PRODUCT", 117, 139], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 141, 146], ["IL-1", "GENE_OR_GENE_PRODUCT", 211, 215], ["IL-6", "GENE_OR_GENE_PRODUCT", 217, 221], ["IL-8", "GENE_OR_GENE_PRODUCT", 223, 227], ["B7", "GENE_OR_GENE_PRODUCT", 256, 258], ["T lymphocytes", "CELL", 287, 300], ["intracellular domain", "PROTEIN", 43, 63], ["TLRs", "PROTEIN", 67, 71], ["extracellular domain", "PROTEIN", 80, 100], ["CD4", "PROTEIN", 104, 107], ["nuclear factor kappa-B", "PROTEIN", 117, 139], ["NF-\u03baB", "PROTEIN", 141, 146], ["inflammatory cytokines", "PROTEIN", 188, 210], ["IL-1, IL-6, IL-8", "PROTEIN", 211, 227], ["costimulatory molecules", "PROTEIN", 232, 255], ["B7", "PROTEIN", 256, 258], ["T lymphocytes", "CELL_TYPE", 287, 300], ["nuclear factor kappa", "TEST", 117, 137], ["inflammatory cytokines IL", "TEST", 188, 213], ["IL", "TEST", 217, 219], ["IL", "TEST", 223, 225], ["inflammatory", "OBSERVATION_MODIFIER", 188, 200]]], ["In 1998, it was recognized that there is a complete set of mammalian TLRs that respond to microbial ligands, while the long-term search for LPS bacterial receptors is TLR4 [37].", [["LPS", "CHEMICAL", 140, 143], ["TLRs", "GENE_OR_GENE_PRODUCT", 69, 73], ["LPS bacterial receptors", "GENE_OR_GENE_PRODUCT", 140, 163], ["TLR4", "GENE_OR_GENE_PRODUCT", 167, 171], ["mammalian TLRs", "PROTEIN", 59, 73], ["LPS bacterial receptors", "PROTEIN", 140, 163], ["TLR4", "PROTEIN", 167, 171], ["mammalian TLRs", "TREATMENT", 59, 73], ["microbial ligands", "TREATMENT", 90, 107], ["LPS bacterial receptors", "TEST", 140, 163]]], ["As of this writing, there are 13 TLRs identified in mammalian species of which TLR11 is non-functional and TLR12-13 are only expressed in mice [38].", [["TLRs", "GENE_OR_GENE_PRODUCT", 33, 37], ["TLR11", "GENE_OR_GENE_PRODUCT", 79, 84], ["TLR12-13", "GENE_OR_GENE_PRODUCT", 107, 115], ["mice", "ORGANISM", 138, 142], ["TLRs", "PROTEIN", 33, 37], ["TLR11", "PROTEIN", 79, 84], ["TLR12", "PROTEIN", 107, 112], ["mice", "SPECIES", 138, 142], ["mice", "SPECIES", 138, 142], ["mammalian species", "PROBLEM", 52, 69], ["TLR12", "TEST", 107, 112], ["13 TLRs", "OBSERVATION_MODIFIER", 30, 37], ["mammalian species", "OBSERVATION", 52, 69]]], ["Although TLRs are widely expressed in mammalian cells such as dendritic cells (DCs), macrophages, neutrophils, monocytes, lymphocytes, fibroblasts, epithelial cells, ECs, nerve cells and so on, each cell type includes a specific group of TLRs, which play a unique role in identifying PAMPs or DAMPs and mediate the immune response [39].", [["mammalian cells", "ANATOMY", 38, 53], ["dendritic cells", "ANATOMY", 62, 77], ["DCs", "ANATOMY", 79, 82], ["macrophages", "ANATOMY", 85, 96], ["neutrophils", "ANATOMY", 98, 109], ["monocytes", "ANATOMY", 111, 120], ["lymphocytes", "ANATOMY", 122, 133], ["fibroblasts", "ANATOMY", 135, 146], ["epithelial cells", "ANATOMY", 148, 164], ["ECs", "ANATOMY", 166, 169], ["nerve cells", "ANATOMY", 171, 182], ["cell", "ANATOMY", 199, 203], ["TLRs", "GENE_OR_GENE_PRODUCT", 9, 13], ["mammalian cells", "CELL", 38, 53], ["dendritic cells", "CELL", 62, 77], ["DCs", "CELL", 79, 82], ["macrophages", "CELL", 85, 96], ["neutrophils", "CELL", 98, 109], ["monocytes", "CELL", 111, 120], ["lymphocytes", "CELL", 122, 133], ["fibroblasts", "CELL", 135, 146], ["epithelial cells", "CELL", 148, 164], ["ECs", "CELL", 166, 169], ["nerve cells", "CELL", 171, 182], ["cell type", "CELL", 199, 208], ["TLRs", "GENE_OR_GENE_PRODUCT", 238, 242], ["PAMPs", "GENE_OR_GENE_PRODUCT", 284, 289], ["DAMPs", "GENE_OR_GENE_PRODUCT", 293, 298], ["TLRs", "PROTEIN", 9, 13], ["mammalian cells", "CELL_TYPE", 38, 53], ["dendritic cells", "CELL_TYPE", 62, 77], ["DCs", "CELL_TYPE", 79, 82], ["macrophages", "CELL_TYPE", 85, 96], ["neutrophils", "CELL_TYPE", 98, 109], ["monocytes", "CELL_TYPE", 111, 120], ["lymphocytes", "CELL_TYPE", 122, 133], ["fibroblasts", "CELL_TYPE", 135, 146], ["epithelial cells", "CELL_TYPE", 148, 164], ["ECs", "CELL_TYPE", 166, 169], ["nerve cells", "CELL_TYPE", 171, 182], ["TLRs", "PROTEIN", 238, 242], ["PAMPs", "PROTEIN", 284, 289], ["DAMPs", "PROTEIN", 293, 298], ["dendritic cells", "PROBLEM", 62, 77], ["macrophages", "TEST", 85, 96], ["neutrophils", "TEST", 98, 109], ["monocytes", "TEST", 111, 120], ["lymphocytes", "TEST", 122, 133], ["fibroblasts", "TEST", 135, 146], ["epithelial cells", "TEST", 148, 164], ["ECs", "TEST", 166, 169], ["nerve cells", "PROBLEM", 171, 182], ["DAMPs", "PROBLEM", 293, 298], ["mammalian cells", "OBSERVATION", 38, 53], ["dendritic cells", "OBSERVATION", 62, 77], ["macrophages", "ANATOMY", 85, 96], ["neutrophils", "ANATOMY", 98, 109], ["monocytes", "ANATOMY", 111, 120], ["lymphocytes", "ANATOMY", 122, 133], ["epithelial cells", "OBSERVATION", 148, 164], ["nerve cells", "OBSERVATION", 171, 182]]], ["Mammalian TLRs can be divided into cell membrane and intracellular receptors according to its location.", [["cell membrane", "ANATOMY", 35, 48], ["intracellular", "ANATOMY", 53, 66], ["TLRs", "GENE_OR_GENE_PRODUCT", 10, 14], ["cell membrane", "CELLULAR_COMPONENT", 35, 48], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 53, 66], ["Mammalian TLRs", "PROTEIN", 0, 14], ["intracellular receptors", "PROTEIN", 53, 76], ["Mammalian TLRs", "TREATMENT", 0, 14], ["intracellular receptors", "TREATMENT", 53, 76], ["cell membrane", "OBSERVATION", 35, 48]]], ["One group consisted of TLR1, 2, 5, 6, 10 and 11, which were expressed on the cell surface and mainly recognized microbial membrane components such as LPS; the other group consisted of TLR3, 7, 8, 9, 12 and 13, which were only expressed in intracellular vesicles and recognized microbial nucleic acids, and TLR4 localizes to the cell surface and intracellular vesicles [40].", [["cell surface", "ANATOMY", 77, 89], ["membrane components", "ANATOMY", 122, 141], ["intracellular vesicles", "ANATOMY", 239, 261], ["cell surface", "ANATOMY", 328, 340], ["intracellular vesicles", "ANATOMY", 345, 367], ["LPS", "CHEMICAL", 150, 153], ["nucleic acids", "CHEMICAL", 287, 300], ["TLR1", "GENE_OR_GENE_PRODUCT", 23, 27], ["2", "GENE_OR_GENE_PRODUCT", 29, 30], ["5", "GENE_OR_GENE_PRODUCT", 32, 33], ["6", "GENE_OR_GENE_PRODUCT", 35, 36], ["10", "GENE_OR_GENE_PRODUCT", 38, 40], ["cell surface", "CELLULAR_COMPONENT", 77, 89], ["membrane components", "CELLULAR_COMPONENT", 122, 141], ["LPS", "GENE_OR_GENE_PRODUCT", 150, 153], ["TLR3", "GENE_OR_GENE_PRODUCT", 184, 188], ["7", "GENE_OR_GENE_PRODUCT", 190, 191], ["8", "GENE_OR_GENE_PRODUCT", 193, 194], ["9", "GENE_OR_GENE_PRODUCT", 196, 197], ["12", "GENE_OR_GENE_PRODUCT", 199, 201], ["13", "GENE_OR_GENE_PRODUCT", 206, 208], ["intracellular vesicles", "CELLULAR_COMPONENT", 239, 261], ["TLR4", "GENE_OR_GENE_PRODUCT", 306, 310], ["cell surface", "CELLULAR_COMPONENT", 328, 340], ["intracellular vesicles", "CELLULAR_COMPONENT", 345, 367], ["TLR1, 2, 5, 6, 10 and 11", "PROTEIN", 23, 47], ["TLR3, 7, 8, 9, 12 and 13", "PROTEIN", 184, 208], ["TLR4", "PROTEIN", 306, 310], ["TLR1", "TEST", 23, 27], ["the cell surface", "TEST", 73, 89], ["LPS", "TEST", 150, 153], ["TLR3", "TEST", 184, 188], ["microbial nucleic acids", "TEST", 277, 300], ["TLR1", "ANATOMY_MODIFIER", 23, 27], ["microbial membrane", "OBSERVATION", 112, 130], ["LPS", "OBSERVATION_MODIFIER", 150, 153], ["intracellular vesicles", "OBSERVATION", 239, 261], ["microbial nucleic acids", "OBSERVATION", 277, 300], ["cell surface", "OBSERVATION", 328, 340], ["intracellular vesicles", "OBSERVATION", 345, 367]]], ["According to sequence analysis and three-dimensional structure, TLR can be further divided into three domains TLR (TLR1, 2, 4, 6, 10) interacting with lipid molecules such as LPS and lipoproteins, and single domain TLR (TLR3, 5, 7, 8, 9) interacting with hydrophilic ligands such as nucleic acids [41].", [["nucleic acids", "CHEMICAL", 283, 296], ["TLR", "GENE_OR_GENE_PRODUCT", 64, 67], ["TLR", "GENE_OR_GENE_PRODUCT", 110, 113], ["TLR1", "GENE_OR_GENE_PRODUCT", 115, 119], ["10", "GENE_OR_GENE_PRODUCT", 130, 132], ["LPS", "SIMPLE_CHEMICAL", 175, 178], ["TLR", "GENE_OR_GENE_PRODUCT", 215, 218], ["TLR3", "GENE_OR_GENE_PRODUCT", 220, 224], ["nucleic acids", "SIMPLE_CHEMICAL", 283, 296], ["TLR", "PROTEIN", 64, 67], ["TLR", "PROTEIN", 110, 113], ["TLR1, 2, 4, 6, 10", "PROTEIN", 115, 132], ["lipid molecules", "PROTEIN", 151, 166], ["lipoproteins", "PROTEIN", 183, 195], ["TLR", "PROTEIN", 215, 218], ["TLR3, 5, 7, 8, 9", "PROTEIN", 220, 236], ["sequence analysis", "TEST", 13, 30], ["TLR", "TREATMENT", 64, 67], ["TLR1", "TEST", 115, 119], ["lipid molecules", "TREATMENT", 151, 166], ["LPS and lipoproteins", "TREATMENT", 175, 195], ["single domain TLR", "TREATMENT", 201, 218], ["hydrophilic ligands", "TREATMENT", 255, 274], ["nucleic acids", "TEST", 283, 296], ["lipoproteins", "ANATOMY", 183, 195]]], ["These TLRs contain three main domains: (1) extracellular domain of hydrophobic leucine rich regions, 16\u201328 leucine rich repeats (LRRs), which mainly perform the function of recognizing receptors and binding with other co receptors to form receptor complexes.", [["extracellular", "ANATOMY", 43, 56], ["leucine", "CHEMICAL", 79, 86], ["leucine", "CHEMICAL", 79, 86], ["leucine", "CHEMICAL", 107, 114], ["TLRs", "GENE_OR_GENE_PRODUCT", 6, 10], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 43, 56], ["leucine", "AMINO_ACID", 79, 86], ["TLRs", "PROTEIN", 6, 10], ["extracellular domain", "PROTEIN", 43, 63], ["hydrophobic leucine rich regions", "PROTEIN", 67, 99], ["16\u201328 leucine rich repeats", "PROTEIN", 101, 127], ["LRRs", "PROTEIN", 129, 133], ["co receptors", "PROTEIN", 218, 230], ["receptor complexes", "PROTEIN", 239, 257], ["hydrophobic leucine rich regions", "PROBLEM", 67, 99], ["LRRs", "TEST", 129, 133], ["other co receptors", "TREATMENT", 212, 230]]], ["(2) transmembrane region; and (3) cytoplasmic region highly homologous with the cytoplasmic region of the members of the IL-1R family (IL-1R-mediated signal transduction system and mechanism are similar to that of Drosophila), which is called the toll-IL-1 receptor domain (TIR domain) [42].", [["transmembrane region", "ANATOMY", 4, 24], ["cytoplasmic", "ANATOMY", 34, 45], ["cytoplasmic", "ANATOMY", 80, 91], ["cytoplasmic", "ORGANISM_SUBSTANCE", 34, 45], ["cytoplasmic", "ORGANISM_SUBSTANCE", 80, 91], ["IL-1R", "GENE_OR_GENE_PRODUCT", 121, 126], ["IL-1R", "GENE_OR_GENE_PRODUCT", 135, 140], ["Drosophila", "ORGANISM", 214, 224], ["IL-1 receptor", "GENE_OR_GENE_PRODUCT", 252, 265], ["transmembrane region", "PROTEIN", 4, 24], ["cytoplasmic region", "PROTEIN", 34, 52], ["cytoplasmic region", "PROTEIN", 80, 98], ["IL-1R family", "PROTEIN", 121, 133], ["IL-1R", "PROTEIN", 135, 140], ["toll-IL-1 receptor domain", "PROTEIN", 247, 272], ["TIR domain", "PROTEIN", 274, 284], ["Drosophila", "SPECIES", 214, 224], ["Drosophila", "SPECIES", 214, 224], ["transmembrane region; and (3) cytoplasmic region", "PROBLEM", 4, 52], ["signal transduction system", "PROBLEM", 150, 176]]], ["TIR has homophilic interaction, by which downstream signal molecules containing TIR, such as MyD88 (myelid differentiation factor 88) and TIRAP (TIR domain containing adapter protein), are recruited to form signal complexes, which play an important role in TLR signaling transmission.", [["TIR", "GENE_OR_GENE_PRODUCT", 0, 3], ["TIR", "GENE_OR_GENE_PRODUCT", 80, 83], ["MyD88", "GENE_OR_GENE_PRODUCT", 93, 98], ["myelid differentiation factor 88", "GENE_OR_GENE_PRODUCT", 100, 132], ["TIRAP", "GENE_OR_GENE_PRODUCT", 138, 143], ["TIR domain containing adapter protein", "GENE_OR_GENE_PRODUCT", 145, 182], ["TLR", "GENE_OR_GENE_PRODUCT", 257, 260], ["TIR", "PROTEIN", 0, 3], ["downstream signal molecules", "PROTEIN", 41, 68], ["TIR", "PROTEIN", 80, 83], ["MyD88", "PROTEIN", 93, 98], ["myelid differentiation factor 88", "PROTEIN", 100, 132], ["TIRAP", "PROTEIN", 138, 143], ["TIR domain containing adapter protein", "PROTEIN", 145, 182], ["signal complexes", "PROTEIN", 207, 223], ["TLR", "PROTEIN", 257, 260], ["homophilic interaction", "PROBLEM", 8, 30], ["MyD88", "TEST", 93, 98], ["myelid differentiation factor", "TEST", 100, 129], ["TIRAP (TIR domain containing adapter protein", "TREATMENT", 138, 182], ["homophilic interaction", "OBSERVATION", 8, 30]]], ["See below for details.Endogenous and exogenous ligands of TLRs ::: Biological characteristics of TLRsTLR ligands are extremely extensive, each type of them has a series of ligands with a certain degree of specificity.", [["TLRs", "GENE_OR_GENE_PRODUCT", 58, 62], ["TLRsTLR ligands", "GENE_OR_GENE_PRODUCT", 97, 112], ["TLRs", "PROTEIN", 58, 62], ["TLRsTLR ligands", "PROTEIN", 97, 112], ["TLRsTLR ligands", "PROBLEM", 97, 112], ["exogenous ligands", "OBSERVATION", 37, 54], ["TLRsTLR ligands", "OBSERVATION", 97, 112], ["extensive", "OBSERVATION_MODIFIER", 127, 136]]], ["Most TLRs are homodimers, but some are heterodimers.", [["TLRs", "GENE_OR_GENE_PRODUCT", 5, 9], ["TLRs", "PROTEIN", 5, 9], ["homodimers", "PROTEIN", 14, 24], ["heterodimers", "PROTEIN", 39, 51], ["homodimers", "TREATMENT", 14, 24]]], ["TLR2 has been proved to be able to sense lipopeptides: it is heterodimerized with TLR1 to recognize triacyl lipopeptides from Gram-negative bacteria and mycoplasma, or heterodimerized with TLR6 to recognize diacyl lipopeptides from Gram-positive bacteria and mycoplasma.", [["diacyl lipopeptides", "CHEMICAL", 207, 226], ["triacyl", "CHEMICAL", 100, 107], ["diacyl lipopeptides", "CHEMICAL", 207, 226], ["TLR2", "GENE_OR_GENE_PRODUCT", 0, 4], ["TLR1", "GENE_OR_GENE_PRODUCT", 82, 86], ["triacyl lipopeptides", "SIMPLE_CHEMICAL", 100, 120], ["Gram", "GENE_OR_GENE_PRODUCT", 126, 130], ["TLR6", "GENE_OR_GENE_PRODUCT", 189, 193], ["diacyl lipopeptides", "SIMPLE_CHEMICAL", 207, 226], ["Gram-", "GENE_OR_GENE_PRODUCT", 232, 237], ["TLR2", "PROTEIN", 0, 4], ["TLR1", "PROTEIN", 82, 86], ["TLR6", "PROTEIN", 189, 193], ["TLR2", "TREATMENT", 0, 4], ["TLR1", "TREATMENT", 82, 86], ["triacyl lipopeptides", "TEST", 100, 120], ["Gram", "TEST", 126, 130], ["negative bacteria", "PROBLEM", 131, 148], ["mycoplasma", "PROBLEM", 153, 163], ["TLR6", "TREATMENT", 189, 193], ["diacyl lipopeptides", "TEST", 207, 226], ["Gram-positive bacteria", "PROBLEM", 232, 254], ["mycoplasma", "PROBLEM", 259, 269], ["negative bacteria", "OBSERVATION_MODIFIER", 131, 148], ["positive bacteria", "OBSERVATION", 237, 254]]], ["TLR2 has also been proved to recognize many other non-lipopeptide PAMPs from various etiologies.", [["TLR2", "GENE_OR_GENE_PRODUCT", 0, 4], ["TLR2", "PROTEIN", 0, 4], ["non-lipopeptide PAMPs", "PROTEIN", 50, 71], ["TLR2", "TREATMENT", 0, 4]]], ["TLR4 recognizes LPS, lipoteichoic acid (LTA), envelope glycoprotein and protein F on the plasma membrane, ox-LDL, Tenascin C, fibronectin extra domain A (EDA) on the endosomes [45, 46].", [["plasma membrane", "ANATOMY", 89, 104], ["endosomes", "ANATOMY", 166, 175], ["LPS", "CHEMICAL", 16, 19], ["lipoteichoic acid", "CHEMICAL", 21, 38], ["LTA", "CHEMICAL", 40, 43], ["TLR4", "GENE_OR_GENE_PRODUCT", 0, 4], ["LPS", "SIMPLE_CHEMICAL", 16, 19], ["lipoteichoic acid", "SIMPLE_CHEMICAL", 21, 38], ["LTA", "SIMPLE_CHEMICAL", 40, 43], ["envelope glycoprotein", "GENE_OR_GENE_PRODUCT", 46, 67], ["protein F", "GENE_OR_GENE_PRODUCT", 72, 81], ["plasma membrane", "CELLULAR_COMPONENT", 89, 104], ["ox-LDL", "GENE_OR_GENE_PRODUCT", 106, 112], ["Tenascin C", "GENE_OR_GENE_PRODUCT", 114, 124], ["fibronectin extra domain A", "GENE_OR_GENE_PRODUCT", 126, 152], ["EDA", "GENE_OR_GENE_PRODUCT", 154, 157], ["endosomes", "CELLULAR_COMPONENT", 166, 175], ["TLR4", "PROTEIN", 0, 4], ["LTA", "PROTEIN", 40, 43], ["envelope glycoprotein", "PROTEIN", 46, 67], ["protein F", "PROTEIN", 72, 81], ["LDL", "PROTEIN", 109, 112], ["Tenascin C", "PROTEIN", 114, 124], ["fibronectin extra domain A", "PROTEIN", 126, 152], ["EDA", "PROTEIN", 154, 157], ["LPS", "TEST", 16, 19], ["lipoteichoic acid (LTA", "TEST", 21, 43], ["envelope glycoprotein", "TEST", 46, 67], ["protein F", "TEST", 72, 81], ["the plasma membrane", "TEST", 85, 104], ["ox", "TEST", 106, 108], ["LDL", "TEST", 109, 112], ["Tenascin C", "TREATMENT", 114, 124]]], ["Before TLR3 was discovered in 2001, it was thought that TLRs were not involved in antiviral reactions.", [["TLR3", "GENE_OR_GENE_PRODUCT", 7, 11], ["TLRs", "GENE_OR_GENE_PRODUCT", 56, 60], ["TLR3", "PROTEIN", 7, 11], ["TLRs", "PROTEIN", 56, 60], ["antiviral reactions", "PROBLEM", 82, 101]]], ["In 2001, TLR3 was proved to be able to recognize double stranded RNA (dsRNA), which is the main component of many viruses, and mediates the activation of NF-\u03baB and type I IFN signaling pathway.", [["TLR3", "GENE_OR_GENE_PRODUCT", 9, 13], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 154, 159], ["type I IFN", "GENE_OR_GENE_PRODUCT", 164, 174], ["TLR3", "PROTEIN", 9, 13], ["double stranded RNA", "RNA", 49, 68], ["NF-\u03baB", "PROTEIN", 154, 159], ["IFN", "PROTEIN", 171, 174], ["TLR3", "TREATMENT", 9, 13], ["double stranded RNA (dsRNA)", "PROBLEM", 49, 76], ["many viruses", "PROBLEM", 109, 121], ["main", "OBSERVATION_MODIFIER", 91, 95], ["many", "OBSERVATION_MODIFIER", 109, 113], ["viruses", "OBSERVATION", 114, 121]]], ["TLR3 was then identified to sense small interfering RNA (siRNA) and self RNA from damaged cells [47].", [["cells", "ANATOMY", 90, 95], ["TLR3", "GENE_OR_GENE_PRODUCT", 0, 4], ["cells", "CELL", 90, 95], ["TLR3", "PROTEIN", 0, 4], ["small interfering RNA", "RNA", 34, 55], ["siRNA", "RNA", 57, 62], ["self RNA", "RNA", 68, 76], ["damaged cells", "CELL_TYPE", 82, 95], ["TLR3", "TREATMENT", 0, 4], ["small interfering RNA (siRNA)", "PROBLEM", 34, 63], ["self RNA from damaged cells", "PROBLEM", 68, 95], ["small", "OBSERVATION_MODIFIER", 34, 39], ["interfering RNA", "OBSERVATION", 40, 55]]], ["In the same year, TLR5 was proved to be able to sense bacterial flagellin (a protein component of flagellin) [48].", [["TLR5", "GENE_OR_GENE_PRODUCT", 18, 22], ["flagellin", "GENE_OR_GENE_PRODUCT", 64, 73], ["flagellin", "GENE_OR_GENE_PRODUCT", 98, 107], ["TLR5", "PROTEIN", 18, 22], ["bacterial flagellin", "PROTEIN", 54, 73], ["flagellin", "PROTEIN", 98, 107], ["TLR5", "TREATMENT", 18, 22], ["bacterial flagellin", "TREATMENT", 54, 73], ["a protein component of flagellin", "TREATMENT", 75, 107]]], ["Further studies showed that TLR5 can regulate the innate and adaptive response of bacteria in the intestinal tract [49].", [["intestinal tract", "ANATOMY", 98, 114], ["TLR5", "GENE_OR_GENE_PRODUCT", 28, 32], ["intestinal tract", "ORGAN", 98, 114], ["TLR5", "PROTEIN", 28, 32], ["Further studies", "TEST", 0, 15], ["TLR5", "TREATMENT", 28, 32], ["bacteria in the intestinal tract", "PROBLEM", 82, 114], ["bacteria", "OBSERVATION_MODIFIER", 82, 90], ["intestinal tract", "ANATOMY", 98, 114]]], ["In 2002, TLR7 was considered as another antiviral TLR because it can sense the synthetic chemical imiquimod, which is believed to stimulate antiviral response.", [["imiquimod", "CHEMICAL", 98, 107], ["imiquimod", "CHEMICAL", 98, 107], ["TLR7", "GENE_OR_GENE_PRODUCT", 9, 13], ["TLR", "GENE_OR_GENE_PRODUCT", 50, 53], ["imiquimod", "SIMPLE_CHEMICAL", 98, 107], ["TLR7", "PROTEIN", 9, 13], ["antiviral TLR", "PROTEIN", 40, 53], ["TLR7", "TREATMENT", 9, 13], ["another antiviral TLR", "TREATMENT", 32, 53], ["the synthetic chemical imiquimod", "TREATMENT", 75, 107]]], ["Subsequently, in 2004, TLR7 and tlr8 were proved to be able to sense single stranded RNA (ssRNA).", [["TLR7", "GENE_OR_GENE_PRODUCT", 23, 27], ["tlr8", "GENE_OR_GENE_PRODUCT", 32, 36], ["TLR7", "PROTEIN", 23, 27], ["tlr8", "PROTEIN", 32, 36], ["single stranded RNA", "RNA", 69, 88], ["TLR7 and tlr8", "TREATMENT", 23, 36]]], ["TLR9 has a specific response to CpG-rich hypomethylated DNA motifs.", [["CpG", "CHEMICAL", 32, 35], ["TLR9", "GENE_OR_GENE_PRODUCT", 0, 4], ["DNA", "CELLULAR_COMPONENT", 56, 59], ["TLR9", "PROTEIN", 0, 4], ["CpG-rich hypomethylated DNA motifs", "DNA", 32, 66], ["TLR9", "TREATMENT", 0, 4], ["CpG-rich hypomethylated DNA motifs", "TREATMENT", 32, 66]]], ["These motifs mainly exist in bacteria, mitochondria and fetal DNA, but rarely in adult DNA of vertebrates [50].", [["mitochondria", "ANATOMY", 39, 51], ["fetal", "ANATOMY", 56, 61], ["mitochondria", "CELLULAR_COMPONENT", 39, 51], ["fetal DNA", "CELLULAR_COMPONENT", 56, 65], ["DNA", "CELLULAR_COMPONENT", 87, 90], ["bacteria", "PROBLEM", 29, 37], ["mitochondria and fetal DNA", "PROBLEM", 39, 65], ["bacteria", "OBSERVATION", 29, 37], ["fetal DNA", "OBSERVATION", 56, 65]]], ["Recent studies have shown that TLR9 also reacts to herpesvirus DNA and the byproduct of Plasmodium falciparum, hemozoline [51].", [["Plasmodium falciparum", "DISEASE", 88, 109], ["hemozoline", "CHEMICAL", 111, 121], ["hemozoline", "CHEMICAL", 111, 121], ["TLR9", "GENE_OR_GENE_PRODUCT", 31, 35], ["herpesvirus", "ORGANISM", 51, 62], ["DNA", "CELLULAR_COMPONENT", 63, 66], ["Plasmodium falciparum", "ORGANISM", 88, 109], ["hemozoline [51]", "SIMPLE_CHEMICAL", 111, 126], ["TLR9", "PROTEIN", 31, 35], ["Plasmodium falciparum", "SPECIES", 88, 109], ["Plasmodium falciparum", "SPECIES", 88, 109], ["Recent studies", "TEST", 0, 14], ["TLR9", "PROBLEM", 31, 35], ["herpesvirus DNA", "TEST", 51, 66], ["Plasmodium falciparum", "TREATMENT", 88, 109], ["hemozoline", "TREATMENT", 111, 121]]], ["Human TLR10 and TLR2 recognize the ligands of Listeria, while mouse TLR10 contains a termination codon, so it is a pseudogene.", [["Human", "ORGANISM", 0, 5], ["TLR10", "GENE_OR_GENE_PRODUCT", 6, 11], ["TLR2", "GENE_OR_GENE_PRODUCT", 16, 20], ["mouse", "ORGANISM", 62, 67], ["TLR10", "GENE_OR_GENE_PRODUCT", 68, 73], ["Human TLR10", "PROTEIN", 0, 11], ["TLR2", "PROTEIN", 16, 20], ["mouse TLR10", "PROTEIN", 62, 73], ["termination codon", "DNA", 85, 102], ["Human", "SPECIES", 0, 5], ["mouse", "SPECIES", 62, 67], ["Human", "SPECIES", 0, 5], ["mouse", "SPECIES", 62, 67], ["Human TLR10", "TREATMENT", 0, 11], ["Listeria", "PROBLEM", 46, 54], ["a termination codon", "TREATMENT", 83, 102], ["Listeria", "OBSERVATION", 46, 54]]], ["TLR10 also responded to influenza A virus infection.", [["influenza A virus infection", "DISEASE", 24, 51], ["TLR10", "GENE_OR_GENE_PRODUCT", 0, 5], ["influenza A virus", "ORGANISM", 24, 41], ["TLR10", "PROTEIN", 0, 5], ["influenza A virus", "SPECIES", 24, 41], ["influenza A virus", "SPECIES", 24, 41], ["TLR10", "TREATMENT", 0, 5], ["influenza A virus infection", "PROBLEM", 24, 51], ["influenza", "OBSERVATION", 24, 33]]], ["TLR11 in mice has been proved to be able to detect a component of urinary pathogenic bacteria, and cooperate with TLR12 in mice to bind with profilin protein of Toxoplasma gondii [52].", [["urinary", "ANATOMY", 66, 73], ["TLR11", "CHEMICAL", 0, 5], ["Toxoplasma gondii", "DISEASE", 161, 178], ["TLR11", "GENE_OR_GENE_PRODUCT", 0, 5], ["mice", "ORGANISM", 9, 13], ["urinary", "ORGANISM_SUBSTANCE", 66, 73], ["TLR12", "GENE_OR_GENE_PRODUCT", 114, 119], ["mice", "ORGANISM", 123, 127], ["profilin", "GENE_OR_GENE_PRODUCT", 141, 149], ["Toxoplasma gondii", "ORGANISM", 161, 178], ["TLR11", "PROTEIN", 0, 5], ["TLR12", "PROTEIN", 114, 119], ["profilin protein", "PROTEIN", 141, 157], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 123, 127], ["Toxoplasma gondii", "SPECIES", 161, 178], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 123, 127], ["Toxoplasma gondii", "SPECIES", 161, 178], ["urinary pathogenic bacteria", "PROBLEM", 66, 93], ["TLR12 in mice", "TREATMENT", 114, 127], ["Toxoplasma gondii", "PROBLEM", 161, 178], ["urinary", "ANATOMY", 66, 73]]], ["Mouse TLR13 has recently been shown to recognize bacterial ribosomal RNA [53].", [["ribosomal", "ANATOMY", 59, 68], ["TLR13", "CHEMICAL", 6, 11], ["Mouse", "ORGANISM", 0, 5], ["TLR13", "GENE_OR_GENE_PRODUCT", 6, 11], ["TLR13", "PROTEIN", 6, 11], ["bacterial ribosomal RNA", "RNA", 49, 72], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5], ["Mouse TLR13", "TREATMENT", 0, 11], ["bacterial ribosomal RNA", "PROBLEM", 49, 72]]], ["All these findings confirm that TLRs are a large family of receptors, which can activate innate immunity and inflammation to deal with dangerous signals such as infection or tissue damage.", [["tissue", "ANATOMY", 174, 180], ["inflammation", "DISEASE", 109, 121], ["infection", "DISEASE", 161, 170], ["tissue damage", "DISEASE", 174, 187], ["TLRs", "GENE_OR_GENE_PRODUCT", 32, 36], ["tissue", "TISSUE", 174, 180], ["TLRs", "PROTEIN", 32, 36], ["inflammation", "PROBLEM", 109, 121], ["dangerous signals", "PROBLEM", 135, 152], ["infection", "PROBLEM", 161, 170], ["tissue damage", "PROBLEM", 174, 187], ["infection", "OBSERVATION", 161, 170]]], ["The details showed in Table 1.TLR signaling pathways ::: Biological characteristics of TLRsThe specific response initiated by an individual TLR depends on the recruitment of a single or specific binding adapter protein containing the TIR domain.", [["TLR", "GENE_OR_GENE_PRODUCT", 30, 33], ["TLRs", "GENE_OR_GENE_PRODUCT", 87, 91], ["TLR", "GENE_OR_GENE_PRODUCT", 140, 143], ["TLR", "PROTEIN", 30, 33], ["TLRs", "PROTEIN", 87, 91], ["TLR", "PROTEIN", 140, 143], ["binding adapter protein", "PROTEIN", 195, 218], ["TIR domain", "PROTEIN", 234, 244]]], ["These adaptors are MyD88, MyD88-adaptor-like (MAL, also known as TIRAP), TIR-domain-containing adaptor protein inducing IFN\u03b2 (TRIF; also known as TICAM1), TRIF-related adaptor molecule (TRAM; also known as TICAM2) and sterile \u03b1- and armadillo-motif-containing protein (SARM).", [["MyD88", "GENE_OR_GENE_PRODUCT", 19, 24], ["MyD88", "GENE_OR_GENE_PRODUCT", 26, 31], ["MAL", "GENE_OR_GENE_PRODUCT", 46, 49], ["TIRAP", "GENE_OR_GENE_PRODUCT", 65, 70], ["TIR-domain-containing adaptor protein inducing IFN\u03b2", "GENE_OR_GENE_PRODUCT", 73, 124], ["TRIF", "GENE_OR_GENE_PRODUCT", 126, 130], ["TICAM1", "GENE_OR_GENE_PRODUCT", 146, 152], ["TRIF-related adaptor molecule", "GENE_OR_GENE_PRODUCT", 155, 184], ["TRAM", "GENE_OR_GENE_PRODUCT", 186, 190], ["TICAM2", "GENE_OR_GENE_PRODUCT", 206, 212], ["sterile \u03b1-", "GENE_OR_GENE_PRODUCT", 218, 228], ["armadillo-motif-containing protein", "GENE_OR_GENE_PRODUCT", 233, 267], ["SARM", "GENE_OR_GENE_PRODUCT", 269, 273], ["MyD88", "PROTEIN", 19, 24], ["MyD88", "PROTEIN", 26, 31], ["adaptor", "PROTEIN", 32, 39], ["MAL", "PROTEIN", 46, 49], ["TIRAP", "PROTEIN", 65, 70], ["TIR-domain-containing adaptor protein", "PROTEIN", 73, 110], ["IFN\u03b2", "PROTEIN", 120, 124], ["TRIF", "PROTEIN", 126, 130], ["TICAM1", "PROTEIN", 146, 152], ["TRIF-related adaptor molecule", "PROTEIN", 155, 184], ["TRAM", "PROTEIN", 186, 190], ["TICAM2", "PROTEIN", 206, 212], ["sterile \u03b1- and armadillo-motif-containing protein", "PROTEIN", 218, 267], ["SARM", "PROTEIN", 269, 273], ["adaptor protein", "TREATMENT", 95, 110], ["TRIF-related adaptor molecule (TRAM", "TREATMENT", 155, 190], ["sterile \u03b1- and armadillo-motif", "TREATMENT", 218, 248]]], ["SARM has now been shown to interact with TRIF and thereby interfere with TRIF function [54].", [["SARM", "CHEMICAL", 0, 4], ["SARM", "GENE_OR_GENE_PRODUCT", 0, 4], ["TRIF", "GENE_OR_GENE_PRODUCT", 41, 45], ["TRIF", "GENE_OR_GENE_PRODUCT", 73, 77], ["SARM", "PROTEIN", 0, 4], ["TRIF", "PROTEIN", 41, 45], ["TRIF", "PROTEIN", 73, 77], ["TRIF", "TREATMENT", 41, 45]]], ["MyD88 is used by all TLRs (except TLR3) and IL-1 receptor family members, and transmits signals in NF-\u03baB and MAP kinase activation and inflammatory cytokine induction.", [["MyD88", "GENE_OR_GENE_PRODUCT", 0, 5], ["TLRs", "GENE_OR_GENE_PRODUCT", 21, 25], ["TLR3", "GENE_OR_GENE_PRODUCT", 34, 38], ["IL-1 receptor", "GENE_OR_GENE_PRODUCT", 44, 57], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 99, 104], ["MAP kinase", "GENE_OR_GENE_PRODUCT", 109, 119], ["MyD88", "PROTEIN", 0, 5], ["TLRs", "PROTEIN", 21, 25], ["TLR3", "PROTEIN", 34, 38], ["IL-1 receptor family members", "PROTEIN", 44, 72], ["NF-\u03baB", "PROTEIN", 99, 104], ["MAP kinase", "PROTEIN", 109, 119], ["inflammatory cytokine", "PROTEIN", 135, 156], ["MAP kinase activation", "TREATMENT", 109, 130], ["inflammatory cytokine induction", "TREATMENT", 135, 166], ["inflammatory", "OBSERVATION_MODIFIER", 135, 147]]], ["Among them, TLR1, 2, 4 and 6 recruit additional adapter MAL as a bridge between TIR domain and MyD88.", [["TLR1", "GENE_OR_GENE_PRODUCT", 12, 16], ["2", "GENE_OR_GENE_PRODUCT", 18, 19], ["4", "GENE_OR_GENE_PRODUCT", 21, 22], ["6", "GENE_OR_GENE_PRODUCT", 27, 28], ["MAL", "GENE_OR_GENE_PRODUCT", 56, 59], ["MyD88", "GENE_OR_GENE_PRODUCT", 95, 100], ["TLR1, 2, 4 and 6", "PROTEIN", 12, 28], ["MAL", "PROTEIN", 56, 59], ["TIR domain", "PROTEIN", 80, 90], ["MyD88", "PROTEIN", 95, 100], ["a bridge between TIR domain", "TREATMENT", 63, 90], ["TLR1", "ANATOMY", 12, 16]]], ["TLR3 and 4 can also induce the production of type I IFN and inflammatory cytokines by using the MyD88-dependent pathway of TRIF.", [["TLR3", "GENE_OR_GENE_PRODUCT", 0, 4], ["4", "GENE_OR_GENE_PRODUCT", 9, 10], ["type I IFN", "GENE_OR_GENE_PRODUCT", 45, 55], ["MyD88", "GENE_OR_GENE_PRODUCT", 96, 101], ["TRIF", "GENE_OR_GENE_PRODUCT", 123, 127], ["TLR3 and 4", "PROTEIN", 0, 10], ["type I IFN", "PROTEIN", 45, 55], ["inflammatory cytokines", "PROTEIN", 60, 82], ["MyD88", "PROTEIN", 96, 101], ["TRIF", "PROTEIN", 123, 127], ["type I IFN", "PROBLEM", 45, 55], ["inflammatory cytokines", "PROBLEM", 60, 82], ["the MyD88-dependent pathway of TRIF", "TREATMENT", 92, 127], ["inflammatory", "OBSERVATION_MODIFIER", 60, 72]]], ["Compared with TLR3, TLR4 does not interact with TRIF directly, but needs TRAM to transmit its signal.", [["TLR3", "GENE_OR_GENE_PRODUCT", 14, 18], ["TLR4", "GENE_OR_GENE_PRODUCT", 20, 24], ["TRIF", "GENE_OR_GENE_PRODUCT", 48, 52], ["TRAM", "GENE_OR_GENE_PRODUCT", 73, 77], ["TLR3", "PROTEIN", 14, 18], ["TLR4", "PROTEIN", 20, 24], ["TRIF", "PROTEIN", 48, 52], ["TRAM", "PROTEIN", 73, 77]]], ["In addition, recent studies have shown that TLR5 in intestinal epithelial cells recruits TRIF in addition to MyD88, which results in activation of NF-\u03baB rather than IRF3.", [["intestinal epithelial cells", "ANATOMY", 52, 79], ["TLR5", "GENE_OR_GENE_PRODUCT", 44, 48], ["intestinal epithelial cells", "CELL", 52, 79], ["TRIF", "GENE_OR_GENE_PRODUCT", 89, 93], ["MyD88", "GENE_OR_GENE_PRODUCT", 109, 114], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 147, 152], ["IRF3", "GENE_OR_GENE_PRODUCT", 165, 169], ["TLR5", "PROTEIN", 44, 48], ["intestinal epithelial cells", "CELL_TYPE", 52, 79], ["TRIF", "PROTEIN", 89, 93], ["MyD88", "PROTEIN", 109, 114], ["NF-\u03baB", "PROTEIN", 147, 152], ["IRF3", "PROTEIN", 165, 169], ["recent studies", "TEST", 13, 27], ["TLR5 in intestinal epithelial cells", "PROBLEM", 44, 79], ["MyD88", "TREATMENT", 109, 114], ["activation of NF", "PROBLEM", 133, 149], ["intestinal", "ANATOMY", 52, 62], ["epithelial cells", "OBSERVATION", 63, 79]]], ["Therefore, TLR4 is the only one that recruits four adaptor proteins.", [["TLR4", "GENE_OR_GENE_PRODUCT", 11, 15], ["TLR4", "PROTEIN", 11, 15], ["adaptor proteins", "PROTEIN", 51, 67]]], ["It recruits TIRAP on the cell surface, promotes the aggregation of MyD88, and initiates a pathway dependent on MyD88.", [["cell surface", "ANATOMY", 25, 37], ["TIRAP", "GENE_OR_GENE_PRODUCT", 12, 17], ["cell surface", "CELLULAR_COMPONENT", 25, 37], ["MyD88", "GENE_OR_GENE_PRODUCT", 67, 72], ["MyD88", "GENE_OR_GENE_PRODUCT", 111, 116], ["TIRAP", "PROTEIN", 12, 17], ["MyD88", "PROTEIN", 67, 72], ["MyD88", "PROTEIN", 111, 116], ["TIRAP", "OBSERVATION", 12, 17], ["cell", "OBSERVATION", 25, 29], ["surface", "OBSERVATION_MODIFIER", 30, 37]]], ["Then, TLR4 depends on the endocytosis of dynein and is transported to endoplasmic body, resulting in the formation of signal complex composed of endoplasmic body, TRAM and TRIF, thus initiating the TRIF-dependent pathway [55].TLR signaling pathways ::: Biological characteristics of TLRsThe two pathways have different dynamics.", [["endoplasmic body", "ANATOMY", 70, 86], ["endoplasmic body", "ANATOMY", 145, 161], ["TLR4", "GENE_OR_GENE_PRODUCT", 6, 10], ["dynein", "GENE_OR_GENE_PRODUCT", 41, 47], ["endoplasmic body", "CELLULAR_COMPONENT", 70, 86], ["endoplasmic body", "CELLULAR_COMPONENT", 145, 161], ["TRAM", "GENE_OR_GENE_PRODUCT", 163, 167], ["TRIF", "GENE_OR_GENE_PRODUCT", 172, 176], ["TRIF", "GENE_OR_GENE_PRODUCT", 198, 202], ["TLR", "GENE_OR_GENE_PRODUCT", 226, 229], ["TLRs", "GENE_OR_GENE_PRODUCT", 283, 287], ["TLR4", "PROTEIN", 6, 10], ["dynein", "PROTEIN", 41, 47], ["signal complex", "PROTEIN", 118, 132], ["TRAM", "PROTEIN", 163, 167], ["TRIF", "PROTEIN", 172, 176], ["TRIF", "PROTEIN", 198, 202], ["TLR", "PROTEIN", 226, 229], ["TLRs", "PROTEIN", 283, 287], ["signal complex", "PROBLEM", 118, 132], ["TRAM", "TREATMENT", 163, 167], ["TRIF", "TREATMENT", 172, 176], ["the TRIF-dependent pathway", "TREATMENT", 194, 220], ["endoplasmic body", "OBSERVATION", 145, 161]]], ["TLR stimulation triggers the binding of MyD88, which interacts with interleukin-1 receptor-associated kinase 4 (IRAK4) which is the most upstream serine/threonine kinase of the complex [56].", [["serine", "CHEMICAL", 146, 152], ["threonine", "CHEMICAL", 153, 162], ["TLR", "GENE_OR_GENE_PRODUCT", 0, 3], ["MyD88", "GENE_OR_GENE_PRODUCT", 40, 45], ["interleukin-1 receptor-associated kinase 4", "GENE_OR_GENE_PRODUCT", 68, 110], ["IRAK4", "GENE_OR_GENE_PRODUCT", 112, 117], ["serine", "AMINO_ACID", 146, 152], ["threonine", "AMINO_ACID", 153, 162], ["TLR", "PROTEIN", 0, 3], ["MyD88", "PROTEIN", 40, 45], ["interleukin-1 receptor-associated kinase 4", "PROTEIN", 68, 110], ["IRAK4", "PROTEIN", 112, 117], ["threonine kinase", "PROTEIN", 153, 169], ["TLR stimulation", "TREATMENT", 0, 15], ["interleukin", "TEST", 68, 79]]], ["IRAK4 phosphorylates IRAK1 and separates it from the receptor complex.", [["IRAK4", "GENE_OR_GENE_PRODUCT", 0, 5], ["IRAK1", "GENE_OR_GENE_PRODUCT", 21, 26], ["IRAK4", "PROTEIN", 0, 5], ["IRAK1", "PROTEIN", 21, 26], ["receptor complex", "PROTEIN", 53, 69], ["IRAK4 phosphorylates IRAK1", "TREATMENT", 0, 26], ["phosphorylates IRAK1", "OBSERVATION", 6, 26]]], ["TRAF6 subsequently binds to phosphorylated IRAK1 [57].", [["TRAF6", "GENE_OR_GENE_PRODUCT", 0, 5], ["IRAK1", "GENE_OR_GENE_PRODUCT", 43, 48], ["TRAF6", "PROTEIN", 0, 5], ["IRAK1", "PROTEIN", 43, 48]]], ["The phosphorylated IRAK1 and TRAF6 separated from the receptor form complexes with transforming growth factor\u03b2-activated kinase 1(TAK1), TAK1-binding protein 1 (TAB1) and TAB2 on the cell surface, which induce the phosphorylation of TAB2 and TAK1 [58].", [["cell surface", "ANATOMY", 183, 195], ["IRAK1", "GENE_OR_GENE_PRODUCT", 19, 24], ["TRAF6", "GENE_OR_GENE_PRODUCT", 29, 34], ["transforming growth factor\u03b2-activated kinase 1", "GENE_OR_GENE_PRODUCT", 83, 129], ["TAK1", "GENE_OR_GENE_PRODUCT", 130, 134], ["TAK1-binding protein 1", "GENE_OR_GENE_PRODUCT", 137, 159], ["TAB1", "GENE_OR_GENE_PRODUCT", 161, 165], ["TAB2", "GENE_OR_GENE_PRODUCT", 171, 175], ["cell surface", "CELLULAR_COMPONENT", 183, 195], ["TAB2", "GENE_OR_GENE_PRODUCT", 233, 237], ["TAK1", "GENE_OR_GENE_PRODUCT", 242, 246], ["IRAK1", "PROTEIN", 19, 24], ["TRAF6", "PROTEIN", 29, 34], ["transforming growth factor\u03b2-activated kinase 1", "PROTEIN", 83, 129], ["TAK1", "PROTEIN", 130, 134], ["TAK1-binding protein 1", "PROTEIN", 137, 159], ["TAB1", "PROTEIN", 161, 165], ["TAB2", "PROTEIN", 171, 175], ["TAB2", "PROTEIN", 233, 237], ["TAK1", "PROTEIN", 242, 246], ["The phosphorylated IRAK1", "TEST", 0, 24], ["TRAF6", "TEST", 29, 34], ["transforming growth factor\u03b2", "TEST", 83, 110], ["activated kinase", "TEST", 111, 127], ["TAK1-binding protein", "TEST", 137, 157], ["phosphorylated IRAK1", "OBSERVATION", 4, 24]]], ["IRAK1 is degraded on the cell surface, and the remaining complex including tumor necrosis factor receptor-associated factor 6 (TRAF6), TAK1, TAB1 and 2 translocates to the cytosol, resulting in ubiquitination of TRAF6 and induction of TAK1 activation.", [["cell surface", "ANATOMY", 25, 37], ["cytosol", "ANATOMY", 172, 179], ["tumor", "DISEASE", 75, 80], ["IRAK1", "GENE_OR_GENE_PRODUCT", 0, 5], ["cell surface", "CELLULAR_COMPONENT", 25, 37], ["tumor necrosis factor receptor-associated factor 6", "GENE_OR_GENE_PRODUCT", 75, 125], ["TRAF6", "GENE_OR_GENE_PRODUCT", 127, 132], ["TAK1", "GENE_OR_GENE_PRODUCT", 135, 139], ["TAB1", "GENE_OR_GENE_PRODUCT", 141, 145], ["2", "GENE_OR_GENE_PRODUCT", 150, 151], ["cytosol", "CELLULAR_COMPONENT", 172, 179], ["TRAF6", "GENE_OR_GENE_PRODUCT", 212, 217], ["TAK1", "GENE_OR_GENE_PRODUCT", 235, 239], ["IRAK1", "PROTEIN", 0, 5], ["tumor necrosis factor receptor-associated factor 6", "PROTEIN", 75, 125], ["TRAF6", "PROTEIN", 127, 132], ["TAK1", "PROTEIN", 135, 139], ["TAB1 and 2", "PROTEIN", 141, 151], ["TRAF6", "PROTEIN", 212, 217], ["TAK1", "PROTEIN", 235, 239], ["IRAK1", "PROBLEM", 0, 5], ["the cell surface", "TEST", 21, 37], ["tumor necrosis", "PROBLEM", 75, 89], ["TAB1", "TREATMENT", 141, 145], ["TRAF6", "TREATMENT", 212, 217], ["TAK1 activation", "TREATMENT", 235, 250], ["cell surface", "OBSERVATION_MODIFIER", 25, 37], ["remaining", "OBSERVATION_MODIFIER", 47, 56], ["complex", "OBSERVATION_MODIFIER", 57, 64], ["tumor", "OBSERVATION_MODIFIER", 75, 80], ["necrosis", "OBSERVATION", 81, 89], ["ubiquitination of TRAF6", "OBSERVATION", 194, 217]]], ["In turn, TAK1 phosphorylates mitogen-activated protein (MAP) kinase and inhibitor kappa B kinase (IKK) complexes [40].", [["TAK1", "GENE_OR_GENE_PRODUCT", 9, 13], ["mitogen-activated protein (MAP) kinase", "GENE_OR_GENE_PRODUCT", 29, 67], ["inhibitor kappa B kinase", "GENE_OR_GENE_PRODUCT", 72, 96], ["IKK", "GENE_OR_GENE_PRODUCT", 98, 101], ["TAK1", "PROTEIN", 9, 13], ["mitogen-activated protein (MAP) kinase", "PROTEIN", 29, 67], ["inhibitor kappa B kinase (IKK) complexes", "PROTEIN", 72, 112], ["TAK1 phosphorylates mitogen", "TEST", 9, 36], ["activated protein", "TEST", 37, 54], ["MAP", "TEST", 56, 59], ["kinase", "TEST", 61, 67], ["inhibitor kappa B kinase (IKK) complexes", "TEST", 72, 112]]], ["This allows NF-\u03baB to translocate to the nucleus and upregulate the expression of its target gene.", [["nucleus", "ANATOMY", 40, 47], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 12, 17], ["nucleus", "CELLULAR_COMPONENT", 40, 47], ["NF-\u03baB", "PROTEIN", 12, 17], ["target gene", "DNA", 85, 96], ["nucleus", "ANATOMY", 40, 47]]], ["In addition to the classical pathway dependent on MyD88, different TLRs can also transmit signals through TRIF-dependent pathway.", [["MyD88", "GENE_OR_GENE_PRODUCT", 50, 55], ["TLRs", "GENE_OR_GENE_PRODUCT", 67, 71], ["TRIF", "GENE_OR_GENE_PRODUCT", 106, 110], ["MyD88", "PROTEIN", 50, 55], ["TLRs", "PROTEIN", 67, 71], ["TRIF", "PROTEIN", 106, 110]]], ["TRIF, together with TRAF6, TRADD, Pellino-1 and RIP1, forms a multiprotein signaling complex that activates TAK1, and also activates NF-\u03baB and mitogen-activated protein kinase (MAPK) pathways.", [["TRIF", "GENE_OR_GENE_PRODUCT", 0, 4], ["TRAF6", "GENE_OR_GENE_PRODUCT", 20, 25], ["TRADD", "GENE_OR_GENE_PRODUCT", 27, 32], ["Pellino-1", "GENE_OR_GENE_PRODUCT", 34, 43], ["RIP1", "GENE_OR_GENE_PRODUCT", 48, 52], ["TAK1", "GENE_OR_GENE_PRODUCT", 108, 112], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 133, 138], ["mitogen-activated protein kinase", "GENE_OR_GENE_PRODUCT", 143, 175], ["MAPK", "GENE_OR_GENE_PRODUCT", 177, 181], ["TRIF", "PROTEIN", 0, 4], ["TRAF6", "PROTEIN", 20, 25], ["TRADD", "PROTEIN", 27, 32], ["Pellino-1", "PROTEIN", 34, 43], ["RIP1", "PROTEIN", 48, 52], ["multiprotein signaling complex", "PROTEIN", 62, 92], ["TAK1", "PROTEIN", 108, 112], ["NF-\u03baB", "PROTEIN", 133, 138], ["mitogen-activated protein kinase", "PROTEIN", 143, 175], ["MAPK", "PROTEIN", 177, 181], ["TRAF6", "TREATMENT", 20, 25], ["TRADD", "TREATMENT", 27, 32], ["Pellino", "TREATMENT", 34, 41], ["RIP1", "TREATMENT", 48, 52], ["a multiprotein signaling complex", "PROBLEM", 60, 92], ["NF", "TEST", 133, 135], ["activated protein kinase", "TREATMENT", 151, 175]]], ["In addition, TRIF recruits signaling complexes including non-canonical Tank-Binding-Kinase 1 (TBK1) and IKKi (IKK\u03b5) that induce the phosphorylation of interferon regulatory factor 3 (IRF3) and 7, followed by translocation to the nucleus and induction of type I IFNs [59].", [["nucleus", "ANATOMY", 229, 236], ["TRIF", "GENE_OR_GENE_PRODUCT", 13, 17], ["Tank-Binding-Kinase 1", "GENE_OR_GENE_PRODUCT", 71, 92], ["TBK1", "GENE_OR_GENE_PRODUCT", 94, 98], ["IKKi", "GENE_OR_GENE_PRODUCT", 104, 108], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 110, 114], ["interferon regulatory factor 3", "GENE_OR_GENE_PRODUCT", 151, 181], ["IRF3", "GENE_OR_GENE_PRODUCT", 183, 187], ["7", "GENE_OR_GENE_PRODUCT", 193, 194], ["nucleus", "CELLULAR_COMPONENT", 229, 236], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 254, 265], ["TRIF", "PROTEIN", 13, 17], ["signaling complexes", "PROTEIN", 27, 46], ["non-canonical Tank-Binding-Kinase 1", "PROTEIN", 57, 92], ["TBK1", "PROTEIN", 94, 98], ["IKKi", "PROTEIN", 104, 108], ["IKK\u03b5", "PROTEIN", 110, 114], ["interferon regulatory factor 3", "PROTEIN", 151, 181], ["IRF3", "PROTEIN", 183, 187], ["type I IFNs", "PROTEIN", 254, 265], ["TRIF recruits signaling complexes", "PROBLEM", 13, 46], ["non-canonical Tank-Binding-Kinase", "TEST", 57, 90], ["TBK1", "TEST", 94, 98], ["IKKi", "TEST", 104, 108], ["interferon regulatory factor", "TREATMENT", 151, 179], ["nucleus", "ANATOMY", 229, 236]]], ["The details are shown in Fig. 1.Chlamydia pneumoniae ::: Role of TLRs in pathogen-induced atherosclerosisChlamydia pneumoniae is an obligate intracellular pathogen with unique developmental cycles and survival strategies in host cells and is an ordinary cause of community-acquired pneumonia [60, 61].", [["intracellular", "ANATOMY", 141, 154], ["cells", "ANATOMY", 229, 234], ["Chlamydia pneumoniae", "DISEASE", 32, 52], ["atherosclerosis", "DISEASE", 90, 105], ["Chlamydia pneumoniae", "DISEASE", 105, 125], ["pneumonia", "DISEASE", 282, 291], ["Chlamydia pneumoniae", "ORGANISM", 32, 52], ["TLRs", "GENE_OR_GENE_PRODUCT", 65, 69], ["Chlamydia pneumoniae", "ORGANISM", 105, 125], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 141, 154], ["host cells", "CELL", 224, 234], ["TLRs", "PROTEIN", 65, 69], ["host cells", "CELL_TYPE", 224, 234], ["Chlamydia pneumoniae", "SPECIES", 32, 52], ["Chlamydia pneumoniae", "SPECIES", 105, 125], ["Chlamydia pneumoniae", "SPECIES", 32, 52], ["Chlamydia pneumoniae", "SPECIES", 105, 125], ["Chlamydia pneumoniae", "PROBLEM", 32, 52], ["pathogen", "PROBLEM", 73, 81], ["atherosclerosisChlamydia pneumoniae", "PROBLEM", 90, 125], ["an obligate intracellular pathogen", "PROBLEM", 129, 163], ["unique developmental cycles", "TREATMENT", 169, 196], ["survival strategies in host cells", "PROBLEM", 201, 234], ["community-acquired pneumonia", "PROBLEM", 263, 291], ["pneumoniae", "OBSERVATION", 42, 52], ["atherosclerosis", "OBSERVATION", 90, 105], ["host cells", "OBSERVATION", 224, 234], ["pneumonia", "OBSERVATION", 282, 291]]], ["Saikku and his colleagues found for the first time that individuals with immunoglobulin G antibody specific for C. pneumoniae had a raised risk of MI and ASVD compared with controls [10].", [["MI", "DISEASE", 147, 149], ["ASVD", "DISEASE", 154, 158], ["immunoglobulin G antibody", "GENE_OR_GENE_PRODUCT", 73, 98], ["C. pneumoniae", "ORGANISM", 112, 125], ["immunoglobulin G antibody", "PROTEIN", 73, 98], ["C. pneumoniae", "SPECIES", 112, 125], ["C. pneumoniae", "SPECIES", 112, 125], ["immunoglobulin G antibody", "TEST", 73, 98], ["C. pneumoniae", "PROBLEM", 112, 125], ["MI", "PROBLEM", 147, 149], ["ASVD", "PROBLEM", 154, 158], ["MI", "OBSERVATION", 147, 149]]], ["Subsequently, serological correlation between antibodies to C. pneumoniae and atherosclerosis were reported by a series of studies [62].", [["C. pneumoniae", "DISEASE", 60, 73], ["atherosclerosis", "DISEASE", 78, 93], ["C. pneumoniae", "ORGANISM", 60, 73], ["antibodies", "PROTEIN", 46, 56], ["C. pneumoniae", "SPECIES", 60, 73], ["C. pneumoniae", "SPECIES", 60, 73], ["serological correlation", "TEST", 14, 37], ["C. pneumoniae", "PROBLEM", 60, 73], ["atherosclerosis", "PROBLEM", 78, 93], ["a series of studies", "TEST", 111, 130], ["pneumoniae", "OBSERVATION", 63, 73], ["atherosclerosis", "OBSERVATION", 78, 93]]], ["The key issue in animal models is whether C. pneumoniae can induce atherosclerosis or accelerate the pathological progress of atherosclerosis.", [["atherosclerosis", "DISEASE", 67, 82], ["atherosclerosis", "DISEASE", 126, 141], ["C. pneumoniae", "ORGANISM", 42, 55], ["C. pneumoniae", "SPECIES", 42, 55], ["C. pneumoniae", "SPECIES", 42, 55], ["C. pneumoniae", "PROBLEM", 42, 55], ["atherosclerosis", "PROBLEM", 67, 82], ["atherosclerosis", "PROBLEM", 126, 141], ["pneumoniae", "OBSERVATION", 45, 55], ["atherosclerosis", "OBSERVATION", 67, 82], ["atherosclerosis", "OBSERVATION", 126, 141]]], ["Studies have presented that C. pneumoniae infection promotes plaque progression in ApoE\u2212/\u2212 mice, diet-induced hyperlipidemic mice (LDLR\u2212/\u2212 and C57BL/6J mice), while C. pneumoniae has no effect on plaque development [63].", [["plaque", "ANATOMY", 61, 67], ["plaque", "ANATOMY", 196, 202], ["C. pneumoniae infection", "DISEASE", 28, 51], ["plaque", "DISEASE", 61, 67], ["hyperlipidemic", "DISEASE", 110, 124], ["C. pneumoniae", "ORGANISM", 28, 41], ["plaque", "PATHOLOGICAL_FORMATION", 61, 67], ["ApoE\u2212/\u2212 mice", "ORGANISM", 83, 95], ["mice", "ORGANISM", 125, 129], ["LDLR", "GENE_OR_GENE_PRODUCT", 131, 135], ["C57BL/6J mice", "ORGANISM", 143, 156], ["C. pneumoniae", "ORGANISM", 165, 178], ["plaque", "PATHOLOGICAL_FORMATION", 196, 202], ["LDLR", "PROTEIN", 131, 135], ["C. pneumoniae", "SPECIES", 28, 41], ["mice", "SPECIES", 91, 95], ["mice", "SPECIES", 125, 129], ["mice", "SPECIES", 152, 156], ["C. pneumoniae", "SPECIES", 165, 178], ["C. pneumoniae", "SPECIES", 28, 41], ["mice", "SPECIES", 91, 95], ["mice", "SPECIES", 125, 129], ["mice", "SPECIES", 152, 156], ["C. pneumoniae", "SPECIES", 165, 178], ["Studies", "TEST", 0, 7], ["C. pneumoniae infection", "PROBLEM", 28, 51], ["plaque progression", "PROBLEM", 61, 79], ["ApoE\u2212/\u2212 mice", "TREATMENT", 83, 95], ["LDLR", "TEST", 131, 135], ["C57BL/6J mice", "TREATMENT", 143, 156], ["C. pneumoniae", "PROBLEM", 165, 178], ["plaque development", "PROBLEM", 196, 214], ["pneumoniae", "OBSERVATION", 31, 41], ["plaque", "OBSERVATION_MODIFIER", 61, 67], ["progression", "OBSERVATION_MODIFIER", 68, 79], ["pneumoniae", "OBSERVATION", 168, 178], ["no", "UNCERTAINTY", 183, 185], ["plaque", "OBSERVATION", 196, 202]]], ["However, it has also been reported that researches on mice infected with C. pneumoniae have failed to observe the deterioration of atherosclerosis [64].", [["atherosclerosis", "DISEASE", 131, 146], ["mice", "ORGANISM", 54, 58], ["C. pneumoniae", "ORGANISM", 73, 86], ["mice", "SPECIES", 54, 58], ["C. pneumoniae", "SPECIES", 73, 86], ["mice", "SPECIES", 54, 58], ["C. pneumoniae", "SPECIES", 73, 86], ["C. pneumoniae", "PROBLEM", 73, 86], ["atherosclerosis", "PROBLEM", 131, 146], ["pneumoniae", "OBSERVATION", 76, 86], ["atherosclerosis", "OBSERVATION", 131, 146]]], ["Interestingly, infection aggravated the aortic sinus lesions in C57BL/6J mice fed a high cholesterol diet, but not if infection preceded such a diet [65].", [["aortic sinus lesions", "ANATOMY", 40, 60], ["infection", "DISEASE", 15, 24], ["aortic sinus lesions", "DISEASE", 40, 60], ["cholesterol", "CHEMICAL", 89, 100], ["infection", "DISEASE", 118, 127], ["cholesterol", "CHEMICAL", 89, 100], ["aortic sinus lesions", "PATHOLOGICAL_FORMATION", 40, 60], ["C57BL/6J mice", "ORGANISM", 64, 77], ["cholesterol", "SIMPLE_CHEMICAL", 89, 100], ["mice", "SPECIES", 73, 77], ["mice", "SPECIES", 73, 77], ["infection", "PROBLEM", 15, 24], ["the aortic sinus lesions", "PROBLEM", 36, 60], ["C57BL/6J mice", "TREATMENT", 64, 77], ["a high cholesterol diet", "TREATMENT", 82, 105], ["infection", "PROBLEM", 118, 127], ["infection", "OBSERVATION", 15, 24], ["aortic sinus", "ANATOMY", 40, 52], ["lesions", "OBSERVATION", 53, 60]]], ["This exhibits that the atherosclerotic effect of C. pneumoniae infection depends on the arterial response to hyperlipidemia.", [["arterial", "ANATOMY", 88, 96], ["atherosclerotic", "DISEASE", 23, 38], ["C. pneumoniae infection", "DISEASE", 49, 72], ["hyperlipidemia", "DISEASE", 109, 123], ["C. pneumoniae", "ORGANISM", 49, 62], ["arterial", "MULTI-TISSUE_STRUCTURE", 88, 96], ["C. pneumoniae", "SPECIES", 49, 62], ["C. pneumoniae", "SPECIES", 49, 62], ["the atherosclerotic effect", "PROBLEM", 19, 45], ["C. pneumoniae infection", "PROBLEM", 49, 72], ["hyperlipidemia", "PROBLEM", 109, 123], ["atherosclerotic", "OBSERVATION_MODIFIER", 23, 38], ["C.", "OBSERVATION_MODIFIER", 49, 51], ["pneumoniae", "OBSERVATION_MODIFIER", 52, 62], ["infection", "OBSERVATION", 63, 72], ["arterial", "ANATOMY", 88, 96], ["hyperlipidemia", "OBSERVATION", 109, 123]]], ["A study directly inoculated C. pneumoniae into porcine coronary artery (damaged by balloon catheter) and pulmonary artery, resulting in thickening of the temporal lobe of the largest coronary artery, but no thickening of the pulmonary artery [66].", [["coronary artery", "ANATOMY", 55, 70], ["balloon", "ANATOMY", 83, 90], ["pulmonary artery", "ANATOMY", 105, 121], ["temporal lobe", "ANATOMY", 154, 167], ["coronary artery", "ANATOMY", 183, 198], ["pulmonary artery", "ANATOMY", 225, 241], ["C. pneumoniae", "ORGANISM", 28, 41], ["porcine", "ORGANISM", 47, 54], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 55, 70], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 105, 121], ["temporal lobe", "MULTI-TISSUE_STRUCTURE", 154, 167], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 183, 198], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 225, 241], ["C. pneumoniae", "SPECIES", 28, 41], ["porcine", "SPECIES", 47, 54], ["C. pneumoniae", "SPECIES", 28, 41], ["A study", "TEST", 0, 7], ["balloon catheter", "TREATMENT", 83, 99], ["thickening of the temporal lobe", "PROBLEM", 136, 167], ["thickening of the pulmonary artery", "PROBLEM", 207, 241], ["pneumoniae", "OBSERVATION", 31, 41], ["porcine coronary artery", "ANATOMY", 47, 70], ["balloon catheter", "OBSERVATION", 83, 99], ["pulmonary artery", "ANATOMY", 105, 121], ["thickening", "OBSERVATION", 136, 146], ["temporal lobe", "ANATOMY", 154, 167], ["largest coronary artery", "ANATOMY", 175, 198], ["no", "UNCERTAINTY", 204, 206], ["thickening", "OBSERVATION", 207, 217], ["pulmonary artery", "ANATOMY", 225, 241]]], ["In addition, C. pneumoniae can reduce the availability of endothelial nitric oxide in ApoE\u2212/\u2212 mice, leading to endothelium-dependent relaxation damage.", [["endothelium", "ANATOMY", 111, 122], ["nitric oxide", "CHEMICAL", 70, 82], ["nitric oxide", "CHEMICAL", 70, 82], ["C. pneumoniae", "ORGANISM", 13, 26], ["endothelial nitric oxide", "SIMPLE_CHEMICAL", 58, 82], ["ApoE\u2212", "GENE_OR_GENE_PRODUCT", 86, 91], ["endothelium", "TISSUE", 111, 122], ["C. pneumoniae", "SPECIES", 13, 26], ["mice", "SPECIES", 94, 98], ["C. pneumoniae", "SPECIES", 13, 26], ["mice", "SPECIES", 94, 98], ["C. pneumoniae", "PROBLEM", 13, 26], ["endothelial nitric oxide", "TREATMENT", 58, 82], ["ApoE\u2212/\u2212 mice", "TREATMENT", 86, 98], ["dependent relaxation damage", "PROBLEM", 123, 150], ["pneumoniae", "OBSERVATION", 16, 26], ["endothelium", "ANATOMY", 111, 122], ["dependent", "OBSERVATION_MODIFIER", 123, 132], ["relaxation damage", "OBSERVATION", 133, 150]]], ["These experiments indicate that besides hyperlipidemia, vascular damage was identified as a prerequisite for C. pneumoniae infection to promote atherosclerosis.", [["vascular", "ANATOMY", 56, 64], ["hyperlipidemia", "DISEASE", 40, 54], ["vascular damage", "DISEASE", 56, 71], ["C. pneumoniae infection", "DISEASE", 109, 132], ["atherosclerosis", "DISEASE", 144, 159], ["vascular", "MULTI-TISSUE_STRUCTURE", 56, 64], ["C. pneumoniae", "ORGANISM", 109, 122], ["C. pneumoniae", "SPECIES", 109, 122], ["C. pneumoniae", "SPECIES", 109, 122], ["hyperlipidemia", "PROBLEM", 40, 54], ["vascular damage", "PROBLEM", 56, 71], ["C. pneumoniae infection", "PROBLEM", 109, 132], ["atherosclerosis", "PROBLEM", 144, 159], ["hyperlipidemia", "OBSERVATION", 40, 54], ["vascular", "ANATOMY", 56, 64], ["damage", "OBSERVATION", 65, 71], ["pneumoniae", "OBSERVATION", 112, 122], ["atherosclerosis", "OBSERVATION", 144, 159]]], ["In animals with advanced atherosclerosis, C. pneumoniae infection did not accelerate the size of lesions, but the production of MMP-2 and MMP-9 and the decrease of fibrous cap area were observed, indicating that the degree of C. pneumoniae promoting lesions decreased with the progress of atherosclerosis [67].", [["lesions", "ANATOMY", 97, 104], ["fibrous cap area", "ANATOMY", 164, 180], ["lesions", "ANATOMY", 250, 257], ["atherosclerosis", "DISEASE", 25, 40], ["C. pneumoniae infection", "DISEASE", 42, 65], ["atherosclerosis", "DISEASE", 289, 304], ["C. pneumoniae", "ORGANISM", 42, 55], ["lesions", "PATHOLOGICAL_FORMATION", 97, 104], ["MMP-2", "GENE_OR_GENE_PRODUCT", 128, 133], ["MMP-9", "GENE_OR_GENE_PRODUCT", 138, 143], ["fibrous cap area", "TISSUE", 164, 180], ["C. pneumoniae", "ORGANISM", 226, 239], ["lesions", "PATHOLOGICAL_FORMATION", 250, 257], ["MMP", "PROTEIN", 128, 131], ["MMP-9", "PROTEIN", 138, 143], ["C. pneumoniae", "SPECIES", 42, 55], ["C. pneumoniae", "SPECIES", 226, 239], ["C. pneumoniae", "SPECIES", 42, 55], ["C. pneumoniae", "SPECIES", 226, 239], ["advanced atherosclerosis", "PROBLEM", 16, 40], ["C. pneumoniae infection", "PROBLEM", 42, 65], ["lesions", "PROBLEM", 97, 104], ["MMP", "TEST", 128, 131], ["MMP", "TEST", 138, 141], ["the decrease of fibrous cap area", "PROBLEM", 148, 180], ["C. pneumoniae promoting lesions", "PROBLEM", 226, 257], ["atherosclerosis", "PROBLEM", 289, 304], ["advanced", "OBSERVATION_MODIFIER", 16, 24], ["atherosclerosis", "OBSERVATION", 25, 40], ["pneumoniae", "OBSERVATION_MODIFIER", 45, 55], ["infection", "OBSERVATION", 56, 65], ["size", "OBSERVATION_MODIFIER", 89, 93], ["lesions", "OBSERVATION", 97, 104], ["decrease", "OBSERVATION_MODIFIER", 152, 160], ["fibrous cap", "OBSERVATION", 164, 175], ["C.", "OBSERVATION_MODIFIER", 226, 228], ["pneumoniae", "OBSERVATION", 229, 239], ["lesions", "OBSERVATION", 250, 257], ["atherosclerosis", "OBSERVATION", 289, 304]]], ["The mechanism of C. pneumoniae promoting atherosclerosis is to induce chronic inflammatory response, leading to tissue injury, repair and fibrosis.", [["tissue", "ANATOMY", 112, 118], ["atherosclerosis", "DISEASE", 41, 56], ["tissue injury", "DISEASE", 112, 125], ["fibrosis", "DISEASE", 138, 146], ["C. pneumoniae", "ORGANISM", 17, 30], ["tissue", "TISSUE", 112, 118], ["C. pneumoniae", "SPECIES", 17, 30], ["C. pneumoniae", "SPECIES", 17, 30], ["C. pneumoniae", "PROBLEM", 17, 30], ["atherosclerosis", "PROBLEM", 41, 56], ["chronic inflammatory response", "PROBLEM", 70, 99], ["tissue injury", "PROBLEM", 112, 125], ["repair", "TREATMENT", 127, 133], ["fibrosis", "PROBLEM", 138, 146], ["C.", "OBSERVATION_MODIFIER", 17, 19], ["pneumoniae", "OBSERVATION", 20, 30], ["atherosclerosis", "OBSERVATION", 41, 56], ["chronic", "OBSERVATION_MODIFIER", 70, 77], ["inflammatory", "OBSERVATION", 78, 90], ["tissue", "ANATOMY", 112, 118], ["injury", "OBSERVATION", 119, 125], ["repair", "OBSERVATION", 127, 133], ["fibrosis", "OBSERVATION", 138, 146]]], ["Infected monocytes/macrophages can transfer C. pneumoniae infection to smooth muscle cells (SMCs) and ECs.", [["monocytes", "ANATOMY", 9, 18], ["macrophages", "ANATOMY", 19, 30], ["smooth muscle cells", "ANATOMY", 71, 90], ["SMCs", "ANATOMY", 92, 96], ["ECs", "ANATOMY", 102, 105], ["infection", "DISEASE", 58, 67], ["monocytes", "CELL", 9, 18], ["macrophages", "CELL", 19, 30], ["C. pneumoniae", "ORGANISM", 44, 57], ["smooth muscle cells", "CELL", 71, 90], ["SMCs", "CELL", 92, 96], ["ECs", "CELL", 102, 105], ["monocytes", "CELL_TYPE", 9, 18], ["macrophages", "CELL_TYPE", 19, 30], ["smooth muscle cells", "CELL_TYPE", 71, 90], ["SMCs", "CELL_TYPE", 92, 96], ["ECs", "CELL_TYPE", 102, 105], ["C. pneumoniae", "SPECIES", 44, 57], ["C. pneumoniae", "SPECIES", 44, 57], ["Infected monocytes/macrophages", "PROBLEM", 0, 30], ["C. pneumoniae infection", "PROBLEM", 44, 67], ["monocytes", "OBSERVATION", 9, 18], ["macrophages", "OBSERVATION", 19, 30], ["pneumoniae", "OBSERVATION_MODIFIER", 47, 57], ["infection", "OBSERVATION", 58, 67], ["smooth muscle cells", "OBSERVATION", 71, 90]]], ["C. pneumoniae up-regulates the expression of integrin beta 2 on the surface of macrophages, thus promoting macrophage adhesion to endothelium.", [["surface", "ANATOMY", 68, 75], ["macrophages", "ANATOMY", 79, 90], ["macrophage", "ANATOMY", 107, 117], ["endothelium", "ANATOMY", 130, 141], ["C. pneumoniae", "ORGANISM", 0, 13], ["integrin beta 2", "GENE_OR_GENE_PRODUCT", 45, 60], ["surface", "CELLULAR_COMPONENT", 68, 75], ["macrophages", "CELL", 79, 90], ["macrophage", "CELL", 107, 117], ["endothelium", "TISSUE", 130, 141], ["integrin beta 2", "PROTEIN", 45, 60], ["macrophages", "CELL_TYPE", 79, 90], ["C. pneumoniae", "SPECIES", 0, 13], ["C. pneumoniae", "SPECIES", 0, 13], ["C. pneumoniae", "PROBLEM", 0, 13], ["integrin beta", "TREATMENT", 45, 58], ["pneumoniae", "OBSERVATION", 3, 13], ["integrin beta", "OBSERVATION_MODIFIER", 45, 58], ["macrophages", "OBSERVATION", 79, 90], ["macrophage adhesion", "OBSERVATION", 107, 126], ["endothelium", "ANATOMY", 130, 141]]], ["ECs infected with C. pneumoniae can upregulate the expression of adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1), VCAM-1, P-selectin and E-selectin, thereby increasing the adhesion and migration of leukocytes to endothelium [68].", [["ECs", "ANATOMY", 0, 3], ["leukocytes", "ANATOMY", 220, 230], ["endothelium", "ANATOMY", 234, 245], ["ECs", "CELL", 0, 3], ["C. pneumoniae", "ORGANISM", 18, 31], ["intercellular adhesion molecule-1", "GENE_OR_GENE_PRODUCT", 92, 125], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 127, 133], ["VCAM-1", "GENE_OR_GENE_PRODUCT", 136, 142], ["P-selectin", "GENE_OR_GENE_PRODUCT", 144, 154], ["E-selectin", "GENE_OR_GENE_PRODUCT", 159, 169], ["leukocytes", "CELL", 220, 230], ["endothelium", "TISSUE", 234, 245], ["ECs", "CELL_TYPE", 0, 3], ["adhesion molecules", "PROTEIN", 65, 83], ["intercellular adhesion molecule-1 (ICAM-1", "PROTEIN", 92, 133], ["VCAM", "PROTEIN", 136, 140], ["P-selectin", "PROTEIN", 144, 154], ["E-selectin", "PROTEIN", 159, 169], ["leukocytes", "CELL_TYPE", 220, 230], ["C. pneumoniae", "SPECIES", 18, 31], ["C. pneumoniae", "SPECIES", 18, 31], ["C. pneumoniae", "PROBLEM", 18, 31], ["adhesion molecules", "PROBLEM", 65, 83], ["intercellular adhesion molecule", "TEST", 92, 123], ["ICAM", "TEST", 127, 131], ["VCAM", "TEST", 136, 140], ["P", "TEST", 144, 145], ["selectin", "TEST", 146, 154], ["the adhesion", "PROBLEM", 190, 202], ["pneumoniae", "OBSERVATION", 21, 31], ["adhesion molecules", "OBSERVATION", 65, 83], ["selectin", "ANATOMY", 161, 169], ["adhesion", "OBSERVATION", 194, 202], ["migration", "OBSERVATION_MODIFIER", 207, 216]]], ["In addition, Microarray analysis showed that C. pneumoniae infects ECs resulting in up-regulation of PDGF-B transcription, while PDGF-B contributed to SMCs proliferation and intimal thickening [69].", [["ECs", "ANATOMY", 67, 70], ["SMCs", "ANATOMY", 151, 155], ["intimal", "ANATOMY", 174, 181], ["C. pneumoniae", "ORGANISM", 45, 58], ["ECs", "CELL", 67, 70], ["PDGF-B", "GENE_OR_GENE_PRODUCT", 101, 107], ["PDGF-B", "GENE_OR_GENE_PRODUCT", 129, 135], ["SMCs", "CELL", 151, 155], ["intimal", "TISSUE", 174, 181], ["ECs", "CELL_TYPE", 67, 70], ["PDGF", "PROTEIN", 101, 105], ["PDGF-B", "PROTEIN", 129, 135], ["SMCs", "CELL_TYPE", 151, 155], ["C. pneumoniae", "SPECIES", 45, 58], ["C. pneumoniae", "SPECIES", 45, 58], ["Microarray analysis", "TEST", 13, 32], ["C. pneumoniae infects ECs", "PROBLEM", 45, 70], ["PDGF-B transcription", "TREATMENT", 101, 121], ["PDGF", "TEST", 129, 133], ["SMCs proliferation", "PROBLEM", 151, 169], ["intimal thickening", "PROBLEM", 174, 192], ["pneumoniae", "OBSERVATION", 48, 58], ["SMCs", "ANATOMY", 151, 155], ["proliferation", "OBSERVATION", 156, 169], ["intimal", "OBSERVATION_MODIFIER", 174, 181], ["thickening", "OBSERVATION", 182, 192]]], ["Coombes and his colleagues reported that repeated C. pneumoniae infection in normal rabbits increases intimal thickening compared with controls, and the presence of C. pneumoniae in aortic tissue is related with the level of PDGF-B [70].", [["intimal", "ANATOMY", 102, 109], ["aortic tissue", "ANATOMY", 182, 195], ["C. pneumoniae infection", "DISEASE", 50, 73], ["C. pneumoniae", "ORGANISM", 50, 63], ["rabbits", "ORGANISM", 84, 91], ["intimal", "TISSUE", 102, 109], ["C. pneumoniae", "ORGANISM", 165, 178], ["aortic tissue", "TISSUE", 182, 195], ["PDGF-B", "GENE_OR_GENE_PRODUCT", 225, 231], ["PDGF", "PROTEIN", 225, 229], ["C. pneumoniae", "SPECIES", 50, 63], ["rabbits", "SPECIES", 84, 91], ["C. pneumoniae", "SPECIES", 165, 178], ["C. pneumoniae", "SPECIES", 50, 63], ["rabbits", "SPECIES", 84, 91], ["C. pneumoniae", "SPECIES", 165, 178], ["repeated C. pneumoniae infection", "PROBLEM", 41, 73], ["intimal thickening", "PROBLEM", 102, 120], ["C. pneumoniae", "PROBLEM", 165, 178], ["aortic tissue", "PROBLEM", 182, 195], ["pneumoniae", "OBSERVATION_MODIFIER", 53, 63], ["infection", "OBSERVATION", 64, 73], ["normal rabbits", "OBSERVATION_MODIFIER", 77, 91], ["increases", "OBSERVATION_MODIFIER", 92, 101], ["intimal", "OBSERVATION_MODIFIER", 102, 109], ["thickening", "OBSERVATION", 110, 120], ["C.", "OBSERVATION_MODIFIER", 165, 167], ["pneumoniae", "OBSERVATION", 168, 178], ["aortic tissue", "ANATOMY", 182, 195]]], ["Chlamydia pneumoniae promotes the activation of macrophages, ECs and SMCs through the above mechanisms.Chlamydia pneumoniae ::: Role of TLRs in pathogen-induced atherosclerosisTLRs play an important role in activating macrophages and ECs, inhibiting cholesterol outflow and promoting foaming after C. pneumoniae infection.", [["macrophages", "ANATOMY", 48, 59], ["ECs", "ANATOMY", 61, 64], ["SMCs", "ANATOMY", 69, 73], ["macrophages", "ANATOMY", 218, 229], ["ECs", "ANATOMY", 234, 237], ["Chlamydia pneumoniae", "DISEASE", 0, 20], ["Chlamydia pneumoniae", "DISEASE", 103, 123], ["atherosclerosisTLRs", "DISEASE", 161, 180], ["cholesterol", "CHEMICAL", 250, 261], ["C. pneumoniae infection", "DISEASE", 298, 321], ["cholesterol", "CHEMICAL", 250, 261], ["Chlamydia pneumoniae", "ORGANISM", 0, 20], ["macrophages", "CELL", 48, 59], ["ECs", "CELL", 61, 64], ["SMCs", "CELL", 69, 73], ["Chlamydia pneumoniae", "ORGANISM", 103, 123], ["TLRs", "GENE_OR_GENE_PRODUCT", 136, 140], ["atherosclerosisTLRs", "GENE_OR_GENE_PRODUCT", 161, 180], ["macrophages", "CELL", 218, 229], ["ECs", "CELL", 234, 237], ["cholesterol", "SIMPLE_CHEMICAL", 250, 261], ["C. pneumoniae", "ORGANISM", 298, 311], ["macrophages", "CELL_TYPE", 48, 59], ["ECs", "CELL_TYPE", 61, 64], ["SMCs", "CELL_TYPE", 69, 73], ["TLRs", "PROTEIN", 136, 140], ["atherosclerosisTLRs", "PROTEIN", 161, 180], ["macrophages", "CELL_TYPE", 218, 229], ["ECs", "CELL_TYPE", 234, 237], ["Chlamydia pneumoniae", "SPECIES", 0, 20], ["Chlamydia pneumoniae", "SPECIES", 103, 123], ["C. pneumoniae", "SPECIES", 298, 311], ["Chlamydia pneumoniae", "SPECIES", 0, 20], ["Chlamydia pneumoniae", "SPECIES", 103, 123], ["C. pneumoniae", "SPECIES", 298, 311], ["Chlamydia pneumoniae", "PROBLEM", 0, 20], ["Chlamydia pneumoniae", "PROBLEM", 103, 123], ["cholesterol outflow", "TREATMENT", 250, 269], ["promoting foaming", "TREATMENT", 274, 291], ["C. pneumoniae infection", "PROBLEM", 298, 321], ["pneumoniae", "OBSERVATION", 10, 20], ["macrophages", "OBSERVATION", 48, 59], ["pneumoniae", "OBSERVATION", 113, 123], ["pneumoniae", "OBSERVATION_MODIFIER", 301, 311], ["infection", "OBSERVATION", 312, 321]]], ["The main molecules involved are TLR2 and 4.", [["TLR2", "GENE_OR_GENE_PRODUCT", 32, 36], ["4", "GENE_OR_GENE_PRODUCT", 41, 42], ["TLR2 and 4", "PROTEIN", 32, 42], ["main", "OBSERVATION_MODIFIER", 4, 8], ["molecules", "OBSERVATION", 9, 18], ["TLR2", "OBSERVATION_MODIFIER", 32, 36]]], ["Massari et al. reported that TLR4 recognizes LPS and cHSP60 on the surface of Chlamydia [71].", [["surface", "ANATOMY", 67, 74], ["LPS", "CHEMICAL", 45, 48], ["TLR4", "GENE_OR_GENE_PRODUCT", 29, 33], ["LPS", "GENE_OR_GENE_PRODUCT", 45, 48], ["cHSP60", "GENE_OR_GENE_PRODUCT", 53, 59], ["surface", "CELLULAR_COMPONENT", 67, 74], ["TLR4", "PROTEIN", 29, 33], ["cHSP60", "PROTEIN", 53, 59], ["LPS", "TEST", 45, 48], ["Chlamydia", "PROBLEM", 78, 87], ["TLR4", "OBSERVATION", 29, 33]]], ["Outer membrane proteins 2 (OMP2) together with cHSP60, Cpn 0980, Cpn 0809 from C. pneumoniae have been presented to activate macrophages via the TLR4 and MAPK pathways [72].", [["Outer membrane", "ANATOMY", 0, 14], ["macrophages", "ANATOMY", 125, 136], ["Cpn 0980", "CHEMICAL", 55, 63], ["Cpn 0809", "CHEMICAL", 65, 73], ["Outer membrane proteins 2", "GENE_OR_GENE_PRODUCT", 0, 25], ["OMP2", "GENE_OR_GENE_PRODUCT", 27, 31], ["cHSP60", "GENE_OR_GENE_PRODUCT", 47, 53], ["Cpn 0980", "GENE_OR_GENE_PRODUCT", 55, 63], ["Cpn 0809", "GENE_OR_GENE_PRODUCT", 65, 73], ["C. pneumoniae", "ORGANISM", 79, 92], ["macrophages", "CELL", 125, 136], ["TLR4", "GENE_OR_GENE_PRODUCT", 145, 149], ["MAPK", "GENE_OR_GENE_PRODUCT", 154, 158], ["Outer membrane proteins 2", "PROTEIN", 0, 25], ["OMP2", "PROTEIN", 27, 31], ["cHSP60", "PROTEIN", 47, 53], ["Cpn 0980", "PROTEIN", 55, 63], ["Cpn 0809", "PROTEIN", 65, 73], ["macrophages", "CELL_TYPE", 125, 136], ["TLR4", "PROTEIN", 145, 149], ["MAPK", "PROTEIN", 154, 158], ["C. pneumoniae", "SPECIES", 79, 92], ["C. pneumoniae", "SPECIES", 79, 92], ["Outer membrane proteins", "TEST", 0, 23], ["C. pneumoniae", "PROBLEM", 79, 92], ["pneumoniae", "OBSERVATION", 82, 92]]], ["Paolillo et al. have proved C. pneumoniae can also induce the production of vascular endothelial growth factors (VEGF) and MMP-9 in human ECs via TLR2/4-dependent pathway [73].", [["ECs", "ANATOMY", 138, 141], ["C. pneumoniae", "ORGANISM", 28, 41], ["vascular endothelial growth factors", "GENE_OR_GENE_PRODUCT", 76, 111], ["VEGF", "GENE_OR_GENE_PRODUCT", 113, 117], ["MMP-9", "GENE_OR_GENE_PRODUCT", 123, 128], ["human", "ORGANISM", 132, 137], ["ECs", "CELL", 138, 141], ["TLR2", "GENE_OR_GENE_PRODUCT", 146, 150], ["4", "GENE_OR_GENE_PRODUCT", 151, 152], ["vascular endothelial growth factors", "PROTEIN", 76, 111], ["VEGF", "PROTEIN", 113, 117], ["MMP-9", "PROTEIN", 123, 128], ["human ECs", "CELL_TYPE", 132, 141], ["TLR2", "PROTEIN", 146, 150], ["C. pneumoniae", "SPECIES", 28, 41], ["human", "SPECIES", 132, 137], ["C. pneumoniae", "SPECIES", 28, 41], ["human", "SPECIES", 132, 137], ["C. pneumoniae", "PROBLEM", 28, 41], ["vascular endothelial growth factors", "PROBLEM", 76, 111], ["MMP", "TEST", 123, 126], ["TLR2", "TEST", 146, 150], ["pneumoniae", "OBSERVATION", 31, 41], ["vascular endothelial", "ANATOMY", 76, 96]]], ["The interaction between TLR4 and C. pneumoniae ligands activates the MyD88-dependent pathway in immune cells and then upregulates the expression of CD68, nitric oxide (NO), human beta-defensin-2 (HBD-2), pro-inflammatory cytokines [74].", [["immune cells", "ANATOMY", 96, 108], ["nitric oxide", "CHEMICAL", 154, 166], ["NO", "CHEMICAL", 168, 170], ["nitric oxide", "CHEMICAL", 154, 166], ["NO", "CHEMICAL", 168, 170], ["TLR4", "GENE_OR_GENE_PRODUCT", 24, 28], ["C. pneumoniae", "ORGANISM", 33, 46], ["MyD88", "GENE_OR_GENE_PRODUCT", 69, 74], ["immune cells", "CELL", 96, 108], ["CD68", "GENE_OR_GENE_PRODUCT", 148, 152], ["nitric oxide", "SIMPLE_CHEMICAL", 154, 166], ["NO", "SIMPLE_CHEMICAL", 168, 170], ["human", "ORGANISM", 173, 178], ["beta-defensin-2", "GENE_OR_GENE_PRODUCT", 179, 194], ["HBD-2", "GENE_OR_GENE_PRODUCT", 196, 201], ["TLR4", "PROTEIN", 24, 28], ["MyD88", "PROTEIN", 69, 74], ["immune cells", "CELL_TYPE", 96, 108], ["CD68", "PROTEIN", 148, 152], ["human beta-defensin-2 (HBD-2", "PROTEIN", 173, 201], ["pro-inflammatory cytokines", "PROTEIN", 204, 230], ["C. pneumoniae", "SPECIES", 33, 46], ["human", "SPECIES", 173, 178], ["C. pneumoniae", "SPECIES", 33, 46], ["human", "SPECIES", 173, 178], ["TLR4 and C. pneumoniae ligands", "TREATMENT", 24, 54], ["immune cells", "TREATMENT", 96, 108], ["CD68", "TEST", 148, 152], ["nitric oxide", "TREATMENT", 154, 166], ["human beta-defensin", "TREATMENT", 173, 192], ["HBD", "TEST", 196, 199], ["pro-inflammatory cytokines", "TEST", 204, 230], ["immune cells", "OBSERVATION", 96, 108]]], ["In the presence of LDL, C. pneumoniae can induce foam cell formation and LDL oxidation.", [["foam cell", "ANATOMY", 49, 58], ["LDL", "SIMPLE_CHEMICAL", 19, 22], ["C. pneumoniae", "ORGANISM", 24, 37], ["foam cell", "CELL", 49, 58], ["LDL", "SIMPLE_CHEMICAL", 73, 76], ["LDL", "PROTEIN", 19, 22], ["LDL", "PROTEIN", 73, 76], ["C. pneumoniae", "SPECIES", 24, 37], ["C. pneumoniae", "SPECIES", 24, 37], ["LDL", "PROBLEM", 19, 22], ["C. pneumoniae", "PROBLEM", 24, 37], ["foam cell formation", "PROBLEM", 49, 68], ["LDL oxidation", "PROBLEM", 73, 86], ["LDL", "ANATOMY", 19, 22], ["pneumoniae", "OBSERVATION", 27, 37], ["foam cell formation", "OBSERVATION", 49, 68], ["LDL oxidation", "OBSERVATION", 73, 86]]], ["Cao et al. reported that foam cell formation induced by C. pneumoniae is modulated by TLR2 but not TLR4 [75].", [["foam cell", "ANATOMY", 25, 34], ["foam cell", "CELL", 25, 34], ["C. pneumoniae", "ORGANISM", 56, 69], ["TLR2", "GENE_OR_GENE_PRODUCT", 86, 90], ["TLR4", "GENE_OR_GENE_PRODUCT", 99, 103], ["TLR2", "PROTEIN", 86, 90], ["TLR4", "PROTEIN", 99, 103], ["C. pneumoniae", "SPECIES", 56, 69], ["C. pneumoniae", "SPECIES", 56, 69], ["foam cell formation", "PROBLEM", 25, 44], ["C. pneumoniae", "PROBLEM", 56, 69], ["foam cell formation", "OBSERVATION", 25, 44], ["pneumoniae", "OBSERVATION", 59, 69]]], ["However, Yoshikazu et al. demonstrated that C. pneumoniae can affect atherosclerotic plaque development in a TLR2/4/MyD88-dependent manner by promoting foam cell formation and enhancing activated DCs in plaques.", [["atherosclerotic plaque", "ANATOMY", 69, 91], ["foam cell", "ANATOMY", 152, 161], ["DCs", "ANATOMY", 196, 199], ["plaques", "ANATOMY", 203, 210], ["atherosclerotic plaque", "DISEASE", 69, 91], ["C. pneumoniae", "ORGANISM", 44, 57], ["atherosclerotic plaque", "PATHOLOGICAL_FORMATION", 69, 91], ["TLR2", "GENE_OR_GENE_PRODUCT", 109, 113], ["4", "GENE_OR_GENE_PRODUCT", 114, 115], ["MyD88", "GENE_OR_GENE_PRODUCT", 116, 121], ["foam cell", "CELL", 152, 161], ["DCs", "CELL", 196, 199], ["plaques", "PATHOLOGICAL_FORMATION", 203, 210], ["TLR2", "PROTEIN", 109, 113], ["MyD88", "PROTEIN", 116, 121], ["activated DCs", "CELL_TYPE", 186, 199], ["C. pneumoniae", "SPECIES", 44, 57], ["C. pneumoniae", "SPECIES", 44, 57], ["C. pneumoniae", "PROBLEM", 44, 57], ["atherosclerotic plaque", "PROBLEM", 69, 91], ["a TLR2/4/MyD88-dependent manner", "TREATMENT", 107, 138], ["promoting foam cell formation", "TREATMENT", 142, 171], ["enhancing activated DCs in plaques", "PROBLEM", 176, 210], ["pneumoniae", "OBSERVATION", 47, 57], ["atherosclerotic", "OBSERVATION_MODIFIER", 69, 84], ["plaque", "OBSERVATION", 85, 91], ["foam cell formation", "OBSERVATION", 152, 171], ["enhancing", "OBSERVATION_MODIFIER", 176, 185], ["activated DCs", "OBSERVATION", 186, 199], ["plaques", "OBSERVATION", 203, 210]]], ["LXR signaling can counteract C. pneumoniae-induced atherosclerosis by reducing cholesterol efflux and blocking TLR-dependent proinflammatory signaling [76].", [["atherosclerosis", "DISEASE", 51, 66], ["cholesterol", "CHEMICAL", 79, 90], ["cholesterol", "CHEMICAL", 79, 90], ["LXR", "GENE_OR_GENE_PRODUCT", 0, 3], ["C. pneumoniae", "ORGANISM", 29, 42], ["cholesterol", "SIMPLE_CHEMICAL", 79, 90], ["TLR", "GENE_OR_GENE_PRODUCT", 111, 114], ["LXR", "PROTEIN", 0, 3], ["TLR", "PROTEIN", 111, 114], ["C. pneumoniae", "SPECIES", 29, 42], ["C. pneumoniae", "SPECIES", 29, 42], ["C. pneumoniae", "PROBLEM", 29, 42], ["atherosclerosis", "PROBLEM", 51, 66], ["reducing cholesterol efflux", "PROBLEM", 70, 97], ["blocking TLR", "TREATMENT", 102, 114], ["dependent proinflammatory signaling", "PROBLEM", 115, 150], ["pneumoniae", "OBSERVATION", 32, 42], ["atherosclerosis", "OBSERVATION", 51, 66], ["cholesterol efflux", "OBSERVATION", 79, 97], ["proinflammatory", "OBSERVATION_MODIFIER", 125, 140]]], ["In the same year, Chen et al. demonstrated C. pneumoniae promotes foam cell formation through activation of TLR2 and TLR4 signaling, but not TLR3, and activates downstream MyD88/TRIF-dependent pathways.", [["foam cell", "ANATOMY", 66, 75], ["C. pneumoniae", "ORGANISM", 43, 56], ["foam cell", "CELL", 66, 75], ["TLR2", "GENE_OR_GENE_PRODUCT", 108, 112], ["TLR4", "GENE_OR_GENE_PRODUCT", 117, 121], ["TLR3", "GENE_OR_GENE_PRODUCT", 141, 145], ["MyD88", "GENE_OR_GENE_PRODUCT", 172, 177], ["TRIF", "GENE_OR_GENE_PRODUCT", 178, 182], ["TLR2", "PROTEIN", 108, 112], ["TLR4", "PROTEIN", 117, 121], ["TLR3", "PROTEIN", 141, 145], ["MyD88", "PROTEIN", 172, 177], ["TRIF", "PROTEIN", 178, 182], ["C. pneumoniae", "SPECIES", 43, 56], ["C. pneumoniae", "SPECIES", 43, 56], ["C. pneumoniae", "PROBLEM", 43, 56], ["TLR2 and TLR4 signaling", "TREATMENT", 108, 131], ["pneumoniae", "OBSERVATION", 46, 56], ["foam cell formation", "OBSERVATION", 66, 85], ["TLR2", "ANATOMY", 108, 112]]], ["They also demonstrated that LXR agonists can in turn reduce C. pneumoniae-mediated IRF3 activation in macrophages [77].", [["macrophages", "ANATOMY", 102, 113], ["LXR", "GENE_OR_GENE_PRODUCT", 28, 31], ["C. pneumoniae", "ORGANISM", 60, 73], ["IRF3", "GENE_OR_GENE_PRODUCT", 83, 87], ["macrophages", "CELL", 102, 113], ["LXR", "PROTEIN", 28, 31], ["IRF3", "PROTEIN", 83, 87], ["macrophages", "CELL_TYPE", 102, 113], ["C. pneumoniae", "SPECIES", 60, 73], ["C. pneumoniae", "SPECIES", 60, 73], ["LXR agonists", "TREATMENT", 28, 40], ["C. pneumoniae", "PROBLEM", 60, 73], ["pneumoniae", "OBSERVATION", 63, 73], ["IRF3 activation", "OBSERVATION", 83, 98]]], ["Futhermore, Yang et al. reported that C. pneumoniae can negatively regulate ABCA1 expression by the TLR2-NF-\u03baB and miR-33 pathway in THP-1 macrophage-derived foam cells.", [["THP-1 macrophage", "ANATOMY", 133, 149], ["foam cells", "ANATOMY", 158, 168], ["C. pneumoniae", "ORGANISM", 38, 51], ["ABCA1", "GENE_OR_GENE_PRODUCT", 76, 81], ["TLR2", "GENE_OR_GENE_PRODUCT", 100, 104], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 105, 110], ["miR-33", "GENE_OR_GENE_PRODUCT", 115, 121], ["THP-1 macrophage-derived foam cells", "CELL", 133, 168], ["ABCA1", "PROTEIN", 76, 81], ["TLR2", "PROTEIN", 100, 104], ["THP-1 macrophage-derived foam cells", "CELL_LINE", 133, 168], ["C. pneumoniae", "SPECIES", 38, 51], ["C. pneumoniae", "SPECIES", 38, 51], ["C. pneumoniae", "PROBLEM", 38, 51], ["the TLR2", "TEST", 96, 104], ["NF", "TEST", 105, 107], ["miR", "TEST", 115, 118], ["THP", "TEST", 133, 136], ["pneumoniae", "OBSERVATION", 41, 51], ["foam cells", "OBSERVATION", 158, 168]]], ["ABCA1 is the key to macrophage cholesterol efflux and has a protective influence on atherosclerosis.", [["macrophage", "ANATOMY", 20, 30], ["cholesterol", "CHEMICAL", 31, 42], ["atherosclerosis", "DISEASE", 84, 99], ["cholesterol", "CHEMICAL", 31, 42], ["ABCA1", "GENE_OR_GENE_PRODUCT", 0, 5], ["macrophage", "CELL", 20, 30], ["cholesterol", "SIMPLE_CHEMICAL", 31, 42], ["ABCA1", "PROTEIN", 0, 5], ["ABCA1", "TEST", 0, 5], ["macrophage cholesterol efflux", "PROBLEM", 20, 49], ["atherosclerosis", "PROBLEM", 84, 99], ["macrophage", "OBSERVATION_MODIFIER", 20, 30], ["cholesterol efflux", "OBSERVATION", 31, 49], ["atherosclerosis", "OBSERVATION", 84, 99]]], ["Decreased expression or localization of ABCA1 on the cell membrane may lead to cholesterol accumulation in macrophages and aggravate atherosclerosis [78].Periodontal pathogens ::: Role of TLRs in pathogen-induced atherosclerosisPeriodontal disease (PD) is a polymicrobial dysbiotic inflammatory disease with substantial inflammatory destruction of the supporting tissues, including gingival tissue, periodontal ligament, and alveolar bone.", [["cell membrane", "ANATOMY", 53, 66], ["macrophages", "ANATOMY", 107, 118], ["Periodontal", "ANATOMY", 154, 165], ["Periodontal", "ANATOMY", 228, 239], ["tissues", "ANATOMY", 363, 370], ["gingival tissue", "ANATOMY", 382, 397], ["periodontal ligament", "ANATOMY", 399, 419], ["alveolar bone", "ANATOMY", 425, 438], ["cholesterol", "CHEMICAL", 79, 90], ["atherosclerosis", "DISEASE", 133, 148], ["atherosclerosis", "DISEASE", 213, 228], ["Periodontal disease", "DISEASE", 228, 247], ["PD", "DISEASE", 249, 251], ["cholesterol", "CHEMICAL", 79, 90], ["ABCA1", "GENE_OR_GENE_PRODUCT", 40, 45], ["cell membrane", "CELLULAR_COMPONENT", 53, 66], ["cholesterol", "SIMPLE_CHEMICAL", 79, 90], ["macrophages", "CELL", 107, 118], ["TLRs", "GENE_OR_GENE_PRODUCT", 188, 192], ["tissues", "TISSUE", 363, 370], ["gingival tissue", "TISSUE", 382, 397], ["periodontal ligament", "TISSUE", 399, 419], ["alveolar bone", "TISSUE", 425, 438], ["ABCA1", "PROTEIN", 40, 45], ["macrophages", "CELL_TYPE", 107, 118], ["TLRs", "PROTEIN", 188, 192], ["Decreased expression", "PROBLEM", 0, 20], ["the cell membrane", "TREATMENT", 49, 66], ["cholesterol accumulation in macrophages", "PROBLEM", 79, 118], ["aggravate atherosclerosis", "PROBLEM", 123, 148], ["pathogen", "PROBLEM", 196, 204], ["atherosclerosisPeriodontal disease (PD", "PROBLEM", 213, 251], ["a polymicrobial dysbiotic inflammatory disease", "PROBLEM", 256, 302], ["substantial inflammatory destruction of the supporting tissues", "PROBLEM", 308, 370], ["gingival tissue, periodontal ligament, and alveolar bone", "PROBLEM", 382, 438], ["ABCA1", "OBSERVATION", 40, 45], ["cell membrane", "OBSERVATION", 53, 66], ["may lead to", "UNCERTAINTY", 67, 78], ["cholesterol accumulation", "OBSERVATION", 79, 103], ["macrophages", "OBSERVATION_MODIFIER", 107, 118], ["aggravate", "OBSERVATION_MODIFIER", 123, 132], ["atherosclerosis", "OBSERVATION", 133, 148], ["atherosclerosis", "OBSERVATION_MODIFIER", 213, 228], ["Periodontal disease", "OBSERVATION", 228, 247], ["polymicrobial", "OBSERVATION_MODIFIER", 258, 271], ["dysbiotic", "OBSERVATION_MODIFIER", 272, 281], ["inflammatory", "OBSERVATION_MODIFIER", 282, 294], ["substantial", "OBSERVATION_MODIFIER", 308, 319], ["inflammatory", "OBSERVATION_MODIFIER", 320, 332], ["destruction", "OBSERVATION", 333, 344], ["supporting tissues", "OBSERVATION", 352, 370], ["gingival tissue", "ANATOMY", 382, 397], ["periodontal ligament", "ANATOMY", 399, 419], ["alveolar", "ANATOMY_MODIFIER", 425, 433], ["bone", "ANATOMY", 434, 438]]], ["P. gingivalis, the best-studied bacterial pathogen associated with severe PD, is a Gram-negative anaerobic bacterium in which the host\u2019s immune responding to the organism destroys the dental support structure [79].", [["P. gingivalis", "DISEASE", 0, 13], ["PD", "DISEASE", 74, 76], ["P. gingivalis", "ORGANISM", 0, 13], ["P. gingivalis", "SPECIES", 0, 13], ["P. gingivalis", "SPECIES", 0, 13], ["P. gingivalis", "PROBLEM", 0, 13], ["bacterial pathogen", "PROBLEM", 32, 50], ["severe PD", "PROBLEM", 67, 76], ["a Gram", "TEST", 81, 87], ["negative anaerobic bacterium", "PROBLEM", 88, 116], ["the organism", "PROBLEM", 158, 170], ["anaerobic bacterium", "OBSERVATION_MODIFIER", 97, 116]]], ["A series of evidence suggests that P. gingivalis and periodontal disease are risk factors for diabetes, premature labor, and atherosclerotic disease and the presence of P. gingivalis has been detected in atherosclerotic plaques [11, 80, 81].", [["periodontal", "ANATOMY", 53, 64], ["atherosclerotic", "ANATOMY", 125, 140], ["atherosclerotic plaques", "ANATOMY", 204, 227], ["P. gingivalis", "DISEASE", 35, 48], ["periodontal disease", "DISEASE", 53, 72], ["diabetes", "DISEASE", 94, 102], ["premature labor", "DISEASE", 104, 119], ["atherosclerotic disease", "DISEASE", 125, 148], ["P. gingivalis", "DISEASE", 169, 182], ["atherosclerotic plaques", "DISEASE", 204, 227], ["P. gingivalis", "ORGANISM", 35, 48], ["P. gingivalis", "ORGANISM", 169, 182], ["atherosclerotic plaques", "PATHOLOGICAL_FORMATION", 204, 227], ["P. gingivalis", "SPECIES", 35, 48], ["P. gingivalis", "SPECIES", 169, 182], ["P. gingivalis", "SPECIES", 35, 48], ["P. gingivalis", "SPECIES", 169, 182], ["P. gingivalis", "PROBLEM", 35, 48], ["periodontal disease", "PROBLEM", 53, 72], ["diabetes", "PROBLEM", 94, 102], ["premature labor", "PROBLEM", 104, 119], ["atherosclerotic disease", "PROBLEM", 125, 148], ["P. gingivalis", "PROBLEM", 169, 182], ["atherosclerotic plaques", "PROBLEM", 204, 227], ["periodontal", "ANATOMY", 53, 64], ["disease", "OBSERVATION", 65, 72], ["atherosclerotic", "OBSERVATION_MODIFIER", 125, 140], ["atherosclerotic", "OBSERVATION_MODIFIER", 204, 219], ["plaques", "OBSERVATION", 220, 227]]], ["Velsko et al. detected P. gingivalis in aortic plaque by Fluorescent in-situ hybridization (FISH), and reported that chronic oral infection with P. gingivalis results in a specific immune response, significant increases in oral bone resorption, aortic inflammation, viable bacteria in oral epithelium and aorta, and plaque development [20].", [["aortic plaque", "ANATOMY", 40, 53], ["oral", "ANATOMY", 125, 129], ["oral", "ANATOMY", 223, 227], ["bone", "ANATOMY", 228, 232], ["aortic", "ANATOMY", 245, 251], ["oral epithelium", "ANATOMY", 285, 300], ["aorta", "ANATOMY", 305, 310], ["plaque", "ANATOMY", 316, 322], ["oral infection", "DISEASE", 125, 139], ["inflammation", "DISEASE", 252, 264], ["plaque", "DISEASE", 316, 322], ["P. gingivalis", "ORGANISM", 23, 36], ["aortic plaque", "PATHOLOGICAL_FORMATION", 40, 53], ["oral", "ORGANISM_SUBDIVISION", 125, 129], ["P. gingivalis", "ORGANISM", 145, 158], ["oral bone", "MULTI-TISSUE_STRUCTURE", 223, 232], ["aortic", "MULTI-TISSUE_STRUCTURE", 245, 251], ["oral epithelium", "TISSUE", 285, 300], ["aorta", "MULTI-TISSUE_STRUCTURE", 305, 310], ["plaque", "PATHOLOGICAL_FORMATION", 316, 322], ["P. gingivalis", "SPECIES", 23, 36], ["P. gingivalis", "SPECIES", 145, 158], ["P. gingivalis", "SPECIES", 23, 36], ["P. gingivalis", "SPECIES", 145, 158], ["P. gingivalis", "PROBLEM", 23, 36], ["aortic plaque", "PROBLEM", 40, 53], ["Fluorescent", "TEST", 57, 68], ["chronic oral infection", "PROBLEM", 117, 139], ["P. gingivalis", "PROBLEM", 145, 158], ["significant increases", "PROBLEM", 198, 219], ["oral bone resorption", "PROBLEM", 223, 243], ["aortic inflammation", "PROBLEM", 245, 264], ["viable bacteria in oral epithelium and aorta", "PROBLEM", 266, 310], ["plaque development", "PROBLEM", 316, 334], ["gingivalis", "OBSERVATION", 26, 36], ["aortic", "ANATOMY", 40, 46], ["plaque", "OBSERVATION", 47, 53], ["chronic", "OBSERVATION_MODIFIER", 117, 124], ["infection", "OBSERVATION", 130, 139], ["significant", "OBSERVATION_MODIFIER", 198, 209], ["increases", "OBSERVATION_MODIFIER", 210, 219], ["oral bone", "ANATOMY", 223, 232], ["resorption", "OBSERVATION", 233, 243], ["aortic", "ANATOMY", 245, 251], ["inflammation", "OBSERVATION", 252, 264], ["viable", "OBSERVATION_MODIFIER", 266, 272], ["bacteria", "OBSERVATION", 273, 281], ["oral epithelium", "ANATOMY", 285, 300], ["aorta", "ANATOMY", 305, 310], ["plaque", "OBSERVATION", 316, 322]]], ["Proinflammatory cytokine induction by P. gingivalis was reported to be refrained by monoclonal antibodies to TLR2 and 4, CD14 and \u03b22 integrin [82].", [["P. gingivalis", "ORGANISM", 38, 51], ["TLR2", "GENE_OR_GENE_PRODUCT", 109, 113], ["4", "GENE_OR_GENE_PRODUCT", 118, 119], ["CD14", "GENE_OR_GENE_PRODUCT", 121, 125], ["\u03b22 integrin", "GENE_OR_GENE_PRODUCT", 130, 141], ["Proinflammatory cytokine", "PROTEIN", 0, 24], ["monoclonal antibodies", "PROTEIN", 84, 105], ["TLR2 and 4", "PROTEIN", 109, 119], ["CD14", "PROTEIN", 121, 125], ["\u03b22 integrin", "PROTEIN", 130, 141], ["P. gingivalis", "SPECIES", 38, 51], ["P. gingivalis", "SPECIES", 38, 51], ["Proinflammatory cytokine induction", "TREATMENT", 0, 34], ["P. gingivalis", "TEST", 38, 51], ["monoclonal antibodies", "TEST", 84, 105], ["TLR2", "TEST", 109, 113], ["CD14", "TEST", 121, 125]]], ["Frank and his colleagues reported that P. gingivalis demands TLR2 to induce oral inflammatory bone loss in mice, and P. gingivalis infection promotes atherosclerosis in hyperlipidemia mice with increased expression of TLR2 and TLR4.", [["oral", "ANATOMY", 76, 80], ["bone", "ANATOMY", 94, 98], ["bone loss", "DISEASE", 94, 103], ["P. gingivalis infection", "DISEASE", 117, 140], ["atherosclerosis", "DISEASE", 150, 165], ["hyperlipidemia", "DISEASE", 169, 183], ["P. gingivalis", "ORGANISM", 39, 52], ["TLR2", "GENE_OR_GENE_PRODUCT", 61, 65], ["oral", "ORGANISM_SUBDIVISION", 76, 80], ["bone", "TISSUE", 94, 98], ["mice", "ORGANISM", 107, 111], ["P. gingivalis", "ORGANISM", 117, 130], ["mice", "ORGANISM", 184, 188], ["TLR2", "GENE_OR_GENE_PRODUCT", 218, 222], ["TLR4", "GENE_OR_GENE_PRODUCT", 227, 231], ["TLR2", "PROTEIN", 61, 65], ["TLR2", "PROTEIN", 218, 222], ["TLR4", "PROTEIN", 227, 231], ["P. gingivalis", "SPECIES", 39, 52], ["mice", "SPECIES", 107, 111], ["P. gingivalis", "SPECIES", 117, 130], ["mice", "SPECIES", 184, 188], ["P. gingivalis", "SPECIES", 39, 52], ["mice", "SPECIES", 107, 111], ["P. gingivalis", "SPECIES", 117, 130], ["mice", "SPECIES", 184, 188], ["oral inflammatory bone loss in mice", "PROBLEM", 76, 111], ["P. gingivalis infection", "PROBLEM", 117, 140], ["atherosclerosis", "PROBLEM", 150, 165], ["hyperlipidemia", "PROBLEM", 169, 183], ["TLR2 and TLR4", "TREATMENT", 218, 231], ["inflammatory", "OBSERVATION", 81, 93], ["atherosclerosis", "OBSERVATION", 150, 165], ["hyperlipidemia", "OBSERVATION", 169, 183], ["TLR2", "ANATOMY", 218, 222], ["TLR4", "ANATOMY", 227, 231]]], ["Hayashi et al. proved that TLR4 has atherosclerosis protection in response to P. gingivalis infection [83].", [["atherosclerosis", "DISEASE", 36, 51], ["P. gingivalis infection", "DISEASE", 78, 101], ["TLR4", "GENE_OR_GENE_PRODUCT", 27, 31], ["P. gingivalis", "ORGANISM", 78, 91], ["TLR4", "PROTEIN", 27, 31], ["P. gingivalis", "SPECIES", 78, 91], ["P. gingivalis", "SPECIES", 78, 91], ["atherosclerosis protection", "TREATMENT", 36, 62], ["P. gingivalis infection", "PROBLEM", 78, 101], ["atherosclerosis", "OBSERVATION", 36, 51]]], ["In the same year, MyD88 and TRIF are proved to play important roles in the formation of foam cells induced by P. gingivalis [84].", [["foam cells", "ANATOMY", 88, 98], ["MyD88", "GENE_OR_GENE_PRODUCT", 18, 23], ["TRIF", "GENE_OR_GENE_PRODUCT", 28, 32], ["foam cells", "CELL", 88, 98], ["P. gingivalis", "ORGANISM", 110, 123], ["MyD88", "PROTEIN", 18, 23], ["TRIF", "PROTEIN", 28, 32], ["foam cells", "CELL_TYPE", 88, 98], ["P. gingivalis", "SPECIES", 110, 123], ["P. gingivalis", "SPECIES", 110, 123]]], ["P. gingivalis has the ability to regulate C5a signaling in neutrophils, which leads to the degradation of MyD88 by C5aR-TLR2 cross-talk involving the ubiquitin ligase Smurf1, reducing the production of inflammatory markers and resulting in reduced antimicrobial killing.", [["neutrophils", "ANATOMY", 59, 70], ["P. gingivalis", "ORGANISM", 0, 13], ["C5a", "GENE_OR_GENE_PRODUCT", 42, 45], ["neutrophils", "CELL", 59, 70], ["MyD88", "GENE_OR_GENE_PRODUCT", 106, 111], ["C5aR", "GENE_OR_GENE_PRODUCT", 115, 119], ["TLR2", "GENE_OR_GENE_PRODUCT", 120, 124], ["Smurf1", "GENE_OR_GENE_PRODUCT", 167, 173], ["C5a", "PROTEIN", 42, 45], ["neutrophils", "CELL_TYPE", 59, 70], ["MyD88", "PROTEIN", 106, 111], ["C5aR", "PROTEIN", 115, 119], ["TLR2", "PROTEIN", 120, 124], ["ubiquitin ligase", "PROTEIN", 150, 166], ["Smurf1", "PROTEIN", 167, 173], ["inflammatory markers", "PROTEIN", 202, 222], ["P. gingivalis", "SPECIES", 0, 13], ["P. gingivalis", "SPECIES", 0, 13], ["neutrophils", "TEST", 59, 70], ["the ubiquitin ligase Smurf1", "TREATMENT", 146, 173], ["inflammatory markers", "PROBLEM", 202, 222], ["reduced antimicrobial killing", "PROBLEM", 240, 269], ["ligase Smurf1", "OBSERVATION", 160, 173], ["inflammatory", "OBSERVATION_MODIFIER", 202, 214], ["reduced", "OBSERVATION_MODIFIER", 240, 247], ["antimicrobial killing", "OBSERVATION", 248, 269]]], ["Alternative TLR2 signaling through Mal and PI3 kinase (PI3K) in the absence of MyD88 to cause inflammatory activation [85].", [["TLR2", "GENE_OR_GENE_PRODUCT", 12, 16], ["Mal", "GENE_OR_GENE_PRODUCT", 35, 38], ["PI3 kinase", "GENE_OR_GENE_PRODUCT", 43, 53], ["PI3K", "GENE_OR_GENE_PRODUCT", 55, 59], ["MyD88", "GENE_OR_GENE_PRODUCT", 79, 84], ["TLR2", "PROTEIN", 12, 16], ["Mal", "PROTEIN", 35, 38], ["PI3 kinase", "PROTEIN", 43, 53], ["PI3K", "PROTEIN", 55, 59], ["MyD88", "PROTEIN", 79, 84], ["Mal and PI3 kinase", "TEST", 35, 53], ["inflammatory activation", "PROBLEM", 94, 117], ["inflammatory", "OBSERVATION_MODIFIER", 94, 106]]], ["Brown et al. demonstrated that P. gingivalis infection in the oral cavity can result in significant TLR2-CD36/SR-B2-mediated IL1\u03b2 release and promote plaque progression [86].", [["oral cavity", "ANATOMY", 62, 73], ["plaque", "ANATOMY", 150, 156], ["P. gingivalis infection", "DISEASE", 31, 54], ["P. gingivalis", "ORGANISM", 31, 44], ["oral cavity", "ORGAN", 62, 73], ["TLR2", "GENE_OR_GENE_PRODUCT", 100, 104], ["CD36", "GENE_OR_GENE_PRODUCT", 105, 109], ["SR-B2", "GENE_OR_GENE_PRODUCT", 110, 115], ["IL1\u03b2", "GENE_OR_GENE_PRODUCT", 125, 129], ["plaque", "PATHOLOGICAL_FORMATION", 150, 156], ["TLR2", "PROTEIN", 100, 104], ["CD36", "PROTEIN", 105, 109], ["SR", "PROTEIN", 110, 112], ["IL1\u03b2", "PROTEIN", 125, 129], ["P. gingivalis", "SPECIES", 31, 44], ["P. gingivalis", "SPECIES", 31, 44], ["P. gingivalis infection in the oral cavity", "PROBLEM", 31, 73], ["B2-mediated IL1\u03b2 release", "TREATMENT", 113, 137], ["promote plaque progression", "PROBLEM", 142, 168], ["et al", "OBSERVATION", 6, 11], ["gingivalis", "OBSERVATION_MODIFIER", 34, 44], ["infection", "OBSERVATION", 45, 54], ["oral cavity", "ANATOMY", 62, 73], ["plaque", "OBSERVATION", 150, 156]]], ["HSP 60 isolated from P. gingivalis was confirmed to induce TLR-4 mediated ICAM-1, VCAM-1 and expression of the ox-LDL receptor-1 (LOX-1) in mice [87].Periodontal pathogens ::: Role of TLRs in pathogen-induced atherosclerosisIn addition to P. gingivalis, other significant periodontal pathogens also support the potential connection between PD and ASVD.", [["Periodontal", "ANATOMY", 150, 161], ["periodontal", "ANATOMY", 272, 283], ["PD", "DISEASE", 340, 342], ["ASVD", "DISEASE", 347, 351], ["HSP 60", "GENE_OR_GENE_PRODUCT", 0, 6], ["P. gingivalis", "ORGANISM", 21, 34], ["TLR-4", "GENE_OR_GENE_PRODUCT", 59, 64], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 74, 80], ["VCAM-1", "GENE_OR_GENE_PRODUCT", 82, 88], ["ox-LDL receptor-1", "GENE_OR_GENE_PRODUCT", 111, 128], ["LOX-1", "GENE_OR_GENE_PRODUCT", 130, 135], ["mice", "ORGANISM", 140, 144], ["TLRs", "GENE_OR_GENE_PRODUCT", 184, 188], ["P. gingivalis", "ORGANISM", 239, 252], ["HSP 60", "PROTEIN", 0, 6], ["TLR", "PROTEIN", 59, 62], ["ICAM-1", "PROTEIN", 74, 80], ["VCAM", "PROTEIN", 82, 86], ["ox-LDL receptor-1", "PROTEIN", 111, 128], ["LOX", "PROTEIN", 130, 133], ["TLRs", "PROTEIN", 184, 188], ["P. gingivalis", "SPECIES", 21, 34], ["mice", "SPECIES", 140, 144], ["P. gingivalis", "SPECIES", 239, 252], ["P. gingivalis", "SPECIES", 21, 34], ["mice", "SPECIES", 140, 144], ["P. gingivalis", "SPECIES", 239, 252], ["HSP", "TEST", 0, 3], ["P. gingivalis", "TEST", 21, 34], ["TLR", "TEST", 59, 62], ["ICAM", "TEST", 74, 78], ["VCAM", "TEST", 82, 86], ["the ox", "TEST", 107, 113], ["LDL receptor", "TEST", 114, 126], ["LOX", "TEST", 130, 133], ["Periodontal pathogens", "PROBLEM", 150, 171], ["pathogen", "PROBLEM", 192, 200], ["P. gingivalis", "PROBLEM", 239, 252], ["other significant periodontal pathogens", "PROBLEM", 254, 293], ["PD and ASVD", "TREATMENT", 340, 351], ["pathogens", "OBSERVATION", 162, 171]]], ["Treponema denticola (T. denticola) is a predominantly subgingival oral spirochete closely associated with periodontal disease.", [["oral", "ANATOMY", 66, 70], ["periodontal", "ANATOMY", 106, 117], ["Treponema denticola", "DISEASE", 0, 19], ["periodontal disease", "DISEASE", 106, 125], ["Treponema denticola", "ORGANISM", 0, 19], ["T. denticola", "ORGANISM", 21, 33], ["oral", "ORGANISM_SUBDIVISION", 66, 70], ["Treponema denticola", "SPECIES", 0, 19], ["T. denticola", "SPECIES", 21, 33], ["Treponema denticola", "SPECIES", 0, 19], ["T. denticola", "SPECIES", 21, 33], ["Treponema denticola (T. denticola", "PROBLEM", 0, 33], ["a predominantly subgingival oral spirochete", "PROBLEM", 38, 81], ["periodontal disease", "PROBLEM", 106, 125], ["predominantly", "OBSERVATION_MODIFIER", 40, 53], ["subgingival", "OBSERVATION_MODIFIER", 54, 65], ["periodontal", "ANATOMY", 106, 117], ["disease", "OBSERVATION", 118, 125]]], ["Chukkapalli et al. detected T. denticola clusters in both gingival and aortic tissue of infected ApoE\u2212/\u2212 mice by FISH and reported that T. denticola infection increased alveolar bone resorption and aortic plaque area in mice, and changed the gene expression related to atherosclerosis [19].", [["gingival", "ANATOMY", 58, 66], ["aortic tissue", "ANATOMY", 71, 84], ["alveolar bone", "ANATOMY", 169, 182], ["aortic plaque area", "ANATOMY", 198, 216], ["denticola infection", "DISEASE", 139, 158], ["atherosclerosis", "DISEASE", 269, 284], ["T. denticola", "ORGANISM", 28, 40], ["gingival", "TISSUE", 58, 66], ["aortic tissue", "TISSUE", 71, 84], ["ApoE\u2212/\u2212 mice", "ORGANISM", 97, 109], ["T. denticola", "ORGANISM", 136, 148], ["alveolar bone", "MULTI-TISSUE_STRUCTURE", 169, 182], ["aortic plaque", "PATHOLOGICAL_FORMATION", 198, 211], ["mice", "ORGANISM", 220, 224], ["T. denticola", "SPECIES", 28, 40], ["mice", "SPECIES", 105, 109], ["T. denticola", "SPECIES", 136, 148], ["mice", "SPECIES", 220, 224], ["T. denticola", "SPECIES", 28, 40], ["mice", "SPECIES", 105, 109], ["T. denticola", "SPECIES", 136, 148], ["mice", "SPECIES", 220, 224], ["T. denticola clusters", "PROBLEM", 28, 49], ["T. denticola infection", "PROBLEM", 136, 158], ["alveolar bone resorption", "PROBLEM", 169, 193], ["aortic plaque area", "PROBLEM", 198, 216], ["atherosclerosis", "PROBLEM", 269, 284], ["denticola clusters", "OBSERVATION", 31, 49], ["both", "ANATOMY_MODIFIER", 53, 57], ["gingival", "ANATOMY", 58, 66], ["aortic tissue", "ANATOMY", 71, 84], ["infected", "OBSERVATION", 88, 96], ["alveolar", "ANATOMY_MODIFIER", 169, 177], ["bone", "ANATOMY", 178, 182], ["resorption", "OBSERVATION", 183, 193], ["aortic", "ANATOMY", 198, 204], ["plaque", "OBSERVATION", 205, 211], ["atherosclerosis", "OBSERVATION", 269, 284]]], ["Nussbaum et al. reported T. denticola cells and its major outer sheath protein (MSP) induced innate immune responses through TLR2-MyD88, whereas its lipooligosaccharide (LOS or glycolipid) induced a macrophage response through TLR4-MyD88 [88].", [["denticola cells", "ANATOMY", 28, 43], ["macrophage", "ANATOMY", 199, 209], ["T. denticola cells", "CELL", 25, 43], ["outer sheath", "CELLULAR_COMPONENT", 58, 70], ["MSP", "GENE_OR_GENE_PRODUCT", 80, 83], ["TLR2", "GENE_OR_GENE_PRODUCT", 125, 129], ["MyD88", "GENE_OR_GENE_PRODUCT", 130, 135], ["lipooligosaccharide", "SIMPLE_CHEMICAL", 149, 168], ["LOS", "SIMPLE_CHEMICAL", 170, 173], ["glycolipid", "SIMPLE_CHEMICAL", 177, 187], ["macrophage", "CELL", 199, 209], ["TLR4", "GENE_OR_GENE_PRODUCT", 227, 231], ["MyD88", "GENE_OR_GENE_PRODUCT", 232, 237], ["T. denticola cells", "CELL_TYPE", 25, 43], ["major outer sheath protein", "PROTEIN", 52, 78], ["MSP", "PROTEIN", 80, 83], ["TLR2", "PROTEIN", 125, 129], ["MyD88", "PROTEIN", 130, 135], ["TLR4", "PROTEIN", 227, 231], ["MyD88", "PROTEIN", 232, 237], ["T. denticola", "SPECIES", 25, 37], ["T. denticola", "SPECIES", 25, 37], ["T. denticola cells", "PROBLEM", 25, 43], ["TLR2", "TEST", 125, 129], ["denticola cells", "OBSERVATION", 28, 43], ["macrophage response", "OBSERVATION", 199, 218]]], ["Recently Ruby et al. reported that T. denticola periplasmic flagella activate the innate immune system through TLR2 [89].Periodontal pathogens ::: Role of TLRs in pathogen-induced atherosclerosisTannerella forsythia (T. forsythia) is a Gram-negative anaerobic organism that inhabits the subgingival cavity and initiates connective tissue destruction and alveolar bone resorption in PD.", [["flagella", "ANATOMY", 60, 68], ["Periodontal", "ANATOMY", 121, 132], ["subgingival cavity", "ANATOMY", 287, 305], ["connective tissue", "ANATOMY", 320, 337], ["alveolar bone", "ANATOMY", 354, 367], ["atherosclerosis", "DISEASE", 180, 195], ["Tannerella forsythia", "DISEASE", 195, 215], ["T. forsythia", "DISEASE", 217, 229], ["PD", "DISEASE", 382, 384], ["T. denticola", "ORGANISM", 35, 47], ["periplasmic flagella", "CELLULAR_COMPONENT", 48, 68], ["TLR2", "GENE_OR_GENE_PRODUCT", 111, 115], ["TLRs", "GENE_OR_GENE_PRODUCT", 155, 159], ["Tannerella forsythia", "ORGANISM", 195, 215], ["T. forsythia", "ORGANISM", 217, 229], ["subgingival cavity", "PATHOLOGICAL_FORMATION", 287, 305], ["connective tissue", "TISSUE", 320, 337], ["alveolar bone", "MULTI-TISSUE_STRUCTURE", 354, 367], ["TLR2", "PROTEIN", 111, 115], ["TLRs", "PROTEIN", 155, 159], ["T. denticola", "SPECIES", 35, 47], ["Tannerella forsythia", "SPECIES", 195, 215], ["T. forsythia", "SPECIES", 217, 229], ["T. denticola", "SPECIES", 35, 47], ["Tannerella forsythia", "SPECIES", 195, 215], ["T. forsythia", "SPECIES", 217, 229], ["T. denticola periplasmic flagella", "TREATMENT", 35, 68], ["Periodontal pathogens", "PROBLEM", 121, 142], ["pathogen", "PROBLEM", 163, 171], ["atherosclerosis", "PROBLEM", 180, 195], ["Tannerella forsythia (T. forsythia", "PROBLEM", 195, 229], ["a Gram-negative anaerobic organism", "PROBLEM", 234, 268], ["the subgingival cavity", "PROBLEM", 283, 305], ["connective tissue destruction", "PROBLEM", 320, 349], ["alveolar bone resorption", "PROBLEM", 354, 378], ["PD", "PROBLEM", 382, 384], ["pathogens", "OBSERVATION", 133, 142], ["atherosclerosis", "OBSERVATION_MODIFIER", 180, 195], ["Tannerella forsythia", "OBSERVATION", 195, 215], ["anaerobic organism", "OBSERVATION", 250, 268], ["subgingival cavity", "ANATOMY", 287, 305], ["connective tissue destruction", "OBSERVATION", 320, 349], ["alveolar", "ANATOMY_MODIFIER", 354, 362], ["bone", "ANATOMY", 363, 367], ["resorption", "OBSERVATION", 368, 378]]], ["Lee et al. reported T. forsythia and its major surface virulence factor, BspA could induce foam cell formation in THP-1 cells and accelerated the progression of atherosclerotic lesions in ApoE\u2212/\u2212 mice [90].", [["surface", "ANATOMY", 47, 54], ["foam cell", "ANATOMY", 91, 100], ["THP-1 cells", "ANATOMY", 114, 125], ["atherosclerotic lesions", "ANATOMY", 161, 184], ["BspA", "CHEMICAL", 73, 77], ["atherosclerotic", "DISEASE", 161, 176], ["T. forsythia", "ORGANISM", 20, 32], ["BspA", "SIMPLE_CHEMICAL", 73, 77], ["foam cell", "CELL", 91, 100], ["THP-1 cells", "CELL", 114, 125], ["atherosclerotic lesions", "PATHOLOGICAL_FORMATION", 161, 184], ["major surface virulence factor", "PROTEIN", 41, 71], ["BspA", "PROTEIN", 73, 77], ["THP-1 cells", "CELL_LINE", 114, 125], ["T. forsythia", "SPECIES", 20, 32], ["mice", "SPECIES", 196, 200], ["T. forsythia", "SPECIES", 20, 32], ["T. forsythia", "PROBLEM", 20, 32], ["its major surface virulence factor", "PROBLEM", 37, 71], ["atherosclerotic lesions", "PROBLEM", 161, 184], ["forsythia", "OBSERVATION", 23, 32], ["foam cell formation", "OBSERVATION", 91, 110], ["progression", "OBSERVATION_MODIFIER", 146, 157], ["atherosclerotic", "OBSERVATION_MODIFIER", 161, 176], ["lesions", "OBSERVATION", 177, 184]]], ["Ardila et al. analyzed 80 patients with chronic periodontitis and 28 healthy people and found that the levels of serum total cholesterol (TC) and LDL increases in the occurrence of T. forsythia, which is likely to increase the risk of atherosclerosis [91].", [["serum", "ANATOMY", 113, 118], ["periodontitis", "DISEASE", 48, 61], ["cholesterol", "CHEMICAL", 125, 136], ["TC", "CHEMICAL", 138, 140], ["T. forsythia", "DISEASE", 181, 193], ["atherosclerosis", "DISEASE", 235, 250], ["cholesterol", "CHEMICAL", 125, 136], ["patients", "ORGANISM", 26, 34], ["people", "ORGANISM", 77, 83], ["serum", "ORGANISM_SUBSTANCE", 113, 118], ["cholesterol", "SIMPLE_CHEMICAL", 125, 136], ["TC", "SIMPLE_CHEMICAL", 138, 140], ["LDL", "SIMPLE_CHEMICAL", 146, 149], ["T. forsythia", "ORGANISM", 181, 193], ["LDL", "PROTEIN", 146, 149], ["patients", "SPECIES", 26, 34], ["people", "SPECIES", 77, 83], ["T. forsythia", "SPECIES", 181, 193], ["T. forsythia", "SPECIES", 181, 193], ["chronic periodontitis", "PROBLEM", 40, 61], ["serum total cholesterol", "TEST", 113, 136], ["LDL increases", "PROBLEM", 146, 159], ["T. forsythia", "PROBLEM", 181, 193], ["atherosclerosis", "PROBLEM", 235, 250], ["chronic", "OBSERVATION_MODIFIER", 40, 47], ["periodontitis", "OBSERVATION", 48, 61], ["forsythia", "OBSERVATION", 184, 193], ["is likely", "UNCERTAINTY", 201, 210], ["atherosclerosis", "OBSERVATION", 235, 250]]], ["Chukkapalli et al. reported that T. forsythia infection promoted alveolar bone resorption, increased serum inflammatory markers and lipid profile changes in ApoE\u2212/\u2212 mice, but did not increase the growth of aortic plaque [92].", [["alveolar bone", "ANATOMY", 65, 78], ["serum", "ANATOMY", 101, 106], ["aortic plaque", "ANATOMY", 206, 219], ["T. forsythia infection", "DISEASE", 33, 55], ["T. forsythia", "ORGANISM", 33, 45], ["alveolar bone", "MULTI-TISSUE_STRUCTURE", 65, 78], ["serum", "ORGANISM_SUBSTANCE", 101, 106], ["lipid", "SIMPLE_CHEMICAL", 132, 137], ["aortic plaque", "PATHOLOGICAL_FORMATION", 206, 219], ["serum inflammatory markers", "PROTEIN", 101, 127], ["T. forsythia", "SPECIES", 33, 45], ["mice", "SPECIES", 165, 169], ["T. forsythia", "SPECIES", 33, 45], ["mice", "SPECIES", 165, 169], ["T. forsythia infection", "PROBLEM", 33, 55], ["alveolar bone resorption", "PROBLEM", 65, 89], ["increased serum inflammatory markers", "PROBLEM", 91, 127], ["lipid profile changes", "PROBLEM", 132, 153], ["ApoE\u2212/\u2212 mice", "TREATMENT", 157, 169], ["aortic plaque", "PROBLEM", 206, 219], ["forsythia infection", "OBSERVATION", 36, 55], ["alveolar", "ANATOMY_MODIFIER", 65, 73], ["bone", "ANATOMY", 74, 78], ["resorption", "OBSERVATION", 79, 89], ["increased", "OBSERVATION_MODIFIER", 91, 100], ["serum", "OBSERVATION_MODIFIER", 101, 106], ["inflammatory", "OBSERVATION_MODIFIER", 107, 119], ["lipid profile", "OBSERVATION_MODIFIER", 132, 145], ["growth", "OBSERVATION_MODIFIER", 196, 202], ["aortic", "ANATOMY", 206, 212], ["plaque", "OBSERVATION", 213, 219]]], ["Onishi and his colleagues provided direct evidence for BspA binding to TLR2 and demonstrated that the release of the chemokine interleukin-8 (IL-8) from human gingival epithelial cells by BspA is TLR2-dependent [93].", [["gingival epithelial cells", "ANATOMY", 159, 184], ["BspA", "GENE_OR_GENE_PRODUCT", 55, 59], ["TLR2", "GENE_OR_GENE_PRODUCT", 71, 75], ["interleukin-8", "GENE_OR_GENE_PRODUCT", 127, 140], ["IL-8", "GENE_OR_GENE_PRODUCT", 142, 146], ["human", "ORGANISM", 153, 158], ["gingival epithelial cells", "CELL", 159, 184], ["BspA", "GENE_OR_GENE_PRODUCT", 188, 192], ["TLR2", "GENE_OR_GENE_PRODUCT", 196, 200], ["BspA", "PROTEIN", 55, 59], ["TLR2", "PROTEIN", 71, 75], ["chemokine interleukin-8 (IL-8", "PROTEIN", 117, 146], ["human gingival epithelial cells", "CELL_TYPE", 153, 184], ["BspA", "PROTEIN", 188, 192], ["TLR2", "PROTEIN", 196, 200], ["human", "SPECIES", 153, 158], ["human", "SPECIES", 153, 158], ["BspA binding", "PROBLEM", 55, 67], ["the chemokine interleukin", "TEST", 113, 138], ["IL", "TEST", 142, 144], ["human gingival epithelial cells", "TEST", 153, 184], ["gingival", "ANATOMY", 159, 167], ["epithelial cells", "OBSERVATION", 168, 184]]], ["These contradictory experimental results call for further research to confirm the relationship between T. forsythia and atherosclerosis and the role of TLRs in them.Periodontal pathogens ::: Role of TLRs in pathogen-induced atherosclerosisFusobacterium nucleatum (F. nucleatum) is another significant periodontal pathogen with oral infection.", [["Periodontal", "ANATOMY", 165, 176], ["periodontal", "ANATOMY", 301, 312], ["oral", "ANATOMY", 327, 331], ["T. forsythia", "DISEASE", 103, 115], ["atherosclerosis", "DISEASE", 120, 135], ["atherosclerosisFusobacterium nucleatum", "DISEASE", 224, 262], ["oral infection", "DISEASE", 327, 341], ["T. forsythia", "ORGANISM", 103, 115], ["TLRs", "GENE_OR_GENE_PRODUCT", 152, 156], ["TLRs", "GENE_OR_GENE_PRODUCT", 199, 203], ["atherosclerosisFusobacterium nucleatum", "ORGANISM", 224, 262], ["F. nucleatum", "ORGANISM", 264, 276], ["oral", "ORGANISM_SUBDIVISION", 327, 331], ["TLRs", "PROTEIN", 152, 156], ["TLRs", "PROTEIN", 199, 203], ["T. forsythia", "SPECIES", 103, 115], ["atherosclerosisFusobacterium nucleatum", "SPECIES", 224, 262], ["F. nucleatum", "SPECIES", 264, 276], ["T. forsythia", "SPECIES", 103, 115], ["atherosclerosisFusobacterium nucleatum", "SPECIES", 224, 262], ["F. nucleatum", "SPECIES", 264, 276], ["T. forsythia", "PROBLEM", 103, 115], ["atherosclerosis", "PROBLEM", 120, 135], ["pathogen", "PROBLEM", 207, 215], ["atherosclerosisFusobacterium nucleatum", "PROBLEM", 224, 262], ["another significant periodontal pathogen", "PROBLEM", 281, 321], ["oral infection", "PROBLEM", 327, 341], ["atherosclerosis", "OBSERVATION", 120, 135], ["significant", "OBSERVATION_MODIFIER", 289, 300], ["periodontal", "OBSERVATION_MODIFIER", 301, 312], ["pathogen", "OBSERVATION", 313, 321], ["infection", "OBSERVATION", 332, 341]]], ["Heat-shock protein GroEL of F. nucleatum has been reported to induce the expression of monocyte chemokines and cell adhesion molecules, and to promote the progression of atherosclerosis in ApoE\u2212/\u2212 mice [94].", [["monocyte", "ANATOMY", 87, 95], ["cell", "ANATOMY", 111, 115], ["atherosclerosis", "DISEASE", 170, 185], ["Heat-shock protein GroEL", "GENE_OR_GENE_PRODUCT", 0, 24], ["F. nucleatum", "GENE_OR_GENE_PRODUCT", 28, 40], ["monocyte", "CELL", 87, 95], ["cell", "CELL", 111, 115], ["Heat-shock protein GroEL", "PROTEIN", 0, 24], ["monocyte chemokines", "PROTEIN", 87, 106], ["cell adhesion molecules", "PROTEIN", 111, 134], ["F. nucleatum", "SPECIES", 28, 40], ["mice", "SPECIES", 197, 201], ["F. nucleatum", "SPECIES", 28, 40], ["shock protein GroEL of F. nucleatum", "PROBLEM", 5, 40], ["monocyte chemokines", "TREATMENT", 87, 106], ["cell adhesion molecules", "PROBLEM", 111, 134], ["atherosclerosis", "PROBLEM", 170, 185], ["progression", "OBSERVATION_MODIFIER", 155, 166], ["atherosclerosis", "OBSERVATION", 170, 185]]], ["Velsko et al. discovered that F. nucleatum enhanced the vascular inflammation, changed the lipid profile and the gene expression of the aorta in ApoE\u2212/\u2212 mice, and significantly reduced the number of atherosclerotic plaques in the aorta, which suggested that this member of the oral microbiome has a potential protective function [95].", [["vascular", "ANATOMY", 56, 64], ["aorta", "ANATOMY", 136, 141], ["atherosclerotic plaques", "ANATOMY", 199, 222], ["aorta", "ANATOMY", 230, 235], ["oral", "ANATOMY", 277, 281], ["inflammation", "DISEASE", 65, 77], ["atherosclerotic plaques", "DISEASE", 199, 222], ["F. nucleatum", "ORGANISM", 30, 42], ["vascular", "MULTI-TISSUE_STRUCTURE", 56, 64], ["aorta", "MULTI-TISSUE_STRUCTURE", 136, 141], ["ApoE\u2212", "GENE_OR_GENE_PRODUCT", 145, 150], ["atherosclerotic plaques", "PATHOLOGICAL_FORMATION", 199, 222], ["aorta", "MULTI-TISSUE_STRUCTURE", 230, 235], ["oral", "ORGANISM_SUBDIVISION", 277, 281], ["F. nucleatum", "SPECIES", 30, 42], ["mice", "SPECIES", 153, 157], ["F. nucleatum", "SPECIES", 30, 42], ["mice", "SPECIES", 153, 157], ["the vascular inflammation", "PROBLEM", 52, 77], ["the lipid profile", "TEST", 87, 104], ["atherosclerotic plaques in the aorta", "PROBLEM", 199, 235], ["nucleatum", "OBSERVATION", 33, 42], ["vascular", "ANATOMY", 56, 64], ["inflammation", "OBSERVATION", 65, 77], ["aorta", "ANATOMY", 136, 141], ["significantly", "OBSERVATION_MODIFIER", 163, 176], ["reduced", "OBSERVATION_MODIFIER", 177, 184], ["number", "OBSERVATION_MODIFIER", 189, 195], ["atherosclerotic", "OBSERVATION_MODIFIER", 199, 214], ["plaques", "OBSERVATION", 215, 222], ["aorta", "ANATOMY", 230, 235]]], ["Recently they also discovered that in TLR2\u2212/\u2212TLR4\u2212/\u2212 mice infected with polymicrobial infection including P. gingivalis, T. denticola, T. forsythia, and F. nucleatum, atherosclerotic plaque progression was significantly reduced.", [["atherosclerotic plaque", "ANATOMY", 167, 189], ["polymicrobial infection", "DISEASE", 72, 95], ["atherosclerotic plaque", "DISEASE", 167, 189], ["TLR2\u2212", "GENE_OR_GENE_PRODUCT", 38, 43], ["TLR4\u2212", "GENE_OR_GENE_PRODUCT", 45, 50], ["\u2212", "GENE_OR_GENE_PRODUCT", 51, 52], ["P. gingivalis", "ORGANISM", 106, 119], ["T. denticola", "ORGANISM", 121, 133], ["T. forsythia", "ORGANISM", 135, 147], ["F. nucleatum", "ORGANISM", 153, 165], ["atherosclerotic plaque", "PATHOLOGICAL_FORMATION", 167, 189], ["mice", "SPECIES", 53, 57], ["P. gingivalis", "SPECIES", 106, 119], ["T. denticola", "SPECIES", 121, 133], ["T. forsythia", "SPECIES", 135, 147], ["F. nucleatum", "SPECIES", 153, 165], ["mice", "SPECIES", 53, 57], ["P. gingivalis", "SPECIES", 106, 119], ["T. denticola", "SPECIES", 121, 133], ["T. forsythia", "SPECIES", 135, 147], ["F. nucleatum", "SPECIES", 153, 165], ["polymicrobial infection", "PROBLEM", 72, 95], ["P. gingivalis", "PROBLEM", 106, 119], ["T. denticola", "PROBLEM", 121, 133], ["T. forsythia", "PROBLEM", 135, 147], ["atherosclerotic plaque progression", "PROBLEM", 167, 201], ["polymicrobial", "OBSERVATION_MODIFIER", 72, 85], ["infection", "OBSERVATION", 86, 95], ["nucleatum", "ANATOMY", 156, 165], ["atherosclerotic", "OBSERVATION_MODIFIER", 167, 182], ["plaque", "OBSERVATION", 183, 189], ["significantly", "OBSERVATION_MODIFIER", 206, 219], ["reduced", "OBSERVATION_MODIFIER", 220, 227]]], ["However, bacterial genomic DNA was detected in multiple organs indicating an intravascular dissemination from gingival tissue to heart, aorta, kidney and lungs, suggesting that TLR2 and 4 were dispensable for systemic spread after polybacterial infections but TLR2 and 4 deficiency markedly reduces atherosclerosis induced by oral bacteria [96].", [["organs", "ANATOMY", 56, 62], ["intravascular", "ANATOMY", 77, 90], ["gingival tissue", "ANATOMY", 110, 125], ["heart", "ANATOMY", 129, 134], ["aorta", "ANATOMY", 136, 141], ["kidney", "ANATOMY", 143, 149], ["lungs", "ANATOMY", 154, 159], ["oral", "ANATOMY", 326, 330], ["infections", "DISEASE", 245, 255], ["atherosclerosis", "DISEASE", 299, 314], ["DNA", "CELLULAR_COMPONENT", 27, 30], ["organs", "ORGAN", 56, 62], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 77, 90], ["gingival tissue", "TISSUE", 110, 125], ["heart", "ORGAN", 129, 134], ["aorta", "MULTI-TISSUE_STRUCTURE", 136, 141], ["kidney", "ORGAN", 143, 149], ["lungs", "ORGAN", 154, 159], ["TLR2", "GENE_OR_GENE_PRODUCT", 177, 181], ["4", "GENE_OR_GENE_PRODUCT", 186, 187], ["TLR2", "GENE_OR_GENE_PRODUCT", 260, 264], ["4", "GENE_OR_GENE_PRODUCT", 269, 270], ["oral", "ORGANISM_SUBDIVISION", 326, 330], ["bacterial genomic DNA", "DNA", 9, 30], ["TLR2 and 4", "PROTEIN", 177, 187], ["TLR2", "PROTEIN", 260, 264], ["bacterial genomic DNA", "PROBLEM", 9, 30], ["an intravascular dissemination from gingival tissue to heart, aorta, kidney and lungs", "PROBLEM", 74, 159], ["TLR2 and 4", "PROBLEM", 177, 187], ["systemic spread", "PROBLEM", 209, 224], ["polybacterial infections", "PROBLEM", 231, 255], ["TLR2 and 4 deficiency", "PROBLEM", 260, 281], ["atherosclerosis", "PROBLEM", 299, 314], ["oral bacteria", "PROBLEM", 326, 339], ["bacterial genomic DNA", "OBSERVATION", 9, 30], ["intravascular", "OBSERVATION_MODIFIER", 77, 90], ["dissemination", "OBSERVATION", 91, 104], ["gingival tissue", "OBSERVATION", 110, 125], ["heart", "ANATOMY", 129, 134], ["aorta", "ANATOMY", 136, 141], ["kidney", "ANATOMY", 143, 149], ["lungs", "ANATOMY", 154, 159], ["atherosclerosis", "OBSERVATION", 299, 314]]], ["These results illustrated the role of TLR2 and 4 in atherosclerosis of periodontal bacterial infection, suggesting that focusing on periodontal disease may furnish new therapeutic options for the treatment of patients with atherosclerosis.", [["periodontal", "ANATOMY", 132, 143], ["atherosclerosis", "DISEASE", 52, 67], ["periodontal bacterial infection", "DISEASE", 71, 102], ["periodontal disease", "DISEASE", 132, 151], ["atherosclerosis", "DISEASE", 223, 238], ["TLR2", "GENE_OR_GENE_PRODUCT", 38, 42], ["4", "GENE_OR_GENE_PRODUCT", 47, 48], ["patients", "ORGANISM", 209, 217], ["TLR2 and 4", "PROTEIN", 38, 48], ["patients", "SPECIES", 209, 217], ["atherosclerosis", "PROBLEM", 52, 67], ["periodontal bacterial infection", "PROBLEM", 71, 102], ["periodontal disease", "PROBLEM", 132, 151], ["the treatment", "TREATMENT", 192, 205], ["atherosclerosis", "PROBLEM", 223, 238], ["atherosclerosis", "OBSERVATION", 52, 67], ["periodontal", "ANATOMY", 71, 82], ["bacterial", "OBSERVATION_MODIFIER", 83, 92], ["infection", "OBSERVATION", 93, 102], ["atherosclerosis", "OBSERVATION", 223, 238]]], ["However, a recent statement from the American Heart Association (AHA) supported an association between PD and ASVD but did not as of yet support a causal relationship.", [["PD", "DISEASE", 103, 105], ["ASVD", "DISEASE", 110, 114], ["PD", "TREATMENT", 103, 105], ["ASVD", "TREATMENT", 110, 114], ["Heart", "ANATOMY", 46, 51]]], ["Although periodontal interventions can reduce systemic inflammation and endothelial dysfunction in short-term studies, there is still no direct evidence that they can prevent or modify ASVD progression [1].Gut microbiota ::: Role of TLRs in pathogen-induced atherosclerosisIn addition to the oral cavity, the gut is a likely source of microorganisms that could influence ASVD.", [["periodontal", "ANATOMY", 9, 20], ["endothelial", "ANATOMY", 72, 83], ["Gut microbiota", "ANATOMY", 206, 220], ["oral cavity", "ANATOMY", 292, 303], ["gut", "ANATOMY", 309, 312], ["inflammation", "DISEASE", 55, 67], ["endothelial dysfunction", "DISEASE", 72, 95], ["ASVD", "DISEASE", 185, 189], ["atherosclerosis", "DISEASE", 258, 273], ["ASVD", "DISEASE", 371, 375], ["endothelial", "CELL", 72, 83], ["TLRs", "GENE_OR_GENE_PRODUCT", 233, 237], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 292, 303], ["gut", "ORGANISM_SUBDIVISION", 309, 312], ["TLRs", "PROTEIN", 233, 237], ["periodontal interventions", "TREATMENT", 9, 34], ["systemic inflammation", "PROBLEM", 46, 67], ["endothelial dysfunction", "PROBLEM", 72, 95], ["short-term studies", "TEST", 99, 117], ["ASVD progression", "PROBLEM", 185, 201], ["atherosclerosis", "PROBLEM", 258, 273], ["microorganisms", "PROBLEM", 335, 349], ["systemic", "OBSERVATION_MODIFIER", 46, 54], ["inflammation", "OBSERVATION", 55, 67], ["endothelial dysfunction", "OBSERVATION", 72, 95], ["no direct evidence", "UNCERTAINTY", 134, 152], ["atherosclerosis", "OBSERVATION", 258, 273], ["oral cavity", "ANATOMY", 292, 303], ["gut", "ANATOMY", 309, 312], ["microorganisms", "OBSERVATION", 335, 349]]], ["A growing body of literature showed that the permeability of oral and intestinal epithelial barrier increased, which made a small number of pathogens or its products enter the system circulation, inducing chronic low-grade inflammation and promoting inflammatory diseases including atherosclerosis [97].", [["oral", "ANATOMY", 61, 65], ["intestinal epithelial barrier", "ANATOMY", 70, 99], ["inflammation", "DISEASE", 223, 235], ["inflammatory diseases", "DISEASE", 250, 271], ["atherosclerosis", "DISEASE", 282, 297], ["oral", "ORGANISM_SUBDIVISION", 61, 65], ["intestinal epithelial barrier", "TISSUE", 70, 99], ["A growing body of literature", "TEST", 0, 28], ["the permeability of oral and intestinal epithelial barrier", "PROBLEM", 41, 99], ["a small number of pathogens", "PROBLEM", 122, 149], ["chronic low-grade inflammation", "PROBLEM", 205, 235], ["promoting inflammatory diseases", "PROBLEM", 240, 271], ["atherosclerosis", "PROBLEM", 282, 297], ["permeability", "OBSERVATION_MODIFIER", 45, 57], ["intestinal", "ANATOMY", 70, 80], ["epithelial", "ANATOMY_MODIFIER", 81, 91], ["barrier", "OBSERVATION_MODIFIER", 92, 99], ["increased", "OBSERVATION_MODIFIER", 100, 109], ["small", "OBSERVATION_MODIFIER", 124, 129], ["number", "OBSERVATION_MODIFIER", 130, 136], ["pathogens", "OBSERVATION", 140, 149], ["chronic", "OBSERVATION_MODIFIER", 205, 212], ["low", "OBSERVATION_MODIFIER", 213, 216], ["-grade", "OBSERVATION_MODIFIER", 216, 222], ["inflammation", "OBSERVATION", 223, 235], ["inflammatory diseases", "OBSERVATION", 250, 271], ["atherosclerosis", "OBSERVATION", 282, 297]]], ["Karlsson et al. found that the intestinal tract of patients with symptomatic atherosclerosis is rich in Collinsella, while that of healthy people is rich in Roseburia and Eubacterium by shotgun sequencing [98].", [["intestinal tract", "ANATOMY", 31, 47], ["atherosclerosis", "DISEASE", 77, 92], ["intestinal tract", "ORGAN", 31, 47], ["patients", "ORGANISM", 51, 59], ["people", "ORGANISM", 139, 145], ["Eubacterium", "SIMPLE_CHEMICAL", 171, 182], ["patients", "SPECIES", 51, 59], ["people", "SPECIES", 139, 145], ["symptomatic atherosclerosis", "PROBLEM", 65, 92], ["intestinal tract", "ANATOMY", 31, 47], ["symptomatic", "OBSERVATION_MODIFIER", 65, 76], ["atherosclerosis", "OBSERVATION", 77, 92], ["rich", "OBSERVATION_MODIFIER", 96, 100]]], ["Emoto et al. identified a reduction in the operational taxonomic unit (OUT) 853 (Bacteroides) and an increase in the OUT 657 (Lactobacillales) and OUT 990 (Clostridium subcluster XIVa) in fecal samples of ASVD patients.", [["fecal samples", "ANATOMY", 188, 201], ["ASVD", "DISEASE", 205, 209], ["OUT 990", "GENE_OR_GENE_PRODUCT", 147, 154], ["Clostridium subcluster XIVa", "GENE_OR_GENE_PRODUCT", 156, 183], ["fecal samples", "ORGANISM_SUBSTANCE", 188, 201], ["patients", "ORGANISM", 210, 218], ["patients", "SPECIES", 210, 218], ["a reduction", "TREATMENT", 24, 35], ["Bacteroides", "TEST", 81, 92], ["Lactobacillales", "TEST", 126, 141], ["Clostridium subcluster XIVa", "TREATMENT", 156, 183], ["reduction", "OBSERVATION_MODIFIER", 26, 35], ["increase", "OBSERVATION_MODIFIER", 101, 109], ["fecal", "ANATOMY", 188, 193]]], ["The abundance of gut microorganisms such as Bacteroides, Clostridium, and Lactobacillales has been shown to predict ASVD, suggesting that atherosclerosis may be regulated by gut microbiota [99].", [["gut microorganisms", "ANATOMY", 17, 35], ["gut", "ANATOMY", 174, 177], ["ASVD", "DISEASE", 116, 120], ["atherosclerosis", "DISEASE", 138, 153], ["gut", "ORGANISM_SUBDIVISION", 17, 20], ["Bacteroides", "GENE_OR_GENE_PRODUCT", 44, 55], ["Lactobacillales", "GENE_OR_GENE_PRODUCT", 74, 89], ["gut", "ORGANISM_SUBDIVISION", 174, 177], ["gut microorganisms", "PROBLEM", 17, 35], ["Bacteroides", "PROBLEM", 44, 55], ["Clostridium", "PROBLEM", 57, 68], ["Lactobacillales", "TREATMENT", 74, 89], ["atherosclerosis", "PROBLEM", 138, 153], ["gut", "ANATOMY", 17, 20], ["microorganisms", "OBSERVATION", 21, 35], ["atherosclerosis", "OBSERVATION", 138, 153]]], ["Backhed and his colleagues\u2019 groundbreaking study on gut microbiota and lipid metabolism found that mice with normal flora could get more energy from HFD and accumulate more lipid than germ-free mice [100].", [["gut microbiota", "ANATOMY", 52, 66], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 52, 66], ["lipid", "SIMPLE_CHEMICAL", 71, 76], ["mice", "ORGANISM", 99, 103], ["lipid", "SIMPLE_CHEMICAL", 173, 178], ["mice", "ORGANISM", 194, 198], ["mice", "SPECIES", 99, 103], ["mice", "SPECIES", 194, 198], ["mice", "SPECIES", 99, 103], ["lipid metabolism", "TEST", 71, 87]]], ["Maitra and Li discovered LPS produced by intestinal flora can significantly reduce the expression of ABCA1 and ABCG1, and inhibit the reverse transport of cholesterol [101].", [["intestinal flora", "ANATOMY", 41, 57], ["Li", "CHEMICAL", 11, 13], ["LPS", "CHEMICAL", 25, 28], ["cholesterol", "CHEMICAL", 155, 166], ["Li", "CHEMICAL", 11, 13], ["cholesterol", "CHEMICAL", 155, 166], ["Maitra", "SIMPLE_CHEMICAL", 0, 6], ["LPS", "SIMPLE_CHEMICAL", 25, 28], ["intestinal flora", "ORGAN", 41, 57], ["ABCA1", "GENE_OR_GENE_PRODUCT", 101, 106], ["ABCG1", "GENE_OR_GENE_PRODUCT", 111, 116], ["cholesterol", "SIMPLE_CHEMICAL", 155, 166], ["ABCA1", "PROTEIN", 101, 106], ["ABCG1", "PROTEIN", 111, 116], ["LPS", "PROBLEM", 25, 28], ["intestinal flora", "PROBLEM", 41, 57], ["ABCG1", "TEST", 111, 116], ["LPS", "OBSERVATION_MODIFIER", 25, 28], ["intestinal", "ANATOMY", 41, 51], ["flora", "OBSERVATION", 52, 57]]], ["Sayin et al. reported that compared with the normal mice, the gallbladder of germ-free mice was larger and the bile acid level was higher, including the difference of bile acid distribution [102].", [["gallbladder", "ANATOMY", 62, 73], ["germ", "ANATOMY", 77, 81], ["bile acid", "CHEMICAL", 111, 120], ["bile acid", "CHEMICAL", 167, 176], ["bile acid", "CHEMICAL", 111, 120], ["bile acid", "CHEMICAL", 167, 176], ["mice", "ORGANISM", 52, 56], ["gallbladder", "ORGAN", 62, 73], ["germ", "ORGAN", 77, 81], ["mice", "ORGANISM", 87, 91], ["bile acid", "SIMPLE_CHEMICAL", 111, 120], ["bile acid", "SIMPLE_CHEMICAL", 167, 176], ["mice", "SPECIES", 52, 56], ["mice", "SPECIES", 87, 91], ["mice", "SPECIES", 52, 56], ["mice", "SPECIES", 87, 91], ["the bile acid level", "TEST", 107, 126], ["bile acid distribution", "PROBLEM", 167, 189], ["gallbladder", "ANATOMY", 62, 73], ["germ", "OBSERVATION", 77, 81], ["free mice", "OBSERVATION", 82, 91], ["larger", "OBSERVATION_MODIFIER", 96, 102], ["bile", "ANATOMY", 111, 115], ["higher", "OBSERVATION_MODIFIER", 131, 137], ["difference", "OBSERVATION_MODIFIER", 153, 163], ["bile", "ANATOMY", 167, 171], ["acid distribution", "OBSERVATION", 172, 189]]], ["Short chain fatty acids (SCFA) and trimethylamine oxide (TMAO) are the metabolites closely related to atherosclerosis [103].", [["fatty acids", "CHEMICAL", 12, 23], ["SCFA", "CHEMICAL", 25, 29], ["trimethylamine oxide", "CHEMICAL", 35, 55], ["TMAO", "CHEMICAL", 57, 61], ["atherosclerosis", "DISEASE", 102, 117], ["fatty acids", "CHEMICAL", 12, 23], ["SCFA", "CHEMICAL", 25, 29], ["trimethylamine oxide", "CHEMICAL", 35, 55], ["TMAO", "CHEMICAL", 57, 61], ["Short chain fatty acids", "SIMPLE_CHEMICAL", 0, 23], ["SCFA", "SIMPLE_CHEMICAL", 25, 29], ["trimethylamine oxide", "SIMPLE_CHEMICAL", 35, 55], ["TMAO", "SIMPLE_CHEMICAL", 57, 61], ["Short chain fatty acids (SCFA)", "TREATMENT", 0, 30], ["trimethylamine oxide (TMAO)", "TREATMENT", 35, 62], ["atherosclerosis", "PROBLEM", 102, 117], ["atherosclerosis", "OBSERVATION", 102, 117]]], ["SCFA can inhibit NF-\u03baB and tumor necrosis factor (TNF) signaling pathway, resulting in the decrease of expression of VCAM-1 and ICAM-1, thus inhibiting the development of atherosclerosis [104].", [["SCFA", "CHEMICAL", 0, 4], ["tumor", "DISEASE", 27, 32], ["necrosis", "DISEASE", 33, 41], ["atherosclerosis", "DISEASE", 171, 186], ["SCFA", "CHEMICAL", 0, 4], ["SCFA", "SIMPLE_CHEMICAL", 0, 4], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 17, 22], ["tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 27, 48], ["TNF", "GENE_OR_GENE_PRODUCT", 50, 53], ["VCAM-1", "GENE_OR_GENE_PRODUCT", 117, 123], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 128, 134], ["NF-\u03baB", "PROTEIN", 17, 22], ["tumor necrosis factor", "PROTEIN", 27, 48], ["TNF", "PROTEIN", 50, 53], ["VCAM-1", "PROTEIN", 117, 123], ["ICAM-1", "PROTEIN", 128, 134], ["NF", "PROBLEM", 17, 19], ["tumor necrosis factor", "PROBLEM", 27, 48], ["VCAM", "TEST", 117, 121], ["ICAM", "TEST", 128, 132], ["atherosclerosis", "PROBLEM", 171, 186], ["tumor", "ANATOMY", 27, 32], ["necrosis", "OBSERVATION", 33, 41], ["decrease", "OBSERVATION_MODIFIER", 91, 99], ["atherosclerosis", "OBSERVATION", 171, 186]]], ["TMAO, on the one hand, increased the expression of macrophage receptors SR-A1 and CD36, leading macrophages to phagocytize more ox-LDL, on the other hand, reduced the synthesis or transport of bile acids, reduced the reverse transport of cholesterol, thus promoting the occurrence of atherosclerosis [105, 106].", [["macrophage", "ANATOMY", 51, 61], ["macrophages", "ANATOMY", 96, 107], ["TMAO", "CHEMICAL", 0, 4], ["bile acids", "CHEMICAL", 193, 203], ["cholesterol", "CHEMICAL", 238, 249], ["atherosclerosis", "DISEASE", 284, 299], ["TMAO", "CHEMICAL", 0, 4], ["bile acids", "CHEMICAL", 193, 203], ["cholesterol", "CHEMICAL", 238, 249], ["TMAO", "SIMPLE_CHEMICAL", 0, 4], ["macrophage", "CELL", 51, 61], ["SR-A1", "GENE_OR_GENE_PRODUCT", 72, 77], ["CD36", "GENE_OR_GENE_PRODUCT", 82, 86], ["macrophages", "CELL", 96, 107], ["ox-LDL", "SIMPLE_CHEMICAL", 128, 134], ["bile acids", "SIMPLE_CHEMICAL", 193, 203], ["cholesterol", "SIMPLE_CHEMICAL", 238, 249], ["macrophage receptors", "PROTEIN", 51, 71], ["SR", "PROTEIN", 72, 74], ["A1", "PROTEIN", 75, 77], ["CD36", "PROTEIN", 82, 86], ["macrophages", "CELL_TYPE", 96, 107], ["ox-LDL", "PROTEIN", 128, 134], ["TMAO", "TEST", 0, 4], ["macrophage receptors", "TEST", 51, 71], ["CD36", "TEST", 82, 86], ["phagocytize", "TEST", 111, 122], ["LDL", "TEST", 131, 134], ["bile acids", "TREATMENT", 193, 203], ["atherosclerosis", "PROBLEM", 284, 299], ["macrophages", "OBSERVATION", 96, 107], ["atherosclerosis", "OBSERVATION", 284, 299]]], ["It was also reported to promote platelet activation and thus arterial thrombosis [107].", [["platelet", "ANATOMY", 32, 40], ["arterial", "ANATOMY", 61, 69], ["thrombosis", "DISEASE", 70, 80], ["platelet", "CELL", 32, 40], ["arterial", "MULTI-TISSUE_STRUCTURE", 61, 69], ["arterial thrombosis", "PROBLEM", 61, 80], ["platelet activation", "OBSERVATION", 32, 51], ["arterial", "ANATOMY", 61, 69], ["thrombosis", "OBSERVATION", 70, 80]]], ["A choline analogue that has a non-lethal inhibitory effect on TMA, 3,3-dimethyl-1-butanol (DMB) was reported to be able to inhibit choline diet-enhanced endogenous macrophage foam cell formation and atherosclerotic lesion development in ApoE\u2212/\u2212 mice without alterations in circulating cholesterol levels, suggesting that targeting gut microbial production of TMA specifically and non-lethal microbial inhibitors may serve as a potential therapeutic approach for the treatment of atherosclerosis [108].", [["macrophage foam cell", "ANATOMY", 164, 184], ["atherosclerotic lesion", "ANATOMY", 199, 221], ["gut", "ANATOMY", 331, 334], ["choline", "CHEMICAL", 2, 9], ["TMA", "DISEASE", 62, 65], ["3,3-dimethyl-1-butanol", "CHEMICAL", 67, 89], ["DMB", "CHEMICAL", 91, 94], ["choline", "CHEMICAL", 131, 138], ["atherosclerotic lesion", "DISEASE", 199, 221], ["cholesterol", "CHEMICAL", 285, 296], ["TMA", "DISEASE", 359, 362], ["atherosclerosis", "DISEASE", 479, 494], ["choline", "CHEMICAL", 2, 9], ["TMA", "CHEMICAL", 62, 65], ["3,3-dimethyl-1-butanol", "CHEMICAL", 67, 89], ["DMB", "CHEMICAL", 91, 94], ["choline", "CHEMICAL", 131, 138], ["cholesterol", "CHEMICAL", 285, 296], ["TMA", "CHEMICAL", 359, 362], ["choline", "SIMPLE_CHEMICAL", 2, 9], ["TMA", "SIMPLE_CHEMICAL", 62, 65], ["3,3-dimethyl-1-butanol", "SIMPLE_CHEMICAL", 67, 89], ["DMB", "SIMPLE_CHEMICAL", 91, 94], ["choline", "SIMPLE_CHEMICAL", 131, 138], ["macrophage foam cell", "CELL", 164, 184], ["atherosclerotic lesion", "PATHOLOGICAL_FORMATION", 199, 221], ["cholesterol", "SIMPLE_CHEMICAL", 285, 296], ["gut", "ORGANISM_SUBDIVISION", 331, 334], ["TMA", "SIMPLE_CHEMICAL", 359, 362], ["mice", "SPECIES", 245, 249], ["mice", "SPECIES", 245, 249], ["A choline analogue", "TREATMENT", 0, 18], ["a non-lethal inhibitory effect", "PROBLEM", 28, 58], ["TMA", "TEST", 62, 65], ["enhanced endogenous macrophage foam cell formation", "PROBLEM", 144, 194], ["atherosclerotic lesion", "PROBLEM", 199, 221], ["circulating cholesterol levels", "TEST", 273, 303], ["targeting gut microbial production of TMA", "PROBLEM", 321, 362], ["non-lethal microbial inhibitors", "TREATMENT", 380, 411], ["a potential therapeutic approach", "TREATMENT", 425, 457], ["atherosclerosis", "PROBLEM", 479, 494], ["endogenous macrophage foam cell formation", "OBSERVATION", 153, 194], ["atherosclerotic", "OBSERVATION_MODIFIER", 199, 214], ["lesion", "OBSERVATION", 215, 221], ["TMA", "OBSERVATION", 359, 362], ["atherosclerosis", "OBSERVATION", 479, 494]]], ["These results showed that gut microbiota affects the development of atherosclerosis mainly through three pathways: local or distant infections, regulation of cholesterol and lipid metabolism, and the effects of metabolites [109].Gut microbiota ::: Role of TLRs in pathogen-induced atherosclerosisThe commensal gut microbiota is a tonic activating factor of TLRs and other PRRs in the intestine [110].", [["gut microbiota", "ANATOMY", 26, 40], ["Gut microbiota", "ANATOMY", 229, 243], ["gut", "ANATOMY", 310, 313], ["intestine", "ANATOMY", 384, 393], ["atherosclerosis", "DISEASE", 68, 83], ["infections", "DISEASE", 132, 142], ["cholesterol", "CHEMICAL", 158, 169], ["atherosclerosis", "DISEASE", 281, 296], ["cholesterol", "CHEMICAL", 158, 169], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 26, 40], ["cholesterol", "SIMPLE_CHEMICAL", 158, 169], ["lipid", "SIMPLE_CHEMICAL", 174, 179], ["TLRs", "GENE_OR_GENE_PRODUCT", 256, 260], ["gut", "ORGANISM_SUBDIVISION", 310, 313], ["TLRs", "GENE_OR_GENE_PRODUCT", 357, 361], ["PRRs", "GENE_OR_GENE_PRODUCT", 372, 376], ["intestine", "ORGAN", 384, 393], ["TLRs", "PROTEIN", 256, 260], ["tonic activating factor", "PROTEIN", 330, 353], ["TLRs", "PROTEIN", 357, 361], ["PRRs", "PROTEIN", 372, 376], ["atherosclerosis", "PROBLEM", 68, 83], ["local or distant infections", "PROBLEM", 115, 142], ["cholesterol and lipid metabolism", "TREATMENT", 158, 190], ["atherosclerosis", "PROBLEM", 281, 296], ["atherosclerosis", "OBSERVATION", 68, 83], ["distant", "OBSERVATION_MODIFIER", 124, 131], ["infections", "OBSERVATION", 132, 142], ["lipid metabolism", "OBSERVATION", 174, 190], ["atherosclerosis", "OBSERVATION", 281, 296], ["gut microbiota", "ANATOMY", 310, 324], ["intestine", "ANATOMY", 384, 393]]], ["Maitra and his colleagues confirmed high dose LPS can significantly increase the expression of NF-\u03baB, and low dose LPS can induce macrophage inflammation and promote the occurrence of atherosclerosis through TLR4 and IRAK1 [111].", [["macrophage", "ANATOMY", 130, 140], ["LPS", "CHEMICAL", 46, 49], ["LPS", "CHEMICAL", 115, 118], ["inflammation", "DISEASE", 141, 153], ["atherosclerosis", "DISEASE", 184, 199], ["LPS", "SIMPLE_CHEMICAL", 46, 49], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 95, 100], ["LPS", "SIMPLE_CHEMICAL", 115, 118], ["macrophage", "CELL", 130, 140], ["TLR4", "GENE_OR_GENE_PRODUCT", 208, 212], ["IRAK1", "GENE_OR_GENE_PRODUCT", 217, 222], ["NF-\u03baB", "PROTEIN", 95, 100], ["TLR4", "PROTEIN", 208, 212], ["IRAK1", "PROTEIN", 217, 222], ["high dose LPS", "TREATMENT", 36, 49], ["NF", "TEST", 95, 97], ["low dose LPS", "TREATMENT", 106, 118], ["macrophage inflammation", "PROBLEM", 130, 153], ["atherosclerosis", "PROBLEM", 184, 199], ["atherosclerosis", "OBSERVATION", 184, 199]]], ["Li et al. reported that akkermansia muciniphila reduced the expression of CCL2 and ICAM-1 in atherosclerotic lesions, thus reducing macrophage infiltration.", [["atherosclerotic lesions", "ANATOMY", 93, 116], ["macrophage", "ANATOMY", 132, 142], ["Li", "CHEMICAL", 0, 2], ["atherosclerotic", "DISEASE", 93, 108], ["akkermansia muciniphila", "ORGANISM", 24, 47], ["CCL2", "GENE_OR_GENE_PRODUCT", 74, 78], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 83, 89], ["atherosclerotic lesions", "PATHOLOGICAL_FORMATION", 93, 116], ["macrophage", "CELL", 132, 142], ["CCL2", "PROTEIN", 74, 78], ["ICAM-1", "PROTEIN", 83, 89], ["akkermansia muciniphila", "SPECIES", 24, 47], ["akkermansia muciniphila", "SPECIES", 24, 47], ["akkermansia muciniphila", "PROBLEM", 24, 47], ["CCL2", "TEST", 74, 78], ["ICAM", "TEST", 83, 87], ["atherosclerotic lesions", "PROBLEM", 93, 116], ["macrophage infiltration", "PROBLEM", 132, 155], ["atherosclerotic", "OBSERVATION_MODIFIER", 93, 108], ["lesions", "OBSERVATION", 109, 116], ["macrophage infiltration", "OBSERVATION", 132, 155]]], ["This effect was abolished when mice were infused with LPS with subcutaneously implanted osmotic pumps [112].", [["subcutaneously", "ANATOMY", 63, 77], ["LPS", "CHEMICAL", 54, 57], ["mice", "ORGANISM", 31, 35], ["LPS", "SIMPLE_CHEMICAL", 54, 57], ["mice", "SPECIES", 31, 35], ["mice", "SPECIES", 31, 35], ["LPS", "TREATMENT", 54, 57], ["subcutaneously implanted osmotic pumps", "TREATMENT", 63, 101]]], ["In addition to TLR4, Round et al. discovered, a symbiosis factor (PSA, polysaccharide A) of the prominent gut commensal Bacteroides fragilis (B. fragilis) signals through TLR2 directly on Foxp3(+) regulatory T cells to promote immunologic tolerance [113].", [["Foxp3(+) regulatory T cells", "ANATOMY", 188, 215], ["TLR4", "GENE_OR_GENE_PRODUCT", 15, 19], ["PSA", "GENE_OR_GENE_PRODUCT", 66, 69], ["polysaccharide A", "GENE_OR_GENE_PRODUCT", 71, 87], ["gut commensal", "ORGANISM", 106, 119], ["Bacteroides fragilis", "ORGANISM", 120, 140], ["B. fragilis", "ORGANISM", 142, 153], ["TLR2", "GENE_OR_GENE_PRODUCT", 171, 175], ["Foxp3", "GENE_OR_GENE_PRODUCT", 188, 193], ["TLR4", "PROTEIN", 15, 19], ["symbiosis factor", "PROTEIN", 48, 64], ["PSA", "PROTEIN", 66, 69], ["polysaccharide A", "PROTEIN", 71, 87], ["TLR2", "PROTEIN", 171, 175], ["Foxp3(+) regulatory T cells", "CELL_TYPE", 188, 215], ["Bacteroides fragilis", "SPECIES", 120, 140], ["B. fragilis", "SPECIES", 142, 153], ["Bacteroides fragilis", "SPECIES", 120, 140], ["B. fragilis", "SPECIES", 142, 153], ["a symbiosis factor", "PROBLEM", 46, 64], ["PSA", "TEST", 66, 69], ["the prominent gut commensal Bacteroides fragilis", "PROBLEM", 92, 140], ["B. fragilis", "PROBLEM", 142, 153], ["Foxp3(+) regulatory T cells", "TREATMENT", 188, 215], ["TLR4", "ANATOMY", 15, 19], ["prominent", "OBSERVATION_MODIFIER", 96, 105], ["gut commensal", "ANATOMY", 106, 119], ["Bacteroides fragilis", "OBSERVATION", 120, 140]]], ["Jackel et al. reported gut microbiota regulated hepatic von Willebrand Factor (vWF) synthesis and arterial thrombus formation via TLR2 [114].", [["gut", "ANATOMY", 23, 26], ["arterial thrombus", "ANATOMY", 98, 115], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 23, 37], ["hepatic von Willebrand Factor", "GENE_OR_GENE_PRODUCT", 48, 77], ["vWF", "GENE_OR_GENE_PRODUCT", 79, 82], ["arterial thrombus", "PATHOLOGICAL_FORMATION", 98, 115], ["TLR2", "GENE_OR_GENE_PRODUCT", 130, 134], ["hepatic von Willebrand Factor", "PROTEIN", 48, 77], ["vWF", "PROTEIN", 79, 82], ["TLR2", "PROTEIN", 130, 134], ["synthesis and arterial thrombus formation", "PROBLEM", 84, 125], ["et al", "OBSERVATION", 7, 12], ["hepatic", "ANATOMY", 48, 55], ["von", "OBSERVATION", 56, 59], ["arterial", "ANATOMY", 98, 106], ["thrombus", "OBSERVATION", 107, 115]]], ["It is not clear whether ASVD can be successfully treated by targeting microbiota.", [["ASVD", "PROBLEM", 24, 28]]], ["Compared with the long-term use of antibiotics, it may be a new therapeutic strategy to regulate the composition of microbiota or the pathway to produce atherogenic metabolites (such as TMAO and other molecules) or to target TLR signaling pathways.Helicobacter pylori ::: Role of TLRs in pathogen-induced atherosclerosisHelicobacter pylori is a Gram-negative spiral microeosinophilic bacteria, most of which has a disposition to colonize in the gastric mucosa and cause lifelong inflammation in human gastric mucosa.", [["gastric mucosa", "ANATOMY", 445, 459], ["gastric mucosa", "ANATOMY", 501, 515], ["TMAO", "CHEMICAL", 186, 190], ["atherosclerosis", "DISEASE", 305, 320], ["Helicobacter pylori", "DISEASE", 320, 339], ["inflammation", "DISEASE", 479, 491], ["TMAO", "CHEMICAL", 186, 190], ["TMAO", "SIMPLE_CHEMICAL", 186, 190], ["TLR", "GENE_OR_GENE_PRODUCT", 225, 228], ["Helicobacter pylori", "ORGANISM", 248, 267], ["TLRs", "GENE_OR_GENE_PRODUCT", 280, 284], ["Helicobacter pylori", "ORGANISM", 320, 339], ["Gram-", "GENE_OR_GENE_PRODUCT", 345, 350], ["gastric mucosa", "MULTI-TISSUE_STRUCTURE", 445, 459], ["human", "ORGANISM", 495, 500], ["gastric mucosa", "MULTI-TISSUE_STRUCTURE", 501, 515], ["TLR", "PROTEIN", 225, 228], ["TLRs", "PROTEIN", 280, 284], ["Helicobacter pylori", "SPECIES", 248, 267], ["Helicobacter pylori", "SPECIES", 320, 339], ["human", "SPECIES", 495, 500], ["Helicobacter pylori", "SPECIES", 248, 267], ["Helicobacter pylori", "SPECIES", 320, 339], ["human", "SPECIES", 495, 500], ["antibiotics", "TREATMENT", 35, 46], ["a new therapeutic strategy", "TREATMENT", 58, 84], ["atherogenic metabolites", "PROBLEM", 153, 176], ["Helicobacter pylori", "PROBLEM", 248, 267], ["pathogen", "PROBLEM", 288, 296], ["atherosclerosis", "PROBLEM", 305, 320], ["Helicobacter pylori", "PROBLEM", 320, 339], ["a Gram-negative spiral microeosinophilic bacteria", "PROBLEM", 343, 392], ["lifelong inflammation in human gastric mucosa", "PROBLEM", 470, 515], ["atherogenic", "OBSERVATION_MODIFIER", 153, 164], ["pylori", "OBSERVATION", 261, 267], ["atherosclerosis", "OBSERVATION_MODIFIER", 305, 320], ["Helicobacter pylori", "OBSERVATION", 320, 339], ["microeosinophilic bacteria", "OBSERVATION", 366, 392], ["gastric mucosa", "ANATOMY", 445, 459], ["lifelong", "OBSERVATION_MODIFIER", 470, 478], ["inflammation", "OBSERVATION", 479, 491], ["human", "ANATOMY_MODIFIER", 495, 500], ["gastric mucosa", "ANATOMY", 501, 515]]], ["It is closely related to a series of gastric diseases such as chronic gastritis, peptic ulcer, gastric mucosa-associated lymphoid tissue (MALT) lymphoma and gastric cancer [115].", [["gastric", "ANATOMY", 37, 44], ["peptic ulcer", "ANATOMY", 81, 93], ["gastric mucosa-associated lymphoid tissue (MALT) lymphoma", "ANATOMY", 95, 152], ["gastric cancer", "ANATOMY", 157, 171], ["gastric diseases", "DISEASE", 37, 53], ["chronic gastritis", "DISEASE", 62, 79], ["peptic ulcer", "DISEASE", 81, 93], ["gastric mucosa-associated lymphoid tissue (MALT) lymphoma", "DISEASE", 95, 152], ["gastric cancer", "DISEASE", 157, 171], ["gastric", "ORGAN", 37, 44], ["peptic ulcer", "PATHOLOGICAL_FORMATION", 81, 93], ["gastric mucosa-associated lymphoid tissue (MALT) lymphoma", "CANCER", 95, 152], ["gastric cancer", "CANCER", 157, 171], ["gastric diseases", "PROBLEM", 37, 53], ["chronic gastritis", "PROBLEM", 62, 79], ["peptic ulcer", "PROBLEM", 81, 93], ["gastric mucosa-associated lymphoid tissue (MALT) lymphoma", "PROBLEM", 95, 152], ["gastric cancer", "PROBLEM", 157, 171], ["gastric", "ANATOMY", 37, 44], ["diseases", "OBSERVATION", 45, 53], ["chronic", "OBSERVATION_MODIFIER", 62, 69], ["gastritis", "OBSERVATION", 70, 79], ["peptic", "OBSERVATION_MODIFIER", 81, 87], ["ulcer", "OBSERVATION", 88, 93], ["gastric", "ANATOMY", 95, 102], ["mucosa-associated lymphoid tissue", "OBSERVATION", 103, 136], ["lymphoma", "OBSERVATION", 144, 152], ["gastric", "ANATOMY", 157, 164], ["cancer", "OBSERVATION", 165, 171]]], ["In 1994, Patel and his colleagues found that the H. pylori infection rate in patients with coronary atherosclerosis was significantly higher than that in healthy people [116].", [["coronary", "ANATOMY", 91, 99], ["H. pylori infection", "DISEASE", 49, 68], ["coronary atherosclerosis", "DISEASE", 91, 115], ["H. pylori", "ORGANISM", 49, 58], ["patients", "ORGANISM", 77, 85], ["coronary", "MULTI-TISSUE_STRUCTURE", 91, 99], ["H. pylori", "SPECIES", 49, 58], ["patients", "SPECIES", 77, 85], ["people", "SPECIES", 162, 168], ["H. pylori", "SPECIES", 49, 58], ["the H. pylori infection rate", "PROBLEM", 45, 73], ["coronary atherosclerosis", "PROBLEM", 91, 115], ["coronary", "ANATOMY", 91, 99], ["atherosclerosis", "OBSERVATION", 100, 115]]], ["This report has led researchers to explore the relationship between H. pylori and atherosclerotic diseases.", [["atherosclerotic", "ANATOMY", 82, 97], ["H. pylori", "DISEASE", 68, 77], ["atherosclerotic diseases", "DISEASE", 82, 106], ["H. pylori", "ORGANISM", 68, 77], ["H. pylori", "SPECIES", 68, 77], ["H. pylori", "SPECIES", 68, 77], ["H. pylori", "PROBLEM", 68, 77], ["atherosclerotic diseases", "PROBLEM", 82, 106], ["atherosclerotic", "OBSERVATION_MODIFIER", 82, 97], ["diseases", "OBSERVATION", 98, 106]]], ["In the past 30 years, a large number of studies have confirmed its relationship with atherosclerosis, but some studies have reached contradictory conclusions.", [["atherosclerosis", "DISEASE", 85, 100], ["atherosclerosis", "PROBLEM", 85, 100], ["some studies", "TEST", 106, 118], ["large", "OBSERVATION_MODIFIER", 24, 29], ["atherosclerosis", "OBSERVATION", 85, 100]]], ["For example, Vijayvergiya et al. reported higher levels of anti-H. pylori IgG in the serum of CAD patients than in the control group [117].", [["serum", "ANATOMY", 85, 90], ["CAD", "DISEASE", 94, 97], ["anti-H. pylori", "ORGANISM", 59, 73], ["serum", "ORGANISM_SUBSTANCE", 85, 90], ["patients", "ORGANISM", 98, 106], ["anti-H. pylori IgG", "PROTEIN", 59, 77], ["anti-H. pylori", "SPECIES", 59, 73], ["patients", "SPECIES", 98, 106], ["anti-H. pylori", "SPECIES", 59, 73], ["anti-H. pylori IgG", "PROBLEM", 59, 77], ["CAD", "PROBLEM", 94, 97]]], ["Liu et al. conducted a meta-analysis of the relationship between H. pylori and MI, and found that H. pylori infection was significantly associated with the risk of MI [118].", [["H. pylori and MI", "DISEASE", 65, 81], ["H. pylori infection", "DISEASE", 98, 117], ["MI", "DISEASE", 164, 166], ["H. pylori", "ORGANISM", 65, 74], ["H. pylori", "ORGANISM", 98, 107], ["H. pylori", "SPECIES", 65, 74], ["H. pylori", "SPECIES", 98, 107], ["H. pylori", "SPECIES", 65, 74], ["H. pylori", "SPECIES", 98, 107], ["a meta-analysis", "PROBLEM", 21, 36], ["H. pylori", "PROBLEM", 65, 74], ["MI", "PROBLEM", 79, 81], ["H. pylori infection", "PROBLEM", 98, 117], ["MI", "PROBLEM", 164, 166], ["pylori", "OBSERVATION", 101, 107]]], ["However, in vivo studies conducted by Mach et al. in mice with atherosclerosis showed no evidence that H. pylori infection may contribute to the formation of atherosclerosis [119].", [["atherosclerosis", "DISEASE", 63, 78], ["H. pylori infection", "DISEASE", 103, 122], ["atherosclerosis", "DISEASE", 158, 173], ["mice", "ORGANISM", 53, 57], ["H. pylori", "ORGANISM", 103, 112], ["mice", "SPECIES", 53, 57], ["H. pylori", "SPECIES", 103, 112], ["mice", "SPECIES", 53, 57], ["H. pylori", "SPECIES", 103, 112], ["vivo studies", "TEST", 12, 24], ["atherosclerosis", "PROBLEM", 63, 78], ["H. pylori infection", "PROBLEM", 103, 122], ["atherosclerosis", "PROBLEM", 158, 173], ["atherosclerosis", "OBSERVATION", 63, 78], ["no evidence", "UNCERTAINTY", 86, 97], ["pylori", "OBSERVATION", 106, 112], ["atherosclerosis", "OBSERVATION", 158, 173]]], ["Hagiwara et al. reported that H. pylori DNA was not detected by detecting 50 exfoliated plaques in the neck of Japanese patients [120].", [["plaques", "ANATOMY", 88, 95], ["neck", "ANATOMY", 103, 107], ["H. pylori", "ORGANISM", 30, 39], ["DNA", "CELLULAR_COMPONENT", 40, 43], ["neck", "ORGANISM_SUBDIVISION", 103, 107], ["patients", "ORGANISM", 120, 128], ["H. pylori", "SPECIES", 30, 39], ["patients", "SPECIES", 120, 128], ["H. pylori", "SPECIES", 30, 39], ["H. pylori DNA", "PROBLEM", 30, 43], ["exfoliated plaques", "PROBLEM", 77, 95], ["plaques", "OBSERVATION", 88, 95], ["neck", "ANATOMY", 103, 107]]], ["These contradictory results have led researchers to explore whether different subtypes of H. pylori play different roles in promoting the development of atherosclerosis.", [["atherosclerosis", "DISEASE", 153, 168], ["H. pylori", "ORGANISM", 90, 99], ["H. pylori", "SPECIES", 90, 99], ["H. pylori", "SPECIES", 90, 99], ["H. pylori", "PROBLEM", 90, 99], ["atherosclerosis", "PROBLEM", 153, 168], ["H. pylori", "OBSERVATION", 90, 99], ["atherosclerosis", "OBSERVATION", 153, 168]]], ["Vacuolating cytotoxin (VacA) and cytotoxin-associated gene A (CagA) protein encoded by the cytotoxin-associated genes pathogenicity island (cagPAI) are the two major H. pylori virulence factors [121].", [["Vacuolating cytotoxin", "GENE_OR_GENE_PRODUCT", 0, 21], ["VacA", "GENE_OR_GENE_PRODUCT", 23, 27], ["cytotoxin-associated gene A", "GENE_OR_GENE_PRODUCT", 33, 60], ["CagA", "GENE_OR_GENE_PRODUCT", 62, 66], ["cytotoxin-associated genes pathogenicity island", "GENE_OR_GENE_PRODUCT", 91, 138], ["cagPAI", "GENE_OR_GENE_PRODUCT", 140, 146], ["H. pylori", "ORGANISM", 166, 175], ["Vacuolating cytotoxin", "PROTEIN", 0, 21], ["VacA", "PROTEIN", 23, 27], ["cytotoxin-associated gene A (CagA) protein", "PROTEIN", 33, 75], ["cytotoxin-associated genes pathogenicity island", "DNA", 91, 138], ["cagPAI", "DNA", 140, 146], ["H. pylori", "SPECIES", 166, 175], ["H. pylori", "SPECIES", 166, 175], ["Vacuolating cytotoxin (VacA", "TEST", 0, 27], ["cytotoxin", "TEST", 33, 42], ["A (CagA) protein", "TEST", 59, 75], ["the cytotoxin", "TEST", 87, 100], ["genes pathogenicity island", "PROBLEM", 112, 138], ["H. pylori virulence factors", "PROBLEM", 166, 193], ["pathogenicity island", "OBSERVATION", 118, 138]]], ["Some meta-analyses suggest that CagA-positive H. pylori infection is more significantly associated with ASVD than CagA-negative H. pylori infection.", [["H. pylori infection", "DISEASE", 46, 65], ["H. pylori infection", "DISEASE", 128, 147], ["CagA", "GENE_OR_GENE_PRODUCT", 32, 36], ["H. pylori", "ORGANISM", 46, 55], ["CagA", "GENE_OR_GENE_PRODUCT", 114, 118], ["H. pylori", "ORGANISM", 128, 137], ["CagA", "PROTEIN", 32, 36], ["CagA", "PROTEIN", 114, 118], ["H. pylori", "SPECIES", 46, 55], ["H. pylori", "SPECIES", 128, 137], ["H. pylori", "SPECIES", 46, 55], ["H. pylori", "SPECIES", 128, 137], ["Some meta-analyses", "TEST", 0, 18], ["CagA", "TEST", 32, 36], ["positive H. pylori infection", "PROBLEM", 37, 65], ["ASVD", "PROBLEM", 104, 108], ["CagA", "TEST", 114, 118], ["H. pylori infection", "PROBLEM", 128, 147], ["CagA", "OBSERVATION", 32, 36], ["positive", "OBSERVATION_MODIFIER", 37, 45], ["H. pylori", "OBSERVATION_MODIFIER", 46, 55], ["infection", "OBSERVATION", 56, 65], ["pylori infection", "OBSERVATION", 131, 147]]], ["Three animal studies have used H. pylori SS1 to inoculate gastric infections to explore whether H. pylori infection promotes the progression of atherosclerosis, but inconsistent results have been obtained [119, 122, 123].", [["gastric", "ANATOMY", 58, 65], ["gastric infections", "DISEASE", 58, 76], ["H. pylori infection", "DISEASE", 96, 115], ["atherosclerosis", "DISEASE", 144, 159], ["H. pylori", "ORGANISM", 31, 40], ["SS1", "ORGANISM", 41, 44], ["gastric", "ORGAN", 58, 65], ["H. pylori", "ORGANISM", 96, 105], ["H. pylori", "SPECIES", 31, 40], ["H. pylori", "SPECIES", 96, 105], ["H. pylori", "SPECIES", 31, 40], ["H. pylori", "SPECIES", 96, 105], ["Three animal studies", "TEST", 0, 20], ["H. pylori SS1", "PROBLEM", 31, 44], ["gastric infections", "PROBLEM", 58, 76], ["H. pylori infection", "PROBLEM", 96, 115], ["atherosclerosis", "PROBLEM", 144, 159], ["gastric", "ANATOMY", 58, 65], ["infections", "OBSERVATION", 66, 76], ["progression", "OBSERVATION_MODIFIER", 129, 140], ["atherosclerosis", "OBSERVATION", 144, 159]]], ["Although SS1 strain is CagA-positive strain, CagY mutation lacks T4SS system, so CagA can not be effectively transferred into host.", [["SS1 strain", "ORGANISM", 9, 19], ["CagA", "GENE_OR_GENE_PRODUCT", 23, 27], ["CagY", "GENE_OR_GENE_PRODUCT", 45, 49], ["CagA", "GENE_OR_GENE_PRODUCT", 81, 85], ["CagA", "PROTEIN", 23, 27], ["CagY", "PROTEIN", 45, 49], ["CagA", "PROTEIN", 81, 85], ["SS1 strain", "PROBLEM", 9, 19], ["CagA", "TEST", 23, 27], ["positive strain", "PROBLEM", 28, 43], ["CagA", "TREATMENT", 81, 85]]], ["Our research team has proved that H. pylori PMSS1 strain, which can effectively transfect CagA into the host, was inoculated into mice with gastric infection, confirming that CagA derived from gastric epithelial cells infected by H. pylori promotes macrophage-derived foam cell formation and atherosclerosis [124].", [["gastric", "ANATOMY", 140, 147], ["gastric epithelial cells", "ANATOMY", 193, 217], ["macrophage", "ANATOMY", 249, 259], ["foam cell", "ANATOMY", 268, 277], ["gastric infection", "DISEASE", 140, 157], ["atherosclerosis", "DISEASE", 292, 307], ["H. pylori", "ORGANISM", 34, 43], ["PMSS1", "ORGANISM", 44, 49], ["strain", "ORGANISM", 50, 56], ["CagA", "GENE_OR_GENE_PRODUCT", 90, 94], ["mice", "ORGANISM", 130, 134], ["gastric", "ORGAN", 140, 147], ["CagA", "GENE_OR_GENE_PRODUCT", 175, 179], ["gastric epithelial cells", "CELL", 193, 217], ["H. pylori", "ORGANISM", 230, 239], ["macrophage", "CELL", 249, 259], ["foam cell", "CELL", 268, 277], ["CagA", "PROTEIN", 90, 94], ["CagA", "PROTEIN", 175, 179], ["gastric epithelial cells", "CELL_TYPE", 193, 217], ["H. pylori", "SPECIES", 34, 43], ["mice", "SPECIES", 130, 134], ["H. pylori", "SPECIES", 230, 239], ["H. pylori", "SPECIES", 34, 43], ["mice", "SPECIES", 130, 134], ["H. pylori", "SPECIES", 230, 239], ["H. pylori PMSS1 strain", "PROBLEM", 34, 56], ["gastric infection", "PROBLEM", 140, 157], ["CagA", "PROBLEM", 175, 179], ["gastric epithelial cells", "PROBLEM", 193, 217], ["H. pylori promotes macrophage", "PROBLEM", 230, 259], ["atherosclerosis", "PROBLEM", 292, 307], ["gastric", "ANATOMY", 140, 147], ["infection", "OBSERVATION", 148, 157], ["gastric", "ANATOMY", 193, 200], ["epithelial cells", "OBSERVATION", 201, 217], ["foam cell formation", "OBSERVATION", 268, 287], ["atherosclerosis", "OBSERVATION", 292, 307]]], ["Our research also confirmed that CagA protein of H. pylori can increase the adhesion of aortic ECs and promote atherosclerosis through NLRP3-IL1\u03b2 signaling pathway.", [["aortic ECs", "ANATOMY", 88, 98], ["atherosclerosis", "DISEASE", 111, 126], ["CagA", "GENE_OR_GENE_PRODUCT", 33, 37], ["H. pylori", "ORGANISM", 49, 58], ["aortic ECs", "CELL", 88, 98], ["NLRP3-IL1\u03b2", "GENE_OR_GENE_PRODUCT", 135, 145], ["CagA protein", "PROTEIN", 33, 45], ["aortic ECs", "CELL_TYPE", 88, 98], ["NLRP3", "PROTEIN", 135, 140], ["IL1\u03b2", "PROTEIN", 141, 145], ["H. pylori", "SPECIES", 49, 58], ["H. pylori", "SPECIES", 49, 58], ["CagA protein", "TREATMENT", 33, 45], ["H. pylori", "PROBLEM", 49, 58], ["aortic ECs", "PROBLEM", 88, 98], ["atherosclerosis", "PROBLEM", 111, 126], ["NLRP3", "TREATMENT", 135, 140], ["aortic", "ANATOMY", 88, 94], ["atherosclerosis", "OBSERVATION", 111, 126]]], ["It further suggests that CagA, as a key virulence factor of H. pylori, is related to the occurrence and development of atherosclerosis, but the specific mechanism needs to be further studied.Helicobacter pylori ::: Role of TLRs in pathogen-induced atherosclerosisPathological studies of H. pylori infection mediated by TLRs mainly focus on gastric diseases.", [["gastric", "ANATOMY", 340, 347], ["atherosclerosis", "DISEASE", 119, 134], ["atherosclerosis", "DISEASE", 248, 263], ["H. pylori infection", "DISEASE", 287, 306], ["gastric diseases", "DISEASE", 340, 356], ["CagA", "GENE_OR_GENE_PRODUCT", 25, 29], ["H. pylori", "ORGANISM", 60, 69], ["Helicobacter pylori", "ORGANISM", 191, 210], ["TLRs", "GENE_OR_GENE_PRODUCT", 223, 227], ["H. pylori", "ORGANISM", 287, 296], ["TLRs", "GENE_OR_GENE_PRODUCT", 319, 323], ["gastric", "ORGAN", 340, 347], ["CagA", "PROTEIN", 25, 29], ["virulence factor", "PROTEIN", 40, 56], ["TLRs", "PROTEIN", 223, 227], ["TLRs", "PROTEIN", 319, 323], ["H. pylori", "SPECIES", 60, 69], ["Helicobacter pylori", "SPECIES", 191, 210], ["H. pylori", "SPECIES", 287, 296], ["H. pylori", "SPECIES", 60, 69], ["Helicobacter pylori", "SPECIES", 191, 210], ["H. pylori", "SPECIES", 287, 296], ["CagA", "PROBLEM", 25, 29], ["H. pylori", "PROBLEM", 60, 69], ["atherosclerosis", "PROBLEM", 119, 134], ["Helicobacter pylori", "PROBLEM", 191, 210], ["pathogen", "PROBLEM", 231, 239], ["atherosclerosis", "PROBLEM", 248, 263], ["H. pylori infection", "PROBLEM", 287, 306], ["gastric diseases", "PROBLEM", 340, 356], ["CagA", "OBSERVATION", 25, 29], ["pylori", "OBSERVATION", 63, 69], ["atherosclerosis", "OBSERVATION", 119, 134], ["pylori", "OBSERVATION", 204, 210], ["atherosclerosis", "OBSERVATION", 248, 263], ["gastric", "ANATOMY", 340, 347], ["diseases", "OBSERVATION", 348, 356]]], ["LPS derived from H. pylori is regarded as a direct stimulator of innate immunity mediated by TLR4.", [["LPS", "CHEMICAL", 0, 3], ["LPS", "SIMPLE_CHEMICAL", 0, 3], ["H. pylori", "ORGANISM", 17, 26], ["TLR4", "GENE_OR_GENE_PRODUCT", 93, 97], ["TLR4", "PROTEIN", 93, 97], ["H. pylori", "SPECIES", 17, 26], ["H. pylori", "SPECIES", 17, 26], ["LPS", "TEST", 0, 3], ["H. pylori", "PROBLEM", 17, 26], ["a direct stimulator of innate immunity", "TREATMENT", 42, 80]]], ["LPS of H. pylori activates the NF-\u03baB pathway by ligating with TLR4, and then activates the IL-8 pathway [125].", [["LPS", "CHEMICAL", 0, 3], ["LPS", "SIMPLE_CHEMICAL", 0, 3], ["H. pylori", "ORGANISM", 7, 16], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 31, 36], ["TLR4", "GENE_OR_GENE_PRODUCT", 62, 66], ["IL-8", "GENE_OR_GENE_PRODUCT", 91, 95], ["NF-\u03baB", "PROTEIN", 31, 36], ["TLR4", "PROTEIN", 62, 66], ["H. pylori", "SPECIES", 7, 16], ["H. pylori", "SPECIES", 7, 16], ["LPS", "TEST", 0, 3], ["H. pylori", "PROBLEM", 7, 16], ["H. pylori", "OBSERVATION", 7, 16]]], ["However, some studies have shown that the production of inflammatory cytokines in gastric epithelial cells or human macrophages induced by LPS of H. pylori is not related to TLR4.", [["gastric epithelial cells", "ANATOMY", 82, 106], ["macrophages", "ANATOMY", 116, 127], ["LPS", "CHEMICAL", 139, 142], ["gastric epithelial cells", "CELL", 82, 106], ["human", "ORGANISM", 110, 115], ["macrophages", "CELL", 116, 127], ["LPS", "GENE_OR_GENE_PRODUCT", 139, 142], ["H. pylori", "ORGANISM", 146, 155], ["TLR4", "GENE_OR_GENE_PRODUCT", 174, 178], ["inflammatory cytokines", "PROTEIN", 56, 78], ["gastric epithelial cells", "CELL_TYPE", 82, 106], ["human macrophages", "CELL_TYPE", 110, 127], ["TLR4", "PROTEIN", 174, 178], ["human", "SPECIES", 110, 115], ["H. pylori", "SPECIES", 146, 155], ["human", "SPECIES", 110, 115], ["H. pylori", "SPECIES", 146, 155], ["some studies", "TEST", 9, 21], ["inflammatory cytokines", "PROBLEM", 56, 78], ["gastric epithelial cells", "PROBLEM", 82, 106], ["human macrophages", "PROBLEM", 110, 127], ["H. pylori", "PROBLEM", 146, 155], ["TLR4", "PROBLEM", 174, 178], ["inflammatory", "OBSERVATION_MODIFIER", 56, 68], ["gastric", "ANATOMY", 82, 89], ["epithelial cells", "OBSERVATION", 90, 106], ["human macrophages", "OBSERVATION", 110, 127], ["H. pylori", "OBSERVATION", 146, 155], ["not related to", "UNCERTAINTY", 159, 173]]], ["In addition to TLR4, TLR2 has also been reported to be involved in the activation of signaling pathways after H. pylori infection.", [["H. pylori infection", "DISEASE", 110, 129], ["TLR4", "GENE_OR_GENE_PRODUCT", 15, 19], ["TLR2", "GENE_OR_GENE_PRODUCT", 21, 25], ["H. pylori", "ORGANISM", 110, 119], ["TLR4", "PROTEIN", 15, 19], ["TLR2", "PROTEIN", 21, 25], ["H. pylori", "SPECIES", 110, 119], ["H. pylori", "SPECIES", 110, 119], ["TLR2", "TREATMENT", 21, 25], ["H. pylori infection", "PROBLEM", 110, 129]]], ["Triantafilou et al. demonstrated that cell activation induced by LPS from H. pylori and P. gingivalis is mediated by TLR2 and requires the formation of a heteromeric receptor complex containing TLR2, TLR1, CD36 and CD11b/CD18 [126].", [["cell", "ANATOMY", 38, 42], ["LPS", "CHEMICAL", 65, 68], ["cell", "CELL", 38, 42], ["LPS", "SIMPLE_CHEMICAL", 65, 68], ["H. pylori", "ORGANISM", 74, 83], ["P. gingivalis", "ORGANISM", 88, 101], ["TLR2", "GENE_OR_GENE_PRODUCT", 117, 121], ["TLR2", "GENE_OR_GENE_PRODUCT", 194, 198], ["TLR1", "GENE_OR_GENE_PRODUCT", 200, 204], ["CD36", "GENE_OR_GENE_PRODUCT", 206, 210], ["CD11b", "GENE_OR_GENE_PRODUCT", 215, 220], ["CD18", "GENE_OR_GENE_PRODUCT", 221, 225], ["TLR2", "PROTEIN", 117, 121], ["heteromeric receptor complex", "PROTEIN", 154, 182], ["TLR2", "PROTEIN", 194, 198], ["TLR1", "PROTEIN", 200, 204], ["CD36", "PROTEIN", 206, 210], ["CD11b", "PROTEIN", 215, 220], ["CD18", "PROTEIN", 221, 225], ["H. pylori", "SPECIES", 74, 83], ["P. gingivalis", "SPECIES", 88, 101], ["H. pylori", "SPECIES", 74, 83], ["P. gingivalis", "SPECIES", 88, 101], ["cell activation", "PROBLEM", 38, 53], ["LPS", "PROBLEM", 65, 68], ["H. pylori", "PROBLEM", 74, 83], ["P. gingivalis", "PROBLEM", 88, 101], ["cell activation", "OBSERVATION", 38, 53]]], ["Uno and his colleagues demonstrated that TLR2 of gastric epithelial cells activated Tribbles 3-NF-\u03baB signaling pathway under the stimulation of LPS from H. pylori.", [["gastric epithelial cells", "ANATOMY", 49, 73], ["LPS", "CHEMICAL", 144, 147], ["TLR2", "GENE_OR_GENE_PRODUCT", 41, 45], ["gastric epithelial cells", "CELL", 49, 73], ["Tribbles 3", "GENE_OR_GENE_PRODUCT", 84, 94], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 95, 100], ["LPS", "SIMPLE_CHEMICAL", 144, 147], ["H. pylori", "ORGANISM", 153, 162], ["TLR2", "PROTEIN", 41, 45], ["gastric epithelial cells", "CELL_TYPE", 49, 73], ["Tribbles 3", "PROTEIN", 84, 94], ["NF", "PROTEIN", 95, 97], ["\u03baB", "PROTEIN", 98, 100], ["H. pylori", "SPECIES", 153, 162], ["H. pylori", "SPECIES", 153, 162], ["gastric epithelial cells", "TEST", 49, 73], ["Tribbles", "TEST", 84, 92], ["NF", "TEST", 95, 97], ["LPS", "PROBLEM", 144, 147], ["H. pylori", "PROBLEM", 153, 162], ["gastric", "ANATOMY", 49, 56], ["epithelial cells", "OBSERVATION", 57, 73], ["H. pylori", "OBSERVATION", 153, 162]]], ["Other studies have shown that TLR2 and 4 cooperate to cope with H. pylori infection.", [["H. pylori infection", "DISEASE", 64, 83], ["TLR2", "GENE_OR_GENE_PRODUCT", 30, 34], ["4", "GENE_OR_GENE_PRODUCT", 39, 40], ["H. pylori", "ORGANISM", 64, 73], ["TLR2 and 4", "PROTEIN", 30, 40], ["H. pylori", "SPECIES", 64, 73], ["H. pylori", "SPECIES", 64, 73], ["Other studies", "TEST", 0, 13], ["TLR2", "TEST", 30, 34], ["H. pylori infection", "PROBLEM", 64, 83]]], ["For instance, LPS of H. pylori can enhance the expression of TLR2 through TLR4 signal [127].", [["LPS", "CHEMICAL", 14, 17], ["LPS", "SIMPLE_CHEMICAL", 14, 17], ["H. pylori", "ORGANISM", 21, 30], ["TLR2", "GENE_OR_GENE_PRODUCT", 61, 65], ["TLR4", "GENE_OR_GENE_PRODUCT", 74, 78], ["TLR2", "PROTEIN", 61, 65], ["TLR4", "PROTEIN", 74, 78], ["H. pylori", "SPECIES", 21, 30], ["H. pylori", "SPECIES", 21, 30], ["H. pylori", "PROBLEM", 21, 30], ["TLR4 signal", "TEST", 74, 85]]], ["During the proliferation of gastric epithelial cells, TLR2 activated by LPS of H. pylori also enhanced the expression of TLR4 through MAP/ERK 1/2 kinase pathway [128].", [["gastric epithelial cells", "ANATOMY", 28, 52], ["LPS", "CHEMICAL", 72, 75], ["gastric epithelial cells", "CELL", 28, 52], ["TLR2", "GENE_OR_GENE_PRODUCT", 54, 58], ["LPS", "GENE_OR_GENE_PRODUCT", 72, 75], ["H. pylori", "ORGANISM", 79, 88], ["TLR4", "GENE_OR_GENE_PRODUCT", 121, 125], ["MAP/ERK 1/2 kinase", "GENE_OR_GENE_PRODUCT", 134, 152], ["gastric epithelial cells", "CELL_TYPE", 28, 52], ["TLR2", "PROTEIN", 54, 58], ["TLR4", "PROTEIN", 121, 125], ["ERK 1/2 kinase", "PROTEIN", 138, 152], ["H. pylori", "SPECIES", 79, 88], ["H. pylori", "SPECIES", 79, 88], ["gastric epithelial cells", "PROBLEM", 28, 52], ["H. pylori", "PROBLEM", 79, 88], ["MAP", "TEST", 134, 137], ["kinase pathway", "TEST", 146, 160], ["gastric", "ANATOMY", 28, 35], ["epithelial cells", "OBSERVATION", 36, 52]]], ["However, other studies have shown that TLR2 and 4 work in isolation.", [["TLR2", "GENE_OR_GENE_PRODUCT", 39, 43], ["TLR2", "PROTEIN", 39, 43], ["other studies", "TEST", 9, 22], ["TLR2", "TEST", 39, 43]]], ["Obonyo et al. confirmed that H. pylori induces IL-10 and IL-12 via TLR4/MyD88 signaling, and induces less IL-6 and IL-1\u03b2 in TLR2-deficient macrophages, indicating that H. pylori activates TLR2 and 4, resulting in the secretion of different cytokines by macrophages [129].", [["macrophages", "ANATOMY", 139, 150], ["macrophages", "ANATOMY", 253, 264], ["H. pylori", "ORGANISM", 29, 38], ["IL-10", "GENE_OR_GENE_PRODUCT", 47, 52], ["IL-12", "GENE_OR_GENE_PRODUCT", 57, 62], ["TLR4", "GENE_OR_GENE_PRODUCT", 67, 71], ["MyD88", "GENE_OR_GENE_PRODUCT", 72, 77], ["IL-6", "GENE_OR_GENE_PRODUCT", 106, 110], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 115, 120], ["TLR2", "GENE_OR_GENE_PRODUCT", 124, 128], ["macrophages", "CELL", 139, 150], ["H. pylori", "ORGANISM", 168, 177], ["TLR2", "GENE_OR_GENE_PRODUCT", 188, 192], ["4", "GENE_OR_GENE_PRODUCT", 197, 198], ["macrophages", "CELL", 253, 264], ["TLR4", "PROTEIN", 67, 71], ["MyD88", "PROTEIN", 72, 77], ["IL-6", "PROTEIN", 106, 110], ["IL-1\u03b2", "PROTEIN", 115, 120], ["TLR2", "PROTEIN", 124, 128], ["deficient macrophages", "CELL_TYPE", 129, 150], ["TLR2 and 4", "PROTEIN", 188, 198], ["cytokines", "PROTEIN", 240, 249], ["macrophages", "CELL_TYPE", 253, 264], ["H. pylori", "SPECIES", 29, 38], ["H. pylori", "SPECIES", 168, 177], ["H. pylori", "SPECIES", 29, 38], ["H. pylori", "SPECIES", 168, 177], ["H. pylori", "TEST", 29, 38], ["IL", "TEST", 47, 49], ["IL", "TEST", 57, 59], ["IL", "TEST", 106, 108], ["IL", "TEST", 115, 117], ["deficient macrophages", "PROBLEM", 129, 150], ["H. pylori", "PROBLEM", 168, 177]]], ["In addition to TLR2 and 4, TLR5 recognizes H. pylori-flagellin A (FlaA).", [["TLR2", "GENE_OR_GENE_PRODUCT", 15, 19], ["4", "GENE_OR_GENE_PRODUCT", 24, 25], ["TLR5", "GENE_OR_GENE_PRODUCT", 27, 31], ["H. pylori-flagellin A", "GENE_OR_GENE_PRODUCT", 43, 64], ["FlaA", "GENE_OR_GENE_PRODUCT", 66, 70], ["TLR2", "PROTEIN", 15, 19], ["TLR5", "PROTEIN", 27, 31], ["H. pylori-flagellin A", "PROTEIN", 43, 64], ["FlaA", "PROTEIN", 66, 70], ["H. pylori-flagellin A", "SPECIES", 43, 64], ["TLR2", "TEST", 15, 19], ["TLR2", "ANATOMY", 15, 19]]], ["Generally speaking, TLR5 signal induces IL-8 secretion through p38-map kinase signal by recognizing bacterial flagellin.", [["TLR5", "GENE_OR_GENE_PRODUCT", 20, 24], ["IL-8", "GENE_OR_GENE_PRODUCT", 40, 44], ["p38", "GENE_OR_GENE_PRODUCT", 63, 66], ["flagellin", "GENE_OR_GENE_PRODUCT", 110, 119], ["TLR5", "PROTEIN", 20, 24], ["IL-8", "PROTEIN", 40, 44], ["p38", "PROTEIN", 63, 66], ["bacterial flagellin", "PROTEIN", 100, 119], ["IL", "TEST", 40, 42], ["p38", "TEST", 63, 66], ["map kinase signal", "TEST", 67, 84], ["recognizing bacterial flagellin", "PROBLEM", 88, 119], ["bacterial flagellin", "OBSERVATION", 100, 119]]], ["However, some studies have shown that FlaA plays a weak role in IL-8 production [130].", [["FlaA", "CHEMICAL", 38, 42], ["FlaA", "GENE_OR_GENE_PRODUCT", 38, 42], ["IL-8", "GENE_OR_GENE_PRODUCT", 64, 68], ["FlaA", "PROTEIN", 38, 42], ["IL", "PROTEIN", 64, 66], ["some studies", "TEST", 9, 21]]], ["TLR9 has been reported to recognize unmethylated CPG DNA of H. pylori and produce IFN I [131].", [["TLR9", "GENE_OR_GENE_PRODUCT", 0, 4], ["DNA", "CELLULAR_COMPONENT", 53, 56], ["H. pylori", "ORGANISM", 60, 69], ["TLR9", "PROTEIN", 0, 4], ["unmethylated CPG DNA", "DNA", 36, 56], ["IFN I", "PROTEIN", 82, 87], ["H. pylori", "SPECIES", 60, 69], ["H. pylori", "SPECIES", 60, 69], ["TLR9", "TREATMENT", 0, 4], ["H. pylori", "PROBLEM", 60, 69]]], ["Rad and his colleagues demonstrated that TLR9 stimulated by H. pylori could induce pre-inflammatory cytokines such as IL-6 and IL-12 [132].", [["Rad", "GENE_OR_GENE_PRODUCT", 0, 3], ["TLR9", "GENE_OR_GENE_PRODUCT", 41, 45], ["H. pylori", "ORGANISM", 60, 69], ["IL-6", "GENE_OR_GENE_PRODUCT", 118, 122], ["IL-12", "GENE_OR_GENE_PRODUCT", 127, 132], ["TLR9", "PROTEIN", 41, 45], ["pre-inflammatory cytokines", "PROTEIN", 83, 109], ["IL-6", "PROTEIN", 118, 122], ["IL", "PROTEIN", 127, 129], ["H. pylori", "SPECIES", 60, 69], ["H. pylori", "SPECIES", 60, 69], ["TLR9 stimulated", "TREATMENT", 41, 56], ["H. pylori", "PROBLEM", 60, 69], ["pre-inflammatory cytokines", "PROBLEM", 83, 109], ["IL", "TEST", 118, 120], ["IL", "TEST", 127, 129]]], ["Because of the different research background and purity of H. pylori and LPS, the reactivity of TLRs in gastric mucosa infected by H. pylori is uncertain.", [["gastric mucosa", "ANATOMY", 104, 118], ["LPS", "CHEMICAL", 73, 76], ["H. pylori", "ORGANISM", 59, 68], ["LPS", "SIMPLE_CHEMICAL", 73, 76], ["TLRs", "GENE_OR_GENE_PRODUCT", 96, 100], ["gastric mucosa", "MULTI-TISSUE_STRUCTURE", 104, 118], ["H. pylori", "ORGANISM", 131, 140], ["TLRs", "PROTEIN", 96, 100], ["H. pylori", "SPECIES", 59, 68], ["H. pylori", "SPECIES", 131, 140], ["H. pylori", "SPECIES", 59, 68], ["H. pylori", "SPECIES", 131, 140], ["H. pylori", "PROBLEM", 59, 68], ["LPS", "TREATMENT", 73, 76], ["H. pylori", "PROBLEM", 131, 140], ["gastric mucosa", "ANATOMY", 104, 118]]], ["The role of TLRs in gastric mucosa infected by H. pylori provides a possible mechanism for H. pylori to promote the development of atherosclerosis.", [["gastric mucosa", "ANATOMY", 20, 34], ["atherosclerosis", "DISEASE", 131, 146], ["TLRs", "GENE_OR_GENE_PRODUCT", 12, 16], ["gastric mucosa", "MULTI-TISSUE_STRUCTURE", 20, 34], ["H. pylori", "ORGANISM", 47, 56], ["H. pylori", "ORGANISM", 91, 100], ["TLRs", "PROTEIN", 12, 16], ["H. pylori", "SPECIES", 47, 56], ["H. pylori", "SPECIES", 91, 100], ["H. pylori", "SPECIES", 47, 56], ["H. pylori", "SPECIES", 91, 100], ["H. pylori", "PROBLEM", 47, 56], ["H. pylori", "PROBLEM", 91, 100], ["atherosclerosis", "PROBLEM", 131, 146], ["gastric mucosa", "ANATOMY", 20, 34], ["atherosclerosis", "OBSERVATION", 131, 146]]], ["Whether TLRs mediate the occurrence and development of atherosclerosis in H. pylori infection through similar signaling pathways in gastric mucosa is uncertain, and further research is expected.Human immunodeficiency virus ::: Role of TLRs in pathogen-induced atherosclerosisThere is increasing evidence that HIV infection and subsequent inflammation accelerate atherosclerosis.", [["gastric mucosa", "ANATOMY", 132, 146], ["atherosclerosis", "DISEASE", 55, 70], ["H. pylori infection", "DISEASE", 74, 93], ["Human immunodeficiency virus", "DISEASE", 194, 222], ["atherosclerosis", "DISEASE", 260, 275], ["HIV infection", "DISEASE", 309, 322], ["inflammation", "DISEASE", 338, 350], ["atherosclerosis", "DISEASE", 362, 377], ["TLRs", "GENE_OR_GENE_PRODUCT", 8, 12], ["H. pylori", "ORGANISM", 74, 83], ["gastric mucosa", "MULTI-TISSUE_STRUCTURE", 132, 146], ["Human immunodeficiency virus", "ORGANISM", 194, 222], ["TLRs", "GENE_OR_GENE_PRODUCT", 235, 239], ["HIV", "ORGANISM", 309, 312], ["TLRs", "PROTEIN", 8, 12], ["TLRs", "PROTEIN", 235, 239], ["H. pylori", "SPECIES", 74, 83], ["Human", "SPECIES", 194, 199], ["immunodeficiency virus", "SPECIES", 200, 222], ["HIV", "SPECIES", 309, 312], ["H. pylori", "SPECIES", 74, 83], ["Human immunodeficiency virus", "SPECIES", 194, 222], ["HIV", "SPECIES", 309, 312], ["atherosclerosis", "PROBLEM", 55, 70], ["H. pylori infection", "PROBLEM", 74, 93], ["similar signaling pathways in gastric mucosa", "PROBLEM", 102, 146], ["Human immunodeficiency virus", "PROBLEM", 194, 222], ["atherosclerosis", "PROBLEM", 260, 275], ["HIV infection", "PROBLEM", 309, 322], ["subsequent inflammation accelerate atherosclerosis", "PROBLEM", 327, 377], ["atherosclerosis", "OBSERVATION", 55, 70], ["H. pylori infection", "OBSERVATION", 74, 93], ["gastric mucosa", "ANATOMY", 132, 146], ["immunodeficiency virus", "OBSERVATION", 200, 222], ["atherosclerosis", "OBSERVATION", 260, 275], ["increasing", "OBSERVATION_MODIFIER", 284, 294], ["HIV", "OBSERVATION_MODIFIER", 309, 312], ["infection", "OBSERVATION", 313, 322], ["inflammation", "OBSERVATION_MODIFIER", 338, 350], ["accelerate", "OBSERVATION_MODIFIER", 351, 361], ["atherosclerosis", "OBSERVATION", 362, 377]]], ["Imaging studies using coronary CTA showed that the prevalence of coronary atherosclerosis in HIV males was 59.0%, compared with 34.4% in control group [133].", [["coronary", "ANATOMY", 22, 30], ["coronary", "ANATOMY", 65, 73], ["coronary atherosclerosis", "DISEASE", 65, 89], ["coronary", "MULTI-TISSUE_STRUCTURE", 22, 30], ["coronary", "MULTI-TISSUE_STRUCTURE", 65, 73], ["HIV", "SPECIES", 93, 96], ["HIV", "SPECIES", 93, 96], ["Imaging studies", "TEST", 0, 15], ["coronary CTA", "TEST", 22, 34], ["coronary atherosclerosis in HIV males", "PROBLEM", 65, 102], ["coronary", "ANATOMY", 22, 30], ["coronary", "ANATOMY", 65, 73], ["atherosclerosis", "OBSERVATION", 74, 89]]], ["Except for men with HIV, the proportion of people with non-calcified plaques was significantly higher in women with HIV than in women with control subjects (74\u201323%) [134].", [["plaques", "ANATOMY", 69, 76], ["non-calcified plaques", "DISEASE", 55, 76], ["men", "ORGANISM", 11, 14], ["HIV", "ORGANISM", 20, 23], ["people", "ORGANISM", 43, 49], ["plaques", "PATHOLOGICAL_FORMATION", 69, 76], ["women", "ORGANISM", 105, 110], ["women", "ORGANISM", 128, 133], ["men", "SPECIES", 11, 14], ["HIV", "SPECIES", 20, 23], ["people", "SPECIES", 43, 49], ["women", "SPECIES", 105, 110], ["HIV", "SPECIES", 116, 119], ["women", "SPECIES", 128, 133], ["HIV", "SPECIES", 20, 23], ["HIV", "SPECIES", 116, 119], ["HIV", "PROBLEM", 20, 23], ["non-calcified plaques", "PROBLEM", 55, 76], ["HIV", "PROBLEM", 116, 119], ["non-calcified", "OBSERVATION_MODIFIER", 55, 68], ["plaques", "OBSERVATION", 69, 76], ["significantly", "OBSERVATION_MODIFIER", 81, 94], ["higher", "OBSERVATION_MODIFIER", 95, 101]]], ["A meta-analysis showed that there was a correlation between non-calcified coronary plaque and decreased CD4 cell count in HIV patients [135].", [["coronary plaque", "ANATOMY", 74, 89], ["CD4 cell", "ANATOMY", 104, 112], ["coronary plaque", "DISEASE", 74, 89], ["coronary plaque", "PATHOLOGICAL_FORMATION", 74, 89], ["CD4 cell", "CELL", 104, 112], ["patients", "ORGANISM", 126, 134], ["CD4", "PROTEIN", 104, 107], ["HIV", "SPECIES", 122, 125], ["patients", "SPECIES", 126, 134], ["HIV", "SPECIES", 122, 125], ["A meta-analysis", "TEST", 0, 15], ["non-calcified coronary plaque", "PROBLEM", 60, 89], ["decreased CD4 cell count", "PROBLEM", 94, 118], ["non-calcified", "OBSERVATION_MODIFIER", 60, 73], ["coronary", "ANATOMY", 74, 82], ["plaque", "OBSERVATION", 83, 89], ["decreased", "OBSERVATION_MODIFIER", 94, 103], ["CD4 cell count", "OBSERVATION", 104, 118]]], ["These clinical evidence suggests that systemic inflammation and immune activation of HIV infection contribute to the acceleration of atherosclerosis in HIV patients.", [["inflammation", "DISEASE", 47, 59], ["HIV infection", "DISEASE", 85, 98], ["atherosclerosis", "DISEASE", 133, 148], ["HIV", "DISEASE", 152, 155], ["HIV", "ORGANISM", 85, 88], ["HIV", "ORGANISM", 152, 155], ["patients", "ORGANISM", 156, 164], ["HIV", "SPECIES", 152, 155], ["patients", "SPECIES", 156, 164], ["HIV", "SPECIES", 85, 88], ["HIV", "SPECIES", 152, 155], ["systemic inflammation", "PROBLEM", 38, 59], ["immune activation", "PROBLEM", 64, 81], ["HIV infection", "PROBLEM", 85, 98], ["atherosclerosis", "PROBLEM", 133, 148], ["systemic", "OBSERVATION_MODIFIER", 38, 46], ["inflammation", "OBSERVATION", 47, 59], ["acceleration", "OBSERVATION_MODIFIER", 117, 129], ["atherosclerosis", "OBSERVATION", 133, 148]]], ["Because HIV cannot replicate in rodent cells, the application of mouse models in the pathogenesis of HIV is hampered.", [["cells", "ANATOMY", 39, 44], ["HIV", "DISEASE", 101, 104], ["HIV", "ORGANISM", 8, 11], ["cells", "CELL", 39, 44], ["mouse", "ORGANISM", 65, 70], ["HIV", "ORGANISM", 101, 104], ["rodent cells", "CELL_TYPE", 32, 44], ["HIV", "SPECIES", 8, 11], ["mouse", "SPECIES", 65, 70], ["HIV", "SPECIES", 101, 104], ["HIV", "SPECIES", 8, 11], ["mouse", "SPECIES", 65, 70], ["HIV", "SPECIES", 101, 104], ["HIV", "PROBLEM", 8, 11], ["mouse models", "TREATMENT", 65, 77], ["HIV", "PROBLEM", 101, 104], ["HIV", "OBSERVATION", 101, 104]]], ["Studies have shown that macaques infected with simian immunodeficiency virus (SIV) on an atherogenic diet show a faster deterioration of the disease, leading to an increased risk of SIV-related death [136].", [["simian immunodeficiency virus", "DISEASE", 47, 76], ["deterioration of the disease", "DISEASE", 120, 148], ["death", "DISEASE", 194, 199], ["macaques", "ORGANISM", 24, 32], ["simian immunodeficiency virus", "ORGANISM", 47, 76], ["SIV", "ORGANISM", 78, 81], ["SIV", "ORGANISM", 182, 185], ["macaques", "SPECIES", 24, 32], ["simian immunodeficiency virus", "SPECIES", 47, 76], ["simian immunodeficiency virus", "SPECIES", 47, 76], ["SIV", "SPECIES", 78, 81], ["SIV", "SPECIES", 182, 185], ["Studies", "TEST", 0, 7], ["macaques infected", "PROBLEM", 24, 41], ["simian immunodeficiency virus", "PROBLEM", 47, 76], ["an atherogenic diet", "TREATMENT", 86, 105], ["a faster deterioration of the disease", "PROBLEM", 111, 148], ["SIV-related death", "PROBLEM", 182, 199], ["simian immunodeficiency", "OBSERVATION", 47, 70], ["disease", "OBSERVATION", 141, 148], ["increased", "OBSERVATION_MODIFIER", 164, 173], ["SIV", "OBSERVATION", 182, 185]]], ["However, due to the high maintenance costs, the extremely difficult genetic manipulation, and the long time of monitoring the atherosclerosis of SIV-infected monkeys, it is still difficult to apply SIV monkey model to comb the pathogenesis [137].", [["atherosclerosis", "DISEASE", 126, 141], ["SIV-infected", "DISEASE", 145, 157], ["SIV", "ORGANISM", 145, 148], ["monkeys", "ORGANISM", 158, 165], ["SIV", "ORGANISM", 198, 201], ["SIV monkey", "SPECIES", 198, 208], ["the high maintenance costs", "PROBLEM", 16, 42], ["the atherosclerosis of SIV", "PROBLEM", 122, 148], ["atherosclerosis", "OBSERVATION", 126, 141], ["infected", "OBSERVATION", 149, 157]]], ["Animal experiments of HIV accelerating atherosclerosis still need further exploration.Human immunodeficiency virus ::: Role of TLRs in pathogen-induced atherosclerosisTLRs seem to play an irreplaceable role in immune activation and dysfunction caused by HIV infection.", [["atherosclerosis", "DISEASE", 39, 54], ["Human immunodeficiency virus", "DISEASE", 86, 114], ["HIV infection", "DISEASE", 254, 267], ["HIV", "ORGANISM", 22, 25], ["Human immunodeficiency virus", "ORGANISM", 86, 114], ["TLRs", "GENE_OR_GENE_PRODUCT", 127, 131], ["atherosclerosisTLRs", "GENE_OR_GENE_PRODUCT", 152, 171], ["HIV", "ORGANISM", 254, 257], ["TLRs", "PROTEIN", 127, 131], ["atherosclerosisTLRs", "PROTEIN", 152, 171], ["HIV", "SPECIES", 22, 25], ["Human", "SPECIES", 86, 91], ["immunodeficiency virus", "SPECIES", 92, 114], ["HIV", "SPECIES", 254, 257], ["HIV", "SPECIES", 22, 25], ["Human immunodeficiency virus", "SPECIES", 86, 114], ["HIV", "SPECIES", 254, 257], ["HIV accelerating atherosclerosis", "PROBLEM", 22, 54], ["further exploration", "TEST", 66, 85], ["Human immunodeficiency virus", "PROBLEM", 86, 114], ["pathogen", "PROBLEM", 135, 143], ["atherosclerosisTLRs", "PROBLEM", 152, 171], ["immune activation", "PROBLEM", 210, 227], ["dysfunction", "PROBLEM", 232, 243], ["HIV infection", "PROBLEM", 254, 267], ["HIV", "OBSERVATION_MODIFIER", 22, 25], ["accelerating", "OBSERVATION_MODIFIER", 26, 38], ["atherosclerosis", "OBSERVATION", 39, 54], ["immunodeficiency virus", "OBSERVATION", 92, 114], ["immune activation", "OBSERVATION", 210, 227], ["HIV", "OBSERVATION_MODIFIER", 254, 257], ["infection", "OBSERVATION", 258, 267]]], ["It is reported that the ssRNA oligonucleotides rich in guanosine (G) and uridine (U) from HIV-1 can be specifically recognized by TLR7 and 8 [138].", [["guanosine", "CHEMICAL", 55, 64], ["uridine", "CHEMICAL", 73, 80], ["U", "CHEMICAL", 82, 83], ["guanosine", "CHEMICAL", 55, 64], ["uridine", "CHEMICAL", 73, 80], ["guanosine", "SIMPLE_CHEMICAL", 55, 64], ["(G)", "GENE_OR_GENE_PRODUCT", 65, 68], ["uridine", "SIMPLE_CHEMICAL", 73, 80], ["U", "GENE_OR_GENE_PRODUCT", 82, 83], ["HIV-1", "ORGANISM", 90, 95], ["TLR7", "GENE_OR_GENE_PRODUCT", 130, 134], ["TLR7", "PROTEIN", 130, 134], ["HIV-1", "SPECIES", 90, 95], ["HIV-1", "SPECIES", 90, 95], ["the ssRNA oligonucleotides", "TREATMENT", 20, 46], ["guanosine (G", "TREATMENT", 55, 67], ["uridine (U)", "TEST", 73, 84], ["HIV", "PROBLEM", 90, 93]]], ["Neutrophils detect HIV-1 by TLR7 and 8, which recognize viral nucleic acids.", [["Neutrophils", "ANATOMY", 0, 11], ["nucleic acids", "CHEMICAL", 62, 75], ["Neutrophils", "CELL", 0, 11], ["HIV-1", "GENE_OR_GENE_PRODUCT", 19, 24], ["TLR7", "GENE_OR_GENE_PRODUCT", 28, 32], ["8", "GENE_OR_GENE_PRODUCT", 37, 38], ["Neutrophils", "CELL_TYPE", 0, 11], ["TLR7 and 8", "PROTEIN", 28, 38], ["HIV-1", "SPECIES", 19, 24], ["HIV-1", "SPECIES", 19, 24], ["Neutrophils", "TEST", 0, 11], ["HIV", "TEST", 19, 22], ["TLR7", "TEST", 28, 32], ["viral nucleic acids", "TEST", 56, 75], ["viral nucleic acids", "OBSERVATION", 56, 75]]], ["The combination of TLR7 and 8 induces the production of reactive oxygen species (ROS), which trigger network formation and lead to the elimination of network-dependent HIV-1 [139].", [["oxygen", "CHEMICAL", 65, 71], ["ROS", "CHEMICAL", 81, 84], ["oxygen", "CHEMICAL", 65, 71], ["TLR7", "GENE_OR_GENE_PRODUCT", 19, 23], ["8", "GENE_OR_GENE_PRODUCT", 28, 29], ["reactive oxygen species", "SIMPLE_CHEMICAL", 56, 79], ["ROS", "SIMPLE_CHEMICAL", 81, 84], ["HIV-1", "ORGANISM", 168, 173], ["TLR7 and 8", "PROTEIN", 19, 29], ["HIV-1", "SPECIES", 168, 173], ["HIV-1", "SPECIES", 168, 173], ["reactive oxygen species", "PROBLEM", 56, 79], ["dependent HIV", "PROBLEM", 158, 171], ["reactive", "OBSERVATION_MODIFIER", 56, 64], ["oxygen species", "OBSERVATION", 65, 79]]], ["Stimulated by TLR7/8 agonists, the levels of cytokines/chemokines produced by DCs from HIV-infected patients were substantially higher than those from non-infected controls [140].", [["DCs", "ANATOMY", 78, 81], ["HIV-infected", "DISEASE", 87, 99], ["TLR7", "GENE_OR_GENE_PRODUCT", 14, 18], ["8", "GENE_OR_GENE_PRODUCT", 19, 20], ["DCs", "CELL", 78, 81], ["HIV", "ORGANISM", 87, 90], ["patients", "ORGANISM", 100, 108], ["TLR7", "PROTEIN", 14, 18], ["cytokines", "PROTEIN", 45, 54], ["chemokines", "PROTEIN", 55, 65], ["DCs", "CELL_TYPE", 78, 81], ["HIV-", "SPECIES", 87, 91], ["patients", "SPECIES", 100, 108], ["HIV", "SPECIES", 87, 90], ["TLR7/8 agonists", "TREATMENT", 14, 29], ["cytokines/chemokines", "TREATMENT", 45, 65], ["HIV", "PROBLEM", 87, 90]]], ["In addition, Meier et al. reported that plasmacytoid dendritic cells (pDCs) from women responded significantly to TLR7 ligands encoded by HIV-1 and produced more IFN\u03b1 than pDCs from men, which enhanced the secondary activation of CD8 (+) T cells [141].", [["plasmacytoid dendritic cells", "ANATOMY", 40, 68], ["pDCs", "ANATOMY", 70, 74], ["pDCs", "ANATOMY", 172, 176], ["CD8 (+) T cells", "ANATOMY", 230, 245], ["plasmacytoid dendritic cells", "CELL", 40, 68], ["pDCs", "CELL", 70, 74], ["women", "ORGANISM", 81, 86], ["TLR7", "GENE_OR_GENE_PRODUCT", 114, 118], ["HIV-1", "ORGANISM", 138, 143], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 162, 166], ["pDCs", "CELL", 172, 176], ["men", "ORGANISM", 182, 185], ["CD8", "GENE_OR_GENE_PRODUCT", 230, 233], ["plasmacytoid dendritic cells", "CELL_TYPE", 40, 68], ["pDCs", "CELL_TYPE", 70, 74], ["TLR7", "PROTEIN", 114, 118], ["IFN\u03b1", "PROTEIN", 162, 166], ["pDCs", "CELL_TYPE", 172, 176], ["CD8 (+) T cells", "CELL_TYPE", 230, 245], ["women", "SPECIES", 81, 86], ["HIV-1", "SPECIES", 138, 143], ["men", "SPECIES", 182, 185], ["HIV-1", "SPECIES", 138, 143], ["plasmacytoid dendritic cells", "PROBLEM", 40, 68], ["plasmacytoid dendritic cells", "OBSERVATION", 40, 68]]], ["It suggests that regulating TLR7 pathway in pDCs might be a new method to reduce HIV-1-related pathology.", [["pDCs", "ANATOMY", 44, 48], ["TLR7", "GENE_OR_GENE_PRODUCT", 28, 32], ["pDCs", "CELL", 44, 48], ["HIV-1", "ORGANISM", 81, 86], ["TLR7", "PROTEIN", 28, 32], ["pDCs", "CELL_TYPE", 44, 48], ["HIV-1", "SPECIES", 81, 86], ["HIV-1", "SPECIES", 81, 86], ["a new method", "TREATMENT", 58, 70], ["HIV", "PROBLEM", 81, 84], ["related pathology", "PROBLEM", 87, 104]]], ["Baenziger reported that HIV itself may directly lead to immune activation and dysfunction by stimulating TLR7 [142].", [["Baenziger", "CHEMICAL", 0, 9], ["HIV", "ORGANISM", 24, 27], ["TLR7", "GENE_OR_GENE_PRODUCT", 105, 109], ["TLR7", "PROTEIN", 105, 109], ["HIV", "SPECIES", 24, 27], ["HIV", "SPECIES", 24, 27], ["HIV itself", "PROBLEM", 24, 34], ["immune activation", "PROBLEM", 56, 73], ["dysfunction", "PROBLEM", 78, 89]]], ["Borducchi et al. reported that the therapeutic vaccination with AD26/MVA (recombinant adenovirus serotype 26 (AD26) prime, modified vaccine Ankara (MVA) boost) and stimulation by TLR7 can lead to a decrease in viral DNA levels in lymph nodes and peripheral blood, and improve virological control and delay viral rebound after interruption of antiviral therapy [143].", [["lymph nodes", "ANATOMY", 230, 241], ["peripheral blood", "ANATOMY", 246, 262], ["AD26", "CHEMICAL", 64, 68], ["TLR7", "CHEMICAL", 179, 183], ["AD26/MVA", "ORGANISM", 64, 72], ["recombinant adenovirus serotype 26", "ORGANISM", 74, 108], ["AD26", "ORGANISM", 110, 114], ["TLR7", "GENE_OR_GENE_PRODUCT", 179, 183], ["DNA", "CELLULAR_COMPONENT", 216, 219], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 230, 241], ["peripheral blood", "ORGANISM_SUBSTANCE", 246, 262], ["TLR7", "PROTEIN", 179, 183], ["the therapeutic vaccination", "TREATMENT", 31, 58], ["AD26/MVA (recombinant adenovirus serotype", "TREATMENT", 64, 105], ["modified vaccine Ankara (MVA) boost", "TREATMENT", 123, 158], ["stimulation", "TREATMENT", 164, 175], ["a decrease in viral DNA levels in lymph nodes", "PROBLEM", 196, 241], ["peripheral blood", "TEST", 246, 262], ["virological control", "TREATMENT", 276, 295], ["delay viral rebound", "PROBLEM", 300, 319], ["antiviral therapy", "TREATMENT", 342, 359], ["decrease", "OBSERVATION_MODIFIER", 198, 206], ["viral DNA", "OBSERVATION", 210, 219], ["lymph nodes", "OBSERVATION", 230, 241], ["peripheral", "ANATOMY_MODIFIER", 246, 256], ["blood", "ANATOMY", 257, 262]]], ["Therefore, manipulation of TLR7 signaling may be a potential strategy to reduce chronic hyperimmune activation, thereby reducing the progression of HIV infection.", [["hyperimmune", "ANATOMY", 88, 99], ["HIV infection", "DISEASE", 148, 161], ["TLR7", "GENE_OR_GENE_PRODUCT", 27, 31], ["hyperimmune", "ORGANISM", 88, 99], ["HIV", "ORGANISM", 148, 151], ["TLR7", "PROTEIN", 27, 31], ["HIV", "SPECIES", 148, 151], ["manipulation of TLR7 signaling", "TREATMENT", 11, 41], ["a potential strategy", "TREATMENT", 49, 69], ["chronic hyperimmune activation", "PROBLEM", 80, 110], ["HIV infection", "PROBLEM", 148, 161], ["chronic", "OBSERVATION_MODIFIER", 80, 87], ["hyperimmune activation", "OBSERVATION", 88, 110], ["progression", "OBSERVATION_MODIFIER", 133, 144], ["HIV", "OBSERVATION_MODIFIER", 148, 151], ["infection", "OBSERVATION", 152, 161]]], ["Gringhuis et al. reported that the replication of HIV-1 in DCs requires TLR8 and DC-SINT signals.", [["DCs", "ANATOMY", 59, 62], ["DC", "ANATOMY", 81, 83], ["HIV-1", "ORGANISM", 50, 55], ["DCs", "CELL", 59, 62], ["TLR8", "GENE_OR_GENE_PRODUCT", 72, 76], ["SINT", "GENE_OR_GENE_PRODUCT", 84, 88], ["DCs", "CELL_TYPE", 59, 62], ["TLR8", "PROTEIN", 72, 76], ["DC", "CELL_TYPE", 81, 83], ["SINT", "PROTEIN", 84, 88], ["HIV-1", "SPECIES", 50, 55], ["HIV-1", "SPECIES", 50, 55], ["HIV", "PROBLEM", 50, 53], ["TLR8", "TREATMENT", 72, 76]]], ["DC-SIGN signal is necessary to produce full-length viral transcripts [144].", [["DC", "ANATOMY", 0, 2], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 0, 7], ["DC", "CELL_TYPE", 0, 2], ["SIGN", "PROTEIN", 3, 7]]], ["In DCs, HIV-1 evades the detection of TLR8 by using the motilin protein Snapin.", [["DCs", "ANATOMY", 3, 6], ["DCs", "CELL", 3, 6], ["HIV-1", "ORGANISM", 8, 13], ["TLR8", "GENE_OR_GENE_PRODUCT", 38, 42], ["motilin", "GENE_OR_GENE_PRODUCT", 56, 63], ["Snapin", "GENE_OR_GENE_PRODUCT", 72, 78], ["DCs", "CELL_TYPE", 3, 6], ["TLR8", "PROTEIN", 38, 42], ["motilin protein", "PROTEIN", 56, 71], ["Snapin", "PROTEIN", 72, 78], ["HIV-1", "SPECIES", 8, 13], ["HIV-1", "SPECIES", 8, 13], ["HIV", "TEST", 8, 11], ["TLR8", "TREATMENT", 38, 42], ["the motilin protein Snapin", "TREATMENT", 52, 78]]], ["Inhibiting Snapin enhances the localization of early endosomes of HIV-1 and TLR8, triggers the proinflammatory response, and inhibits the infection of CD4 T cells [145].", [["early endosomes", "ANATOMY", 47, 62], ["CD4 T cells", "ANATOMY", 151, 162], ["Snapin", "CHEMICAL", 11, 17], ["infection", "DISEASE", 138, 147], ["Snapin", "GENE_OR_GENE_PRODUCT", 11, 17], ["early endosomes", "CELLULAR_COMPONENT", 47, 62], ["HIV-1", "GENE_OR_GENE_PRODUCT", 66, 71], ["TLR8", "GENE_OR_GENE_PRODUCT", 76, 80], ["Snapin", "PROTEIN", 11, 17], ["TLR8", "PROTEIN", 76, 80], ["CD4 T cells", "CELL_TYPE", 151, 162], ["HIV-1", "SPECIES", 66, 71], ["HIV-1", "SPECIES", 66, 71], ["HIV", "TEST", 66, 69], ["TLR8", "TREATMENT", 76, 80], ["the proinflammatory response", "TEST", 91, 119], ["the infection of CD4 T cells", "PROBLEM", 134, 162], ["early", "OBSERVATION_MODIFIER", 47, 52], ["endosomes", "OBSERVATION_MODIFIER", 53, 62], ["proinflammatory response", "OBSERVATION", 95, 119]]], ["These results show that TLR8 plays a critical role in innate immune sensing of HIV in DCs.", [["DCs", "ANATOMY", 86, 89], ["TLR8", "GENE_OR_GENE_PRODUCT", 24, 28], ["HIV", "ORGANISM", 79, 82], ["DCs", "CELL", 86, 89], ["TLR8", "PROTEIN", 24, 28], ["DCs", "CELL_TYPE", 86, 89], ["HIV", "SPECIES", 79, 82], ["HIV in DCs", "TREATMENT", 79, 89]]], ["Except for TLR7 and 8, Chen and his colleagues reported TAR RNA-containing exosomes from HIV-infected T cells activate ERK cascades in an EGFR/TLR3-dependent manner to promote the growth and progress of specific NADCs [146].", [["exosomes", "ANATOMY", 75, 83], ["T cells", "ANATOMY", 102, 109], ["TLR7", "GENE_OR_GENE_PRODUCT", 11, 15], ["TAR", "GENE_OR_GENE_PRODUCT", 56, 59], ["exosomes", "CELL", 75, 83], ["HIV", "ORGANISM", 89, 92], ["T cells", "CELL", 102, 109], ["ERK", "GENE_OR_GENE_PRODUCT", 119, 122], ["EGFR", "GENE_OR_GENE_PRODUCT", 138, 142], ["TLR3", "GENE_OR_GENE_PRODUCT", 143, 147], ["TLR7", "PROTEIN", 11, 15], ["TAR RNA", "RNA", 56, 63], ["exosomes", "CELL_TYPE", 75, 83], ["HIV-infected T cells", "CELL_TYPE", 89, 109], ["ERK", "PROTEIN", 119, 122], ["EGFR", "PROTEIN", 138, 142], ["TLR3", "PROTEIN", 143, 147], ["HIV", "SPECIES", 89, 92], ["HIV", "SPECIES", 89, 92], ["TAR RNA", "PROBLEM", 56, 63], ["HIV", "PROBLEM", 89, 92], ["infected T cells", "TREATMENT", 93, 109], ["ERK cascades", "TREATMENT", 119, 131], ["an EGFR/TLR3-dependent manner", "TREATMENT", 135, 164]]], ["Tachado et al. demonstrated that HIV infection is associated with macrophage TLR4-mediated signal transduction impairment, especially for MyD88-dependent TLR4-mediated signal transduction pathway [147].", [["macrophage", "ANATOMY", 66, 76], ["HIV infection", "DISEASE", 33, 46], ["HIV", "ORGANISM", 33, 36], ["macrophage", "CELL", 66, 76], ["TLR4", "GENE_OR_GENE_PRODUCT", 77, 81], ["MyD88", "GENE_OR_GENE_PRODUCT", 138, 143], ["TLR4", "GENE_OR_GENE_PRODUCT", 154, 158], ["TLR4", "PROTEIN", 77, 81], ["MyD88", "PROTEIN", 138, 143], ["TLR4", "PROTEIN", 154, 158], ["HIV", "SPECIES", 33, 36], ["HIV", "SPECIES", 33, 36], ["HIV infection", "PROBLEM", 33, 46], ["macrophage TLR4-mediated signal transduction impairment", "PROBLEM", 66, 121], ["MyD88", "TEST", 138, 143], ["HIV", "OBSERVATION_MODIFIER", 33, 36], ["infection", "OBSERVATION", 37, 46], ["associated with", "UNCERTAINTY", 50, 65]]], ["These findings have not yet established a link between HIV infection, TLRs and atherosclerosis, but provide a strong basis for our study on whether TLRs play a role in the process of atherosclerosis associated with HIV infection, and further research is still needed.Other pathogens associated with atherosclerosis ::: Role of TLRs in pathogen-induced atherosclerosisIn addition to the above four pathogens, other pathogens have been identified to be associated with ASVD.", [["HIV infection", "DISEASE", 55, 68], ["atherosclerosis", "DISEASE", 79, 94], ["atherosclerosis", "DISEASE", 183, 198], ["HIV infection", "DISEASE", 215, 228], ["atherosclerosis", "DISEASE", 299, 314], ["atherosclerosis", "DISEASE", 352, 367], ["ASVD", "DISEASE", 467, 471], ["HIV", "ORGANISM", 55, 58], ["TLRs", "GENE_OR_GENE_PRODUCT", 70, 74], ["TLRs", "GENE_OR_GENE_PRODUCT", 148, 152], ["HIV", "ORGANISM", 215, 218], ["TLRs", "GENE_OR_GENE_PRODUCT", 327, 331], ["TLRs", "PROTEIN", 70, 74], ["TLRs", "PROTEIN", 148, 152], ["TLRs", "PROTEIN", 327, 331], ["HIV", "SPECIES", 55, 58], ["HIV", "SPECIES", 55, 58], ["HIV", "SPECIES", 215, 218], ["HIV infection", "PROBLEM", 55, 68], ["TLRs", "PROBLEM", 70, 74], ["atherosclerosis", "PROBLEM", 79, 94], ["our study", "TEST", 127, 136], ["atherosclerosis", "PROBLEM", 183, 198], ["HIV infection", "PROBLEM", 215, 228], ["Other pathogens", "PROBLEM", 267, 282], ["atherosclerosis", "PROBLEM", 299, 314], ["atherosclerosis", "PROBLEM", 352, 367], ["the above four pathogens", "PROBLEM", 382, 406], ["other pathogens", "PROBLEM", 408, 423], ["ASVD", "PROBLEM", 467, 471], ["HIV", "OBSERVATION_MODIFIER", 55, 58], ["infection", "OBSERVATION", 59, 68], ["atherosclerosis", "OBSERVATION", 79, 94], ["atherosclerosis", "OBSERVATION", 183, 198], ["HIV", "OBSERVATION_MODIFIER", 215, 218], ["infection", "OBSERVATION", 219, 228], ["pathogens", "OBSERVATION", 273, 282], ["atherosclerosis", "OBSERVATION", 299, 314], ["atherosclerosis", "OBSERVATION", 352, 367]]], ["For instance, CMV protein was detected in the arterial cells of atherosclerotic patients [148].", [["arterial cells", "ANATOMY", 46, 60], ["atherosclerotic", "DISEASE", 64, 79], ["CMV", "ORGANISM", 14, 17], ["arterial cells", "CELL", 46, 60], ["patients", "ORGANISM", 80, 88], ["CMV protein", "PROTEIN", 14, 25], ["arterial cells", "CELL_TYPE", 46, 60], ["patients", "SPECIES", 80, 88], ["CMV", "SPECIES", 14, 17], ["CMV protein", "TEST", 14, 25], ["CMV protein", "OBSERVATION", 14, 25], ["arterial cells", "ANATOMY", 46, 60], ["atherosclerotic", "OBSERVATION_MODIFIER", 64, 79]]], ["High levels of anti-CMV antibodies are associated with clinically significant atherosclerosis [149].", [["atherosclerosis", "DISEASE", 78, 93], ["anti-CMV antibodies", "PROTEIN", 15, 34], ["anti-CMV antibodies", "TREATMENT", 15, 34], ["clinically significant atherosclerosis", "PROBLEM", 55, 93], ["anti-CMV antibodies", "OBSERVATION", 15, 34], ["significant", "OBSERVATION_MODIFIER", 66, 77], ["atherosclerosis", "OBSERVATION", 78, 93]]], ["HCMV belongs to the beta-herpesvirus subfamily, and its chronic infection of the vasculature is associated with the development of ASVD, including atherosclerosis, restenosis, and transplant vascular sclerosis [150].", [["vasculature", "ANATOMY", 81, 92], ["vascular", "ANATOMY", 191, 199], ["infection of the vasculature", "DISEASE", 64, 92], ["ASVD", "DISEASE", 131, 135], ["atherosclerosis", "DISEASE", 147, 162], ["restenosis", "DISEASE", 164, 174], ["transplant vascular sclerosis", "DISEASE", 180, 209], ["HCMV", "ORGANISM", 0, 4], ["beta-herpesvirus", "GENE_OR_GENE_PRODUCT", 20, 36], ["vasculature", "MULTI-TISSUE_STRUCTURE", 81, 92], ["ASVD", "CANCER", 131, 135], ["vascular", "MULTI-TISSUE_STRUCTURE", 191, 199], ["beta-herpesvirus subfamily", "PROTEIN", 20, 46], ["HCMV", "SPECIES", 0, 4], ["HCMV", "PROBLEM", 0, 4], ["its chronic infection of the vasculature", "PROBLEM", 52, 92], ["ASVD", "PROBLEM", 131, 135], ["atherosclerosis", "PROBLEM", 147, 162], ["restenosis", "PROBLEM", 164, 174], ["transplant vascular sclerosis", "PROBLEM", 180, 209], ["chronic", "OBSERVATION_MODIFIER", 56, 63], ["infection", "OBSERVATION", 64, 73], ["vasculature", "ANATOMY", 81, 92], ["atherosclerosis", "OBSERVATION", 147, 162], ["restenosis", "OBSERVATION", 164, 174], ["transplant", "OBSERVATION_MODIFIER", 180, 190], ["vascular", "ANATOMY", 191, 199], ["sclerosis", "OBSERVATION", 200, 209]]], ["In vivo studies showed that HCMV infection of the vessel wall affects a variety of cells, including monocytes/macrophages, SMCs and ECs [151].", [["vessel wall", "ANATOMY", 50, 61], ["cells", "ANATOMY", 83, 88], ["monocytes", "ANATOMY", 100, 109], ["macrophages", "ANATOMY", 110, 121], ["SMCs", "ANATOMY", 123, 127], ["ECs", "ANATOMY", 132, 135], ["HCMV infection", "DISEASE", 28, 42], ["HCMV", "ORGANISM", 28, 32], ["vessel wall", "MULTI-TISSUE_STRUCTURE", 50, 61], ["cells", "CELL", 83, 88], ["monocytes", "CELL", 100, 109], ["macrophages", "CELL", 110, 121], ["SMCs", "CELL", 123, 127], ["ECs", "CELL", 132, 135], ["monocytes", "CELL_TYPE", 100, 109], ["macrophages", "CELL_TYPE", 110, 121], ["SMCs", "CELL_TYPE", 123, 127], ["ECs", "CELL_TYPE", 132, 135], ["HCMV", "SPECIES", 28, 32], ["vivo studies", "TEST", 3, 15], ["HCMV infection of the vessel wall", "PROBLEM", 28, 61], ["monocytes", "TEST", 100, 109], ["macrophages", "TEST", 110, 121], ["SMCs", "TEST", 123, 127], ["ECs", "TEST", 132, 135], ["HCMV", "OBSERVATION_MODIFIER", 28, 32], ["infection", "OBSERVATION", 33, 42], ["vessel", "ANATOMY", 50, 56], ["wall", "ANATOMY_MODIFIER", 57, 61], ["variety of cells", "OBSERVATION", 72, 88], ["macrophages", "ANATOMY", 110, 121]]], ["CMV infection mainly influences the proliferation of SMCs, leading to thickening of the intima.", [["SMCs", "ANATOMY", 53, 57], ["intima", "ANATOMY", 88, 94], ["CMV infection", "DISEASE", 0, 13], ["CMV", "ORGANISM", 0, 3], ["SMCs", "CELL", 53, 57], ["intima", "TISSUE", 88, 94], ["SMCs", "CELL_TYPE", 53, 57], ["CMV", "SPECIES", 0, 3], ["CMV infection", "PROBLEM", 0, 13], ["the proliferation of SMCs", "PROBLEM", 32, 57], ["thickening of the intima", "PROBLEM", 70, 94], ["infection", "OBSERVATION", 4, 13], ["proliferation", "OBSERVATION_MODIFIER", 36, 49], ["SMCs", "ANATOMY", 53, 57], ["thickening", "OBSERVATION", 70, 80], ["intima", "ANATOMY", 88, 94]]], ["Another study suggests that the TLR-2 gene polymorphism may be associated with congenital CMV infection, but its mechanism remains to be elucidated [152].", [["congenital CMV infection", "DISEASE", 79, 103], ["TLR-2", "GENE_OR_GENE_PRODUCT", 32, 37], ["CMV", "ORGANISM", 90, 93], ["TLR-2 gene", "DNA", 32, 42], ["CMV", "SPECIES", 90, 93], ["Another study", "TEST", 0, 13], ["the TLR-2 gene polymorphism", "PROBLEM", 28, 55], ["congenital CMV infection", "PROBLEM", 79, 103], ["may be associated with", "UNCERTAINTY", 56, 78], ["congenital", "OBSERVATION_MODIFIER", 79, 89], ["CMV infection", "OBSERVATION", 90, 103]]], ["Assinger et al. demonstrated HCMV binds to a TLR-2 positive platelet subpopulation, leading to signal transduction, degranulation and release of CD40L, IL-1\u03b2 and VEGF [153]. pDCs is a major source of IFN-I during CMV infection.", [["platelet", "ANATOMY", 60, 68], ["pDCs", "ANATOMY", 174, 178], ["CMV infection", "DISEASE", 213, 226], ["HCMV", "ORGANISM", 29, 33], ["TLR-2", "GENE_OR_GENE_PRODUCT", 45, 50], ["CD40L", "GENE_OR_GENE_PRODUCT", 145, 150], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 152, 157], ["VEGF", "GENE_OR_GENE_PRODUCT", 162, 166], ["pDCs", "CELL", 174, 178], ["IFN-I", "GENE_OR_GENE_PRODUCT", 200, 205], ["CMV", "ORGANISM", 213, 216], ["TLR", "PROTEIN", 45, 48], ["CD40L", "PROTEIN", 145, 150], ["IL-1\u03b2", "PROTEIN", 152, 157], ["VEGF", "PROTEIN", 162, 166], ["pDCs", "CELL_TYPE", 174, 178], ["IFN", "PROTEIN", 200, 203], ["HCMV", "SPECIES", 29, 33], ["CMV", "SPECIES", 213, 216], ["HCMV binds", "PROBLEM", 29, 39], ["a TLR", "TEST", 43, 48], ["positive platelet subpopulation", "PROBLEM", 51, 82], ["signal transduction", "TEST", 95, 114], ["degranulation", "PROBLEM", 116, 129], ["CD40L", "TEST", 145, 150], ["IL", "TEST", 152, 154], ["IFN", "PROBLEM", 200, 203], ["CMV infection", "PROBLEM", 213, 226], ["HCMV", "OBSERVATION", 29, 33], ["platelet subpopulation", "OBSERVATION", 60, 82], ["infection", "OBSERVATION", 217, 226]]], ["This response requires pDC-endogenous MyD88-dependent signaling by TLR7 and 9.", [["pDC", "GENE_OR_GENE_PRODUCT", 23, 26], ["MyD88", "GENE_OR_GENE_PRODUCT", 38, 43], ["TLR7", "GENE_OR_GENE_PRODUCT", 67, 71], ["MyD88", "PROTEIN", 38, 43], ["TLR7 and 9", "PROTEIN", 67, 77], ["pDC", "TEST", 23, 26]]], ["In addition to CMV, evidence of the association between HSV and atherosclerosis was initially confirmed by Benditt et al. by in situ hybridization of atherosclerotic vessel walls [154].", [["atherosclerotic vessel walls", "ANATOMY", 150, 178], ["atherosclerosis", "DISEASE", 64, 79], ["atherosclerotic", "DISEASE", 150, 165], ["CMV", "ORGANISM", 15, 18], ["HSV", "ORGANISM", 56, 59], ["vessel", "MULTI-TISSUE_STRUCTURE", 166, 172], ["CMV", "SPECIES", 15, 18], ["HSV", "SPECIES", 56, 59], ["CMV", "PROBLEM", 15, 18], ["HSV", "PROBLEM", 56, 59], ["atherosclerosis", "PROBLEM", 64, 79], ["CMV", "OBSERVATION", 15, 18], ["atherosclerosis", "OBSERVATION", 64, 79], ["atherosclerotic", "OBSERVATION", 150, 165], ["vessel", "ANATOMY", 166, 172], ["walls", "ANATOMY_MODIFIER", 173, 178]]], ["In vitro studies by Hajjar et al. found that herpes infection affects the nervous system of smooth muscle cells, and excessive cholesterol ester accumulation in infected cells [155].", [["nervous system", "ANATOMY", 74, 88], ["smooth muscle cells", "ANATOMY", 92, 111], ["cells", "ANATOMY", 170, 175], ["herpes infection", "DISEASE", 45, 61], ["cholesterol ester", "CHEMICAL", 127, 144], ["cholesterol ester", "CHEMICAL", 127, 144], ["herpes", "ORGANISM", 45, 51], ["nervous system", "ANATOMICAL_SYSTEM", 74, 88], ["smooth muscle cells", "CELL", 92, 111], ["cholesterol ester", "SIMPLE_CHEMICAL", 127, 144], ["cells", "CELL", 170, 175], ["smooth muscle cells", "CELL_TYPE", 92, 111], ["infected cells", "CELL_TYPE", 161, 175], ["vitro studies", "TEST", 3, 16], ["herpes infection", "PROBLEM", 45, 61], ["smooth muscle cells", "PROBLEM", 92, 111], ["excessive cholesterol ester accumulation in infected cells", "PROBLEM", 117, 175], ["herpes infection", "OBSERVATION", 45, 61], ["nervous system", "ANATOMY", 74, 88], ["smooth muscle", "ANATOMY", 92, 105], ["cells", "OBSERVATION", 106, 111], ["excessive", "OBSERVATION_MODIFIER", 117, 126], ["cholesterol ester", "OBSERVATION", 127, 144], ["infected cells", "OBSERVATION", 161, 175]]], ["Sato and his colleagues found that during infection with HSV-1, TLR3 recruited the metabolic checkpoint kinase complex mtorc2 to activate the molecules needed to induce IFN I [156].", [["infection", "DISEASE", 42, 51], ["HSV-1", "ORGANISM", 57, 62], ["TLR3", "GENE_OR_GENE_PRODUCT", 64, 68], ["mtorc2", "GENE_OR_GENE_PRODUCT", 119, 125], ["TLR3", "PROTEIN", 64, 68], ["metabolic checkpoint kinase complex", "PROTEIN", 83, 118], ["mtorc2", "PROTEIN", 119, 125], ["IFN I", "PROTEIN", 169, 174], ["HSV-1", "SPECIES", 57, 62], ["HSV-1", "SPECIES", 57, 62], ["HSV", "TEST", 57, 60], ["TLR3", "TREATMENT", 64, 68], ["the metabolic checkpoint kinase complex mtorc2", "TREATMENT", 79, 125], ["infection", "OBSERVATION", 42, 51]]], ["Reinert et al. reported that TLR3 plays a role in astrocytes, preventing HSV from spreading beyound the neurons that mediate the entry into the central nervous system (CNS) [157].", [["astrocytes", "ANATOMY", 50, 60], ["neurons", "ANATOMY", 104, 111], ["central nervous system", "ANATOMY", 144, 166], ["CNS", "ANATOMY", 168, 171], ["TLR3", "GENE_OR_GENE_PRODUCT", 29, 33], ["astrocytes", "CELL", 50, 60], ["HSV", "ORGANISM", 73, 76], ["neurons", "CELL", 104, 111], ["central nervous system", "ANATOMICAL_SYSTEM", 144, 166], ["CNS", "ANATOMICAL_SYSTEM", 168, 171], ["TLR3", "PROTEIN", 29, 33], ["astrocytes", "CELL_TYPE", 50, 60], ["HSV", "SPECIES", 73, 76], ["astrocytes", "PROBLEM", 50, 60], ["HSV", "PROBLEM", 73, 76], ["central", "ANATOMY_MODIFIER", 144, 151], ["nervous system", "ANATOMY", 152, 166]]], ["In addition, Ahmad et al. demonstrated that HSV-1 induced activation of TLR2-dependent IL-15 gene expression, which required recruitment of MyD88 and TIRAP/MAL and the activation of IRAK 1 and TRAF6 resulting in nuclear transfer of NF-\u03baB [158].", [["nuclear", "ANATOMY", 212, 219], ["HSV-1", "ORGANISM", 44, 49], ["TLR2", "GENE_OR_GENE_PRODUCT", 72, 76], ["IL-15", "GENE_OR_GENE_PRODUCT", 87, 92], ["MyD88", "GENE_OR_GENE_PRODUCT", 140, 145], ["TIRAP", "GENE_OR_GENE_PRODUCT", 150, 155], ["MAL", "GENE_OR_GENE_PRODUCT", 156, 159], ["IRAK 1", "GENE_OR_GENE_PRODUCT", 182, 188], ["TRAF6", "GENE_OR_GENE_PRODUCT", 193, 198], ["nuclear", "CELLULAR_COMPONENT", 212, 219], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 232, 237], ["TLR2", "PROTEIN", 72, 76], ["IL", "PROTEIN", 87, 89], ["MyD88", "PROTEIN", 140, 145], ["TIRAP", "PROTEIN", 150, 155], ["MAL", "PROTEIN", 156, 159], ["IRAK 1", "PROTEIN", 182, 188], ["TRAF6", "PROTEIN", 193, 198], ["NF-\u03baB", "PROTEIN", 232, 237], ["HSV-1", "SPECIES", 44, 49], ["HSV", "TEST", 44, 47], ["TLR2-dependent IL", "TREATMENT", 72, 89], ["recruitment of MyD88", "TREATMENT", 125, 145], ["TIRAP/MAL", "TREATMENT", 150, 159], ["IRAK", "TEST", 182, 186]]], ["Krug et al. demonstrated that the secretion of IFN I induced by HSV-1 stimulation in vitro was mediated by TLR9/MYD88 pathway [51].", [["IFN I", "GENE_OR_GENE_PRODUCT", 47, 52], ["HSV-1", "ORGANISM", 64, 69], ["TLR9", "GENE_OR_GENE_PRODUCT", 107, 111], ["MYD88", "GENE_OR_GENE_PRODUCT", 112, 117], ["IFN I", "PROTEIN", 47, 52], ["TLR9", "PROTEIN", 107, 111], ["MYD88", "PROTEIN", 112, 117], ["HSV-1", "SPECIES", 64, 69], ["the secretion of IFN I", "PROBLEM", 30, 52], ["HSV", "TEST", 64, 67]]], ["Lund et al. reported that the genomic DNA of HSV-2 could bind to TLR9 and secrete interferon-alpha through pDCs [159].", [["DNA", "CELLULAR_COMPONENT", 38, 41], ["HSV-2", "ORGANISM", 45, 50], ["TLR9", "GENE_OR_GENE_PRODUCT", 65, 69], ["interferon-alpha", "GENE_OR_GENE_PRODUCT", 82, 98], ["genomic DNA", "DNA", 30, 41], ["TLR9", "PROTEIN", 65, 69], ["interferon-alpha", "PROTEIN", 82, 98], ["pDCs", "CELL_TYPE", 107, 111], ["HSV-2", "SPECIES", 45, 50], ["HSV", "TEST", 45, 48], ["TLR9", "TEST", 65, 69], ["secrete interferon", "TEST", 74, 92], ["et al", "OBSERVATION", 5, 10]]], ["Welner et al. found that the common lymphoid progenitor cells (CLPS) of mice infected with active HSV-1 tended to differentiate into DCs, which was largely dependent on TLR9 [160].Anti-infective treatment ::: Potential therapeutic targetsMuhlestein and his colleagues found that C. pneumoniae infection accelerated the thickness of the intimal wall and the degree of atherosclerosis in a rabbit model, and treatment with azithromycin lead to attenuation of atherosclerosis [161].", [["lymphoid progenitor cells", "ANATOMY", 36, 61], ["CLPS", "ANATOMY", 63, 67], ["DCs", "ANATOMY", 133, 136], ["intimal wall", "ANATOMY", 336, 348], ["C. pneumoniae infection", "DISEASE", 279, 302], ["atherosclerosis", "DISEASE", 367, 382], ["azithromycin", "CHEMICAL", 421, 433], ["atherosclerosis", "DISEASE", 457, 472], ["azithromycin", "CHEMICAL", 421, 433], ["lymphoid progenitor cells", "CELL", 36, 61], ["CLPS", "CELL", 63, 67], ["mice", "ORGANISM", 72, 76], ["HSV-1", "ORGANISM", 98, 103], ["DCs", "CELL", 133, 136], ["TLR9", "GENE_OR_GENE_PRODUCT", 169, 173], ["C. pneumoniae", "ORGANISM", 279, 292], ["intimal wall", "TISSUE", 336, 348], ["rabbit", "ORGANISM", 388, 394], ["azithromycin", "SIMPLE_CHEMICAL", 421, 433], ["common lymphoid progenitor cells", "CELL_TYPE", 29, 61], ["CLPS", "CELL_TYPE", 63, 67], ["DCs", "CELL_TYPE", 133, 136], ["TLR9", "PROTEIN", 169, 173], ["mice", "SPECIES", 72, 76], ["HSV-1", "SPECIES", 98, 103], ["C. pneumoniae", "SPECIES", 279, 292], ["rabbit", "SPECIES", 388, 394], ["mice", "SPECIES", 72, 76], ["HSV-1", "SPECIES", 98, 103], ["C. pneumoniae", "SPECIES", 279, 292], ["rabbit", "SPECIES", 388, 394], ["mice infected", "PROBLEM", 72, 85], ["active HSV", "TEST", 91, 101], ["C. pneumoniae infection", "PROBLEM", 279, 302], ["atherosclerosis", "PROBLEM", 367, 382], ["a rabbit model", "TREATMENT", 386, 400], ["treatment", "TREATMENT", 406, 415], ["azithromycin", "TREATMENT", 421, 433], ["atherosclerosis", "PROBLEM", 457, 472], ["common lymphoid", "ANATOMY", 29, 44], ["progenitor cells", "OBSERVATION", 45, 61], ["active", "OBSERVATION_MODIFIER", 91, 97], ["HSV", "OBSERVATION", 98, 101], ["dependent", "OBSERVATION_MODIFIER", 156, 165], ["pneumoniae", "OBSERVATION_MODIFIER", 282, 292], ["infection", "OBSERVATION", 293, 302], ["thickness", "OBSERVATION_MODIFIER", 319, 328], ["intimal wall", "ANATOMY", 336, 348], ["degree", "OBSERVATION_MODIFIER", 357, 363], ["atherosclerosis", "OBSERVATION", 367, 382], ["rabbit model", "OBSERVATION", 388, 400], ["attenuation", "OBSERVATION_MODIFIER", 442, 453], ["atherosclerosis", "OBSERVATION", 457, 472]]], ["However, Rothstein et al. reported that C. pneumoniae infection increased the size of lesions in mice, but azithromycin did not reduce the size of aortic lesions [162].", [["lesions", "ANATOMY", 86, 93], ["aortic lesions", "ANATOMY", 147, 161], ["C. pneumoniae infection", "DISEASE", 40, 63], ["azithromycin", "CHEMICAL", 107, 119], ["azithromycin", "CHEMICAL", 107, 119], ["C. pneumoniae", "ORGANISM", 40, 53], ["lesions", "PATHOLOGICAL_FORMATION", 86, 93], ["mice", "ORGANISM", 97, 101], ["azithromycin", "SIMPLE_CHEMICAL", 107, 119], ["aortic lesions", "PATHOLOGICAL_FORMATION", 147, 161], ["C. pneumoniae", "SPECIES", 40, 53], ["mice", "SPECIES", 97, 101], ["C. pneumoniae", "SPECIES", 40, 53], ["mice", "SPECIES", 97, 101], ["C. pneumoniae infection", "PROBLEM", 40, 63], ["lesions in mice", "PROBLEM", 86, 101], ["azithromycin", "TREATMENT", 107, 119], ["aortic lesions", "PROBLEM", 147, 161], ["pneumoniae", "OBSERVATION_MODIFIER", 43, 53], ["infection", "OBSERVATION", 54, 63], ["size", "OBSERVATION_MODIFIER", 78, 82], ["lesions", "OBSERVATION", 86, 93], ["size", "OBSERVATION_MODIFIER", 139, 143], ["aortic", "ANATOMY", 147, 153], ["lesions", "OBSERVATION", 154, 161]]], ["Madan et al. have demonstrated that doxycycline treatment reduced circulating pro-inflammatory cytokine levels and the development of related atherosclerosis in ApoE\u2212/\u2212 model mice infected with P. gingivalis [163].", [["doxycycline", "CHEMICAL", 36, 47], ["atherosclerosis", "DISEASE", 142, 157], ["doxycycline", "CHEMICAL", 36, 47], ["doxycycline", "SIMPLE_CHEMICAL", 36, 47], ["ApoE\u2212/\u2212", "ORGANISM", 161, 168], ["mice", "ORGANISM", 175, 179], ["P. gingivalis", "ORGANISM", 194, 207], ["pro-inflammatory cytokine", "PROTEIN", 78, 103], ["mice", "SPECIES", 175, 179], ["P. gingivalis", "SPECIES", 194, 207], ["mice", "SPECIES", 175, 179], ["P. gingivalis", "SPECIES", 194, 207], ["doxycycline treatment", "TREATMENT", 36, 57], ["circulating pro-inflammatory cytokine levels", "PROBLEM", 66, 110], ["related atherosclerosis", "PROBLEM", 134, 157], ["P. gingivalis", "PROBLEM", 194, 207], ["doxycycline", "OBSERVATION", 36, 47], ["atherosclerosis", "OBSERVATION", 142, 157]]], ["Amar et al. found that treatment with metronidazole before vaccination with P. gingivalis can significantly reduce the size of circulating inflammatory markers and atherosclerotic lesions [164].", [["atherosclerotic lesions", "ANATOMY", 164, 187], ["metronidazole", "CHEMICAL", 38, 51], ["atherosclerotic lesions", "DISEASE", 164, 187], ["metronidazole", "CHEMICAL", 38, 51], ["metronidazole", "SIMPLE_CHEMICAL", 38, 51], ["P. gingivalis", "ORGANISM", 76, 89], ["atherosclerotic lesions", "PATHOLOGICAL_FORMATION", 164, 187], ["circulating inflammatory markers", "PROTEIN", 127, 159], ["P. gingivalis", "SPECIES", 76, 89], ["P. gingivalis", "SPECIES", 76, 89], ["metronidazole", "TREATMENT", 38, 51], ["vaccination", "TREATMENT", 59, 70], ["P. gingivalis", "PROBLEM", 76, 89], ["circulating inflammatory markers", "PROBLEM", 127, 159], ["atherosclerotic lesions", "PROBLEM", 164, 187], ["size", "OBSERVATION_MODIFIER", 119, 123], ["circulating", "OBSERVATION_MODIFIER", 127, 138], ["inflammatory", "OBSERVATION_MODIFIER", 139, 151], ["atherosclerotic", "OBSERVATION_MODIFIER", 164, 179], ["lesions", "OBSERVATION", 180, 187]]], ["Ayada et al. showed that triple drug therapy (leserazole, amoxicillin, clarithromycin) can reduce the atherogenic effect of H. pylori infection in gastrointestinal tract [122].", [["gastrointestinal tract", "ANATOMY", 147, 169], ["leserazole", "CHEMICAL", 46, 56], ["amoxicillin", "CHEMICAL", 58, 69], ["clarithromycin", "CHEMICAL", 71, 85], ["H. pylori infection", "DISEASE", 124, 143], ["leserazole", "CHEMICAL", 46, 56], ["amoxicillin", "CHEMICAL", 58, 69], ["clarithromycin", "CHEMICAL", 71, 85], ["leserazole", "SIMPLE_CHEMICAL", 46, 56], ["amoxicillin", "SIMPLE_CHEMICAL", 58, 69], ["clarithromycin", "SIMPLE_CHEMICAL", 71, 85], ["H. pylori", "ORGANISM", 124, 133], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 147, 169], ["H. pylori", "SPECIES", 124, 133], ["H. pylori", "SPECIES", 124, 133], ["triple drug therapy", "TREATMENT", 25, 44], ["leserazole", "TREATMENT", 46, 56], ["amoxicillin", "TREATMENT", 58, 69], ["clarithromycin", "TREATMENT", 71, 85], ["H. pylori infection in gastrointestinal tract", "PROBLEM", 124, 169], ["atherogenic", "OBSERVATION_MODIFIER", 102, 113], ["H. pylori infection", "OBSERVATION", 124, 143], ["gastrointestinal tract", "ANATOMY", 147, 169]]], ["In addition to animal studies, anti-infective therapies for the treatment of atherosclerosis in humans are also underway.", [["atherosclerosis", "DISEASE", 77, 92], ["humans", "ORGANISM", 96, 102], ["humans", "SPECIES", 96, 102], ["humans", "SPECIES", 96, 102], ["animal studies", "TEST", 15, 29], ["anti-infective therapies", "TREATMENT", 31, 55], ["atherosclerosis in humans", "PROBLEM", 77, 102], ["atherosclerosis", "OBSERVATION", 77, 92]]], ["However, contrary to the results of animal studies, most clinical trials of anti-infective therapy did not demonstrate a role in delaying atherosclerotic events, although the antibiotic selection, treatment regimen and duration of treatment in these clinical trials are sufficient [165, 166].", [["atherosclerotic", "ANATOMY", 138, 153], ["atherosclerotic", "DISEASE", 138, 153], ["atherosclerotic", "IMMATERIAL_ANATOMICAL_ENTITY", 138, 153], ["animal studies", "TEST", 36, 50], ["anti-infective therapy", "TREATMENT", 76, 98], ["atherosclerotic events", "PROBLEM", 138, 160], ["the antibiotic selection", "TREATMENT", 171, 195], ["treatment regimen", "TREATMENT", 197, 214], ["treatment", "TREATMENT", 231, 240], ["atherosclerotic", "OBSERVATION", 138, 153]]], ["The negative results of these trials indicate that although pathogens are present in atherosclerotic plaques, they may not be the indispensable culprit in the progression of atherosclerosis.", [["atherosclerotic plaques", "ANATOMY", 85, 108], ["atherosclerotic plaques", "DISEASE", 85, 108], ["atherosclerosis", "DISEASE", 174, 189], ["atherosclerotic plaques", "PATHOLOGICAL_FORMATION", 85, 108], ["these trials", "TEST", 24, 36], ["pathogens", "PROBLEM", 60, 69], ["atherosclerotic plaques", "PROBLEM", 85, 108], ["atherosclerosis", "PROBLEM", 174, 189], ["atherosclerotic", "OBSERVATION_MODIFIER", 85, 100], ["plaques", "OBSERVATION", 101, 108], ["may not be", "UNCERTAINTY", 115, 125], ["progression", "OBSERVATION_MODIFIER", 159, 170], ["atherosclerosis", "OBSERVATION", 174, 189]]], ["However, these results do not fully confirm this point of view, because the treatment ineffectiveness of antibiotics in atherosclerotic diseases is also reasonable.", [["atherosclerotic", "ANATOMY", 120, 135], ["atherosclerotic diseases", "DISEASE", 120, 144], ["antibiotics", "TREATMENT", 105, 116], ["atherosclerotic diseases", "PROBLEM", 120, 144], ["atherosclerotic", "OBSERVATION_MODIFIER", 120, 135], ["diseases", "OBSERVATION", 136, 144]]], ["First, long-term antibiotic treatment can lead to drug resistance.", [["long-term antibiotic treatment", "TREATMENT", 7, 37], ["drug resistance", "PROBLEM", 50, 65], ["drug resistance", "OBSERVATION", 50, 65]]], ["Secondly, it may be that antibiotic treatment is too late to produce significant clinical effects.", [["antibiotic treatment", "TREATMENT", 25, 45]]], ["Thirdly, persistent low-grade chronic inflammation does not respond to antibiotic treatment.", [["inflammation", "DISEASE", 38, 50], ["persistent low-grade chronic inflammation", "PROBLEM", 9, 50], ["antibiotic treatment", "TREATMENT", 71, 91], ["persistent", "OBSERVATION_MODIFIER", 9, 19], ["low-grade", "OBSERVATION_MODIFIER", 20, 29], ["chronic", "OBSERVATION_MODIFIER", 30, 37], ["inflammation", "OBSERVATION", 38, 50]]], ["Recently, a hypothesis has been proposed that infection plays a \u201cmatch\u201d role for atherosclerosis.", [["infection", "DISEASE", 46, 55], ["atherosclerosis", "DISEASE", 81, 96], ["infection", "PROBLEM", 46, 55], ["atherosclerosis", "PROBLEM", 81, 96], ["infection", "OBSERVATION", 46, 55], ["atherosclerosis", "OBSERVATION", 81, 96]]], ["After igniting this pathological process, the fight against this \u201cspark\u201d does not inhibit the progression of atherosclerosis.", [["atherosclerosis", "DISEASE", 109, 124], ["this pathological process", "PROBLEM", 15, 40], ["atherosclerosis", "PROBLEM", 109, 124], ["progression", "OBSERVATION_MODIFIER", 94, 105], ["atherosclerosis", "OBSERVATION", 109, 124]]], ["Therefore, the fact that anti-infective treatment is ineffective does not deny the potential link between infection and atherosclerotic disease.Animal experiments ::: Vaccine against exogenous antigens ::: Vaccine treatment ::: Potential therapeutic targetsGiven the large number of studies confirming the close association between infection and atherosclerosis, some researchers have investigated the effects of vaccination against these microorganisms on the progression of atherosclerosis.", [["atherosclerotic", "ANATOMY", 120, 135], ["infection", "DISEASE", 106, 115], ["atherosclerotic disease", "DISEASE", 120, 143], ["infection", "DISEASE", 332, 341], ["atherosclerosis", "DISEASE", 346, 361], ["atherosclerosis", "DISEASE", 476, 491], ["exogenous antigens", "PROTEIN", 183, 201], ["anti-infective treatment", "TREATMENT", 25, 49], ["infection", "PROBLEM", 106, 115], ["atherosclerotic disease", "PROBLEM", 120, 143], ["Vaccine", "TREATMENT", 167, 174], ["studies", "TEST", 283, 290], ["infection", "PROBLEM", 332, 341], ["atherosclerosis", "PROBLEM", 346, 361], ["vaccination", "TREATMENT", 413, 424], ["these microorganisms", "PROBLEM", 433, 453], ["atherosclerosis", "PROBLEM", 476, 491], ["anti-infective", "OBSERVATION", 25, 39], ["infection", "OBSERVATION", 106, 115], ["atherosclerotic", "OBSERVATION_MODIFIER", 120, 135], ["disease", "OBSERVATION", 136, 143], ["large", "OBSERVATION_MODIFIER", 267, 272], ["infection", "OBSERVATION", 332, 341], ["atherosclerosis", "OBSERVATION", 346, 361], ["progression", "OBSERVATION_MODIFIER", 461, 472], ["atherosclerosis", "OBSERVATION", 476, 491]]], ["In animal models, exposure to P. gingivalis accelerated atherosclerosis, and its immunity reduced the extent of atherosclerosis [167].", [["atherosclerosis", "DISEASE", 56, 71], ["atherosclerosis", "DISEASE", 112, 127], ["P. gingivalis", "ORGANISM", 30, 43], ["P. gingivalis", "SPECIES", 30, 43], ["P. gingivalis", "SPECIES", 30, 43], ["P. gingivalis accelerated atherosclerosis", "PROBLEM", 30, 71], ["atherosclerosis", "PROBLEM", 112, 127], ["atherosclerosis", "OBSERVATION", 56, 71], ["extent", "OBSERVATION_MODIFIER", 102, 108], ["atherosclerosis", "OBSERVATION", 112, 127]]], ["Koizumi et al. used nasal cavity immunization with P. gingivalis outer membrane protein, which confirmed that the size of atherosclerotic lesions in the aortic sinus of mice was significantly reduced, and the concentration of circulating inflammatory cytokines was decreased [168].", [["nasal cavity", "ANATOMY", 20, 32], ["outer membrane", "ANATOMY", 65, 79], ["atherosclerotic lesions", "ANATOMY", 122, 145], ["aortic sinus", "ANATOMY", 153, 165], ["atherosclerotic", "DISEASE", 122, 137], ["nasal cavity", "MULTI-TISSUE_STRUCTURE", 20, 32], ["P. gingivalis outer membrane protein", "GENE_OR_GENE_PRODUCT", 51, 87], ["atherosclerotic lesions", "PATHOLOGICAL_FORMATION", 122, 145], ["aortic sinus", "MULTI-TISSUE_STRUCTURE", 153, 165], ["mice", "ORGANISM", 169, 173], ["P. gingivalis outer membrane protein", "PROTEIN", 51, 87], ["circulating inflammatory cytokines", "PROTEIN", 226, 260], ["P. gingivalis", "SPECIES", 51, 64], ["mice", "SPECIES", 169, 173], ["P. gingivalis", "SPECIES", 51, 64], ["mice", "SPECIES", 169, 173], ["nasal cavity immunization", "TREATMENT", 20, 45], ["P. gingivalis outer membrane protein", "TEST", 51, 87], ["atherosclerotic lesions", "PROBLEM", 122, 145], ["circulating inflammatory cytokines", "PROBLEM", 226, 260], ["nasal cavity", "ANATOMY", 20, 32], ["size", "OBSERVATION_MODIFIER", 114, 118], ["atherosclerotic", "OBSERVATION_MODIFIER", 122, 137], ["lesions", "OBSERVATION", 138, 145], ["aortic sinus", "ANATOMY", 153, 165], ["significantly", "OBSERVATION_MODIFIER", 178, 191], ["reduced", "OBSERVATION_MODIFIER", 192, 199], ["circulating", "OBSERVATION_MODIFIER", 226, 237], ["inflammatory", "OBSERVATION_MODIFIER", 238, 250]]], ["Binder et al. confirmed that when homozygous LDLR\u2212/\u2212 mice were immunized with S. pneumoniae, the specific antibodies to oxidized LDL increased and atherosclerosis decreased [169].", [["atherosclerosis", "DISEASE", 147, 162], ["LDLR", "GENE_OR_GENE_PRODUCT", 45, 49], ["S. pneumoniae", "ORGANISM", 78, 91], ["LDL", "SIMPLE_CHEMICAL", 129, 132], ["LDLR", "PROTEIN", 45, 49], ["specific antibodies", "PROTEIN", 97, 116], ["oxidized LDL", "PROTEIN", 120, 132], ["mice", "SPECIES", 53, 57], ["S. pneumoniae", "SPECIES", 78, 91], ["mice", "SPECIES", 53, 57], ["S. pneumoniae", "SPECIES", 78, 91], ["homozygous LDLR", "PROBLEM", 34, 49], ["S. pneumoniae", "PROBLEM", 78, 91], ["the specific antibodies", "TEST", 93, 116], ["oxidized LDL", "TEST", 120, 132], ["atherosclerosis", "PROBLEM", 147, 162], ["LDL", "OBSERVATION_MODIFIER", 129, 132], ["increased", "OBSERVATION_MODIFIER", 133, 142], ["atherosclerosis", "OBSERVATION_MODIFIER", 147, 162], ["decreased", "OBSERVATION_MODIFIER", 163, 172]]], ["Anti-phosphorylcholine (PC) can be produced after immunization with S. pneumoniae.", [["Anti-phosphorylcholine", "CHEMICAL", 0, 22], ["Anti-phosphorylcholine", "CHEMICAL", 0, 22], ["Anti-phosphorylcholine", "SIMPLE_CHEMICAL", 0, 22], ["PC", "SIMPLE_CHEMICAL", 24, 26], ["S. pneumoniae", "ORGANISM", 68, 81], ["S. pneumoniae", "SPECIES", 68, 81], ["S. pneumoniae", "SPECIES", 68, 81], ["Anti-phosphorylcholine (PC)", "TREATMENT", 0, 27], ["immunization", "TREATMENT", 50, 62], ["S. pneumoniae", "PROBLEM", 68, 81], ["pneumoniae", "OBSERVATION", 71, 81]]], ["It has been proved that immunizing ApoE\u2212/\u2212 mice with PC conjugate results in the increase of PC antibody and ox-LDL antibody and the decrease of atherosclerosis.", [["atherosclerosis", "DISEASE", 145, 160], ["ApoE\u2212/\u2212 mice", "ORGANISM", 35, 47], ["PC conjugate", "SIMPLE_CHEMICAL", 53, 65], ["PC antibody", "GENE_OR_GENE_PRODUCT", 93, 104], ["ox-LDL antibody", "GENE_OR_GENE_PRODUCT", 109, 124], ["ApoE\u2212", "PROTEIN", 35, 40], ["PC antibody", "PROTEIN", 93, 104], ["ox-LDL antibody", "PROTEIN", 109, 124], ["mice", "SPECIES", 43, 47], ["mice", "SPECIES", 43, 47], ["immunizing ApoE\u2212", "TREATMENT", 24, 40], ["PC conjugate", "TEST", 53, 65], ["PC antibody", "TEST", 93, 104], ["ox", "TEST", 109, 111], ["LDL antibody", "TEST", 112, 124], ["atherosclerosis", "PROBLEM", 145, 160], ["decrease", "OBSERVATION_MODIFIER", 133, 141], ["atherosclerosis", "OBSERVATION", 145, 160]]], ["These results suggest that immunization against exogenous antigens may be a new objective for the treatment of atherosclerosis.Clinical trials ::: Vaccine against exogenous antigens ::: Vaccine treatment ::: Potential therapeutic targetsThe exciting results of animal experiments have driven clinical trials to explore the role of vaccination in reducing atherosclerotic events.", [["atherosclerotic", "ANATOMY", 355, 370], ["atherosclerosis", "DISEASE", 111, 126], ["atherosclerotic", "DISEASE", 355, 370], ["atherosclerotic", "IMMATERIAL_ANATOMICAL_ENTITY", 355, 370], ["exogenous antigens", "PROTEIN", 48, 66], ["exogenous antigens", "PROTEIN", 163, 181], ["immunization", "TREATMENT", 27, 39], ["exogenous antigens", "PROBLEM", 48, 66], ["atherosclerosis", "PROBLEM", 111, 126], ["Vaccine", "TREATMENT", 147, 154], ["animal experiments", "TREATMENT", 261, 279], ["clinical trials", "TREATMENT", 292, 307], ["vaccination", "TREATMENT", 331, 342], ["reducing atherosclerotic events", "PROBLEM", 346, 377], ["atherosclerosis", "OBSERVATION", 111, 126], ["atherosclerotic", "OBSERVATION", 355, 370]]], ["Lamontagne et al. conducted a hospital-based case\u2013control study and found no hypothetical protective effect of the pneumococcal vaccination (adjusted 0.85, 95% confidence interval 0.54\u20131.33) in patients vaccinated 1 year before MI.", [["MI", "DISEASE", 228, 230], ["pneumococcal", "ORGANISM", 115, 127], ["patients", "ORGANISM", 194, 202], ["patients", "SPECIES", 194, 202], ["pneumococcal", "SPECIES", 115, 127], ["based case\u2013control study", "TEST", 39, 63], ["the pneumococcal vaccination", "TREATMENT", 111, 139], ["MI", "PROBLEM", 228, 230]]], ["However, a prospective cohort study found no evidence of association between pneumococcal vaccination and reduced risk of acute myocardial infarction (AMI) (adjusted to 1.09; 95% confidence interval 0.98\u20131.21) or stroke (adjusted to 1.14; 95% confidence interval 1.00\u20131.31) [171].", [["myocardial", "ANATOMY", 128, 138], ["acute myocardial infarction", "DISEASE", 122, 149], ["AMI", "DISEASE", 151, 154], ["stroke", "DISEASE", 213, 219], ["myocardial", "MULTI-TISSUE_STRUCTURE", 128, 138], ["pneumococcal", "SPECIES", 77, 89], ["a prospective cohort study", "TEST", 9, 35], ["pneumococcal vaccination", "TREATMENT", 77, 101], ["acute myocardial infarction", "PROBLEM", 122, 149], ["AMI", "PROBLEM", 151, 154], ["stroke", "PROBLEM", 213, 219], ["no evidence of", "UNCERTAINTY", 42, 56], ["acute", "OBSERVATION_MODIFIER", 122, 127], ["myocardial", "ANATOMY", 128, 138], ["infarction", "OBSERVATION", 139, 149]]], ["Some studies have shown that influenza vaccination can reduce cardiovascular events, such as ischemia, re-admission after MI, and ASVD.", [["cardiovascular", "ANATOMY", 62, 76], ["influenza", "DISEASE", 29, 38], ["ischemia", "DISEASE", 93, 101], ["MI", "DISEASE", 122, 124], ["ASVD", "DISEASE", 130, 134], ["cardiovascular", "ANATOMICAL_SYSTEM", 62, 76], ["Some studies", "TEST", 0, 12], ["influenza vaccination", "TREATMENT", 29, 50], ["cardiovascular events", "PROBLEM", 62, 83], ["ischemia", "PROBLEM", 93, 101], ["MI", "PROBLEM", 122, 124], ["ASVD", "PROBLEM", 130, 134], ["ischemia", "OBSERVATION", 93, 101]]], ["A growing body of evidence supports annual influenza vaccination, leading to a reduction in ASVD, stroke and all-cause mortality in known ASVD patients; moreover, there is no proof that the vaccine has a negative impact on recipients.Vaccine against endogenous antigens ::: Vaccine treatment ::: Potential therapeutic targetsIn addition to vaccination against exogenous antigens, many studies have been conducted to explore vaccination against endogenous antigens.", [["ASVD", "DISEASE", 92, 96], ["stroke", "DISEASE", 98, 104], ["ASVD", "DISEASE", 138, 142], ["patients", "ORGANISM", 143, 151], ["recipients", "ORGANISM", 223, 233], ["endogenous antigens", "PROTEIN", 250, 269], ["exogenous antigens", "PROTEIN", 360, 378], ["endogenous antigens", "PROTEIN", 444, 463], ["patients", "SPECIES", 143, 151], ["annual influenza vaccination", "PROBLEM", 36, 64], ["a reduction in ASVD", "PROBLEM", 77, 96], ["stroke", "PROBLEM", 98, 104], ["Vaccine", "TREATMENT", 234, 241], ["vaccination", "TREATMENT", 340, 351], ["exogenous antigens", "PROBLEM", 360, 378], ["many studies", "TEST", 380, 392], ["vaccination", "TREATMENT", 424, 435], ["endogenous antigens", "PROBLEM", 444, 463], ["influenza vaccination", "OBSERVATION", 43, 64]]], ["The most common research antigens are natural or modified homologous LDL and lipoproteins containing ApoB100, a major component of LDL.", [["LDL", "GENE_OR_GENE_PRODUCT", 69, 72], ["ApoB100", "GENE_OR_GENE_PRODUCT", 101, 108], ["LDL", "GENE_OR_GENE_PRODUCT", 131, 134], ["LDL", "PROTEIN", 69, 72], ["lipoproteins", "PROTEIN", 77, 89], ["ApoB100", "PROTEIN", 101, 108], ["LDL", "PROTEIN", 131, 134], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["major", "OBSERVATION_MODIFIER", 112, 117], ["component", "OBSERVATION_MODIFIER", 118, 127], ["LDL", "OBSERVATION_MODIFIER", 131, 134]]], ["Because LDL has the strongest pathogenic relationship with atherosclerosis, antigens from LDL and ApoB100 are the most potent targets for vaccine development.", [["atherosclerosis", "DISEASE", 59, 74], ["LDL", "GENE_OR_GENE_PRODUCT", 8, 11], ["LDL", "GENE_OR_GENE_PRODUCT", 90, 93], ["ApoB100", "GENE_OR_GENE_PRODUCT", 98, 105], ["LDL", "PROTEIN", 8, 11], ["antigens", "PROTEIN", 76, 84], ["LDL", "PROTEIN", 90, 93], ["ApoB100", "PROTEIN", 98, 105], ["LDL", "TEST", 8, 11], ["atherosclerosis", "PROBLEM", 59, 74], ["LDL", "TEST", 90, 93], ["ApoB100", "TREATMENT", 98, 105], ["vaccine development", "TREATMENT", 138, 157], ["atherosclerosis", "OBSERVATION", 59, 74]]], ["Immunization of animals with homologous natural or ox-LDL in vaccine formulations containing different adjuvants demonstrates atherosclerotic protection [172].", [["atherosclerotic", "DISEASE", 126, 141], ["animals", "ORGANISM", 16, 23], ["ox-LDL", "SIMPLE_CHEMICAL", 51, 57], ["LDL", "PROTEIN", 54, 57], ["Immunization", "TREATMENT", 0, 12], ["homologous natural", "TREATMENT", 29, 47], ["LDL in vaccine formulations", "TREATMENT", 54, 81], ["different adjuvants", "TREATMENT", 93, 112], ["atherosclerotic protection", "TREATMENT", 126, 152], ["atherosclerotic", "OBSERVATION_MODIFIER", 126, 141]]], ["However, precise mechanisms and epitopes have not been fully established until several immunoreactive peptides including p2, p143 and p210 are found to cause a 40\u201370% reduction in atherosclerosis and reduce plaque inflammation.", [["plaque", "ANATOMY", 207, 213], ["atherosclerosis", "DISEASE", 180, 195], ["inflammation", "DISEASE", 214, 226], ["p2, p143", "GENE_OR_GENE_PRODUCT", 121, 129], ["p210", "GENE_OR_GENE_PRODUCT", 134, 138], ["plaque inflammation", "PATHOLOGICAL_FORMATION", 207, 226], ["epitopes", "PROTEIN", 32, 40], ["several immunoreactive peptides", "PROBLEM", 79, 110], ["atherosclerosis", "PROBLEM", 180, 195], ["reduce plaque inflammation", "PROBLEM", 200, 226], ["reduction", "OBSERVATION_MODIFIER", 167, 176], ["atherosclerosis", "OBSERVATION", 180, 195], ["reduce", "OBSERVATION_MODIFIER", 200, 206], ["plaque", "OBSERVATION_MODIFIER", 207, 213], ["inflammation", "OBSERVATION", 214, 226]]], ["P210-based vaccines have demonstrated clear atherosclerotic protection [173].", [["P210", "CHEMICAL", 0, 4], ["atherosclerotic", "DISEASE", 44, 59], ["P210", "SIMPLE_CHEMICAL", 0, 4], ["P210", "PROTEIN", 0, 4], ["P210-based vaccines", "TREATMENT", 0, 19], ["clear atherosclerotic protection", "PROBLEM", 38, 70], ["clear", "OBSERVATION_MODIFIER", 38, 43], ["atherosclerotic", "OBSERVATION", 44, 59]]], ["Therefore, the entire LDL particle is no longer used as an antigen, and the determination of antigenic epitopes makes more efficient vaccine development possible.Targeting TLRs ::: Potential therapeutic targetsThe role of TLRs in atherosclerosis has led researchers to explore the therapeutic potential of targeting TLRs in atherosclerosis and related diseases.", [["atherosclerosis", "DISEASE", 230, 245], ["atherosclerosis", "DISEASE", 324, 339], ["LDL", "GENE_OR_GENE_PRODUCT", 22, 25], ["TLRs", "GENE_OR_GENE_PRODUCT", 172, 176], ["TLRs", "GENE_OR_GENE_PRODUCT", 222, 226], ["TLRs", "GENE_OR_GENE_PRODUCT", 316, 320], ["antigenic epitopes", "PROTEIN", 93, 111], ["TLRs", "PROTEIN", 172, 176], ["TLRs", "PROTEIN", 222, 226], ["TLRs", "PROTEIN", 316, 320], ["the entire LDL particle", "TEST", 11, 34], ["an antigen", "TEST", 56, 66], ["antigenic epitopes", "PROBLEM", 93, 111], ["atherosclerosis", "PROBLEM", 230, 245], ["atherosclerosis", "PROBLEM", 324, 339], ["related diseases", "PROBLEM", 344, 360], ["no longer", "UNCERTAINTY", 38, 47], ["atherosclerosis", "OBSERVATION", 230, 245], ["atherosclerosis", "OBSERVATION", 324, 339]]], ["Over the past decades, further attempts have been made to identify specific agonists and antagonists of TLRs.", [["TLRs", "GENE_OR_GENE_PRODUCT", 104, 108], ["TLRs", "PROTEIN", 104, 108], ["antagonists of TLRs", "TREATMENT", 89, 108]]], ["The initial clinical application of TLR therapy mainly focused on tumors and infections, but now more and more molecules are targeted at immune diseases.", [["tumors", "ANATOMY", 66, 72], ["tumors", "DISEASE", 66, 72], ["infections", "DISEASE", 77, 87], ["TLR", "GENE_OR_GENE_PRODUCT", 36, 39], ["tumors", "CANCER", 66, 72], ["TLR", "PROTEIN", 36, 39], ["TLR therapy", "TREATMENT", 36, 47], ["tumors", "PROBLEM", 66, 72], ["infections", "PROBLEM", 77, 87], ["immune diseases", "PROBLEM", 137, 152], ["tumors", "OBSERVATION", 66, 72], ["infections", "OBSERVATION", 77, 87]]], ["Animal models of atherosclerosis suggest that inhibiting TLR-dependent signals or limiting arterial exposure to PAMPS may provide therapy for the treatment or prevention of atherosclerosis [174].", [["arterial", "ANATOMY", 91, 99], ["atherosclerosis", "DISEASE", 17, 32], ["PAMPS", "CHEMICAL", 112, 117], ["atherosclerosis", "DISEASE", 173, 188], ["TLR", "GENE_OR_GENE_PRODUCT", 57, 60], ["arterial", "MULTI-TISSUE_STRUCTURE", 91, 99], ["PAMPS", "SIMPLE_CHEMICAL", 112, 117], ["TLR", "PROTEIN", 57, 60], ["atherosclerosis", "PROBLEM", 17, 32], ["dependent signals", "PROBLEM", 61, 78], ["limiting arterial exposure to PAMPS", "PROBLEM", 82, 117], ["therapy", "TREATMENT", 130, 137], ["the treatment", "TREATMENT", 142, 155], ["atherosclerosis", "PROBLEM", 173, 188], ["atherosclerosis", "OBSERVATION", 17, 32], ["dependent", "OBSERVATION_MODIFIER", 61, 70], ["atherosclerosis", "OBSERVATION", 173, 188]]], ["Statins, as the most commonly prescribed drugs for hypercholesterolemia worldwide, may slow the progression of atherosclerosis and other inflammatory diseases by inhibiting the expression of TLR4 and regulating TLR4/MYD88/NF-\u03baB signaling pathway [175].", [["Statins", "CHEMICAL", 0, 7], ["hypercholesterolemia", "DISEASE", 51, 71], ["atherosclerosis", "DISEASE", 111, 126], ["Statins", "CHEMICAL", 0, 7], ["TLR4", "GENE_OR_GENE_PRODUCT", 191, 195], ["TLR4", "GENE_OR_GENE_PRODUCT", 211, 215], ["MYD88", "GENE_OR_GENE_PRODUCT", 216, 221], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 222, 227], ["TLR4", "PROTEIN", 191, 195], ["TLR4", "PROTEIN", 211, 215], ["MYD88", "PROTEIN", 216, 221], ["NF-\u03baB", "PROTEIN", 222, 227], ["Statins", "TREATMENT", 0, 7], ["drugs", "TREATMENT", 41, 46], ["hypercholesterolemia", "PROBLEM", 51, 71], ["atherosclerosis", "PROBLEM", 111, 126], ["other inflammatory diseases", "PROBLEM", 131, 158], ["TLR4", "TEST", 191, 195], ["atherosclerosis", "OBSERVATION", 111, 126], ["inflammatory", "OBSERVATION_MODIFIER", 137, 149]]], ["Drugs that competitively inhibit the binding of intestinal bacterial LPS to TLR4/MD2 complexes, such as lipid IVa (compound 406) and Eritrean, have been reported to effectively inhibit TLR4 signaling in vitro and in vivo [176].", [["LPS", "CHEMICAL", 69, 72], ["compound 406", "CHEMICAL", 115, 127], ["intestinal", "ORGAN", 48, 58], ["LPS", "GENE_OR_GENE_PRODUCT", 69, 72], ["TLR4", "GENE_OR_GENE_PRODUCT", 76, 80], ["MD2", "GENE_OR_GENE_PRODUCT", 81, 84], ["lipid IVa", "SIMPLE_CHEMICAL", 104, 113], ["Eritrean", "SIMPLE_CHEMICAL", 133, 141], ["TLR4", "GENE_OR_GENE_PRODUCT", 185, 189], ["TLR4", "PROTEIN", 76, 80], ["MD2 complexes", "PROTEIN", 81, 94], ["TLR4", "PROTEIN", 185, 189], ["Drugs", "TREATMENT", 0, 5], ["intestinal bacterial LPS", "TREATMENT", 48, 72], ["TLR4/MD2 complexes", "TREATMENT", 76, 94], ["lipid IVa", "TREATMENT", 104, 113], ["Eritrean", "TREATMENT", 133, 141], ["intestinal", "ANATOMY", 48, 58]]], ["Since PAMPs of intestinal flora contribute to systemic inflammatory tension, treatment to modify intestinal flora is also being attempted.", [["intestinal flora", "ANATOMY", 15, 31], ["intestinal flora", "ANATOMY", 97, 113], ["PAMPs", "GENE_OR_GENE_PRODUCT", 6, 11], ["intestinal flora", "PATHOLOGICAL_FORMATION", 15, 31], ["intestinal", "ORGAN", 97, 107], ["intestinal flora", "PROBLEM", 15, 31], ["systemic inflammatory tension", "PROBLEM", 46, 75], ["treatment", "TREATMENT", 77, 86], ["intestinal flora", "PROBLEM", 97, 113], ["intestinal", "ANATOMY", 15, 25], ["flora", "OBSERVATION", 26, 31], ["systemic", "OBSERVATION_MODIFIER", 46, 54], ["inflammatory tension", "OBSERVATION", 55, 75], ["intestinal", "ANATOMY", 97, 107], ["flora", "OBSERVATION", 108, 113]]], ["Prebiotic inulin has been shown to reduce LPS lumen concentration and reduce atherosclerosis in ApoE\u2212/\u2212 mice by about 35% [177].", [["lumen", "ANATOMY", 46, 51], ["inulin", "CHEMICAL", 10, 16], ["LPS", "CHEMICAL", 42, 45], ["atherosclerosis", "DISEASE", 77, 92], ["inulin", "SIMPLE_CHEMICAL", 10, 16], ["LPS", "SIMPLE_CHEMICAL", 42, 45], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 46, 51], ["mice", "SPECIES", 104, 108], ["mice", "SPECIES", 104, 108], ["Prebiotic inulin", "TREATMENT", 0, 16], ["LPS lumen concentration", "TREATMENT", 42, 65], ["atherosclerosis", "PROBLEM", 77, 92], ["reduce", "OBSERVATION_MODIFIER", 70, 76], ["atherosclerosis", "OBSERVATION", 77, 92]]], ["Therefore, the possibility of regulating atherosclerosis by regulating intestinal flora should not be excluded.", [["intestinal flora", "ANATOMY", 71, 87], ["atherosclerosis", "DISEASE", 41, 56], ["intestinal flora", "ORGAN", 71, 87], ["regulating atherosclerosis", "PROBLEM", 30, 56], ["regulating intestinal flora", "PROBLEM", 60, 87], ["possibility of", "UNCERTAINTY", 15, 29], ["regulating", "OBSERVATION_MODIFIER", 30, 40], ["atherosclerosis", "OBSERVATION", 41, 56], ["intestinal", "ANATOMY", 71, 81], ["flora", "OBSERVATION", 82, 87], ["should not be excluded", "UNCERTAINTY", 88, 110]]], ["In a recent study, TLR4 antagonist, Rhodobacter globosa lipopolysaccharide (RS-LPS), did not alleviate the early atherosclerosis process in ApoE\u2212/\u2212 mice.", [["lipopolysaccharide", "CHEMICAL", 56, 74], ["RS-LPS", "CHEMICAL", 76, 82], ["atherosclerosis", "DISEASE", 113, 128], ["TLR4", "GENE_OR_GENE_PRODUCT", 19, 23], ["Rhodobacter globosa", "ORGANISM", 36, 55], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 56, 74], ["RS-LPS", "SIMPLE_CHEMICAL", 76, 82], ["ApoE\u2212/\u2212 mice", "ORGANISM", 140, 152], ["TLR4", "PROTEIN", 19, 23], ["Rhodobacter globosa", "SPECIES", 36, 55], ["mice", "SPECIES", 148, 152], ["Rhodobacter globosa", "SPECIES", 36, 55], ["mice", "SPECIES", 148, 152], ["a recent study", "TEST", 3, 17], ["TLR4 antagonist", "TREATMENT", 19, 34], ["Rhodobacter globosa lipopolysaccharide", "TEST", 36, 74], ["the early atherosclerosis process", "PROBLEM", 103, 136], ["early", "OBSERVATION_MODIFIER", 107, 112], ["atherosclerosis", "OBSERVATION", 113, 128]]], ["However, RS-LPS reduced lesion formation in ApoE\u2212/\u2212 diabetic mice, suggesting the potential environmental dependence of TLR4 blockade on atherosclerosis [178].", [["lesion", "ANATOMY", 24, 30], ["LPS", "CHEMICAL", 12, 15], ["diabetic", "DISEASE", 52, 60], ["atherosclerosis", "DISEASE", 137, 152], ["RS-LPS", "SIMPLE_CHEMICAL", 9, 15], ["lesion", "PATHOLOGICAL_FORMATION", 24, 30], ["ApoE\u2212/\u2212 diabetic mice", "ORGANISM", 44, 65], ["TLR4", "GENE_OR_GENE_PRODUCT", 120, 124], ["TLR4", "PROTEIN", 120, 124], ["mice", "SPECIES", 61, 65], ["RS", "TEST", 9, 11], ["LPS reduced lesion formation", "PROBLEM", 12, 40], ["TLR4 blockade", "TREATMENT", 120, 133], ["atherosclerosis", "PROBLEM", 137, 152], ["reduced", "OBSERVATION_MODIFIER", 16, 23], ["lesion", "OBSERVATION", 24, 30], ["TLR4 blockade", "OBSERVATION", 120, 133], ["atherosclerosis", "OBSERVATION", 137, 152]]], ["A new peptide inhibitor, Viper (derived from vaccine virus protein A46), inhibits TLR4-dependent signal transduction by blocking TIR-TIR domain interactions.", [["vaccine virus", "ORGANISM", 45, 58], ["A46", "GENE_OR_GENE_PRODUCT", 67, 70], ["TLR4", "GENE_OR_GENE_PRODUCT", 82, 86], ["TLR4", "PROTEIN", 82, 86], ["TIR", "PROTEIN", 129, 132], ["TIR domain", "PROTEIN", 133, 143], ["A new peptide inhibitor", "TREATMENT", 0, 23], ["Viper", "TREATMENT", 25, 30], ["vaccine virus protein A46", "TREATMENT", 45, 70], ["TLR4-dependent signal transduction", "TREATMENT", 82, 116]]], ["In addition, blocking the TLR2 signaling pathway can reduce the inflammation-promoting pathway in human atherosclerosis [179].", [["inflammation", "DISEASE", 64, 76], ["atherosclerosis", "DISEASE", 104, 119], ["TLR2", "GENE_OR_GENE_PRODUCT", 26, 30], ["human", "ORGANISM", 98, 103], ["TLR2", "PROTEIN", 26, 30], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 98, 103], ["blocking the TLR2 signaling pathway", "TREATMENT", 13, 48], ["the inflammation", "PROBLEM", 60, 76], ["human atherosclerosis", "PROBLEM", 98, 119], ["inflammation", "OBSERVATION", 64, 76], ["human", "OBSERVATION_MODIFIER", 98, 103], ["atherosclerosis", "OBSERVATION", 104, 119]]], ["Opn301, an antibody against TLR2, can block TLR2-induced pro-inflammatory cytokine signaling and was reported to improve cardiac function and reduce infarct size in mice with ischemia/reperfusion (I/R) injury [180].", [["cardiac", "ANATOMY", 121, 128], ["infarct", "ANATOMY", 149, 156], ["Opn301", "CHEMICAL", 0, 6], ["infarct", "DISEASE", 149, 156], ["ischemia", "DISEASE", 175, 183], ["Opn301", "CHEMICAL", 0, 6], ["Opn301", "SIMPLE_CHEMICAL", 0, 6], ["TLR2", "GENE_OR_GENE_PRODUCT", 28, 32], ["TLR2", "GENE_OR_GENE_PRODUCT", 44, 48], ["cardiac", "ORGAN", 121, 128], ["mice", "ORGANISM", 165, 169], ["Opn301", "PROTEIN", 0, 6], ["TLR2", "PROTEIN", 28, 32], ["TLR2", "PROTEIN", 44, 48], ["pro-inflammatory cytokine", "PROTEIN", 57, 82], ["mice", "SPECIES", 165, 169], ["mice", "SPECIES", 165, 169], ["an antibody", "TEST", 8, 19], ["TLR2", "PROBLEM", 28, 32], ["pro-inflammatory cytokine signaling", "PROBLEM", 57, 92], ["infarct size", "PROBLEM", 149, 161], ["ischemia", "PROBLEM", 175, 183], ["reperfusion (I/R) injury", "PROBLEM", 184, 208], ["infarct", "OBSERVATION", 149, 156], ["size", "OBSERVATION_MODIFIER", 157, 161], ["ischemia", "OBSERVATION", 175, 183], ["reperfusion", "OBSERVATION", 184, 195]]], ["Most existing studies only reported the effect of TLRs on lipid accumulation, but the role of TLRs in other mechanisms of atherosclerosis, such as plaque instability and cell death, remains to be further studied.", [["plaque", "ANATOMY", 147, 153], ["cell", "ANATOMY", 170, 174], ["atherosclerosis", "DISEASE", 122, 137], ["plaque instability", "DISEASE", 147, 165], ["death", "DISEASE", 175, 180], ["TLRs", "GENE_OR_GENE_PRODUCT", 50, 54], ["lipid", "SIMPLE_CHEMICAL", 58, 63], ["TLRs", "GENE_OR_GENE_PRODUCT", 94, 98], ["cell", "CELL", 170, 174], ["TLRs", "PROTEIN", 50, 54], ["TLRs", "PROTEIN", 94, 98], ["Most existing studies", "TEST", 0, 21], ["TLRs on lipid accumulation", "TREATMENT", 50, 76], ["TLRs", "TREATMENT", 94, 98], ["atherosclerosis", "PROBLEM", 122, 137], ["plaque instability", "PROBLEM", 147, 165], ["cell death", "PROBLEM", 170, 180], ["atherosclerosis", "OBSERVATION", 122, 137], ["plaque", "OBSERVATION", 147, 153], ["cell death", "OBSERVATION", 170, 180]]], ["In addition, TLR plays an essential role in host defense against pathogens, and blocking TLR signals may increase the risk of infection in patients.", [["infection", "DISEASE", 126, 135], ["TLR", "GENE_OR_GENE_PRODUCT", 13, 16], ["TLR", "GENE_OR_GENE_PRODUCT", 89, 92], ["patients", "ORGANISM", 139, 147], ["TLR", "PROTEIN", 13, 16], ["TLR", "PROTEIN", 89, 92], ["patients", "SPECIES", 139, 147], ["pathogens", "PROBLEM", 65, 74], ["blocking TLR signals", "TREATMENT", 80, 100], ["infection", "PROBLEM", 126, 135], ["infection", "OBSERVATION", 126, 135]]], ["Therefore, an appropriate risk/benefit ratio needs to be assessed.", [["an appropriate risk/benefit ratio", "TREATMENT", 11, 44]]], ["Another way to prevent TLR and its signal mediators is to focus on finding and selectively targeting atherosclerosis-related molecular patterns identified by TLRs, eliminating the risk of host defense.Conclusion and future perspectivesOver the past few decades, our understanding of the classical risk factors for atherosclerotic progression, the complex interactions of inflammation and immune activation has grown rapidly.", [["atherosclerotic", "ANATOMY", 314, 329], ["atherosclerosis", "DISEASE", 101, 116], ["atherosclerotic", "DISEASE", 314, 329], ["inflammation", "DISEASE", 371, 383], ["TLR", "GENE_OR_GENE_PRODUCT", 23, 26], ["TLRs", "GENE_OR_GENE_PRODUCT", 158, 162], ["TLR", "PROTEIN", 23, 26], ["TLRs", "PROTEIN", 158, 162], ["TLR", "PROBLEM", 23, 26], ["selectively targeting atherosclerosis", "PROBLEM", 79, 116], ["atherosclerotic progression", "PROBLEM", 314, 341], ["inflammation", "PROBLEM", 371, 383], ["immune activation", "PROBLEM", 388, 405], ["atherosclerosis", "OBSERVATION", 101, 116], ["host defense", "OBSERVATION", 188, 200], ["atherosclerotic", "OBSERVATION_MODIFIER", 314, 329], ["progression", "OBSERVATION_MODIFIER", 330, 341], ["inflammation", "OBSERVATION", 371, 383], ["rapidly", "OBSERVATION_MODIFIER", 416, 423]]], ["There is an emerging epidemiological link between infection and ASVD.", [["infection", "DISEASE", 50, 59], ["ASVD", "DISEASE", 64, 68], ["infection", "PROBLEM", 50, 59], ["ASVD", "PROBLEM", 64, 68], ["infection", "OBSERVATION", 50, 59]]], ["Chronic infections and atherosclerosis have a variety of biological mechanisms, and there is sufficient experimental evidence to support the atherogenic properties of various bacterial and viral infections.", [["Chronic infections", "DISEASE", 0, 18], ["atherosclerosis", "DISEASE", 23, 38], ["bacterial and viral infections", "DISEASE", 175, 205], ["Chronic infections", "PROBLEM", 0, 18], ["atherosclerosis", "PROBLEM", 23, 38], ["various bacterial and viral infections", "PROBLEM", 167, 205], ["infections", "OBSERVATION", 8, 18], ["atherosclerosis", "OBSERVATION", 23, 38], ["variety", "OBSERVATION_MODIFIER", 46, 53], ["atherogenic", "OBSERVATION_MODIFIER", 141, 152], ["various", "OBSERVATION_MODIFIER", 167, 174], ["bacterial", "OBSERVATION_MODIFIER", 175, 184], ["viral infections", "OBSERVATION", 189, 205]]], ["The most convincing evidence is that infectious agents are detected in the atherosclerotic vascular wall, and pathogen-specific antibodies are associated with atherosclerosis.", [["atherosclerotic vascular wall", "ANATOMY", 75, 104], ["atherosclerotic", "DISEASE", 75, 90], ["atherosclerosis", "DISEASE", 159, 174], ["vascular wall", "MULTI-TISSUE_STRUCTURE", 91, 104], ["pathogen-specific antibodies", "PROTEIN", 110, 138], ["infectious agents", "TREATMENT", 37, 54], ["the atherosclerotic vascular wall", "PROBLEM", 71, 104], ["pathogen", "PROBLEM", 110, 118], ["atherosclerosis", "PROBLEM", 159, 174], ["most convincing evidence is", "UNCERTAINTY", 4, 31], ["infectious", "OBSERVATION", 37, 47], ["atherosclerotic", "OBSERVATION", 75, 90], ["vascular wall", "ANATOMY", 91, 104], ["atherosclerosis", "OBSERVATION", 159, 174]]], ["These pathogens include C. pneumoniae, periodontal pathogens including P. gingivalis, H. pylori, CMV, EBV, HIV, HSV-1, HSV-2, and HCV.", [["C. pneumoniae", "DISEASE", 24, 37], ["C. pneumoniae", "ORGANISM", 24, 37], ["P. gingivalis", "ORGANISM", 71, 84], ["H. pylori", "ORGANISM", 86, 95], ["CMV", "ORGANISM", 97, 100], ["EBV", "ORGANISM", 102, 105], ["HIV", "ORGANISM", 107, 110], ["HSV-1", "ORGANISM", 112, 117], ["HSV-2", "ORGANISM", 119, 124], ["HCV", "ORGANISM", 130, 133], ["C. pneumoniae", "SPECIES", 24, 37], ["P. gingivalis", "SPECIES", 71, 84], ["H. pylori", "SPECIES", 86, 95], ["HIV", "SPECIES", 107, 110], ["HSV-1", "SPECIES", 112, 117], ["HSV-2", "SPECIES", 119, 124], ["C. pneumoniae", "SPECIES", 24, 37], ["P. gingivalis", "SPECIES", 71, 84], ["H. pylori", "SPECIES", 86, 95], ["CMV", "SPECIES", 97, 100], ["EBV", "SPECIES", 102, 105], ["HIV", "SPECIES", 107, 110], ["HSV-1", "SPECIES", 112, 117], ["HSV-2", "SPECIES", 119, 124], ["HCV", "SPECIES", 130, 133], ["These pathogens", "PROBLEM", 0, 15], ["C. pneumoniae", "PROBLEM", 24, 37], ["periodontal pathogens", "PROBLEM", 39, 60], ["P. gingivalis", "PROBLEM", 71, 84], ["H. pylori", "PROBLEM", 86, 95], ["CMV", "PROBLEM", 97, 100], ["EBV", "PROBLEM", 102, 105], ["HIV", "PROBLEM", 107, 110], ["HSV", "TEST", 112, 115], ["HSV", "PROBLEM", 119, 122], ["HCV", "PROBLEM", 130, 133], ["pneumoniae", "OBSERVATION", 27, 37], ["periodontal", "ANATOMY", 39, 50], ["HCV", "OBSERVATION", 130, 133]]], ["However, despite the pathophysiological correlation, clinical studies of anti-infection have not achieved satisfactory results.", [["clinical studies", "TEST", 53, 69], ["anti-infection", "TREATMENT", 73, 87]]], ["First, long-term antibiotic treatment can lead to drug resistance.", [["long-term antibiotic treatment", "TREATMENT", 7, 37], ["drug resistance", "PROBLEM", 50, 65], ["drug resistance", "OBSERVATION", 50, 65]]], ["Second, antibiotic treatment may be too late to produce significant clinical effects.", [["antibiotic treatment", "TREATMENT", 8, 28]]], ["Third, persistent low-grade chronic inflammation is ineffective for antibiotic treatment.", [["inflammation", "DISEASE", 36, 48], ["persistent low-grade chronic inflammation", "PROBLEM", 7, 48], ["antibiotic treatment", "TREATMENT", 68, 88], ["persistent", "OBSERVATION_MODIFIER", 7, 17], ["low-grade", "OBSERVATION_MODIFIER", 18, 27], ["chronic", "OBSERVATION_MODIFIER", 28, 35], ["inflammation", "OBSERVATION", 36, 48], ["ineffective", "OBSERVATION_MODIFIER", 52, 63]]], ["Recently, a hypothesis has been proposed that infection plays a \u201cmatch\u201d role for atherosclerosis.", [["infection", "DISEASE", 46, 55], ["atherosclerosis", "DISEASE", 81, 96], ["infection", "PROBLEM", 46, 55], ["atherosclerosis", "PROBLEM", 81, 96], ["infection", "OBSERVATION", 46, 55], ["atherosclerosis", "OBSERVATION", 81, 96]]], ["After igniting this pathological process, the fight against this \u201cspark\u201d does not inhibit the progression of atherosclerosis.", [["atherosclerosis", "DISEASE", 109, 124], ["this pathological process", "PROBLEM", 15, 40], ["atherosclerosis", "PROBLEM", 109, 124], ["progression", "OBSERVATION_MODIFIER", 94, 105], ["atherosclerosis", "OBSERVATION", 109, 124]]], ["Therefore, the fact that anti-infective treatment is ineffective does not deny the potential link between infection and atherosclerotic disease.", [["atherosclerotic", "ANATOMY", 120, 135], ["infection", "DISEASE", 106, 115], ["atherosclerotic disease", "DISEASE", 120, 143], ["anti-infective treatment", "TREATMENT", 25, 49], ["infection", "PROBLEM", 106, 115], ["atherosclerotic disease", "PROBLEM", 120, 143], ["anti-infective", "OBSERVATION", 25, 39], ["infection", "OBSERVATION", 106, 115], ["atherosclerotic", "OBSERVATION_MODIFIER", 120, 135], ["disease", "OBSERVATION", 136, 143]]], ["More research is needed to determine the exact role of microbial infections in atherosclerosis.Conclusion and future perspectivesAs the most characteristic member of PRRs, TLRs are highly evolved conserved proteins.", [["infections", "DISEASE", 65, 75], ["atherosclerosis", "DISEASE", 79, 94], ["PRRs", "GENE_OR_GENE_PRODUCT", 166, 170], ["TLRs", "GENE_OR_GENE_PRODUCT", 172, 176], ["PRRs", "PROTEIN", 166, 170], ["TLRs", "PROTEIN", 172, 176], ["conserved proteins", "PROTEIN", 196, 214], ["microbial infections", "PROBLEM", 55, 75], ["atherosclerosis", "PROBLEM", 79, 94], ["microbial", "OBSERVATION_MODIFIER", 55, 64], ["infections", "OBSERVATION", 65, 75], ["atherosclerosis", "OBSERVATION", 79, 94]]], ["TLR signaling pathway can be broadly classified as a MyD88-dependent pathway that drives the production of inflammatory cytokines and a TRIF-dependent pathway responsible for the production of IFN I and inflammatory cytokines.", [["TLR", "GENE_OR_GENE_PRODUCT", 0, 3], ["MyD88", "GENE_OR_GENE_PRODUCT", 53, 58], ["TRIF", "GENE_OR_GENE_PRODUCT", 136, 140], ["IFN I", "GENE_OR_GENE_PRODUCT", 193, 198], ["TLR", "PROTEIN", 0, 3], ["MyD88", "PROTEIN", 53, 58], ["inflammatory cytokines", "PROTEIN", 107, 129], ["TRIF", "PROTEIN", 136, 140], ["IFN I", "PROTEIN", 193, 198], ["inflammatory cytokines", "PROTEIN", 203, 225], ["a MyD88-dependent pathway", "TREATMENT", 51, 76], ["inflammatory cytokines", "PROBLEM", 107, 129], ["a TRIF-dependent pathway", "TREATMENT", 134, 158], ["IFN I and inflammatory cytokines", "PROBLEM", 193, 225], ["inflammatory", "OBSERVATION_MODIFIER", 107, 119], ["inflammatory", "OBSERVATION_MODIFIER", 203, 215]]], ["The role of TLRs in the development of related atherosclerosis has just begun to be discovered.", [["atherosclerosis", "DISEASE", 47, 62], ["TLRs", "GENE_OR_GENE_PRODUCT", 12, 16], ["TLRs", "PROTEIN", 12, 16], ["TLRs", "TREATMENT", 12, 16], ["related atherosclerosis", "PROBLEM", 39, 62], ["atherosclerosis", "OBSERVATION", 47, 62]]], ["Both critical and resident vascular cells express multiple TLRs in the initiation and progression of atherosclerosis, suggesting that these receptors and their ligands are key players in atherosclerosis.", [["vascular cells", "ANATOMY", 27, 41], ["atherosclerosis", "DISEASE", 101, 116], ["atherosclerosis", "DISEASE", 187, 202], ["vascular cells", "CELL", 27, 41], ["TLRs", "GENE_OR_GENE_PRODUCT", 59, 63], ["resident vascular cells", "CELL_TYPE", 18, 41], ["TLRs", "PROTEIN", 59, 63], ["multiple TLRs", "TREATMENT", 50, 63], ["atherosclerosis", "PROBLEM", 101, 116], ["atherosclerosis", "PROBLEM", 187, 202], ["vascular", "ANATOMY", 27, 35], ["multiple", "OBSERVATION_MODIFIER", 50, 58], ["TLRs", "OBSERVATION_MODIFIER", 59, 63], ["progression", "OBSERVATION_MODIFIER", 86, 97], ["atherosclerosis", "OBSERVATION", 101, 116], ["atherosclerosis", "OBSERVATION", 187, 202]]], ["Many experiments have proved that TLRs are involved in signal pathways that affect the progression of atherosclerosis after microbial infection.", [["atherosclerosis", "DISEASE", 102, 117], ["microbial infection", "DISEASE", 124, 143], ["TLRs", "GENE_OR_GENE_PRODUCT", 34, 38], ["TLRs", "PROTEIN", 34, 38], ["atherosclerosis", "PROBLEM", 102, 117], ["microbial infection", "PROBLEM", 124, 143], ["progression", "OBSERVATION_MODIFIER", 87, 98], ["atherosclerosis", "OBSERVATION", 102, 117], ["microbial", "OBSERVATION_MODIFIER", 124, 133], ["infection", "OBSERVATION", 134, 143]]], ["For example, TLR2 and 4 play an important role in activating macrophages and ECs after C. pneumoniae infection, inhibiting cholesterol outflow and promoting foam formation.", [["macrophages", "ANATOMY", 61, 72], ["ECs", "ANATOMY", 77, 80], ["foam", "ANATOMY", 157, 161], ["infection", "DISEASE", 101, 110], ["cholesterol", "CHEMICAL", 123, 134], ["cholesterol", "CHEMICAL", 123, 134], ["TLR2", "GENE_OR_GENE_PRODUCT", 13, 17], ["4", "GENE_OR_GENE_PRODUCT", 22, 23], ["macrophages", "CELL", 61, 72], ["ECs", "CELL", 77, 80], ["C. pneumoniae", "ORGANISM", 87, 100], ["cholesterol", "SIMPLE_CHEMICAL", 123, 134], ["foam", "TISSUE", 157, 161], ["TLR2 and 4", "PROTEIN", 13, 23], ["macrophages", "CELL_TYPE", 61, 72], ["ECs", "CELL_TYPE", 77, 80], ["C. pneumoniae", "SPECIES", 87, 100], ["C. pneumoniae", "SPECIES", 87, 100], ["activating macrophages", "TREATMENT", 50, 72], ["C. pneumoniae infection", "PROBLEM", 87, 110], ["cholesterol outflow", "TREATMENT", 123, 142], ["promoting foam formation", "TREATMENT", 147, 171], ["pneumoniae", "OBSERVATION_MODIFIER", 90, 100], ["infection", "OBSERVATION", 101, 110], ["cholesterol outflow", "OBSERVATION", 123, 142], ["foam formation", "OBSERVATION", 157, 171]]], ["P. gingivalis infection can accelerate atherosclerosis in hyperlipidemic mice and increase the expression of TLR2 and 4.", [["P. gingivalis infection", "DISEASE", 0, 23], ["atherosclerosis", "DISEASE", 39, 54], ["hyperlipidemic", "DISEASE", 58, 72], ["P. gingivalis", "ORGANISM", 0, 13], ["mice", "ORGANISM", 73, 77], ["TLR2", "GENE_OR_GENE_PRODUCT", 109, 113], ["4", "GENE_OR_GENE_PRODUCT", 118, 119], ["TLR2 and 4", "PROTEIN", 109, 119], ["P. gingivalis", "SPECIES", 0, 13], ["mice", "SPECIES", 73, 77], ["P. gingivalis", "SPECIES", 0, 13], ["mice", "SPECIES", 73, 77], ["P. gingivalis infection", "PROBLEM", 0, 23], ["atherosclerosis in hyperlipidemic mice", "PROBLEM", 39, 77], ["gingivalis", "OBSERVATION_MODIFIER", 3, 13], ["infection", "OBSERVATION", 14, 23], ["atherosclerosis", "OBSERVATION", 39, 54], ["hyperlipidemic", "OBSERVATION_MODIFIER", 58, 72]]], ["LPS derived from H. pylori is regarded as a direct stimulator of innate immunity mediated by TLR4.", [["LPS", "CHEMICAL", 0, 3], ["LPS", "SIMPLE_CHEMICAL", 0, 3], ["H. pylori", "ORGANISM", 17, 26], ["TLR4", "GENE_OR_GENE_PRODUCT", 93, 97], ["TLR4", "PROTEIN", 93, 97], ["H. pylori", "SPECIES", 17, 26], ["H. pylori", "SPECIES", 17, 26], ["LPS", "TEST", 0, 3], ["H. pylori", "PROBLEM", 17, 26], ["a direct stimulator of innate immunity", "TREATMENT", 42, 80]]], ["The crucial role of TLRs in gastric mucosa infected by H. pylori provides a possible mechanism for H. pylori to promote the development of atherosclerosis.", [["gastric mucosa", "ANATOMY", 28, 42], ["atherosclerosis", "DISEASE", 139, 154], ["TLRs", "GENE_OR_GENE_PRODUCT", 20, 24], ["gastric mucosa", "MULTI-TISSUE_STRUCTURE", 28, 42], ["H. pylori", "ORGANISM", 55, 64], ["H. pylori", "ORGANISM", 99, 108], ["TLRs", "PROTEIN", 20, 24], ["H. pylori", "SPECIES", 55, 64], ["H. pylori", "SPECIES", 99, 108], ["H. pylori", "SPECIES", 55, 64], ["H. pylori", "SPECIES", 99, 108], ["H. pylori", "PROBLEM", 55, 64], ["H. pylori", "PROBLEM", 99, 108], ["atherosclerosis", "PROBLEM", 139, 154], ["crucial", "OBSERVATION_MODIFIER", 4, 11], ["TLRs", "ANATOMY_MODIFIER", 20, 24], ["gastric mucosa", "ANATOMY", 28, 42], ["atherosclerosis", "OBSERVATION", 139, 154]]], ["TLRs seem to also play an irreplaceable role in immune activation and dysfunction caused by HIV infection.", [["HIV infection", "DISEASE", 92, 105], ["TLRs", "GENE_OR_GENE_PRODUCT", 0, 4], ["HIV", "ORGANISM", 92, 95], ["TLRs", "PROTEIN", 0, 4], ["HIV", "SPECIES", 92, 95], ["HIV", "SPECIES", 92, 95], ["immune activation", "PROBLEM", 48, 65], ["dysfunction", "PROBLEM", 70, 81], ["HIV infection", "PROBLEM", 92, 105], ["HIV", "OBSERVATION_MODIFIER", 92, 95], ["infection", "OBSERVATION", 96, 105]]], ["Overall, the activation of TLR 2 and 4 seems to provide a new mechanism for infection-related atherosclerosis.Conclusion and future perspectivesIn summary, this review highlights the role of TLRs in the pathogenesis of atherosclerosis associated with microbial infections, particularly C. pneumoniae, periodontal pathogens, H. pylori and CMV.", [["periodontal", "ANATOMY", 301, 312], ["infection", "DISEASE", 76, 85], ["atherosclerosis", "DISEASE", 94, 109], ["atherosclerosis", "DISEASE", 219, 234], ["microbial infections", "DISEASE", 251, 271], ["C. pneumoniae", "DISEASE", 286, 299], ["TLR 2", "GENE_OR_GENE_PRODUCT", 27, 32], ["4", "GENE_OR_GENE_PRODUCT", 37, 38], ["TLRs", "GENE_OR_GENE_PRODUCT", 191, 195], ["C. pneumoniae", "ORGANISM", 286, 299], ["H. pylori", "ORGANISM", 324, 333], ["CMV", "ORGANISM", 338, 341], ["TLR 2 and 4", "PROTEIN", 27, 38], ["TLRs", "PROTEIN", 191, 195], ["C. pneumoniae", "SPECIES", 286, 299], ["H. pylori", "SPECIES", 324, 333], ["C. pneumoniae", "SPECIES", 286, 299], ["H. pylori", "SPECIES", 324, 333], ["CMV", "SPECIES", 338, 341], ["infection", "PROBLEM", 76, 85], ["atherosclerosis", "PROBLEM", 94, 109], ["atherosclerosis", "PROBLEM", 219, 234], ["microbial infections", "PROBLEM", 251, 271], ["C. pneumoniae", "PROBLEM", 286, 299], ["periodontal pathogens", "PROBLEM", 301, 322], ["H. pylori", "PROBLEM", 324, 333], ["CMV", "PROBLEM", 338, 341], ["infection", "OBSERVATION", 76, 85], ["atherosclerosis", "OBSERVATION", 94, 109], ["atherosclerosis", "OBSERVATION", 219, 234], ["microbial", "OBSERVATION_MODIFIER", 251, 260], ["infections", "OBSERVATION", 261, 271], ["pneumoniae", "OBSERVATION", 289, 299], ["periodontal", "ANATOMY", 301, 312]]], ["In our efforts to reduce atherosclerosis, determining the right target pathway has been our Achilles heel.", [["Achilles heel", "ANATOMY", 92, 105], ["atherosclerosis", "DISEASE", 25, 40], ["Achilles heel", "TISSUE", 92, 105], ["atherosclerosis", "PROBLEM", 25, 40], ["atherosclerosis", "OBSERVATION", 25, 40], ["right", "ANATOMY_MODIFIER", 58, 63], ["Achilles heel", "ANATOMY", 92, 105]]], ["Is it the microbe itself or the myriad of signaling pathways, including TLRs that are activated in chronic infections, which ultimately lead to atherosclerosis?", [["infections", "DISEASE", 107, 117], ["atherosclerosis", "DISEASE", 144, 159], ["TLRs", "GENE_OR_GENE_PRODUCT", 72, 76], ["TLRs", "PROTEIN", 72, 76], ["TLRs", "TREATMENT", 72, 76], ["chronic infections", "PROBLEM", 99, 117], ["atherosclerosis", "PROBLEM", 144, 159], ["chronic", "OBSERVATION_MODIFIER", 99, 106], ["infections", "OBSERVATION", 107, 117], ["atherosclerosis", "OBSERVATION", 144, 159]]], ["More research is needed to demonstrate the hypothesis that pathogens contribute to atherosclerosis through TLR activation.", [["atherosclerosis", "DISEASE", 83, 98], ["TLR", "GENE_OR_GENE_PRODUCT", 107, 110], ["TLR", "PROTEIN", 107, 110], ["atherosclerosis through TLR activation", "PROBLEM", 83, 121], ["atherosclerosis", "OBSERVATION", 83, 98]]], ["Identification of pathogenesis of microbial induction may reveal drug targets for therapeutic intervention or prevention of atherosclerosis through vaccines or immunomodulatory therapy.", [["atherosclerosis", "DISEASE", 124, 139], ["microbial induction", "TREATMENT", 34, 53], ["therapeutic intervention", "TREATMENT", 82, 106], ["atherosclerosis", "PROBLEM", 124, 139], ["vaccines", "TREATMENT", 148, 156], ["immunomodulatory therapy", "TREATMENT", 160, 184], ["atherosclerosis", "OBSERVATION", 124, 139]]], ["Since the direct role of these pathogens in atherosclerosis remains uncertain, it is unclear whether vaccines against these microorganisms are useful strategies for treating human atherosclerosis.", [["atherosclerosis", "DISEASE", 44, 59], ["atherosclerosis", "DISEASE", 180, 195], ["human", "ORGANISM", 174, 179], ["human", "SPECIES", 174, 179], ["human", "SPECIES", 174, 179], ["these pathogens", "PROBLEM", 25, 40], ["atherosclerosis", "PROBLEM", 44, 59], ["vaccines", "TREATMENT", 101, 109], ["these microorganisms", "PROBLEM", 118, 138], ["human atherosclerosis", "PROBLEM", 174, 195], ["pathogens", "OBSERVATION", 31, 40], ["atherosclerosis", "OBSERVATION", 44, 59], ["atherosclerosis", "OBSERVATION", 180, 195]]], ["In this conjecture, the development of atherosclerotic vaccines for various signaling pathways associated with infection may be promising.", [["atherosclerotic", "DISEASE", 39, 54], ["infection", "DISEASE", 111, 120], ["atherosclerotic vaccines", "TREATMENT", 39, 63], ["various signaling pathways", "PROBLEM", 68, 94], ["infection", "PROBLEM", 111, 120], ["atherosclerotic", "OBSERVATION_MODIFIER", 39, 54], ["vaccines", "OBSERVATION", 55, 63], ["infection", "OBSERVATION", 111, 120]]]], "7957d654d295d290ba1492c76ec7e31f4a862e02": [["IntroductionThe SARS-CoV-2 induces severe respiratory syndrome in humans (1) .", [["respiratory syndrome", "DISEASE", 42, 62], ["SARS-CoV-2", "ORGANISM", 16, 26], ["humans", "ORGANISM", 66, 72], ["humans", "SPECIES", 66, 72], ["SARS-CoV", "SPECIES", 16, 24], ["humans", "SPECIES", 66, 72], ["The SARS", "TEST", 12, 20], ["severe respiratory syndrome", "PROBLEM", 35, 62], ["severe", "OBSERVATION_MODIFIER", 35, 41], ["respiratory syndrome", "OBSERVATION", 42, 62]]], ["The viral major proteins include spike (S) protein, matrix protein (M), small envelope protein (E) protein, and nucleocapsid protein (N) (2) .", [["spike (S) protein", "GENE_OR_GENE_PRODUCT", 33, 50], ["matrix protein", "GENE_OR_GENE_PRODUCT", 52, 66], ["small envelope protein (E)", "GENE_OR_GENE_PRODUCT", 72, 98], ["nucleocapsid protein (N)", "GENE_OR_GENE_PRODUCT", 112, 136], ["viral major proteins", "PROTEIN", 4, 24], ["spike (S) protein", "PROTEIN", 33, 50], ["matrix protein", "PROTEIN", 52, 66], ["M", "PROTEIN", 68, 69], ["small envelope protein (E) protein", "PROTEIN", 72, 106], ["nucleocapsid protein", "PROTEIN", 112, 132], ["N", "PROTEIN", 134, 135], ["The viral major proteins", "TEST", 0, 24], ["matrix protein", "TEST", 52, 66], ["small envelope protein", "TEST", 72, 94], ["protein", "TEST", 99, 106], ["nucleocapsid protein", "TEST", 112, 132]]], ["The location of viral attachment to the host cell resides within the S protein (3) .", [["cell", "ANATOMY", 45, 49], ["host cell", "CELL", 40, 49], ["S protein", "PROTEIN", 69, 78], ["viral attachment", "PROBLEM", 16, 32], ["viral attachment", "OBSERVATION", 16, 32], ["host cell", "OBSERVATION", 40, 49]]], ["SARS-CoV-2 is able to bind to angiotensin-converting enzyme 2 (ACE2) (4), transmembrane protease serine 2 (TMPRSS2) (5) , glucose regulating protein 78 (GRP78) (6) .IntroductionThere are several strategies to tackle the SARS-CoV-2, including inhibiting virus multiplication, inhibiting virus entry through receptors (blocking receptors), and blocking viral proteins.", [["SARS", "DISEASE", 0, 4], ["angiotensin", "CHEMICAL", 30, 41], ["glucose", "CHEMICAL", 122, 129], ["SARS", "DISEASE", 220, 224], ["serine", "CHEMICAL", 97, 103], ["glucose", "CHEMICAL", 122, 129], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 30, 61], ["ACE2", "GENE_OR_GENE_PRODUCT", 63, 67], ["transmembrane protease serine 2", "GENE_OR_GENE_PRODUCT", 74, 105], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 107, 114], ["glucose regulating protein 78", "GENE_OR_GENE_PRODUCT", 122, 151], ["GRP78", "GENE_OR_GENE_PRODUCT", 153, 158], ["SARS-CoV-2", "ORGANISM", 220, 230], ["angiotensin-converting enzyme 2 (ACE2) (4", "PROTEIN", 30, 71], ["transmembrane protease serine 2 (TMPRSS2) (5) , glucose regulating protein 78", "PROTEIN", 74, 151], ["GRP78", "PROTEIN", 153, 158], ["blocking receptors", "PROTEIN", 317, 335], ["viral proteins", "PROTEIN", 351, 365], ["angiotensin", "TEST", 30, 41], ["converting enzyme", "TEST", 42, 59], ["ACE2", "TEST", 63, 67], ["transmembrane protease serine", "TREATMENT", 74, 103], ["glucose regulating protein", "TEST", 122, 148], ["the SARS", "PROBLEM", 216, 224], ["CoV", "TEST", 225, 228], ["inhibiting virus multiplication", "PROBLEM", 242, 273], ["receptors (blocking receptors", "TREATMENT", 306, 335], ["blocking viral proteins", "PROBLEM", 342, 365], ["viral proteins", "OBSERVATION", 351, 365]]], ["The first approach is using miRNAs' to attach to the 3'UTR of the SARS-CoV-2 genome, so that viral translation will be inhibited (7, 8) .", [["3'UTR", "CELLULAR_COMPONENT", 53, 58], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 66, 76], ["3'UTR", "DNA", 53, 58], ["SARS-CoV-2 genome", "DNA", 66, 83], ["miRNAs'", "TREATMENT", 28, 35], ["the SARS", "TEST", 62, 70], ["viral translation", "PROBLEM", 93, 110]]], ["Blocking the aforementioned three receptors is the second approach to prevent SARS-CoV-2.", [["SARS", "DISEASE", 78, 82], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 78, 88], ["SARS-CoV", "SPECIES", 78, 86], ["SARS", "PROBLEM", 78, 82]]], ["It has suggested that decreasing the levels of ACE2 on the cell surface or inhibiting its function, helps in preventing SARS-CoV-2 infection (9) .", [["cell surface", "ANATOMY", 59, 71], ["infection", "DISEASE", 131, 140], ["ACE2", "GENE_OR_GENE_PRODUCT", 47, 51], ["cell surface", "CELLULAR_COMPONENT", 59, 71], ["CoV-2", "ORGANISM", 125, 130], ["ACE2", "PROTEIN", 47, 51], ["SARS-CoV", "SPECIES", 120, 128], ["the cell surface", "TREATMENT", 55, 71], ["SARS", "PROBLEM", 120, 124], ["CoV-2 infection", "PROBLEM", 125, 140], ["decreasing", "OBSERVATION_MODIFIER", 22, 32]]], ["By binding the spike protein to the ACE2, the angiotensin 2 is produced in large quantities by the ACE and then binds to the AT1R receptor.", [["angiotensin", "CHEMICAL", 46, 57], ["ACE2", "GENE_OR_GENE_PRODUCT", 36, 40], ["angiotensin 2", "GENE_OR_GENE_PRODUCT", 46, 59], ["ACE", "GENE_OR_GENE_PRODUCT", 99, 102], ["AT1R receptor", "GENE_OR_GENE_PRODUCT", 125, 138], ["spike protein", "PROTEIN", 15, 28], ["ACE2", "PROTEIN", 36, 40], ["angiotensin 2", "PROTEIN", 46, 59], ["ACE", "PROTEIN", 99, 102], ["AT1R receptor", "PROTEIN", 125, 138], ["large", "OBSERVATION_MODIFIER", 75, 80]]], ["This process leads to fibrosis and damage lung tissues.", [["lung tissues", "ANATOMY", 42, 54], ["fibrosis", "DISEASE", 22, 30], ["lung tissues", "TISSUE", 42, 54], ["fibrosis", "PROBLEM", 22, 30], ["damage lung tissues", "PROBLEM", 35, 54], ["fibrosis", "OBSERVATION", 22, 30], ["damage", "OBSERVATION", 35, 41], ["lung tissues", "ANATOMY", 42, 54]]], ["A possible way of combating the infection could be the injection of soluble ACE2 into the bloodstream which will have the two-fold effect; preventing the attachment of the virus to noninfected cells and replenishing ACE2 in infected cells (3) .", [["bloodstream", "ANATOMY", 90, 101], ["cells", "ANATOMY", 193, 198], ["cells", "ANATOMY", 233, 238], ["infection", "DISEASE", 32, 41], ["ACE2", "GENE_OR_GENE_PRODUCT", 76, 80], ["cells", "CELL", 193, 198], ["ACE2", "GENE_OR_GENE_PRODUCT", 216, 220], ["cells", "CELL", 233, 238], ["ACE2", "PROTEIN", 76, 80], ["noninfected cells", "CELL_TYPE", 181, 198], ["ACE2", "PROTEIN", 216, 220], ["infected cells", "CELL_TYPE", 224, 238], ["the infection", "PROBLEM", 28, 41], ["soluble ACE2", "TREATMENT", 68, 80], ["the two-fold effect", "PROBLEM", 118, 137], ["the virus to noninfected cells", "PROBLEM", 168, 198], ["replenishing ACE2 in infected cells", "PROBLEM", 203, 238], ["infection", "OBSERVATION", 32, 41], ["bloodstream", "ANATOMY", 90, 101], ["infected cells", "OBSERVATION", 224, 238]]], ["Secondly, it is assumed that SARS-CoV-2 uses the serine protease TMPRSS2 for S protein priming (10, 11) .", [["SARS", "DISEASE", 29, 33], ["serine", "CHEMICAL", 49, 55], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 29, 39], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 65, 72], ["S protein", "GENE_OR_GENE_PRODUCT", 77, 86], ["serine protease", "PROTEIN", 49, 64], ["TMPRSS2", "PROTEIN", 65, 72], ["S protein", "PROTEIN", 77, 86], ["SARS", "PROBLEM", 29, 33], ["CoV", "TEST", 34, 37], ["the serine protease TMPRSS2", "TREATMENT", 45, 72], ["S protein priming", "TEST", 77, 94], ["SARS", "OBSERVATION", 29, 33]]], ["So, the inhibition of TMPRSS2 protease is required for a robust blockade of viral entry.", [["TMPRSS2 protease", "GENE_OR_GENE_PRODUCT", 22, 38], ["TMPRSS2 protease", "PROTEIN", 22, 38], ["TMPRSS2 protease", "TREATMENT", 22, 38], ["a robust blockade", "TREATMENT", 55, 72], ["viral entry", "OBSERVATION", 76, 87]]], ["Thirdly, given the fact that diabetic individuals are more likely to get infected by the SARS-CoV-2 virus as its receptor is highly expressed on the lung and intestine and liver cells of individuals with type 2 diabetes.", [["lung", "ANATOMY", 149, 153], ["intestine", "ANATOMY", 158, 167], ["liver cells", "ANATOMY", 172, 183], ["diabetic", "DISEASE", 29, 37], ["SARS", "DISEASE", 89, 93], ["type 2 diabetes", "DISEASE", 204, 219], ["individuals", "ORGANISM", 38, 49], ["SARS-CoV-2 virus", "ORGANISM", 89, 105], ["lung", "ORGAN", 149, 153], ["intestine", "ORGAN", 158, 167], ["liver cells", "CELL", 172, 183], ["liver cells", "CELL_TYPE", 172, 183], ["CoV-2 virus", "SPECIES", 94, 105], ["SARS-CoV-2 virus", "SPECIES", 89, 105], ["diabetic individuals", "PROBLEM", 29, 49], ["the SARS-CoV-2 virus", "PROBLEM", 85, 105], ["type 2 diabetes", "PROBLEM", 204, 219], ["diabetic", "OBSERVATION", 29, 37], ["lung", "ANATOMY", 149, 153], ["intestine", "ANATOMY", 158, 167], ["liver", "ANATOMY", 172, 177], ["diabetes", "OBSERVATION", 211, 219]]], ["To J o u r n a l P r e -p r o o f our knowledge the role of GRP78 is facilitating the entrance of virus to the host cells (12) .IntroductionFinally, the AT1R receptor is one of the important receptors in modulating of blood pressure.IntroductionHigh blood pressure is directly linked to the SARS-CoV-2 virus, by inhibition of this receptor, presumably we would be able to prohibit lung injury.", [["cells", "ANATOMY", 116, 121], ["blood", "ANATOMY", 218, 223], ["blood", "ANATOMY", 250, 255], ["lung", "ANATOMY", 381, 385], ["SARS", "DISEASE", 291, 295], ["lung injury", "DISEASE", 381, 392], ["GRP78", "GENE_OR_GENE_PRODUCT", 60, 65], ["host cells", "CELL", 111, 121], ["AT1R receptor", "GENE_OR_GENE_PRODUCT", 153, 166], ["blood", "ORGANISM_SUBSTANCE", 218, 223], ["blood", "ORGANISM_SUBSTANCE", 250, 255], ["SARS-CoV-2 virus", "ORGANISM", 291, 307], ["lung", "ORGAN", 381, 385], ["GRP78", "PROTEIN", 60, 65], ["host cells", "CELL_TYPE", 111, 121], ["AT1R receptor", "PROTEIN", 153, 166], ["SARS-CoV-2 virus", "SPECIES", 291, 307], ["the AT1R receptor", "TREATMENT", 149, 166], ["blood pressure", "TEST", 218, 232], ["IntroductionHigh blood pressure", "TEST", 233, 264], ["the SARS", "PROBLEM", 287, 295], ["CoV", "TEST", 296, 299], ["this receptor", "TREATMENT", 326, 339], ["lung injury", "PROBLEM", 381, 392], ["virus", "OBSERVATION", 98, 103], ["host cells", "OBSERVATION", 111, 121], ["pressure", "OBSERVATION_MODIFIER", 256, 264], ["lung", "ANATOMY", 381, 385], ["injury", "OBSERVATION", 386, 392]]], ["Researches have shown that some of the AT1R-blockers such as Azilsartan and Olmesartan can overexpress the ACE2 and it could be a risky situation for SARA-CoV-2 entry (13) .", [["Azilsartan", "CHEMICAL", 61, 71], ["Olmesartan", "CHEMICAL", 76, 86], ["Azilsartan", "CHEMICAL", 61, 71], ["Olmesartan", "CHEMICAL", 76, 86], ["AT1R", "GENE_OR_GENE_PRODUCT", 39, 43], ["Azilsartan", "SIMPLE_CHEMICAL", 61, 71], ["Olmesartan", "SIMPLE_CHEMICAL", 76, 86], ["ACE2", "GENE_OR_GENE_PRODUCT", 107, 111], ["SARA-CoV-2", "GENE_OR_GENE_PRODUCT", 150, 160], ["AT1R", "PROTEIN", 39, 43], ["ACE2", "PROTEIN", 107, 111], ["the AT1R-blockers", "TREATMENT", 35, 52], ["Azilsartan", "TREATMENT", 61, 71], ["Olmesartan", "TREATMENT", 76, 86]]], ["The third approach could be to target the respective enzyme to prevent the virus from progressing and surviving in the host cell.", [["cell", "ANATOMY", 124, 128], ["host cell", "CELL", 119, 128], ["host cell", "CELL_TYPE", 119, 128], ["the respective enzyme", "TEST", 38, 59], ["the virus", "PROBLEM", 71, 80], ["virus", "OBSERVATION", 75, 80], ["host cell", "OBSERVATION", 119, 128]]], ["In this study, we have surveyed these approaches to address alternative therapeutic methods against viral infection.", [["viral infection", "DISEASE", 100, 115], ["this study", "TEST", 3, 13], ["alternative therapeutic methods", "TREATMENT", 60, 91], ["viral infection", "PROBLEM", 100, 115], ["infection", "OBSERVATION", 106, 115]]], ["For this purpose, thirty medicinal herbs that have the most impact on the pathways associated with each receptor were selected to analyze their affinity to bind the ACE2, TMPRSS2, GRP78, and AT1R receptors.", [["ACE2", "GENE_OR_GENE_PRODUCT", 165, 169], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 171, 178], ["GRP78", "GENE_OR_GENE_PRODUCT", 180, 185], ["AT1R receptors", "GENE_OR_GENE_PRODUCT", 191, 205], ["ACE2", "PROTEIN", 165, 169], ["TMPRSS2", "PROTEIN", 171, 178], ["GRP78", "PROTEIN", 180, 185], ["AT1R receptors", "PROTEIN", 191, 205], ["thirty medicinal herbs", "TREATMENT", 18, 40], ["the ACE2", "TEST", 161, 169], ["TMPRSS2", "TEST", 171, 178], ["GRP78", "TEST", 180, 185], ["AT1R receptors", "TREATMENT", 191, 205]]], ["Besides, to control the virus genome, a comprehensive investigation was performed on the SARS-CoV-2 genome inhibitors.Material and MethodsInformation about the virus (structure, reproduction, and genome) was obtained from the Viral Zone database (www.viralzone.expasy.org) (14) .Calculation of 3'UTR and miRNAs affinityThe nucleotide sequences of all 1872 miRNAs were downloaded from the miRBase database (http://mirbase.org) (15) and their expression levels were determined in normal lung squamous cells and lung tissue through TCGA-Assembler 2 package by R software, version 4.0.0 (16); non-expressed microRNAs were deleted.", [["lung squamous cells", "ANATOMY", 485, 504], ["lung tissue", "ANATOMY", 509, 520], ["nucleotide", "CHEMICAL", 323, 333], ["3'UTR", "CELLULAR_COMPONENT", 294, 299], ["lung squamous cells", "CELL", 485, 504], ["lung tissue", "TISSUE", 509, 520], ["virus genome", "DNA", 24, 36], ["SARS-CoV-2 genome", "DNA", 89, 106], ["3'UTR", "DNA", 294, 299], ["miRBase database", "DNA", 388, 404], ["normal lung squamous cells", "CELL_TYPE", 478, 504], ["non-expressed microRNAs", "DNA", 589, 612], ["SARS-CoV", "SPECIES", 89, 97], ["the virus genome", "PROBLEM", 20, 36], ["a comprehensive investigation", "TEST", 38, 67], ["the SARS", "TEST", 85, 93], ["CoV-2 genome inhibitors", "TREATMENT", 94, 117], ["the virus", "PROBLEM", 156, 165], ["Calculation", "TEST", 279, 290], ["3'UTR", "TREATMENT", 294, 299], ["miRNAs affinity", "TEST", 304, 319], ["The nucleotide sequences", "TEST", 319, 343], ["the miRBase database", "TEST", 384, 404], ["their expression levels", "TEST", 435, 458], ["version", "TEST", 569, 576], ["lung", "ANATOMY", 485, 489], ["squamous cells", "OBSERVATION", 490, 504], ["lung", "ANATOMY", 509, 513]]], ["Then, the 3'UTR sequence of the SARS-COV-2 RNA was obtained from NCBI database entry MTO49951.1 (www.ncbi.nlm.nih.gov) (17) .", [["SARS-COV-2", "GENE_OR_GENE_PRODUCT", 32, 42], ["3'UTR sequence", "DNA", 10, 24], ["SARS-COV-2 RNA", "RNA", 32, 46], ["the SARS", "TEST", 28, 36], ["COV", "TEST", 37, 40]]], ["The J o u r n a l P r e -p r o o f affinity between each miRNA and 3'UTR of the viral genome was computed by the RNAhybrid database (https://bio.tools/rnahybrid) (18) .Identification of the efficient miRNAs, and transcriptional factorsBy using the miRWalk database (http://mirwalk.umm.uni-heidelberg.de/) (19) and the TransmiR database (http://www.cuilab.cn/) (20) the targetome and transcription factors of the best miRNA were achieved.", [["3'UTR", "DNA", 67, 72], ["viral genome", "DNA", 80, 92], ["RNAhybrid database", "DNA", 113, 131], ["transcriptional factorsBy", "PROTEIN", 212, 237], ["miRWalk database", "DNA", 248, 264], ["TransmiR database", "DNA", 318, 335], ["transcription factors", "PROTEIN", 383, 404], ["affinity", "PROBLEM", 35, 43], ["each miRNA", "PROBLEM", 52, 62], ["the viral genome", "PROBLEM", 76, 92], ["the efficient miRNAs", "PROBLEM", 186, 206], ["the miRWalk database", "TEST", 244, 264], ["the TransmiR database", "TEST", 314, 335], ["viral genome", "OBSERVATION", 80, 92], ["efficient miRNAs", "OBSERVATION", 190, 206]]], ["Then, those which had expression in lung tissue were checked and selected by the TCGA-Assembler 2 package of R software.", [["lung tissue", "ANATOMY", 36, 47], ["lung tissue", "TISSUE", 36, 47], ["expression in lung tissue", "PROBLEM", 22, 47], ["lung tissue", "ANATOMY", 36, 47]]], ["Finally, the signaling pathways of the selected miRNAs, targetome, and transcription factors were separately obtained from the KEGG database (www.kegg.jp) (21) .", [["transcription factors", "PROTEIN", 71, 92], ["the KEGG database", "TEST", 123, 140]]], ["The schematic figure of the signaling pathways related to both targetome and transcription factors of the best miRNAs were drowned by the Biorender software.", [["transcription factors", "PROTEIN", 77, 98], ["the signaling pathways", "PROBLEM", 24, 46]]], ["The targetome schematic figure was produced by Cytoscape software, version 3.8.0 (22) .Modeling analysis for each receptorFirst, the sequence of ACE2, GRP78, TMPRSS2, and AT1R receptors were acquired from the NCBI database and modeled using SWISS-MODEL modeling tools (https://swissmodel.expasy.org/) (23).", [["ACE2", "GENE_OR_GENE_PRODUCT", 145, 149], ["GRP78", "GENE_OR_GENE_PRODUCT", 151, 156], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 158, 165], ["AT1R receptors", "GENE_OR_GENE_PRODUCT", 171, 185], ["receptorFirst", "DNA", 114, 127], ["ACE2", "PROTEIN", 145, 149], ["GRP78", "PROTEIN", 151, 156], ["TMPRSS2", "PROTEIN", 158, 165], ["AT1R receptors", "PROTEIN", 171, 185], ["version", "TEST", 67, 74], ["Modeling analysis", "TEST", 87, 104], ["ACE2", "TEST", 145, 149], ["GRP78", "TEST", 151, 156], ["TMPRSS2", "TEST", 158, 165], ["AT1R receptors", "TEST", 171, 185], ["the NCBI database", "TEST", 205, 222]]], ["The SARS-CoV-2 structure was downloaded from the RCSB PDB database (https://www.rcsb.org/) (24) and the binding site of each receptor related to SARS-CoV-2 obtained from articles.Collecting the herbal phytochemicalsAfter determining thirty medicinal herbs (Preparation and molecular docking analysisThe 3-D structure of receptor blockers (Table2) and herbal compounds were prepared for docking by removing all water and H-bond optimization, then, Gasteiger charges were added.Preparation and molecular docking analysisAfter that, molecular docking analysis was performed for each herbal compound and receptor blockers using AutoDock vina.", [["H", "CHEMICAL", 420, 421], ["H", "CHEMICAL", 420, 421], ["Table2", "SIMPLE_CHEMICAL", 339, 345], ["Gasteiger", "SIMPLE_CHEMICAL", 447, 456], ["SARS-CoV-2 structure", "DNA", 4, 24], ["binding site", "DNA", 104, 116], ["SARS-CoV-2", "DNA", 145, 155], ["The SARS", "TEST", 0, 8], ["the RCSB PDB database", "TEST", 45, 66], ["the binding site", "PROBLEM", 100, 116], ["SARS", "TEST", 145, 149], ["CoV", "TEST", 150, 153], ["thirty medicinal herbs", "TREATMENT", 233, 255], ["molecular docking analysis", "TEST", 273, 299], ["The 3-D structure of receptor blockers", "TREATMENT", 299, 337], ["Table2)", "TREATMENT", 339, 346], ["herbal compounds", "TREATMENT", 351, 367], ["all water and H-bond optimization", "TREATMENT", 406, 439], ["Gasteiger charges", "TREATMENT", 447, 464], ["molecular docking analysis", "TEST", 530, 556], ["each herbal compound", "TREATMENT", 575, 595], ["receptor blockers", "TREATMENT", 600, 617], ["AutoDock vina", "TREATMENT", 624, 637], ["PDB", "ANATOMY", 54, 57], ["herbal phytochemicals", "OBSERVATION", 194, 215]]], ["Figures were made by Chimera software version 1.14 (26).Determination of beneficial compounds characteristicsThe activity, daily dose carcinogenicity, blood-brain barrier penetration, and antiviral features caught from way 2 drug (27) (www.pharmaexpert.ru/passonline/predict.php), lazar (lazar.insilico.ch/predict) (28) and AVCpred (http://crdd.osdd.net/servers/avcpred) (29), respectively.Selecting the most efficient miRNAsAccording to affinity examination between 3'UTR of SARS-CoV-2 and all 1872 miRNAs, 42 miRNAs with the highest score were identified (Table 3) .", [["blood", "ANATOMY", 151, 156], ["brain", "ANATOMY", 157, 162], ["blood", "ORGANISM_SUBSTANCE", 151, 156], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 157, 170], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 476, 486], ["3'UTR", "DNA", 467, 472], ["SARS-CoV-2", "DNA", 476, 486], ["SARS-CoV", "SPECIES", 476, 484], ["Chimera software version", "TEST", 21, 45], ["daily dose carcinogenicity", "TREATMENT", 123, 149], ["blood-brain barrier penetration", "TREATMENT", 151, 182], ["antiviral features", "PROBLEM", 188, 206], ["affinity examination", "TEST", 438, 458], ["SARS", "TEST", 476, 480], ["CoV", "TEST", 481, 484], ["brain", "ANATOMY", 157, 162], ["barrier penetration", "OBSERVATION", 163, 182]]], ["Among them, hsa-miR-1307 3p had the highest score among miRNAs with -37.6 kCal/mol, and high expression level in lung and squamous tissues ( Figure 1 ).The hsa-miR-1307 3p targetome enrichment studyApproximately 377 predicted and valid targets of hsa-miR-1307 which were predicted The best herbal compounds for ACE2, TMPRSS2, GRP78, and AT1R receptors were identified based on their binding energy.The common medicinal herbs and blocker drugsThirty-five common medicinal herbal compounds and blocker drugs were investigated between ACE2, TMPRSS2, GRP78, and AT1R; with a score of -7 kCal/mol or higher.", [["lung", "ANATOMY", 113, 117], ["squamous tissues", "ANATOMY", 122, 138], ["hsa-miR-1307", "CHEMICAL", 12, 24], ["hsa-miR-1307", "CHEMICAL", 247, 259], ["hsa-miR-1307 3p", "GENE_OR_GENE_PRODUCT", 12, 27], ["lung", "ORGAN", 113, 117], ["squamous tissues", "TISSUE", 122, 138], ["hsa-miR-1307", "GENE_OR_GENE_PRODUCT", 156, 168], ["hsa-miR-1307", "GENE_OR_GENE_PRODUCT", 247, 259], ["ACE2", "GENE_OR_GENE_PRODUCT", 311, 315], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 317, 324], ["GRP78", "GENE_OR_GENE_PRODUCT", 326, 331], ["AT1R", "GENE_OR_GENE_PRODUCT", 337, 341], ["blocker drugs", "SIMPLE_CHEMICAL", 492, 505], ["ACE2", "GENE_OR_GENE_PRODUCT", 532, 536], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 538, 545], ["GRP78", "GENE_OR_GENE_PRODUCT", 547, 552], ["AT1R", "GENE_OR_GENE_PRODUCT", 558, 562], ["hsa-miR-1307 3p", "DNA", 12, 27], ["hsa-miR-1307 3p targetome", "DNA", 156, 181], ["hsa-miR-1307", "DNA", 247, 259], ["ACE2", "PROTEIN", 311, 315], ["TMPRSS2", "PROTEIN", 317, 324], ["GRP78", "PROTEIN", 326, 331], ["AT1R receptors", "PROTEIN", 337, 351], ["ACE2", "PROTEIN", 532, 536], ["TMPRSS2", "PROTEIN", 538, 545], ["GRP78", "PROTEIN", 547, 552], ["AT1R", "PROTEIN", 558, 562], ["miRNAs", "TEST", 56, 62], ["high expression level in lung and squamous tissues", "PROBLEM", 88, 138], ["The hsa-miR", "TEST", 152, 163], ["hsa-miR", "TEST", 247, 254], ["ACE2", "TEST", 311, 315], ["TMPRSS2", "TEST", 317, 324], ["GRP78", "TEST", 326, 331], ["AT1R receptors", "TREATMENT", 337, 351], ["The common medicinal herbs", "TREATMENT", 398, 424], ["blocker drugs", "TREATMENT", 429, 442], ["medicinal herbal compounds", "TREATMENT", 461, 487], ["blocker drugs", "TREATMENT", 492, 505], ["ACE2", "TEST", 532, 536], ["TMPRSS2", "TEST", 538, 545], ["AT1R", "TEST", 558, 562], ["a score", "TEST", 569, 576], ["lung", "ANATOMY", 113, 117], ["squamous tissues", "ANATOMY", 122, 138]]], ["Among them,The common medicinal herbs and blocker drugsBerbamine had the highest binding energy for all four receptors (Supplementary Table 1 ).Selecting top common compoundsBerbamine, Hesperidin, and Hypericin were the best common compounds for interaction with The results of molecular docking also showed a high tendency of compounds to receptors.", [["Berbamine", "CHEMICAL", 55, 64], ["Berbamine", "CHEMICAL", 174, 183], ["Hesperidin", "CHEMICAL", 185, 195], ["Hypericin", "CHEMICAL", 201, 210], ["Berbamine", "CHEMICAL", 55, 64], ["Berbamine", "CHEMICAL", 174, 183], ["Hesperidin", "CHEMICAL", 185, 195], ["Hypericin", "CHEMICAL", 201, 210], ["Berbamine", "SIMPLE_CHEMICAL", 55, 64], ["Berbamine", "SIMPLE_CHEMICAL", 174, 183], ["Hesperidin", "SIMPLE_CHEMICAL", 185, 195], ["Hypericin", "SIMPLE_CHEMICAL", 201, 210], ["The common medicinal herbs", "TREATMENT", 11, 37], ["blocker drugsBerbamine", "TREATMENT", 42, 64], ["Berbamine", "TREATMENT", 174, 183], ["Hesperidin", "TREATMENT", 185, 195], ["Hypericin", "TREATMENT", 201, 210], ["a high tendency of compounds to receptors", "PROBLEM", 308, 349], ["common compounds", "OBSERVATION", 158, 174]]], ["The molecular docking results of the ACE2, TMPRSS2, GRP78, and AT1R receptors with medicinal herbal compounds are presented in Supplementary Table 2 .Comparison of the binding energy for receptorsThe results of molecular docking to compare the binding energy between the available blocking drugs and the herbal compounds investigated from the present study presented that the affinity of herbal compounds to bind to the ACE2, TMPRSS2, GRP78, and ACE2 receptors were higher.Comparison of the binding energy for receptors( Table 4 )Attaining the specifications of top common compoundsThe lazar database had no result for Hestridine, but characteristics of other top three common compounds include antitussive, respiratory analeptic, hepatoprotection, antivirus, RNA synthesis J o u r n a l P r e -p r o o f inhibitor.", [["Hestridine", "CHEMICAL", 619, 629], ["Hestridine", "CHEMICAL", 619, 629], ["ACE2", "GENE_OR_GENE_PRODUCT", 37, 41], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 43, 50], ["GRP78", "GENE_OR_GENE_PRODUCT", 52, 57], ["AT1R", "GENE_OR_GENE_PRODUCT", 63, 67], ["ACE2", "GENE_OR_GENE_PRODUCT", 420, 424], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 426, 433], ["GRP78", "GENE_OR_GENE_PRODUCT", 435, 440], ["ACE2", "GENE_OR_GENE_PRODUCT", 446, 450], ["Hestridine", "SIMPLE_CHEMICAL", 619, 629], ["ACE2", "PROTEIN", 37, 41], ["TMPRSS2", "PROTEIN", 43, 50], ["GRP78", "PROTEIN", 52, 57], ["AT1R receptors", "PROTEIN", 63, 77], ["ACE2", "PROTEIN", 420, 424], ["TMPRSS2", "PROTEIN", 426, 433], ["GRP78", "PROTEIN", 435, 440], ["ACE2 receptors", "PROTEIN", 446, 460], ["the ACE2", "TEST", 33, 41], ["TMPRSS2", "TEST", 43, 50], ["GRP78", "TEST", 52, 57], ["AT1R receptors", "TREATMENT", 63, 77], ["medicinal herbal compounds", "TREATMENT", 83, 109], ["the binding energy", "PROBLEM", 240, 258], ["the available blocking drugs", "TREATMENT", 267, 295], ["the herbal compounds", "TREATMENT", 300, 320], ["the present study", "TEST", 339, 356], ["herbal compounds", "PROBLEM", 388, 404], ["TMPRSS2", "TEST", 426, 433], ["GRP78", "TEST", 435, 440], ["ACE2 receptors", "TEST", 446, 460], ["The lazar database", "TEST", 582, 600], ["Hestridine", "TREATMENT", 619, 629], ["antitussive", "PROBLEM", 695, 706], ["respiratory analeptic", "PROBLEM", 708, 729], ["hepatoprotection", "TREATMENT", 731, 747], ["antivirus", "TREATMENT", 749, 758], ["RNA synthesis", "TREATMENT", 760, 773], ["a l P r e -p r o o f inhibitor", "TREATMENT", 784, 814], ["herbal compounds", "OBSERVATION", 93, 109], ["respiratory analeptic", "OBSERVATION", 708, 729]]], ["Furthermore, features such as blood-brain barrier penetration, carcinogenicity, maximum recommended daily dose, and antiviral ability of each three common herbal compounds were surveyed and presented in Table 4 .DiscussionThe high mortality rate around the world due to COVID-19 has led to the recognition and treatment of the SARS-CoV-2.", [["blood", "ANATOMY", 30, 35], ["brain", "ANATOMY", 36, 41], ["COVID-19", "CHEMICAL", 270, 278], ["SARS", "DISEASE", 327, 331], ["blood", "ORGANISM_SUBSTANCE", 30, 35], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 36, 49], ["SARS-CoV-2", "ORGANISM", 327, 337], ["COVID-19", "DNA", 270, 278], ["SARS-CoV", "SPECIES", 327, 335], ["blood-brain barrier penetration", "PROBLEM", 30, 61], ["antiviral ability of each three common herbal compounds", "TREATMENT", 116, 171], ["The high mortality rate", "PROBLEM", 222, 245], ["COVID", "TEST", 270, 275], ["treatment", "TREATMENT", 310, 319], ["the SARS", "TEST", 323, 331], ["brain", "ANATOMY", 36, 41], ["barrier penetration", "OBSERVATION", 42, 61], ["high", "OBSERVATION_MODIFIER", 226, 230]]], ["There has been a lot of research on this disease over the past few months, but there is still a need for a comprehensive study that considers all aspects of the disease (30) .", [["this disease", "PROBLEM", 36, 48], ["a comprehensive study", "TEST", 105, 126], ["lot", "OBSERVATION_MODIFIER", 17, 20], ["disease", "OBSERVATION", 161, 168]]], ["In this bioinformatics study, it was tried to attend different approaches related to the SARS-CoV-2 before and after the infection.DiscussionThe most important receptors for SARS-Cov-2 are ACE2 (31) TMPRSS2 (32) , and GRP78 (6), which by blocking these receptors can protect the body against the virus.", [["body", "ANATOMY", 279, 283], ["SARS", "DISEASE", 89, 93], ["infection", "DISEASE", 121, 130], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 174, 184], ["ACE2 (31) TMPRSS2 (32)", "GENE_OR_GENE_PRODUCT", 189, 211], ["GRP78 (6", "GENE_OR_GENE_PRODUCT", 218, 226], ["body", "ORGANISM_SUBDIVISION", 279, 283], ["ACE2", "PROTEIN", 189, 193], ["GRP78 (6", "PROTEIN", 218, 226], ["SARS-CoV", "SPECIES", 89, 97], ["this bioinformatics study", "TEST", 3, 28], ["the SARS", "TEST", 85, 93], ["the infection", "PROBLEM", 117, 130], ["SARS", "TEST", 174, 178], ["Cov", "TEST", 179, 182], ["ACE2", "TEST", 189, 193], ["TMPRSS2", "TEST", 199, 206], ["the virus", "PROBLEM", 292, 301], ["infection", "OBSERVATION", 121, 130], ["virus", "OBSERVATION", 296, 301]]], ["In the process of infecting by SARS-CoV-2, binding the virus to ACE2 prevents the attachment of angiotensin 1 If the lung cell is infected with the SARS-CoV-2, preventing the virus from replicating is another treatment option (38) .", [["lung cell", "ANATOMY", 117, 126], ["angiotensin", "CHEMICAL", 96, 107], ["SARS-CoV-2", "ORGANISM", 31, 41], ["ACE2", "GENE_OR_GENE_PRODUCT", 64, 68], ["angiotensin 1", "GENE_OR_GENE_PRODUCT", 96, 109], ["lung cell", "CELL", 117, 126], ["SARS-CoV-2", "ORGANISM", 148, 158], ["ACE2", "PROTEIN", 64, 68], ["lung cell", "CELL_TYPE", 117, 126], ["SARS-CoV", "SPECIES", 31, 39], ["SARS-CoV", "SPECIES", 148, 156], ["binding the virus", "PROBLEM", 43, 60], ["angiotensin", "TREATMENT", 96, 107], ["the lung cell", "PROBLEM", 113, 126], ["the SARS", "TEST", 144, 152], ["the virus", "PROBLEM", 171, 180], ["another treatment option", "TREATMENT", 201, 225], ["lung", "ANATOMY", 117, 121], ["cell", "OBSERVATION", 122, 126], ["infected", "OBSERVATION", 130, 138]]], ["Many studies have shown that miRNAs play an important role in inhibiting viruses' replication by preventing the translation of the viral genome (7) .", [["miRNAs", "DNA", 29, 35], ["viral genome", "DNA", 131, 143], ["Many studies", "TEST", 0, 12], ["viruses' replication", "TREATMENT", 73, 93], ["viral genome", "OBSERVATION", 131, 143]]], ["In this study, among 1872 miRNAs, has-miR-1307-3p was selected as the best miRNA because of its high J o u r n a l P r e -p r o o f affinity to SARS-CoV-2 genome 3'UTR and high expression in lung tissue (39) .", [["lung tissue", "ANATOMY", 191, 202], ["miR-1307-3p", "GENE_OR_GENE_PRODUCT", 38, 49], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 144, 154], ["lung tissue", "TISSUE", 191, 202], ["miR-1307-3p", "DNA", 38, 49], ["SARS-CoV-2 genome 3'UTR", "DNA", 144, 167], ["this study", "TEST", 3, 13], ["affinity", "PROBLEM", 132, 140], ["SARS", "PROBLEM", 144, 148], ["CoV", "TEST", 149, 152], ["high expression in lung tissue", "PROBLEM", 172, 202], ["high expression", "OBSERVATION", 172, 187], ["lung", "ANATOMY", 191, 195], ["tissue", "ANATOMY_MODIFIER", 196, 202]]], ["Increased expression of hsa-miR-1307-3p may lead to a reduction in SARS-CoV-2 replication through binding to the 3'UTR site of the virus genome. miRNAs can be synthesized for therapeutic purposes and inserted into the target area, but their delivery is a complicated and meticulous process.", [["hsa-miR-1307-3p", "CHEMICAL", 24, 39], ["hsa-miR-1307-3p", "GENE_OR_GENE_PRODUCT", 24, 39], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 67, 77], ["hsa-miR-1307-3p", "DNA", 24, 39], ["3'UTR site", "DNA", 113, 123], ["virus genome", "DNA", 131, 143], ["miRNAs", "RNA", 145, 151], ["SARS-CoV", "SPECIES", 67, 75], ["hsa-miR", "TEST", 24, 31], ["a reduction", "PROBLEM", 52, 63], ["SARS", "PROBLEM", 67, 71], ["CoV-2 replication", "TREATMENT", 72, 89], ["the virus genome", "PROBLEM", 127, 143], ["therapeutic purposes", "TREATMENT", 175, 195], ["a complicated and meticulous process", "PROBLEM", 253, 289], ["reduction", "OBSERVATION_MODIFIER", 54, 63], ["SARS", "OBSERVATION", 67, 71], ["virus genome", "OBSERVATION", 131, 143], ["meticulous", "OBSERVATION", 271, 281]]], ["Therefore, the use of TFs to induce the expression of the desired miRNA by lung cells may be a better choice.", [["TFs", "ANATOMY", 22, 25], ["lung cells", "ANATOMY", 75, 85], ["TFs", "CELL", 22, 25], ["lung cells", "CELL", 75, 85], ["TFs", "PROTEIN", 22, 25], ["lung cells", "CELL_TYPE", 75, 85], ["TFs", "TREATMENT", 22, 25], ["lung", "ANATOMY", 75, 79]]], ["After obtaining all the signaling pathways related to the hsa-miR-1307-3p transcription factors, the receptors responsible for activating the TFs were also examined.", [["TFs", "ANATOMY", 142, 145], ["hsa-miR-1307", "GENE_OR_GENE_PRODUCT", 58, 70], ["TFs", "CELL", 142, 145], ["hsa-miR-1307-3p transcription factors", "PROTEIN", 58, 95], ["TFs", "DNA", 142, 145], ["the hsa-miR", "TEST", 54, 65], ["the receptors", "TREATMENT", 97, 110], ["activating the TFs", "TREATMENT", 127, 145]]], ["As a result, using the ligand of each of these receptors can lead to the expression of the TFs genes;Discussioneventually triggers the induction of the hsa-miR-1307-3p production.DiscussionOf important, hsa-miR-1307-3p can affect receptors that are responsible for survival and proliferation.", [["hsa-miR-1307-3p", "CHEMICAL", 152, 167], ["hsa-miR-1307-3p", "CHEMICAL", 203, 218], ["TFs", "CELL", 91, 94], ["hsa-miR-1307-3p", "GENE_OR_GENE_PRODUCT", 152, 167], ["hsa-miR-1307-3p", "GENE_OR_GENE_PRODUCT", 203, 218], ["TFs genes", "DNA", 91, 100], ["hsa-miR-1307-3p", "DNA", 152, 167], ["hsa-miR-1307-3p", "DNA", 203, 218], ["these receptors", "TREATMENT", 41, 56], ["the hsa-miR", "TEST", 148, 159], ["proliferation", "PROBLEM", 278, 291], ["responsible for", "UNCERTAINTY", 249, 264], ["proliferation", "OBSERVATION", 278, 291]]], ["The hsa-miR-1307-3p also affects anti-apoptotic proteins like BCL2 and inhibits them to induce apoptosis, leading to the prohibition of the proliferation.", [["hsa-miR-1307-3p", "CHEMICAL", 4, 19], ["hsa-miR-1307-3p", "GENE_OR_GENE_PRODUCT", 4, 19], ["BCL2", "GENE_OR_GENE_PRODUCT", 62, 66], ["hsa-miR-1307-3p", "DNA", 4, 19], ["anti-apoptotic proteins", "PROTEIN", 33, 56], ["BCL2", "PROTEIN", 62, 66], ["The hsa-miR", "TEST", 0, 11], ["anti-apoptotic proteins", "PROBLEM", 33, 56], ["BCL2", "PROBLEM", 62, 66], ["apoptosis", "PROBLEM", 95, 104], ["the proliferation", "PROBLEM", 136, 153], ["proliferation", "OBSERVATION", 140, 153]]], ["Investigations have proven that the PI3K signaling pathway is so critical for virus survival and spread (40) .", [["PI3K", "GENE_OR_GENE_PRODUCT", 36, 40], ["PI3K", "PROTEIN", 36, 40], ["the PI3K signaling pathway", "PROBLEM", 32, 58], ["virus survival", "PROBLEM", 78, 92]]], ["The hsa-miR-1307-3p inhibits the PI3K pathway by suppressing the activators of PI3K, and eventually, the cell cycle proliferation is prevented.", [["cell", "ANATOMY", 105, 109], ["hsa-miR-1307-3p", "CHEMICAL", 4, 19], ["hsa-miR-1307-3p", "GENE_OR_GENE_PRODUCT", 4, 19], ["PI3K", "GENE_OR_GENE_PRODUCT", 33, 37], ["PI3K", "GENE_OR_GENE_PRODUCT", 79, 83], ["cell", "CELL", 105, 109], ["hsa-miR-1307-3p", "DNA", 4, 19], ["PI3K", "PROTEIN", 33, 37], ["PI3K", "PROTEIN", 79, 83], ["The hsa-miR", "TEST", 0, 11], ["the PI3K pathway", "TREATMENT", 29, 45], ["the cell cycle proliferation", "TREATMENT", 101, 129], ["cell cycle proliferation", "OBSERVATION", 105, 129]]], ["On the other hand, hsa-miR-1307-3p can ban clathrindependent endocytosis by inhibiting AP-2, PIP5K, and might suppress exocytosis by inhibiting of actin.", [["hsa-miR-1307-3p", "GENE_OR_GENE_PRODUCT", 19, 34], ["AP-2", "GENE_OR_GENE_PRODUCT", 87, 91], ["PIP5K", "GENE_OR_GENE_PRODUCT", 93, 98], ["actin", "GENE_OR_GENE_PRODUCT", 147, 152], ["hsa-miR-1307-3p", "DNA", 19, 34], ["AP-2", "PROTEIN", 87, 91], ["PIP5K", "PROTEIN", 93, 98], ["actin", "PROTEIN", 147, 152], ["hsa-miR", "TEST", 19, 26], ["AP", "TEST", 87, 89], ["PIP5K", "TEST", 93, 98]]], ["It has been confirmed that endocytosis and exocytosis are associated with virus entry and spread, therefore, controlling these pathways by hsa-miR-1307-3p could be an effective strategy for SARS-CoV-2 infection.DiscussionThe WHO has stated that obesity and Diabetes mellitus are other risk factors for developing COVID-19.", [["hsa-miR-1307-3p", "CHEMICAL", 139, 154], ["SARS-CoV-2 infection", "DISEASE", 190, 210], ["obesity", "DISEASE", 245, 252], ["Diabetes mellitus", "DISEASE", 257, 274], ["COVID-19", "CHEMICAL", 313, 321], ["hsa-miR-1307-3p", "GENE_OR_GENE_PRODUCT", 139, 154], ["SARS-CoV-2", "ORGANISM", 190, 200], ["hsa-miR-1307-3p", "DNA", 139, 154], ["SARS-CoV-2", "SPECIES", 190, 200], ["endocytosis", "PROBLEM", 27, 38], ["exocytosis", "PROBLEM", 43, 53], ["virus entry", "PROBLEM", 74, 85], ["hsa-miR", "TEST", 139, 146], ["SARS", "PROBLEM", 190, 194], ["CoV-2 infection", "PROBLEM", 195, 210], ["obesity", "PROBLEM", 245, 252], ["Diabetes mellitus", "PROBLEM", 257, 274], ["other risk factors", "PROBLEM", 279, 297], ["COVID", "TEST", 313, 318], ["endocytosis", "OBSERVATION", 27, 38], ["infection", "OBSERVATION", 201, 210], ["obesity", "OBSERVATION", 245, 252]]], ["In obesity that leads to type 2 diabetes, hyperglycemia leads to inhibition of the immune system (41) as well as the activation of PKC, as a result of its activity, inhibits IRS2, and leads to indirect inhibition of ACT, which in turn leads to glycogenesis and glucose uptake.J o u r n a l P r e -p r o o fOn the other hand, hyperglycemia increases the expression of GRP78 on the cell surface, which can activate the ACT pathway to reduce blood sugar (42) .", [["cell surface", "ANATOMY", 380, 392], ["blood", "ANATOMY", 439, 444], ["obesity", "DISEASE", 3, 10], ["type 2 diabetes", "DISEASE", 25, 40], ["hyperglycemia", "DISEASE", 42, 55], ["glucose", "CHEMICAL", 261, 268], ["hyperglycemia", "DISEASE", 325, 338], ["glucose", "CHEMICAL", 261, 268], ["sugar", "CHEMICAL", 445, 450], ["PKC", "GENE_OR_GENE_PRODUCT", 131, 134], ["IRS2", "GENE_OR_GENE_PRODUCT", 174, 178], ["ACT", "GENE_OR_GENE_PRODUCT", 216, 219], ["glucose", "SIMPLE_CHEMICAL", 261, 268], ["GRP78", "GENE_OR_GENE_PRODUCT", 367, 372], ["cell surface", "CELLULAR_COMPONENT", 380, 392], ["ACT", "GENE_OR_GENE_PRODUCT", 417, 420], ["blood", "ORGANISM_SUBSTANCE", 439, 444], ["sugar", "SIMPLE_CHEMICAL", 445, 450], ["PKC", "PROTEIN", 131, 134], ["IRS2", "PROTEIN", 174, 178], ["ACT", "PROTEIN", 216, 219], ["GRP78", "PROTEIN", 367, 372], ["ACT", "PROTEIN", 417, 420], ["obesity", "PROBLEM", 3, 10], ["type 2 diabetes", "PROBLEM", 25, 40], ["hyperglycemia", "PROBLEM", 42, 55], ["the immune system", "TEST", 79, 96], ["PKC", "PROBLEM", 131, 134], ["IRS2", "PROBLEM", 174, 178], ["indirect inhibition of ACT", "PROBLEM", 193, 219], ["glycogenesis and glucose uptake", "PROBLEM", 244, 275], ["hyperglycemia", "PROBLEM", 325, 338], ["blood sugar", "TEST", 439, 450], ["obesity", "OBSERVATION", 3, 10], ["diabetes", "OBSERVATION", 32, 40], ["hyperglycemia", "OBSERVATION", 42, 55], ["glucose uptake", "OBSERVATION", 261, 275], ["hyperglycemia", "OBSERVATION", 325, 338]]], ["Activating the tyrosine kinase receptor activates the ERK protein, and this protein inhibits IRS1 that also indirectly prevents the ACT and its downstream pathway.", [["tyrosine", "CHEMICAL", 15, 23], ["tyrosine", "CHEMICAL", 15, 23], ["ERK", "GENE_OR_GENE_PRODUCT", 54, 57], ["IRS1", "GENE_OR_GENE_PRODUCT", 93, 97], ["ACT", "GENE_OR_GENE_PRODUCT", 132, 135], ["tyrosine kinase receptor", "PROTEIN", 15, 39], ["ERK protein", "PROTEIN", 54, 65], ["IRS1", "PROTEIN", 93, 97], ["ACT", "PROTEIN", 132, 135], ["the tyrosine kinase receptor", "TREATMENT", 11, 39], ["the ERK protein", "TEST", 50, 65], ["this protein inhibits IRS1", "PROBLEM", 71, 97]]], ["Studies have implicated that GRP78, which is increased in response to hyperglycemia in diabetes, is a receptor for COVID-19.", [["hyperglycemia", "DISEASE", 70, 83], ["diabetes", "DISEASE", 87, 95], ["COVID-19", "CHEMICAL", 115, 123], ["GRP78", "GENE_OR_GENE_PRODUCT", 29, 34], ["COVID-19", "GENE_OR_GENE_PRODUCT", 115, 123], ["GRP78", "PROTEIN", 29, 34], ["GRP78", "TEST", 29, 34], ["hyperglycemia", "PROBLEM", 70, 83], ["diabetes", "PROBLEM", 87, 95], ["COVID", "TEST", 115, 120], ["increased", "OBSERVATION_MODIFIER", 45, 54], ["hyperglycemia", "OBSERVATION", 70, 83], ["diabetes", "OBSERVATION", 87, 95]]], ["The hsa-miR-1307-3p can induce glycogenesis and glucose uptaking by inhibiting PKC and ERK, which are inhibitors of RS1 and RS2.", [["hsa-miR-1307-3p", "CHEMICAL", 4, 19], ["glucose", "CHEMICAL", 48, 55], ["glucose", "CHEMICAL", 48, 55], ["hsa-miR-1307-3p", "GENE_OR_GENE_PRODUCT", 4, 19], ["glucose", "SIMPLE_CHEMICAL", 48, 55], ["PKC", "GENE_OR_GENE_PRODUCT", 79, 82], ["ERK", "GENE_OR_GENE_PRODUCT", 87, 90], ["RS1", "GENE_OR_GENE_PRODUCT", 116, 119], ["RS2", "GENE_OR_GENE_PRODUCT", 124, 127], ["hsa-miR-1307-3p", "DNA", 4, 19], ["PKC", "PROTEIN", 79, 82], ["ERK", "PROTEIN", 87, 90], ["RS1", "DNA", 116, 119], ["RS2", "DNA", 124, 127], ["The hsa-miR", "TEST", 0, 11], ["glycogenesis", "PROBLEM", 31, 43], ["glucose", "TEST", 48, 55], ["PKC", "TEST", 79, 82], ["ERK", "TEST", 87, 90], ["RS1", "TEST", 116, 119]]], ["Thus, this miRNA indirectly reduces GRP78 production by lowering blood sugar.J o u r n a l P r e -p r o o fOn the other hand, hsa-miR-1307-3p inhibits insulin expression by inhibiting PDX1 and VDCC, which activates insulin, increasing insulin-dependent proliferative pathways in type 2 diabetes.J o u r n a l P r e -p r o o fMicroRNA 1307 also inhibits insulin expression by inhibiting insulin-activated PDX1 and VDCC, resulting in insulin-dependent proliferative pathways in type 2 diabetes, thus controlling insulin-dependent proliferative pathways in type 2 diabetes.", [["blood", "ANATOMY", 65, 70], ["hsa-miR-1307-3p", "CHEMICAL", 126, 141], ["type 2 diabetes", "DISEASE", 279, 294], ["fMicroRNA 1307", "CHEMICAL", 324, 338], ["type 2 diabetes", "DISEASE", 476, 491], ["type 2 diabetes", "DISEASE", 554, 569], ["sugar", "CHEMICAL", 71, 76], ["fMicroRNA 1307", "CHEMICAL", 324, 338], ["GRP78", "GENE_OR_GENE_PRODUCT", 36, 41], ["blood", "ORGANISM_SUBSTANCE", 65, 70], ["sugar", "SIMPLE_CHEMICAL", 71, 76], ["hsa-miR-1307-3p", "SIMPLE_CHEMICAL", 126, 141], ["insulin", "GENE_OR_GENE_PRODUCT", 151, 158], ["PDX1", "GENE_OR_GENE_PRODUCT", 184, 188], ["VDCC", "GENE_OR_GENE_PRODUCT", 193, 197], ["insulin", "GENE_OR_GENE_PRODUCT", 215, 222], ["insulin", "GENE_OR_GENE_PRODUCT", 235, 242], ["fMicroRNA 1307", "SIMPLE_CHEMICAL", 324, 338], ["insulin", "GENE_OR_GENE_PRODUCT", 353, 360], ["insulin", "GENE_OR_GENE_PRODUCT", 386, 393], ["PDX1", "GENE_OR_GENE_PRODUCT", 404, 408], ["VDCC", "GENE_OR_GENE_PRODUCT", 413, 417], ["insulin", "GENE_OR_GENE_PRODUCT", 432, 439], ["insulin", "GENE_OR_GENE_PRODUCT", 510, 517], ["GRP78", "PROTEIN", 36, 41], ["insulin", "PROTEIN", 151, 158], ["PDX1", "PROTEIN", 184, 188], ["VDCC", "PROTEIN", 193, 197], ["insulin", "PROTEIN", 353, 360], ["PDX1", "PROTEIN", 404, 408], ["VDCC", "PROTEIN", 413, 417], ["lowering blood sugar", "TEST", 56, 76], ["hsa-miR", "TEST", 126, 133], ["insulin expression", "TREATMENT", 151, 169], ["VDCC", "TREATMENT", 193, 197], ["insulin", "TREATMENT", 215, 222], ["increasing insulin", "TREATMENT", 224, 242], ["type 2 diabetes", "PROBLEM", 279, 294], ["a l P r e -p r o o fMicroRNA", "TEST", 305, 333], ["insulin expression", "TREATMENT", 353, 371], ["inhibiting insulin", "TREATMENT", 375, 393], ["activated PDX1", "TREATMENT", 394, 408], ["VDCC", "TREATMENT", 413, 417], ["insulin", "TREATMENT", 432, 439], ["type 2 diabetes", "PROBLEM", 476, 491], ["type 2 diabetes", "PROBLEM", 554, 569], ["hand", "ANATOMY", 120, 124], ["diabetes", "OBSERVATION", 286, 294], ["diabetes", "OBSERVATION", 483, 491], ["diabetes", "OBSERVATION", 561, 569]]], ["Studies have shown (40) that in COVID-19, with increased cytokine storms, lung tissue damage increases.", [["lung tissue", "ANATOMY", 74, 85], ["lung tissue damage", "DISEASE", 74, 92], ["COVID-19", "CELL", 32, 40], ["lung tissue", "TISSUE", 74, 85], ["cytokine", "PROTEIN", 57, 65], ["Studies", "TEST", 0, 7], ["COVID", "TEST", 32, 37], ["increased cytokine storms", "PROBLEM", 47, 72], ["lung tissue damage", "PROBLEM", 74, 92], ["increased", "OBSERVATION_MODIFIER", 47, 56], ["cytokine storms", "OBSERVATION", 57, 72], ["lung", "ANATOMY", 74, 78], ["tissue", "OBSERVATION", 79, 85], ["damage", "OBSERVATION_MODIFIER", 86, 92], ["increases", "OBSERVATION_MODIFIER", 93, 102]]], ["For example, one of the treatment strategies for receptor inhibition is cytokines such as interleukin 6 receptor.J o u r n a l P r e -p r o o fTherefore, hsa-miR-1307-3p can be a therapeutic solution to inhibit tissue damage by inhibiting cytokine receptors.ConclusionThe results of this study have indicated the inhibiting effect of Berbamine, Hypericin, and Hesperidin on ACE2, TMPRSS2, GRP78, and AT1R receptors.", [["tissue", "ANATOMY", 211, 217], ["hsa-miR-1307-3p", "CHEMICAL", 154, 169], ["Berbamine", "CHEMICAL", 334, 343], ["Hypericin", "CHEMICAL", 345, 354], ["Hesperidin", "CHEMICAL", 360, 370], ["hsa-miR-1307-3p", "CHEMICAL", 154, 169], ["Berbamine", "CHEMICAL", 334, 343], ["Hypericin", "CHEMICAL", 345, 354], ["Hesperidin", "CHEMICAL", 360, 370], ["interleukin 6 receptor", "GENE_OR_GENE_PRODUCT", 90, 112], ["hsa-miR-1307-3p", "SIMPLE_CHEMICAL", 154, 169], ["tissue", "TISSUE", 211, 217], ["cytokine receptors", "GENE_OR_GENE_PRODUCT", 239, 257], ["Berbamine", "SIMPLE_CHEMICAL", 334, 343], ["Hypericin", "SIMPLE_CHEMICAL", 345, 354], ["Hesperidin", "SIMPLE_CHEMICAL", 360, 370], ["ACE2", "GENE_OR_GENE_PRODUCT", 374, 378], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 380, 387], ["GRP78", "GENE_OR_GENE_PRODUCT", 389, 394], ["AT1R receptors", "GENE_OR_GENE_PRODUCT", 400, 414], ["cytokines", "PROTEIN", 72, 81], ["interleukin 6 receptor", "PROTEIN", 90, 112], ["cytokine receptors", "PROTEIN", 239, 257], ["ACE2", "PROTEIN", 374, 378], ["TMPRSS2", "PROTEIN", 380, 387], ["GRP78", "PROTEIN", 389, 394], ["AT1R receptors", "PROTEIN", 400, 414], ["the treatment strategies", "TREATMENT", 20, 44], ["receptor inhibition", "TREATMENT", 49, 68], ["cytokines", "TREATMENT", 72, 81], ["interleukin 6 receptor", "TREATMENT", 90, 112], ["fTherefore", "TEST", 142, 152], ["hsa-miR", "TEST", 154, 161], ["a therapeutic solution", "TREATMENT", 177, 199], ["tissue damage", "PROBLEM", 211, 224], ["cytokine receptors", "TREATMENT", 239, 257], ["this study", "TEST", 283, 293], ["Berbamine", "TREATMENT", 334, 343], ["Hypericin", "TREATMENT", 345, 354], ["Hesperidin", "TREATMENT", 360, 370], ["ACE2", "TEST", 374, 378], ["TMPRSS2", "TEST", 380, 387], ["GRP78", "TEST", 389, 394], ["AT1R receptors", "TREATMENT", 400, 414]]], ["Also, enrichment analysis of hsa-mir-1307-3p revealed the suppressing role of this miRNA on proliferative, endocytosis, exocytosis, and diabetes signaling pathways.", [["hsa-mir-1307-3p", "CHEMICAL", 29, 44], ["diabetes", "DISEASE", 136, 144], ["hsa-mir-1307-3p", "GENE_OR_GENE_PRODUCT", 29, 44], ["hsa-mir-1307-3p", "DNA", 29, 44], ["enrichment analysis", "TEST", 6, 25], ["hsa-mir", "TEST", 29, 36], ["this miRNA", "PROBLEM", 78, 88], ["exocytosis", "PROBLEM", 120, 130], ["diabetes signaling pathways", "PROBLEM", 136, 163]]], ["Additionally, hsa-miR-1307-3p targets genes in type 2 diabetes indirectly by repressing the GRP78 receptor expression.", [["type 2 diabetes", "DISEASE", 47, 62], ["hsa-miR-1307-3p", "GENE_OR_GENE_PRODUCT", 14, 29], ["GRP78 receptor", "GENE_OR_GENE_PRODUCT", 92, 106], ["hsa-miR-1307-3p targets genes", "DNA", 14, 43], ["GRP78 receptor", "PROTEIN", 92, 106], ["hsa-miR", "TEST", 14, 21], ["type 2 diabetes", "PROBLEM", 47, 62]]], ["Overall, further clinical J o u r n a l P r e -p r o o f assessment of these herbal compounds and hsa-miR-1307-3p is required to validate the treating ability of these compounds over COVID-19 infection.Conflict of interest statementThe authors declare that there are no conflicts of interest.Funding SourcesThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.", [["hsa-miR-1307-3p", "CHEMICAL", 98, 113], ["COVID-19", "CHEMICAL", 183, 191], ["infection", "DISEASE", 192, 201], ["hsa-miR-1307-3p", "SIMPLE_CHEMICAL", 98, 113], ["COVID-19", "ORGANISM", 183, 191], ["assessment", "TEST", 57, 67], ["these compounds", "PROBLEM", 162, 177], ["infection", "PROBLEM", 192, 201], ["infection", "OBSERVATION", 192, 201], ["no", "UNCERTAINTY", 267, 269]]], ["VDCC, Voltage-dependent calcium channels; WHO, World Health Organization.", [["calcium", "CHEMICAL", 24, 31], ["calcium", "CHEMICAL", 24, 31], ["VDCC", "SIMPLE_CHEMICAL", 0, 4], ["calcium", "SIMPLE_CHEMICAL", 24, 31], ["Voltage-dependent calcium channels", "PROTEIN", 6, 40], ["VDCC", "PROBLEM", 0, 4], ["dependent calcium channels", "PROBLEM", 14, 40], ["dependent", "OBSERVATION_MODIFIER", 14, 23], ["calcium channels", "OBSERVATION", 24, 40]]]], "PMC7537001": [["M. El\u2010Shayeb contributed to the medical treatment decisions.", [["the medical treatment", "TREATMENT", 28, 49]]], ["Y. Eid advised the treatment and follow\u2010up plan.", [["the treatment", "TREATMENT", 15, 28]]], ["A. Saeed advised the investigations.", [["the investigations", "TEST", 17, 35]]], ["D. Abdou, T. Aly, S. Samy, R. Elziaty, S. Aboelyazed were the treating physicians on the frontline who implemented the treatment plan and followed\u2010up the patient along the course of admission in isolation.", [["patient", "ORGANISM", 154, 161], ["D.", "SPECIES", 0, 2], ["patient", "SPECIES", 154, 161], ["D.", "SPECIES", 0, 2], ["the treatment plan", "TREATMENT", 115, 133]]], ["A. Osman and A. Sheha were involved in interpretation of the imaging of the patient.", [["patient", "ORGANISM", 76, 83], ["patient", "SPECIES", 76, 83], ["the imaging", "TEST", 57, 68]]]]}